



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>C12N 15/12, C07K 14/47, C12N 15/62, C07K 16/18</b>		A1	(11) International Publication Number: <b>WO 99/21998</b> (43) International Publication Date: <b>6 May 1999 (06.05.99)</b>
(21) International Application Number: <b>PCT/US98/22991</b>			(74) Agent: BRUESS, Steven, C.; Merchant, Gould, Smith, Edell, Welter & Schmidt, P.A., 3100 Norwest Center, 90 South Seventh Street, Minneapolis, MN 55402 (US).
(22) International Filing Date: <b>29 October 1998 (29.10.98)</b>			
(30) Priority Data:	60/063,704 60/073,612 60/081,695	29 October 1997 (29.10.97) 3 February 1998 (03.02.98) 14 April 1998 (14.04.98)	US US US
(71) Applicant: GENENTECH, INC. [US/US]; 1 DNA Way, South San Francisco, CA 94080-4990 (US).			(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(72) Inventors: BOTSTEIN, David, A.; 2539 Somerset Drive, Belmont, CA 94002 (US). COHEN, Robert, L.; 660 Parrott Drive, San Mateo, CA 94402 (US). GURNEY, Austin, L.; 1 Debbie Lane, Belmont, CA 94002 (US). HILLAN, Kenneth; 64 Seward Street, San Francisco, CA 94114 (US). LAWRENCE, David, A.; 1659 12th Avenue, San Francisco, CA 94122 (US). LEVINE, Arnold, J.; 138 FitzRandolph Road, Princeton, NJ 08540 (US). PENNICA, Diane; 2417 Hale Drive, Burlingame, CA 94010 (US). ROY, Margaret, Ann; 2960 Webster Street #4, San Francisco, CA 94123 (US). GODDARD, Audrey; 110 Congo Street, San Francisco, CA 94131 (US). WOOD, William, I.; 35 Southdown Court, Hillsborough, CA 94010 (US).			Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: <b>WNT-1 INDUCED SECRETED POLYPEPTIDES: WISP-1, -2 AND -3</b>			
(57) Abstract			
<p>Wnt-1-Induced Secreted Proteins (WISPs) are provided, whose genes are induced at least by Wnt-1. Also provided are nucleic acid molecules encoding those polypeptides, as well as vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides, and methods for producing the polypeptides.</p>			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## WNT-1 INDUCED SECRETED POLYPEPTIDES: WISP-1, -2 AND -3

This invention was made with government support under grant no. 5PO1 CA41086, awarded by the National Institutes of Health, National Cancer Institute. The government has certain rights in the invention.

5

FIELD OF THE INVENTION

The present invention relates generally to the identification and isolation of novel DNA and to the recombinant production of novel polypeptides having homology to connective tissue growth factor, designated herein as Wnt-1-Induced Secreted Proteins (WISPs).

BACKGROUND OF THE INVENTION

10 Malignant tumors (cancers) are the second leading cause of death in the United States, after heart disease. Boring *et al.*, CA Cancer J. Clin., 43: 7 (1993).

15 Cancer is characterized by the increase in the number of abnormal, or neoplastic, cells derived from a normal tissue which proliferate to form a tumor mass, the invasion of adjacent tissues by these neoplastic tumor cells, and the generation of malignant cells which eventually spread via the blood or lymphatic system to regional lymph nodes and to distant sites (metastasis). In a cancerous state a cell proliferates under conditions in which normal cells would not grow. Cancer manifests itself in a wide variety of forms, characterized by different degrees of invasiveness and aggressiveness.

20 Alteration of gene expression is intimately related to the uncontrolled cell growth and dedifferentiation which are a common feature of all cancers. The genomes of certain well studied tumors have been found to show decreased expression of recessive genes, usually referred to as tumor suppression genes, which would normally function to prevent malignant cell growth, and/or overexpression of certain dominant genes, such as oncogenes, that act to promote malignant growth. Each of these genetic changes appears to be responsible for imparting some of the traits that, in aggregate, represent the full neoplastic phenotype. Hunter, Cell, 64: 1129 (1991); Bishop, Cell, 64: 235-248 (1991).

25 A well-known mechanism of gene (e.g., oncogene) overexpression in cancer cells is gene amplification. This is a process where in the chromosome of the ancestral cell multiple copies of a particular gene are produced. The process involves unscheduled replication of the region of chromosome comprising the gene, followed by recombination of the replicated segments back into the chromosome. Alitalo *et al.*, Adv. Cancer Res., 47: 235-281 (1986). It is believed that the overexpression of the gene parallels gene 30 amplification, i.e., is proportionate to the number of copies made.

35 Proto-oncogenes that encode growth factors and growth factor receptors have been identified to play important roles in the pathogenesis of various human malignancies, including breast cancer. For example, it has been found that the human ErbB2 gene (*erbB2*, also known as *her2*, or *c-erbB-2*), which encodes a 185-kd transmembrane glycoprotein receptor (p185<sup>HER2</sup>; HER2) related to the epidermal growth factor receptor (EGFR), is overexpressed in about 25% to 30% of human breast cancer. Slamon *et al.*, Science, 235: 177-182 (1987); Slamon *et al.*, Science, 244: 707-712 (1989).

It has been reported that gene amplification of a protooncogen is an event typically involved in the more malignant forms of cancer, and could act as a predictor of clinical outcome. Schwab *et al.*, Genes

5 Chromosomes Cancer, 1: 181-193 (1990); Alitalo *et al.*, *supra*. Thus, erbB2 overexpression is commonly regarded as a predictor of a poor prognosis, especially in patients with primary disease that involves axillary lymph nodes (Slamon *et al.*, (1987) and (1989), *supra*; Ravdin and Chamness, Gene, 159:19-27 (1995); and Hynes and Stern, Biochim Biophys Acta, 1198:165-184 (1994)), and has been linked to sensitivity and/or resistance to hormone therapy and chemotherapeutic regimens, including CMF (cyclophosphamide, methotrexate, and fluorouracil) and anthracyclines. Baselga *et al.*, Oncology, 11(3 Suppl 1):43-48 (1997). However, despite the association of erbB2 overexpression with poor prognosis, the odds of HER2-positive patients responding clinically to treatment with taxanes were greater than three times those of HER2-negative patients. Baselga *et al.*, *supra*. A recombinant humanized anti-ErbB2 (anti-HER2) monoclonal antibody (a 10 humanized version of the murine anti-ErbB2 antibody 4D5, referred to as rhuMAb HER2 or HERCEPTIN®) has been clinically active in patients with ErbB2-overexpressing metastatic breast cancers that had received extensive prior anticancer therapy. Baselga *et al.*, J. Clin. Oncol., 14:737-744 (1996).

15 Cytokines have been implicated in the pathogenesis of a number of brain diseases in which neurological dysfunction has been attributed to a change in amino acid neurotransmitter metabolism. In particular, members of the transforming growth factor- $\beta$  (TGF- $\beta$ ) family have been implicated. TGF peptides are small polypeptides that were first identified by their ability to induce proliferation and transformation in noncancerous cells in culture. Although initially defined as a growth factor, TGF- $\beta$  also inhibits proliferation 20 of epithelial, endothelial, lymphoid, and hematopoietic cells. This cytokine is thought to play an important role in regulating the duration of the inflammatory response, allowing the healing process to proceed. It is also a potent immunomodulator, which has many pleiotrophic effects, including regulating many other cytokines.

25 The TGF- $\beta$  superfamily includes bone morphogenetic proteins (BMP-2, BMP-4, BMP-5, BMP-6, BMP-7), activins A & B, decapentaplegic(dpp), 60A, OP-2, dorsalin, growth differentiation factors (GDFs), nodal, MIS, Inhibin- $\alpha$ , TGF- $\beta$ 1, TGF- $\beta$ 2, TGF- $\beta$ 3, TGF- $\beta$ 5, and glial-derived neurotrophic factor (GDNF). Atrisano, *et al.*, J. Biochemica et Biophysica Acta, 1222:71-80 (1994). Of particular interest are the growth differentiation factors, for as their name implies, these factors are implicated in the differentiation of cells.

30 Connective tissue growth factor (CTGF) is a growth factor induced in fibroblasts by many factors, including TGF- $\beta$ , and is essential for the ability of TGF- $\beta$  to induce anchorage-independent growth (AIG), a property of transformed cells. CTGF was discovered in an attempt to identify the type of platelet-derived growth factor (PDGF) dimers present in the growth media of cultured endothelial cells, and is related 35 immunologically and biologically to PDGF. See U.S. Pat. No. 5,408,040. CTGF also is mitogenic and chemotactic for cells, and hence growth factors in this family are believed to play a role in the normal development, growth, and repair of human tissue.

35 Seven proteins related to CTGF, including the chicken ortholog for Cyr61, CEF10, human, mouse, and *Xenopus laevis* CTGF, and human, chicken, and *Xenopus laevis* Nov have been isolated, cloned, sequenced, and characterized as belonging to the CTGF gene family. Oemar and Luescher, Arterioscler. Thromb. Vasc. Biol., 17: 1483-1489 (1997). The gene encoding Cyr61 has been found to promote angiogenesis, tumor growth, and vascularization. Babic *et al.*, Proc. Natl. Acad. Sci. USA, 95: 6355-6360 (1998). The nov gene is expressed in the kidney essentially at the embryonic stage, and alterations of nov

expression, relative to the normal kidney, have been detected in both avian nephroblastomas and human Wilms' tumors. Martinerie *et al.*, Oncogene, 9: 2729-2732 (1994). *Wt1* downregulates human *nov* expression, which downregulation might represent a key element in normal and tumoral nephrogenesis. Martinerie *et al.*, Oncogene, 12: 1479-1492 (1996). It has recently been proposed that the CTGF, *nov*, and *cyr61* genes, which encode secreted proteins that contain conserved sequences and IGFBP motifs in their N-termini and bind IGFs with low affinity, represent more members of the IGFBP superfamily, along with the low-affinity mac25/IGFBP-7 (Yamanaka *et al.*, J. Biol. Chem., 272: 30729-30734 (1997)) and the high-affinity IGFBPs 1-6. CTGF under this proposal would be designated IGFBP-8. Kim *et al.*, Proc. Natl. Acad. Sci. USA, 94: 12981-12986 (1997).

Recently, a protein was found in the mouse designated ELM1 that is expressed in low metastatic cells. Hashimoto *et al.*, J. Exp. Med., 187: 289-296 (1998). The *elm1* gene, a mouse homologue of WISP-1 disclosed below, is another member of the CTGF, *Cyr61/Cef10*, and neuroblastoma overexpressed-gene family and suppresses *in vivo* tumor growth and metastasis of K-1735 murine melanoma cells. Another recent article on rCop-1, the rat orthologue of WISP-2 described below describes the loss of expression of this gene after cell transformation Zhang *et al.*, Mol. Cell. Biol., 18:6131-6141 (1998).

CTGF family members (with the exception of *nov*) are immediate early growth-responsive genes that are thought to regulate cell proliferation, differentiation, embryogenesis, and wound healing. Sequence homology among members of the CTGF gene family is high; however, functions of these proteins *in vitro* range from growth stimulatory (*i.e.*, human CTGF) to growth inhibitory (*i.e.*, chicken *Nov* and also possibly hCTGF). Further, some molecules homologous to CTGF are indicated to be useful in the prevention of desmoplasia, the formation of highly cellular, excessive connective tissue stroma associated with some cancers, and fibrotic lesions associated with various skin disorders such as scleroderma, keloid, eosinophilic fasciitis, nodular fasciitis, and Dupuytren's contracture. Moreover, CTGF expression has recently been demonstrated in the fibrous stroma of mammary tumors, suggesting cancer stroma formation involves the induction of similar fibroproliferative growth factors as wound repair. Human CTGF is also expressed at very high levels in advanced atherosclerotic lesions, but not in normal arteries, suggesting it may play a role in atherosclerosis. Oemar and Luescher, *supra*. Therefore, molecules homologous to CTGF are of importance.

Extracellular and membrane-bound proteins play important roles in the formation, differentiation, and maintenance of multicellular organisms. The fate of many individual cells, *e.g.*, proliferation, migration, differentiation, or interaction with other cells, is typically governed by information received from other cells and/or the immediate environment. This information is often transmitted by secreted polypeptides (for instance, mitogenic factors, survival factors, cytotoxic factors, differentiation factors, neuropeptides, and hormones), which are, in turn, received and interpreted by diverse cell receptors or membrane-bound proteins. These secreted polypeptides or signaling molecules normally pass through the cellular secretory pathway to reach their site of action in the extracellular environment, usually at a membrane-bound receptor protein.

Secreted proteins have various industrial applications, including use as pharmaceuticals, diagnostics, biosensors, and bioreactors. In fact, most protein drugs available at present, such as thrombolytic agents, interferons, interleukins, erythropoietins, colony stimulating factors, and various other cytokines, are secreted proteins. Their receptors, which are membrane-bound proteins, also have potential as therapeutic or

diagnostic agents. Receptor immunoadhesins, for instance, can be employed as therapeutic agents to block receptor-ligand interaction. Membrane-bound proteins can also be employed for screening of potential peptide or small molecule inhibitors of the relevant receptor/ligand interaction. Such membrane-bound proteins and cell receptors include, but are not limited to, cytokine receptors, receptor kinases, receptor phosphatases, receptors involved in cell-cell interactions, and cellular adhesin molecules like selectins and integrins. Transduction of signals that regulate cell growth and differentiation is regulated in part by phosphorylation of various cellular proteins. Protein tyrosine kinases, enzymes that catalyze that process, can also act as growth factor receptors. Examples include fibroblast growth factor receptor and nerve growth factor receptor.

Efforts are being undertaken by both industry and academia to identify new, native secreted and membrane-bound receptor proteins, particularly those having homology to CTGF. Many efforts are focused on the screening of mammalian recombinant DNA libraries to identify the coding sequences for novel secreted and membrane-bound receptor proteins. Examples of screening methods and techniques are described in the literature. See, for example, Klein *et al.*, Proc. Natl. Acad. Sci., 93:7108-7113 (1996); and U.S. Patent No. 5,536,637.

Wnts are encoded by a large gene family whose members have been found in round worms, insects, cartilaginous fish, and vertebrates. Holland *et al.*, Dev. Suppl., 125-133 (1994). Wnts are thought to function in a variety of developmental and physiological processes since many diverse species have multiple conserved *Wnt* genes. McMahon, Trends Genet., 8: 236-242 (1992); Nusse and Varmus, Cell, 69: 1073-1087 (1992). *Wnt* genes encode secreted glycoproteins that are thought to function as paracrine or autocrine signals active in several primitive cell types. McMahon, *supra* (1992); Nusse and Varmus, *supra* (1992). The Wnt growth factor family includes more than ten genes identified in the mouse (*Wnt-1, -2, -3A, -3B, -4, -5A, -5B, -6, -7A, -7B, -8A, -8B, -10B, -11, -12, and -13*) (see, e.g., Gavin *et al.*, Genes Dev., 4: 2319-2332 (1990); Lee *et al.*, Proc. Natl. Acad. Sci. USA, 92: 2268-2272 (1995); Christiansen *et al.*, Mech. Dev., 51: 341-350 (1995)) and at least nine genes identified in the human (*Wnt-1, -2, -3, -5A, -7A, -7B, -8B, -10B, and -11*) by cDNA cloning. See, e.g., Vant Veer *et al.*, Mol. Cell. Biol., 4: 2532-2534 (1984).

The *Wnt-1* proto-oncogene (*int-1*) was originally identified from mammary tumors induced by mouse mammary tumor virus (MMTV) due to an insertion of viral DNA sequence. Nusse and Varmus, Cell, 31: 99-109 (1982). In adult mice, the expression level of *Wnt-1* mRNA is detected only in the testis during later stages of sperm development. *Wnt-1* protein is about 42 KDa and contains an amino-terminal hydrophobic region, which may function as a signal sequence for secretion (Nusse and Varmus, *supra*, 1992). The expression of *Wnt-2/irp* is detected in mouse fetal and adult tissues and its distribution does not overlap with the expression pattern for *Wnt-1*. *Wnt-3* is associated with mouse mammary tumorigenesis. The expression of *Wnt-3* in mouse embryos is detected in the neural tubes and in the limb buds. *Wnt-5a* transcripts are detected in the developing fore- and hind limbs at 9.5 through 14.5 days and highest levels are concentrated in apical ectoderm at the distal tip of limbs. Nusse and Varmus, *supra* (1992). Recently, a Wnt growth factor, termed *Wnt-x*, was described (WO95/17416) along with the detection of *Wnt-x* expression in bone tissues and in bone-derived cells. Also described was the role of *Wnt-x* in the maintenance of mature bone tissues and in bone-derived cells.

osteoblasts and the use of the *Wnt-x* growth factor as a therapeutic agent or in the development of other therapeutic agents to treat bone-related diseases.

5           Wnts may play a role in local cell signaling. Biochemical studies have shown that much of the secreted Wnt protein can be found associated with the cell surface or extracellular matrix rather than freely diffusible in the medium. Papkoff and Schryver. Mol. Cell. Biol., 10: 2723-2730 (1990); Bradley and Brown. EMBO J., 9: 1569-1575 (1990).

10           Studies of mutations in *Wnt* genes have indicated a role for *Wnts* in growth control and tissue patterning. In *Drosophila*, *wingless* (*wg*) encodes a *Wnt*-related gene (Rijsewijk *et al.*, Cell, 50: 649-657 (1987)) and *wg* mutations alter the pattern of embryonic ectoderm, neurogenesis, and imaginal disc outgrowth. Morata and Lawrence. Dev. Biol., 56: 227-240 (1977); Baker, Dev. Biol., 125: 96-108 (1988); Klingensmith and Nusse. Dev. Biol., 166: 396-414 (1994). In *Caenorhabditis elegans*, *lin-44* encodes a *Wnt* homolog which is required for asymmetric cell divisions. Herman and Horvitz. Development, 120: 1035-1047 (1994). Knock-out mutations in mice have shown Wnts to be essential for brain development (McMahon and Bradley, Cell, 62: 1073-1085 (1990); Thomas and Cappelli. Nature, 346: 847-850 (1990)). (McMahon and Bradley, Cell, 62: 1073-1085 (1990); Thomas and Cappelli. Nature, 346: 847-850 (1990)).  
15           Takada *et al.*, Genes Dev., 8: 174-189 (1994)), and limb bud. Parr and McMahon. Nature, 374: 350-353 (1995). Overexpression of *Wnts* in the mammary gland can result in mammary hyperplasia (McMahon, *supra* (1992); Nusse and Varmus, *supra* (1992)), and precocious alveolar development. Bradbury *et al.*, Dev. Biol., 170: 553-563 (1995).

20           *Wnt-5a* and *Wnt-5b* are expressed in the posterior and lateral mesoderm and the extraembryonic mesoderm of the day 7-8 murine embryo. Gavin *et al.*, *supra* (1990). These embryonic domains contribute to the AGM region and yolk sac tissues from which multipotent hematopoietic precursors and HSCs are derived. Dzierzak and Medvinsky. Trends Genet., 11: 359-366 (1995); Zon *et al.*, in Gluckman and Coulombel, ed., *Colloque, INSERM*, 235: 17-22 (1995), presented at the Joint International Workshop on Foetal and Neonatal Hematopoiesis and Mechanism of Bone Marrow Failure, Paris France, April 3-6, 1995: Kanatsu and Nishikawa. Development, 122: 823-830 (1996). *Wnt-5a*, *Wnt-10b*, and other *Wnts* have been detected in limb buds, indicating possible roles in the development and patterning of the early bone microenvironment as shown for *Wnt-7b*. Gavin *et al.*, *supra* (1990); Christiansen *et al.*, Mech. Devel., 51: 341-350 (1995); Parr and McMahon. *supra* (1995).

30           The *Wnt/Wg* signal transduction pathway plays an important role in the biological development of the organism and has been implicated in several human cancers. This pathway also includes the tumor suppressor gene, APC. Mutations in the APC gene are associated with the development of sporadic and inherited forms of human colorectal cancer. The *Wnt/Wg* signal leads to the accumulation of beta-catenin/Armadillo in the cell, resulting in the formation of a bipartite transcription complex consisting of beta-catenin and a member of the lymphoid enhancer binding factor/T cell factor (LEF/TCF)HMG box transcription factor family. This complex translocates to the nucleus where it can activate expression of genes downstream of the *Wnt/Wg* signal, such as the engrailed and Ultrabithorax genes in *Drosophila*. The downstream target genes of *Wnt-1* signaling in vertebrates that presumably function in tumorigenesis, however, are currently unknown.

For a most recent review on Wnt, see Cadigan and Nusse, *Genes & Dev.*, 11: 3286-3305 (1997).

There is a need to elucidate the further members of the above families, including cell-surface molecules that may be tumor-specific antigens or proteins that serve a regulatory function in initiating the Wnt pathway of tumorigenesis. These would also include downstream components of the Wnt signaling pathway that are important to the transformed phenotype and the development of cancer.

#### SUMMARY OF THE INVENTION

Several putative Wnt-1-induced genes have been identified at the mRNA level in a high-throughput cDNA subtraction experiment. Thus, applicants have identified novel cDNA clones (*WISP1*, *WISP2*, and *WISP3*) that encode novel polypeptides of the WISP family, designated as WISP-1, WISP-2, and WISP-3, respectively. This class of polypeptides was formerly referred to as Wnt-1-Induced Gene (WIG) polypeptides, with WISP-1 and WISP-2 formerly designated as WIG-1 and WIG-2, respectively. One of the cDNA clones encodes a novel polypeptide, human WISP-2, having homology to CTGF, wherein the polypeptide is designated in the present application as "human WISP-2" or "PRO261". The WISP-1 and WISP-3 molecules also have homology to CTGF.

In one embodiment, this invention provides isolated nucleic acid comprising DNA having at least about 600 nucleotides and at least about a 75% sequence identity to (a) a DNA molecule encoding a human WISP-1 polypeptide comprising the sequence of amino acids 23 to 367 of Figures 3A and 3B (SEQ ID NO:3), or (b) the complement of the DNA molecule of (a). Preferably, this nucleic acid has at least one WISP biological activity. In a more preferred embodiment, this nucleic acid has at least about a 95% sequence identity to (a) a DNA molecule encoding a human WISP-1 polypeptide comprising the sequence of amino acids 23 to 367 of Figures 3A and 3B (SEQ ID NO: 3), or (b) the complement of the DNA molecule of (a).

More preferred is the nucleic acid comprising DNA encoding a human WISP-1 polypeptide having amino acid residues 23 to 367 of Figures 3A and 3B (SEQ ID NO:3), or DNA encoding a human WISP-1 polypeptide having amino acid residues 1 to 367 of Figures 3A and 3B (SEQ ID NO:4), or the complement of either of the encoding DNAs. Further preferred is this nucleic acid comprising DNA encoding a human WISP-1 polypeptide having amino acid residues 23 to 367 or 1 to 367 of Figures 3A and 3B except for an isoleucine residue at position 184 rather than a valine residue or a serine residue at position 202 rather than an alanine residue (SEQ ID NOS:5-8, respectively). Further preferred also is this nucleic acid comprising DNA encoding a human WISP-1 polypeptide having amino acid residues 23 to 367 or 1 to 367 of Figures 3A and 3B except for an isoleucine residue at position 184 rather than a valine residue and a serine residue at position 202 rather than an alanine residue (SEQ ID NOS:21-22, respectively).

Also preferred is this nucleic acid comprising DNA encoding a mouse WISP-1 polypeptide having amino acid residues 23 to 367 of Figure 1 (SEQ ID NO:11), or DNA encoding a mouse WISP-1 polypeptide having amino acid residues 1 to 367 of Figure 1 (SEQ ID NO:12), or the complement of either of the encoding DNAs.

Also provided by this invention is isolated nucleic acid comprising DNA having at least about 600 nucleotides and at least about a 85% sequence identity to (a) a DNA molecule encoding a mouse WISP-1 polypeptide comprising the sequence of amino acids 23 to 367 of Figure 1 (SEQ ID NO:11), or (b) the complement of the DNA molecule of (a). Preferably, this nucleic acid has at least one WISP biological

activity. More preferably, this nucleic acid comprises DNA having at least about a 95% sequence identity to (a) a DNA molecule encoding a mouse WISP-1 polypeptide comprising the sequence of amino acids 23 to 367 of Figure 1 (SEQ ID NO:11), or (b) the complement of the DNA molecule of (a).

In another preferred embodiment, the invention provides an isolated nucleic acid comprising DNA having at least about 600 nucleotides and at least about a 75% sequence identity to (a) a DNA molecule encoding the same full-length polypeptide encoded by the human WISP-1 polypeptide cDNA in ATCC Deposit No. 209533 (pRK5E.h.WISP-1.568.38), or (b) the complement of the DNA molecule of (a). This nucleic acid preferably comprises DNA having at least about 600 nucleotides and at least about a 95% sequence identity to (a) a DNA molecule encoding the same full-length polypeptide encoded by the human WISP-1 polypeptide cDNA in ATCC Deposit No. 209533 (pRK5E.h.WISP-1.568.38), or (b) the complement of the DNA molecule of (a).

In another aspect, the invention provides a process for producing a WISP-1 polypeptide comprising culturing a host cell comprising the above nucleic acid under conditions suitable for expression of the WISP-1 polypeptide and recovering the WISP-1 polypeptide from the cell culture. Additionally provided is an isolated WISP-1 polypeptide encoded by the above nucleic acid, including where the polypeptide is human WISP-1 or mouse WISP-1.

In another embodiment, the invention provides isolated nucleic acid comprising SEQ ID NO:23, 24, 25, 26, 27, 28, or 29, and an isolated WISP-1 polypeptide encoded by such a nucleic acid.

Also provided by this invention is an isolated nucleic acid having at least about 600 nucleotides and produced by hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a human WISP-1 polypeptide comprising the sequence of amino acids 23 to 367 of Figures 3A and 3B (SEQ ID NO:3), or (b) the complement of the DNA molecule of (a), and, if the test DNA molecule has at least about a 75% sequence identity to (a) or (b), isolating the test DNA molecule.

Further provided is a polypeptide produced by (i) hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a human WISP-1 polypeptide comprising the sequence of amino acids 23 to 367 of Figures 3A and 3B (SEQ ID NO:3), or (b) the complement of the DNA molecule of (a), and if the test DNA molecule has at least about a 75% sequence identity to (a) or (b), (ii) culturing a host cell comprising the test DNA molecule under conditions suitable for expression of the polypeptide, and (iii) recovering the polypeptide from the cell culture.

In another aspect, the invention provides isolated nucleic acid comprising DNA having at least about an 80% sequence identity to (a) a DNA molecule encoding a human WISP-2 polypeptide comprising the sequence of amino acids 24 to 250 of Figure 4 (SEQ ID NO:15), or (b) the complement of the DNA molecule of (a). Preferably, this nucleic acid has at least one WISP biological activity. Also, preferably this nucleic acid comprises DNA having at least about a 95% sequence identity to (a) a DNA molecule encoding a human WISP-2 polypeptide comprising the sequence of amino acids 24 to 250 of Figure 4 (SEQ ID NO:15), or (b) the complement of the DNA molecule of (a). In another preferred embodiment, this nucleic acid comprises DNA encoding a human WISP-2 polypeptide having amino acid residues 24 to 250 of Figure 4 (SEQ ID NO:15), or DNA encoding a human WISP-2 polypeptide having amino acid residues 1 to 250 of Figure 4 (SEQ ID NO:16), or a complement of either of the encoding DNAs.

In another aspect, the invention provides isolated nucleic acid comprising DNA having at least about an 80% sequence identity to (a) a DNA molecule encoding a human WISP-2 polypeptide comprising the sequence of amino acids 1 to 250 of Figure 4 (SEQ ID NO:16), or (b) the complement of the DNA molecule of (a).

5 In another aspect, the invention provides isolated nucleic acid comprising DNA having at least about 500 nucleotides and at least about an 80% sequence identity to (a) a DNA molecule encoding a mouse WISP-2 polypeptide comprising the sequence of amino acids 24 to 251 of Figure 2 (SEQ ID NO:19), or (b) the complement of the DNA molecule of (a). In a preferred embodiment, this nucleic acid comprises DNA having at least about a 95% sequence identity to (a) a DNA molecule encoding a mouse WISP-2 polypeptide comprising the sequence of amino acids 24 to 251 of Figure 2 (SEQ ID NO:19), or (b) the complement of the DNA molecule of (a). More preferably, the nucleic acid comprises DNA encoding a mouse WISP-2 polypeptide having amino acid residues 24 to 251 of Figure 2 (SEQ ID NO:19), or DNA encoding a mouse WISP-2 polypeptide having amino acid residues 1 to 251 of Figure 2 (SEQ ID NO:20), or the complement of either of these encoding DNAs.

10 15 In a further aspect, the invention provides isolated nucleic acid comprising DNA having at least about 500 nucleotides and at least about an 80% sequence identity to (a) a DNA molecule encoding a mouse WISP-2 polypeptide comprising the sequence of amino acids 1 to 251 of Figure 2 (SEQ ID NO:20), or (b) the complement of the DNA molecule of (a).

20 25 In yet another aspect, the invention provides an isolated nucleic acid comprising DNA having at least about 400 nucleotides and at least about a 75% sequence identity to (a) a DNA molecule encoding the same full-length polypeptide encoded by the human WISP-2 polypeptide cDNA in ATCC Deposit No. 209391 (DNA33473), or (b) the complement of the DNA molecule of (a). Preferably, this nucleic acid comprises DNA having at least about a 95% sequence identity to (a) a DNA molecule encoding the same full-length polypeptide encoded by the human WISP-2 polypeptide cDNA in ATCC Deposit No. 209391 (DNA33473), or (b) the complement of the DNA molecule of (a).

30 In another embodiment, this invention provides an isolated nucleic acid comprising the nucleotide sequence of the full-length coding sequence of clone UNQ228 (DNA33473) deposited under accession number ATCC 209391.

35 In another aspect, the invention provides a process for producing a WISP-2 polypeptide comprising culturing a host cell comprising the above nucleic acid under conditions suitable for expression of the WISP-2 polypeptide and recovering the WISP-2 polypeptide from the cell culture. Additionally provided is a WISP-2 polypeptide encoded by the isolated nucleic acid, including where the polypeptide is human WISP-2 or mouse WISP-2. In a specific embodiment of this, the invention provides isolated native-sequence human WISP-2 polypeptide comprising amino acid residues 1 to 250 of Figure 4 (SEQ ID NO:16) or comprising amino acid residues 24 to 250 of Figure 4 (SEQ ID NO:15).

40 In a further embodiment, the invention provides an isolated nucleic acid having at least about 400 nucleotides and produced by hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a human WISP-2 polypeptide comprising the sequence of amino acids 24 to 250 of Figure

4 (SEQ ID NO:15), or (b) the complement of the DNA molecule of (a), and, if the test DNA molecule has at least about a 75% sequence identity to (a) or (b), isolating the test DNA molecule.

In a still further embodiment, the invention provides a polypeptide produced by (i) hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a human WISP-2 polypeptide comprising the sequence of amino acids 24 to 250 of Figure 4 (SEQ ID NO:15), or (b) the complement of the DNA molecule of (a), and if the test DNA molecule has at least about a 75% sequence identity to (a) or (b), (ii) culturing a host cell comprising the test DNA molecule under conditions suitable for expression of the polypeptide, and (iii) recovering the polypeptide from the cell culture.

In yet another embodiment, the invention provides isolated nucleic acid comprising DNA having 10 a 100% sequence identity in more than about 500 nucleotides to (a) a DNA molecule encoding a human WISP-3 polypeptide comprising the sequence of amino acids 34 to 372 of Figures 6A and 6B (SEQ ID NO:32), or (b) the complement of the DNA molecule of (a). Preferably, this nucleic acid has at least one WISP biological activity. Preferably, this nucleic acid comprises DNA encoding a human WISP-3 polypeptide having amino acid residues 34 to 372 of Figures 6A and 6B (SEQ ID NO:32) or amino acids 15 1 to 372 of Figures 6A and 6B (SEQ ID NO:33), or the complement thereof.

In a still further embodiment, the invention provides an isolated nucleic acid comprising DNA having a 100% sequence identity in more than about 500 nucleotides to (a) a DNA molecule encoding the same full-length polypeptide encoded by the human WISP-3 polypeptide cDNA in ATCC Deposit No. 209706 (DNA56350-1176-2), or (b) the complement of the DNA molecule of (a). A still further aspect 20 of the invention involves a process for producing a WISP-3 polypeptide comprising culturing a host cell comprising WISP-3-encoding nucleic acid under conditions suitable for expression of the WISP-3 polypeptide and recovering the WISP-3 polypeptide from the cell culture.

Further provided is an isolated WISP-3 polypeptide encoded by the WISP-3-encoding nucleic acid. Preferably, this polypeptide is human WISP-3.

25 In another embodiment, the invention provides an isolated nucleic acid produced by hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a human WISP-3 polypeptide comprising the sequence of amino acids 34 to 372 of Figures 6A and 6B (SEQ ID NO:32), or (b) the complement of the DNA molecule of (a), and, if the test DNA molecule has a 100% sequence identity to (a) or (b) in more than about 500 nucleotides, isolating the test DNA molecule.

30 Also provided is a polypeptide produced by (i) hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a human WISP-3 polypeptide comprising the sequence of amino acids 34 to 372 of Figures 6A and 6B (SEQ ID NO:32), or (b) the complement of the DNA molecule of (a), and if the test DNA molecule has a 100% sequence identity to (a) or (b) in more than about 500 nucleotides, (ii) culturing a host cell comprising the test DNA molecule under conditions suitable for expression of the polypeptide, and (iii) recovering the polypeptide from the cell culture.

35 In yet another embodiment, the invention provides isolated nucleic acid comprising DNA having a 100% sequence identity in more than about 400 nucleotides to (a) a DNA molecule encoding a human WISP-3 polypeptide comprising the sequence of amino acids 16 to 355 of Figures 7A and 7B (SEQ ID NO:36), or (b) the complement of the DNA molecule of (a). Preferably, this nucleic acid has at least one

WISP biological activity. Preferably, this nucleic acid comprises DNA encoding a human WISP-3 polypeptide having amino acid residues 16 to 355 of Figures 7A and 7B (SEQ ID NO:36), or amino acid residues 1 to 355 of Figures 7A and 7B (SEQ ID NO:37) or the complement thereof.

In a still further embodiment, the invention provides an isolated nucleic acid comprising DNA having a 100% sequence identity in more than about 400 nucleotides to (a) a DNA molecule encoding the same full-length polypeptide encoded by the human WISP-3 polypeptide cDNA in ATCC Deposit No. 209707 (DNA58800-1176-2), or (b) the complement of the DNA molecule of (a).

A still further aspect of the invention involves a process for producing a WISP-3 polypeptide of Fig. 7A and 7B comprising culturing a host cell comprising WISP-3-encoding nucleic acid under conditions suitable for expression of the WISP-3 polypeptide and recovering the WISP-3 polypeptide from the cell culture.

Further provided is an isolated WISP-3 polypeptide of Fig. 7A and 7B encoded by the WISP-3-encoding nucleic acid. Preferably, this polypeptide is human WISP-3.

In another embodiment, the invention provides an isolated nucleic acid produced by hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a human WISP-3 polypeptide comprising the sequence of amino acids 16 to 355 of Figures 7A and 7B (SEQ ID NO:36), or (b) the complement of the DNA molecule of (a), and, if the test DNA molecule has a 100% sequence identity to (a) or (b) in more than about 400 nucleotides, isolating the test DNA molecule.

Also provided is a polypeptide produced by (i) hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a human WISP-3 polypeptide comprising the sequence of amino acids 16 to 355 of Figures 7A and 7B (SEQ ID NO:36), or (b) the complement of the DNA molecule of (a), and if the test DNA molecule has a 100% sequence identity to (a) or (b) in more than about 400 nucleotides, (ii) culturing a host cell comprising the test DNA molecule under conditions suitable for expression of the polypeptide, and (iii) recovering the polypeptide from the cell culture.

Preferably the complements of the DNA molecules herein remain stably bound to the primary sequence under at least moderate, and optionally, under high stringency conditions.

Also provided are vectors comprising the above nucleic acids, host cells comprising the vector, preferably wherein the cell is a Chinese hamster ovary (CHO) cell, an *E. coli* cell, a baculovirus-infected cell, or a yeast cell.

Additionally provided are a chimeric molecule comprising one of the above polypeptides or an inactivated variant thereof, fused to a heterologous amino acid sequence, wherein the heterologous amino acid sequence may be, for example, an epitope tag sequence, a polyamino acid such as poly-histidine, or an immunoglobulin constant region (Fc). Also provided is an antibody which specifically binds to one of the above polypeptides, wherein the antibody can be a monoclonal antibody.

Further provided are a composition comprising one of the above polypeptides and a carrier therefor, and a composition comprising an antagonist to one of the polypeptides and a carrier therefor. In one such embodiment, the invention provides a composition comprising a WISP-1, WISP-2, or WISP-3 polypeptide and a pharmaceutically acceptable carrier. Preferably, the polypeptide is a human polypeptide. Also, preferably, these compositions may also comprise a chemotherapeutic agent or growth-inhibitory agent.

In another aspect, the invention provides a pharmaceutical product comprising:

- (a) the composition comprising WISP-1, WISP-2, or WISP-3 polypeptide and a pharmaceutically acceptable carrier;
- (b) a container containing said composition; and
- 5 (c) a label affixed to said container, or a package insert included in said pharmaceutical product referring to the use of said WISP-1, WISP-2, or WISP-3 polypeptide in the treatment of a WISP-related disorder.

In yet another embodiment, the invention provides a method for treating a WISP-related disorder in a mammal comprising administering to the mammal an effective amount of any of the above compositions, including the composition of a WISP-1, WISP-2, or WISP-3 polypeptide in a pharmaceutically acceptable carrier, and including the composition of an antagonist to a WISP-1, WISP-2, or WISP-3 polypeptide in a pharmaceutically acceptable carrier. Preferably, the disorder is a malignant disorder or arteriosclerosis. More preferably, the malignant disorder is breast cancer, ovarian cancer, colon cancer, or melanoma. Also, preferably the mammal is human. In another preferred embodiment, the WISP-1, WISP-2, or WISP-3 polypeptide is administered in combination with a chemotherapeutic agent, a growth inhibitory agent, or a cytotoxic agent.

In another embodiment, the invention supplies a process for diagnosing a disease or a susceptibility to a disease related to a mutation in a nucleic acid sequence encoding a WISP-1, WISP-2, or WISP-3 polypeptide comprising:

- 20 (a) isolating a nucleic acid sequence encoding a WISP-1, WISP-2, or WISP-3 polypeptide from a sample derived from a host; and
- (b) determining a mutation in the nucleic acid sequence encoding a WISP-1, WISP-2, or WISP-3 polypeptide.

In another embodiment, the invention provides a method of diagnosing a WISP-related disorder in a mammal comprising detecting the level of expression of a gene encoding a WISP-1, WISP-2, or WISP-3 polypeptide (a) in a test sample of tissue cells obtained from the mammal, and (b) in a control sample of known normal tissue cells of the same cell type, wherein a higher or lower expression level in the test sample indicates the presence of a WISP-related dysfunction in the mammal from which the test tissue cells were obtained. Preferably, such a disorder is a type of cancer and a higher expression level in the test sample indicates the presence of a tumor in the mammal.

In a still further embodiment, the invention provides an isolated antibody binding a WISP-1, WISP-2, or WISP-3 polypeptide. Preferably, the antibody induces death of a cell overexpressing a WISP-1, WISP-2, or WISP-3 polypeptide, more preferably a cancer cell. Also preferred is an antibody that binds to a human WISP-1, WISP-2, or WISP-3 polypeptide, and is a human or humanized antibody. More preferred is a monoclonal antibody, still more preferred, a monoclonal antibody that has complementary-determining regions and constant immunoglobulin regions, and in other embodiments is an antibody fragment, a single-chain antibody, or an anti-idiotypic antibody. In addition, the antibody is suitably labeled with a detectable label or immobilized on a solid support.

Also provided is a composition comprising an antibody to a WISP-1, WISP-2, or WISP-3 polypeptide in admixture with a pharmaceutically acceptable carrier. Preferably, the antibody is to a human WISP-1, WISP-2, or WISP-3 polypeptide, and is a human or humanized antibody, most preferably a monoclonal antibody against human WISP-1. Further, the composition may comprise a growth-inhibitory amount of said antibody.

5 In another embodiment, the invention provides a method for treating cancer in a mammal comprising administering to the mammal an effective amount of the above antibody composition. In a preferred aspect of this method, the cancer is colon cancer, the antibody is against human WISP-1 and is a humanized or human monoclonal antibody, and the mammal is human.

10 In another aspect, the invention provides a method for treating a WISP-related disorder in a mammal comprising administering to the mammal an effective amount of a composition comprising an antagonist to a WISP-1, WISP-2, or WISP-3 polypeptide in a pharmaceutically acceptable carrier.

15 In a further aspect, the invention provides a method for inhibiting the growth of tumor cells comprising exposing a cell that overexpresses a Wnt-1-induced gene to an effective amount of an antagonist that inhibits the expression or activity of a WISP-1, WISP-2, or WISP-3 polypeptide.

20 A further aspect entails a method for inhibiting the growth of tumor cells comprising exposing said cells to an effective amount of the composition with the growth-inhibiting amount of an anti-WISP-1, anti-WISP-2, or anti-WISP-3 antibody in admixture with the carrier. In a preferred aspect of this method, the tumor cells are colon cancer cells, the antibody is against human WISP-1 and is a humanized or human monoclonal antibody, and the mammal is human.

25 Also provided herein is a kit comprising one of the above WISP polypeptides or WISP antagonists, such as anti-WISP antibodies, and instructions for using the polypeptide or antagonist to detect or treat a WISP-related disorder, such as cancer induced by Wnt. One such preferred kit is a cancer diagnostic kit comprising an anti-WISP-1, anti-WISP-2, or anti-WISP-3 antibody and a carrier in suitable packaging. Preferably, this kit further comprises instructions for using said antibody to detect the WISP-1, WISP-2, or WISP-3 polypeptide.

30 Also provided is a method for inducing cell death comprising exposing a cell which is induced by Wnt to an effective amount of one of the above WISP polypeptides or WISP antagonists, such as anti-WISP antibodies. Preferably, such cell is a cancer cell. More preferably, the cell is in a mammal, more preferably a human. In addition, an effective amount of another chemotherapeutic antibody is used in the exposure of the cell, such as an anti-ErbB2 antibody. Further, optionally the method comprises exposing the cell to a chemotherapeutic agent, a growth-inhibitory agent, or radiation. Optionally, the cell is exposed to the growth-inhibitory agent prior to exposure to the antibody.

35 In a further aspect, the invention provides an article of manufacture, comprising:  
a container;  
a label on the container; and  
a composition comprising an active agent contained within the container; wherein the composition is effective for inducing cell death or inhibiting the growth of tumor cells, the label on the container indicates that the composition can be used for treating conditions characterized by overinduction of Wnt or a WISP-

related disorder or by overexpression of a WISP-1, WISP-2, or WISP-3 polypeptide, and the active agent in the composition is an antagonist to one of the polypeptides, that is, an agent that inhibits the expression and/or activity of the WISP-1, WISP-2, or WISP-3 polypeptide. Preferably, the active agent in such article of manufacture is an anti-WISP-1, anti-WISP-2, or anti-WISP-3 antibody, and the label on the container indicates that the composition can be used for treating a WISP-related disorder.

5 In another embodiment, the invention provides a process for identifying agonists to a WISP-1, WISP-2, or WISP-3 polypeptide comprising:

(a) contacting cells and a compound to be screened under conditions suitable for the stimulation of cell proliferation by the polypeptide; and

10 (b) measuring the proliferation of the cells to determine if the compound is an effective agonist.

Additionally, the invention provides an agonist to a WISP-1, WISP-2, or WISP-3 polypeptide identified by the above process.

15 Further, the invention provides a method for identifying a compound that inhibits the expression or activity of a WISP-1, WISP-2, or WISP-3 polypeptide, comprising contacting a candidate compound with a WISP-1, WISP-2, or WISP-3 polypeptide under conditions and for a time sufficient to allow the compound and polypeptide to interact. In a preferred embodiment, this method comprises the steps of:

(a) contacting cells and a compound to be screened in the presence of the WISP-1, WISP-2, or WISP-3 polypeptide under conditions suitable for the stimulation of cell proliferation by polypeptide; and

(b) measuring the proliferation of the cells to determine if the compound is an effective antagonist.

20 Further, a compound identified by this method is provided.

In another aspect, this invention provides a compound that inhibits the expression or activity of a WISP-1, WISP-2, or WISP-3 polypeptide.

25 In another embodiment, the invention provides a method for determining the presence of a WISP-1, WISP-2, or WISP-3 polypeptide comprising exposing a cell suspected of containing the WISP-1, WISP-2, or WISP-3 polypeptide to an anti-WISP-1, anti-WISP-2, or anti-WISP-3 antibody and determining binding of said antibody to said cell.

30 In another preferred embodiment, the invention provides a method of diagnosing a WISP-related disorder in a mammal comprising (a) contacting an anti-WISP-1, anti-WISP-2, or anti-WISP-3 antibody with a test sample of tissue cells obtained from the mammal, and (b) detecting the formation of a complex between the anti-WISP-1, anti-WISP-2, or anti-WISP-3 antibody and the WISP-1, WISP-2, or WISP-3 polypeptide in the test sample. Preferably, said test sample is obtained from an individual suspected to have neoplastic cell growth or proliferation. Also, preferably the antibody is labeled with a detectable label and/or is immobilized on a solid support.

#### BRIEF DESCRIPTION OF THE DRAWINGS

35 Figure 1 shows the derived amino acid sequence of a native-sequence mouse WISP-1 protein from amino acids 1 to 367 (SEQ ID NO:12) and the nucleotide sequence (and complementary sequence) encoding the protein (SEQ ID NOS:9 and 10, respectively). There is a 1104-bp coding region and 584 bp of 3' untranslated region. In the Figure, amino acids 1 through 22 form a putative signal sequence, amino acids 23 through 367 are the putative mature protein (SEQ ID NO:11), with amino acids 86 to 88, 143 to 145, 284

to 286, and 343 to 345 being potential glycosylation sites. Potential protein kinase C phosphorylation sites are at amino acids 43-45, 159-161, 235-237, 292-294, 295-297, and 345-347. Potential casein kinase II phosphorylation sites are at amino acids 44-47, 131-134, 145-148, and 358-361. Potential N-myristoylation sites are at amino acids 18-23, 72-77, 127-132, 149-154, 231-236, and 289-294. A potential amidation site is at amino acids 269-272. A potential prokaryotic membrane lipoprotein lipid attachment site is at amino acids 113-123. A potential von Willebrand C1 domain is at amino acids 130-146. A potential thrombospondin I domain is at amino acids 223-237. A potential CT module is at amino acids 301-312. A potential IGF binding protein consensus site is at amino acids 72-80.

Figure 2 shows the derived amino acid sequence of a native-sequence mouse WISP-2 protein from amino acids 1 to 251 (SEQ ID NO:20) and the nucleotide sequence (and complementary sequence) encoding the protein (SEQ ID NOS:17 and 18, respectively) from a clone 1367.3. There are 756 bp of coding nucleotides and 722 bp of 3' untranslated region. In the Figure, amino acids 1 through 23 form a putative signal sequence; amino acids 24 through 251 are the putative mature protein (SEQ ID NO:19). A potential N-glycosylation site is at amino acids 197-200. A potential glycosaminoglycan attachment site is at amino acids 85-88. Potential protein kinase C phosphorylation sites are at amino acids 85-87 and 112-114. Potential N-myristoylation sites are at amino acids 49-54, 81-86, 126-131, 210-215, and 245-250. A potential amidation site is at amino acids 103-106. A potential phospholipase A2 aspartic acid active site is at amino acids 120-130. A potential IGF binding protein consensus signature is at amino acids 49-64. A potential von Willebrand C1 domain is at amino acids 107-123. A potential thrombospondin I domain is at amino acids 202-216. A potential IGF binding protein consensus site is at amino acids 49-57.

Figures 3A and 3B show the derived amino acid sequence of a native-sequence human WISP-1 protein from amino acids 1 to 367 (SEQ ID NO:4) and the nucleotide sequence (and complementary sequence) encoding the protein (SEQ ID NOS:1 and 2, respectively). There are 1104 bp of coding region in this human clone 568.38, and 1638 bp of 3' untranslated region. In the Figure, amino acids 1 through 22 form a putative signal sequence, amino acids 23 through 367 are the putative mature protein (SEQ ID NO:3), with amino acids 85 to 87, 143 to 145, 284 to 286, and 343 to 345 being potential glycosylation sites. A potential cAMP- and cGMP-dependent protein kinase phosphorylation site is from amino acids 171 to 174; potential protein kinase C phosphorylation sites are at amino acids 43-45, 235-237, 292-294, and 345-347. Potential casein kinase II phosphorylation sites are at amino acids 30-33, 145-148, and 358-361. Potential N-myristoylation sites are at amino acids 72-77, 127-132, 149-154, 201-206, 231-236, 289-294, and 327-332. A potential amidation site is at amino acids 269-272. A potential prokaryotic membrane lipoprotein lipid attachment site is at amino acids 113-123. A potential von Willebrand C1 domain is at amino acids 130-146. A potential thrombospondin I domain is at amino acids 223-237. A potential CT (C-Terminal) module is at amino acids 301-312. A potential IGF binding protein consensus site is at amino acids 72-80.

Figure 4 shows the derived amino acid sequence of a native-sequence human WISP-2 protein from amino acids 1 to 250 (SEQ ID NO:16) and the nucleotide sequence (and complementary sequence) encoding the protein (SEQ ID NOS:13 and 14, respectively). The coding region is 753 bp and the 3' untranslated region is 519 bp. The putative signal sequence is from amino acid residues 1 through 23 and the putative mature region is from 24 through 250 (SEQ ID NO:15). The clone designated herein as "UNQ228" and/or

“DNA33473-seqmin” (SEQ ID NO:38) begins at nucleotide 13 of SEQ ID NO:13. Potential protein kinase C phosphorylation sites are at amino acids 4-6, 118-120, and 227-229. A potential casein kinase II phosphorylation site is at amino acids 98-101. A potential N-myristoylation site is at amino acids 3-8, 49-54, 81-86, 85-90, 126-131, 164-169, 166-171, 167-172, 183-188, and 209-214. A potential IGF binding protein consensus signature is at amino acids 49-64. A potential von Willebrand C1 domain is at amino acids 107-123. A potential thrombospondin 1 domain is at amino acids 201-215. A potential IGF binding protein consensus site is at amino acids 49-57.

Figure 5 shows a 841-bp consensus nucleotide sequence designated “DNA30843” (SEQ ID NO:39) derived from the nucleotide sequences of twenty different expressed sequence tags from Incyte. When aligned with the other sequences, DNA30843 has 3 gaps. It has 441 bp orf (+1). DNA30843 was used to design probes for isolation of human WISP-2.

Figures 6A and 6B show the derived amino acid sequence of a native-sequence human WISP-3 protein from amino acids 1 to 372 (SEQ ID NO:33) and the nucleotide sequence (and complementary sequence) encoding the protein (SEQ ID NOS:30 and 31, respectively). In the Figure, amino acids 1 through 33 form a putative signal sequence, amino acids 34 through 372 are the putative mature protein (SEQ ID NO:32), with amino acids 196 to 198 and 326 to 328 being potential glycosylation sites. Potential protein kinase C phosphorylation sites are at amino acids 209-211, 246-248, 277-279, 308-310, and 342-344. Potential casein kinase II phosphorylation sites are at amino acids 47-50, 254-257, and 293-296. Potential N-myristoylation sites are at amino acids 21-26, 89-94, 139-144, 166-171, 180-185, 185-190, 188-193, 242-247, and 302-307. A potential amidation site is at amino acids 188-191. Potential prokaryotic membrane lipoprotein lipid attachment sites are at amino acids 130-140 and 160-170. A potential IGF binding protein signature site is at amino acids 89-104. A potential IGF binding protein site (less stringent than prosite's) is at amino acids 89-97.

Figures 7A and 7B show the derived amino acid sequence of a native-sequence human WISP-3 protein from amino acids 1 to 355 (SEQ ID NO:37) and the nucleotide sequence (and complementary sequence) encoding the protein (SEQ ID NOS:34 and 35, respectively). This protein is believed to be a splice variant of the nucleotide sequence shown in Figure 6 with a shorter 5' end. In the Figure, amino acids 1 through 15 form a putative signal sequence, amino acids 16 through 355 are the putative mature protein (SEQ ID NO:36), with amino acids 178 to 180 and 308 to 310 being potential glycosylation sites. Potential protein kinase C phosphorylation sites are at amino acids 191-193, 228-230, 259-261, 290-292, and 324-326. Potential casein kinase II phosphorylation sites are at amino acids 29-32, 236-239, and 275-278. Potential N-myristoylation sites are at amino acids 3-8, 71-76, 121-126, 148-153, 162-167, 167-172, 170-175, 224-229, and 284-289. A potential amidation site is at amino acids 170-173. Potential prokaryotic membrane lipoprotein lipid attachment sites are at amino acids 112-122 and 142-152. A potential IGF binding protein signature site is at amino acids 71-87. A potential IGF binding protein site (less stringent than prosite's) is at amino acids 71-79.

Figure 8 shows an alignment of the full-length amino acid sequences of the human and mouse WISP-1 (SEQ ID NOS:4 and 12, respectively).

Figure 9 shows an alignment of the full-length amino acid sequences of the human and mouse WISP-2 (SEQ ID NOS:16 and 20, respectively).

Figure 10 shows an alignment of the amino acid sequences of the two clones of human WISP-3.

Figures 11A-11C show an alignment of the nucleotide sequences of human WISP-1 and the human WISP-3 shown in Fig. 6.

Figure 12 shows an alignment of the amino acid sequences of human WISP-1 and the human WISP-3 shown in Fig. 6.

Figure 13 shows a map of the vector pBabe puro (5.1 kb) used to transform cells for purposes of differential expression. The vector includes both unique restriction sites and multiple restriction sites. It is shown here in modified form for Wnt-1 cloning wherein the *Hind*III site after the SV40 promoter in the original pBabe puro vector has been removed and a *Hind*III site added to the multiple cloning site of the original pBabe puro vector. Wnt-1 is cloned from *Eco*RI-*Hind*III in the multiple cloning site. Constructs derived from this vector are selected in ampicillin (100 µg/ml) and the cells infected in culture are selected in 1.0-2.5 µg/ml puromycin.

Figure 14 shows the sequences of the PCR-Select™ cDNA synthesis primer (SEQ ID NO:40), adaptors 1 and 2 (SEQ ID NOS:41 and 42, respectively) and complementary sequences for the adaptors (SEQ ID NOS:43 and 44, respectively), PCR primer 1 (SEQ ID NO:45), PCR primer 2 (SEQ ID NO:46), nested PCR primer 1 (SEQ ID NO:47), nested PCR primer 2 (SEQ ID NO:48), control primer G3PDH 5' primer (SEQ ID NO:49), and control primer G3PDH 3' primer (SEQ ID NO:50) used for suppression subtractive hybridization for identifying WISP clones. When the adaptors are ligated to *Rsa*I-digested cDNA, the *Rsa*I site is restored.

Figure 15 shows the cloning site region of the plasmid pGEM-T used to clone all of the WISP sequences herein (SEQ ID NOS:51 and 52 for 5' and 3' sequences, respectively).

Figures 16A-16D show the sequence (SEQ ID NO:53) of a plasmid that is used to prepare an expression plasmid for expression of mouse WISP-1 in mammalian cells, the latter being designated pRK5.CMV.puro-dhfR.mWISP-1.6His.

Figures 17A-17D show the sequence (SEQ ID NO:54) of plasmid pb.PH.IgG, which is used to prepare an expression plasmid for expression of mouse WISP-1 DNA in baculovirus-infected insect cells.

Figures 18A-18D show the sequence (SEQ ID NO:55) of plasmid pbPH.His.c. which is used to prepare an expression plasmid for expression of mouse WISP-1 DNA in baculovirus-infected insect cells, the latter being designated pbPH.mu.568.8his.baculo.

Figures 19A-19D show graphs of the delta CT in nine colon cancer cell lines and DNA from the blood of ten normal human donors (Nor Hu) as control, for human TNF, human WISP-1, Lyra, and human Apo2 ligand, respectively, using the ABI Prism 7700™ Sequence Detection System procedure for testing genomic amplification.

Figures 20A-20D show graphs of the delta CT in nine colon cancer cell lines and Nor Hu as control, for human DCR1, huFAS, human WISP-2, and Apo3, respectively, using the ABI Prism 7700™ Sequence Detection System procedure for testing genomic amplification.

Figures 21A-21D show graphs of the delta CT in nine colon cancer cell lines and Nor Hu as control. for three different runs of human WISP-1 (designated in the figure as huWISP-1c, -1b, and -1a) and the average of these three runs of human WISP-1, respectively, using the ABI Prism 7700<sup>TM</sup> Sequence Detection System procedure for testing genomic amplification.

5 Figures 22A-22D show graphs of the delta CT in nine colon cancer cell lines and Nor Hu as control. for three different runs of human WISP-2 (designated in the figure as huWISP-2c, -2b, and -2a; Figs. 22A, C, and D, respectively) and the average of these three runs of human WISP-2 (Fig. 22B), using the ABI Prism 7700<sup>TM</sup> Sequence Detection System procedure for testing genomic amplification.

10 Figures 23A-23C show graphs of the delta CT in nine colon cancer cell lines and Nor Hu as control. for two different runs of human DR5 (DR5a and DR5b) and the average of these two runs of DR5, respectively, using the ABI Prism 7700<sup>TM</sup> Sequence Detection System procedure for testing genomic amplification.

15 Figures 24A-24D show graphs of the delta CT in nine colon cancer cell lines and Nor Hu as control, for four different runs of *c-myc* (*c-myc(a1), c-myc(b1), c-myc(b), and c-myc(a)*), respectively, using the ABI Prism 7700<sup>TM</sup> Sequence Detection System procedure for testing genomic amplification.

20 Figures 25A-25D show graphs of the delta CT in nine colon cancer cell lines and Nor Hu as control. for two different runs of human WISP-1 (designated in the figure as huWISP-1(a) and huWISP-1(b)) and for two different runs of human WISP-2 (designated in the figure as huWISP-2(a) and huWISP-2(b)), respectively, using the ABI Prism 7700<sup>TM</sup> Sequence Detection System procedure for testing genomic amplification.

Figure 26 shows the sequence (SEQ ID NO:23) of clone 568.13, a potential splice variant of human WISP-1 obtained by screening with a probe derived from clone 568.15A, which is the initial clone isolated from a human lung library in the process to obtain full-length human WISP-1 DNA.

25 Figure 27 shows the sequence (SEQ ID NO:24) of clone 568.1A, a potential human WISP-1 splice variant, 5' end only, obtained by screening with a probe derived from clone 568.15A.

Figure 28 shows the sequence (SEQ ID NO:25) of clone 568.39, a potential human WISP-1 splice variant, 5' end only, obtained by screening with a probe derived from clone 568.15A.

30 Figure 29 shows the sequence (SEQ ID NO:26) of clone 568.4A, a potential human WISP-1 splice variant obtained by screening with a probe derived from clone 568.15A.

Figure 30 shows the sequence (SEQ ID NO:27) of clone 568.5A, a potential human WISP-1 splice variant, 5' end only, obtained by screening with a probe derived from clone 568.15A.

35 Figure 31 shows the sequence (SEQ ID NO:28) of clone 568.6B, a potential human WISP-1 splice variant, 5' end only, obtained by screening with a probe derived from clone 568.15A.

Figure 32 shows the sequence (SEQ ID NO:29) of clone 568.7, a potential human WISP-1 splice variant, 5' end only, obtained by screening with a probe derived from clone 568.15A.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTSI. Definitions

5 The term "WISP polypeptide" refers to the family of native- sequence human and mouse WISP- proteins and variants described herein whose genes are induced at least by Wnt-1. This term includes WISP- 1, WISP-2, and WISP-3.

10 The terms "WISP-1 polypeptide", "WISP-1 homologue" and grammatical variants thereof, as used herein, encompass native- sequence WISP-1 protein and variants (which are further defined herein). The WISP-1 polypeptide may be isolated from a variety of sources, such as from human tissue types or from another source, or prepared by recombinant or synthetic methods, or by any combination of these and similar 15 techniques.

15 The terms "WISP-2 polypeptide", "WISP-2 homologue", "PRO261", and "PRO261 polypeptide" and grammatical variants thereof, as used herein, encompass native-sequence WISP-2 protein and variants (which are further defined herein). The WISP-2 polypeptide may be isolated from a variety of sources, such as from human tissue types or from another source, or prepared by recombinant or synthetic methods, or by any combination of these and similar 20 techniques.

20 The terms "WISP-3 polypeptide", "WISP-3 homologue", and grammatical variants thereof, as used herein, encompass native-sequence WISP-3 protein and variants (which are further defined herein). The WISP-3 polypeptide may be isolated from a variety of sources, such as from human tissue types or from another source, or prepared by recombinant or synthetic methods, or by any combination of these and similar 25 techniques.

25 A "native-sequence WISP-1 polypeptide" comprises a polypeptide having the same amino acid sequence as a WISP-1 polypeptide derived from nature. Such native-sequence WISP-1 polypeptides can be isolated from nature or can be produced by recombinant or synthetic means. The term "native-sequence WISP-1 polypeptide" specifically encompasses naturally occurring truncated or secreted forms of a WISP-1 polypeptide disclosed herein, naturally occurring variant forms (e.g., alternatively spliced forms or splice 30 variants), and naturally occurring allelic variants of a WISP-1 polypeptide. In one embodiment of the invention, the native-sequence WISP-1 polypeptide is a mature or full-length native-sequence human WISP-1 polypeptide comprising amino acids 23 to 267 of Figures 3A and 3B (SEQ ID NO:3) or amino acids 1 to 267 of Figures 3A and 3B (SEQ ID NO:4), respectively, with or without the N-terminal methionine.

30 In another embodiment of the invention, the native-sequence WISP-1 polypeptide is the full-length or mature native-sequence human WISP-1 polypeptide comprising amino acids 23 to 267 or 1 to 267 of Figures 3A and 3B wherein the valine residue at position 184 or the alanine residue at position 202 has/have been changed to an isoleucine or serine residue, respectively. (SEQ ID NOS:5-8) with or without the N-terminal methionine. In another embodiment of the invention, the native-sequence WISP-1 polypeptide is the full-length or mature native-sequence human WISP-1 polypeptide comprising amino acids 23 to 267 or 1 to 267 of Figures 3A and 3B wherein the valine residue at position 184 and the alanine residue at position 35 202 has/have been changed to an isoleucine or serine residue, respectively. (SEQ ID NOS:21 and 22, respectively) with or without the N-terminal methionine. In another embodiment of the invention, the native- sequence WISP-1 polypeptide is a mature or full-length native-sequence mouse WISP-1 polypeptide

comprising amino acids 23 to 367 of Figure 1 (SEQ ID NO:11), or amino acids 1 to 367 of Figure 1 (SEQ ID NO:12), respectively, with or without the N-terminal methionine.

5 In another embodiment of the invention, the native-sequence WISP-1 polypeptide is one which is encoded by a nucleotide sequence comprising one of the human WISP-1 splice or other native-sequence variants, including SEQ ID NOS:23, 24, 25, 26, 27, 28, or 29, with or without an N-terminal methionine.

A "native-sequence WISP-2 polypeptide" or a "native-sequence PRO261 polypeptide" comprises a polypeptide having the same amino acid sequence as a WISP-2 polypeptide derived from nature. Such native-sequence WISP-2 polypeptides can be isolated from nature or can be produced by recombinant or synthetic means. The term "native-sequence WISP-2 polypeptide" specifically encompasses naturally occurring truncated or secreted forms of a WISP-2 polypeptide disclosed herein, naturally occurring variant forms (e.g., alternatively spliced forms or splice variants), and naturally occurring allelic variants of a WISP-2 polypeptide. In one embodiment of the invention, the native-sequence WISP-2 polypeptide is a mature or full-length native-sequence human WISP-2 polypeptide comprising amino acids 1-24 up to 250 of Figure 4 (SEQ ID NOS:15, 16, and 56-77), including amino acids 24 to 250 and amino acids 1 to 250 of Figure 4 (SEQ ID NOS:15 and 16, respectively), with or without the N-terminal methionine. In another embodiment of the invention, the native-sequence WISP-2 polypeptide is a mature or full-length native-sequence mouse WISP-2 polypeptide comprising amino acids 1-24 up to 251 of Figure 2 (SEQ ID NOS:19, 20, and 78-99), including amino acids 24 to 251 and amino acids 1 to 251 of Figure 2 (SEQ ID NOS:19 and 20, respectively), with or without the N-terminal methionine.

20 A "native-sequence WISP-3 polypeptide" comprises a polypeptide having the same amino acid sequence as a WISP-3 polypeptide derived from nature. Such native-sequence WISP-3 polypeptides can be isolated from nature or can be produced by recombinant or synthetic means. The term "native-sequence WISP-3 polypeptide" specifically encompasses naturally occurring truncated or other forms of a WISP-3 polypeptide disclosed herein, naturally occurring variant forms (e.g., alternatively spliced forms or splice variants), and naturally occurring allelic variants of a WISP-3 polypeptide. In one embodiment of the invention, the native-sequence WISP-3 polypeptide is a mature or full-length native-sequence human WISP-3 polypeptide comprising amino acids 34 to 372 of Figures 6A and 6B (SEQ ID NO:32) or amino acids 1 to 372 of Figures 6A and 6B (SEQ ID NO:33), respectively, with or without the N-terminal methionine. In another embodiment of the invention, the native-sequence WISP-3 polypeptide is a mature or full-length native-sequence human WISP-3 polypeptide comprising amino acids 16 to 355 of Figures 7A and 7B (SEQ ID NO:36) or amino acids 1 to 355 of Figures 7A and 7B (SEQ ID NO:37), respectively, with or without the N-terminal methionine.

25 The term "WISP-1 variant" means an active WISP-1 polypeptide as defined below having at least about 80%, preferably at least about 85%, more preferably at least about 90%, most preferably at least about 95% amino acid sequence identity with human mature WISP-1 having the deduced amino acid sequence shown in Figs. 3A and 3B (SEQ ID NO:3), and/or with human full-length WISP-1 having the deduced amino acid sequence shown in Figs. 3A and 3B (SEQ ID NO:4), and/or with mouse mature WISP-1 having the deduced amino acid sequence shown in Fig. 1 (SEQ ID NO:11), and/or with mouse full-length WISP-2 having the deduced amino acid sequence shown in Fig. 1 (SEQ ID NO:12). Such variants include, for

instance. WISP-1 polypeptides wherein one or more amino acid residues are added to, or deleted from, the N- or C-terminus of the full-length or mature sequences of Figures 3A-3B and 1 (SEQ ID NOS:4, 3, 12, and 11, respectively), including variants from other species, but excludes a native-sequence WISP-1 polypeptide.

5 The term "WISP-2 variant" or "PRO261 variant" means an active WISP-2 polypeptide as defined below having at least about 80%, preferably at least about 85%, more preferably at least about 90%, most preferably at least about 95% amino acid sequence identity with human mature WISP-2 having the putative deduced amino acid sequence shown in Fig. 4 (SEQ ID NO:15), and/or with human full-length WISP-2 having the deduced amino acid sequence shown in Fig. 4 (SEQ ID NO:16), and/or with mouse mature WISP-2 having the putative deduced amino acid sequence shown in Fig. 2 (SEQ ID NO:19), and/or with mouse full-length WISP-2 having the deduced amino acid sequence shown in Fig. 2 (SEQ ID NO:20). Such variants include, for instance, WISP-2 polypeptides wherein one or more amino acid residues are added to, or deleted from, the N- or C-terminus of the full-length and putative mature sequences of Figures 4 and 2 (SEQ ID NOS:16, 15, 20, and 19, respectively), including variants from other species, but excludes a native-sequence WISP-2 polypeptide.

10 15 The term "WISP-3 variant" means an active WISP-3 polypeptide as defined below having at least about 80%, preferably at least about 85%, more preferably at least about 90%, most preferably at least about 95% amino acid sequence identity with human mature WISP-3 having the deduced amino acid sequence shown in Figs. 6A and 6B (SEQ ID NO:32), and/or with human full-length WISP-3 having the deduced amino acid sequence shown in Figs. 6A and 6B (SEQ ID NO:33), and/or with human mature WISP-3 having the deduced amino acid sequence shown in Figs. 7A and 7B (SEQ ID NO:36), or with human full-length WISP-3 having the deduced amino acid sequence shown in Figs. 7A and 7B (SEQ ID NO:37). Such variants include, for instance, WISP-3 polypeptides wherein one or more amino acid residues are added to, or deleted from, the N- or C-terminus of the full-length or mature sequences of Figures 6A-6B and 7A-7B (SEQ ID NOS:32, 33, 36, and 37, respectively), including variants from other species, but excludes a native-sequence WISP-3 polypeptide.

20 25 30 "Percent (%) amino acid sequence identity" with respect to the WISP sequences identified herein is defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in a WISP polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, ALIGN, or Megalign (DNASTAR<sup>TM</sup>) software. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared.

35 "Percent (%) nucleic acid sequence identity" with respect to the coding region of the WISP sequences identified herein, including UNQ228 (DNA34387-seq min) sequence, and the coding region therein, is defined as the percentage of nucleotides in a candidate sequence that are identical with the nucleotides in the coding region of the WISP sequence of interest, e.g., in the UNQ228 (DNA34387-seq min) sequence (SEQ ID NO:38) or coding region therein (SEQ ID NO:16), after aligning the sequences and

introducing gaps, if necessary, to achieve the maximum percent sequence identity. Alignment for purposes of determining percent nucleic acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, ALIGN, or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared.

5 "Stringent conditions" are those that (1) employ low ionic strength and high temperature for washing, for example, 0.015 M sodium chloride/0.0015 M sodium citrate/0.1% sodium dodecyl sulfate at 50°C; (2) employ during hybridization a denaturing agent, such as formamide, for example, 50% (vol/vol) 10 formamide with 0.1% bovine serum albumin/0.1% Ficoll/0.1% polyvinylpyrrolidone/50 mM sodium phosphate buffer at pH 6.5 with 750 mM sodium chloride, 75 mM sodium citrate at 42°C; (3) employ 50% formamide, 5 x SSC (0.75 M NaCl, 0.075 M sodium citrate), 50 mM sodium phosphate (pH 6.8), 0.1% sodium pyrophosphate, 5 x Denhardt's solution, sonicated salmon sperm DNA (50 µg/ml), 0.1% SDS, and 15 10% dextran sulfate at 42°C, with washes at 42°C in 0.2 x SSC and 0.1% SDS; or (4) employ a buffer of 10% dextran sulfate, 2 x SSC (sodium chloride/sodium citrate), and 50% formamide at 55°C, followed by a high-stringency wash consisting of 0.1 x SSC containing EDTA at 55°C.

15 "Moderately stringent conditions" are described in Sambrook *et al.*, Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989), and include the use of a washing solution and hybridization conditions (e.g., temperature, ionic strength, and percent SDS) less stringent than described above. An example of moderately stringent conditions is a condition such as 20 overnight incubation at 37°C in a solution comprising: 20% formamide, 5 x SSC (150 mM NaCl, 15 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5 x Denhardt's solution, 10% dextran sulfate, and 20 25 20 mg/mL denatured sheared salmon sperm DNA, followed by washing the filters in 1 x SSC at about 37-50°C. The skilled artisan will recognize how to adjust the temperature, ionic strength, *etc.*, as necessary to accommodate factors such as probe length and the like.

25 "Isolated," when used to describe the various polypeptides disclosed herein, means polypeptide that has been identified and separated and/or recovered from a component of its natural environment. Contaminant components of its natural environment are materials that would typically interfere with diagnostic or therapeutic uses for the polypeptide, and may include enzymes, hormones, and other 30 proteinaceous or non-proteinaceous solutes. In preferred embodiments, the polypeptide will be purified (1) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence by use of a spinning cup sequenator, or (2) to homogeneity by SDS-PAGE under non-reducing or reducing conditions using Coomassie blue or, preferably, silver stain. Isolated polypeptide includes polypeptide *in situ* within recombinant cells, since at least one component of the WISP natural environment will not be present. 35 Ordinarily, however, isolated polypeptide will be prepared by at least one purification step.

35 An "isolated" nucleic acid encoding a WISP polypeptide or "isolated" DNA33473 or "isolated" PRO261 polypeptide-encoding nucleic acid molecule is a nucleic acid molecule that is identified and separated from at least one contaminant nucleic acid molecule with which it is ordinarily associated in the natural source of the respective nucleic acid. Isolated DNA33473 or an isolated WISP-encoding nucleic acid

5 molecule is other than in the form or setting in which it is found in nature. An isolated WISP-encoding or DNA33473 nucleic acid molecule therefore is distinguished from the WISP-encoding or DNA33473 nucleic acid molecule, respectively, as it exists in natural cells. However, an isolated WISP-encoding or DNA33473 nucleic acid molecule includes a nucleic acid molecule contained in cells that ordinarily express WISP-encoding DNA or DNA33473, respectively, where, for example, the nucleic acid molecule is in a chromosomal location different from that of natural cells.

10 The term "control sequences" refers to DNA sequences necessary for the expression of an operably linked coding sequence in a particular host organism. The control sequences that are suitable for prokaryotes, for example, include a promoter, optionally an operator sequence, and a ribosome binding site. Eukaryotic cells are known to utilize promoters, polyadenylation signals, and enhancers.

15 Nucleic acid is "operably linked" when it is placed into a functional relationship with another nucleic acid sequence. For example, DNA for a presequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation. Generally, "operably linked" means that the DNA sequences being linked are contiguous, and, in the case of a secretory leader, contiguous and in reading phase. However, enhancers do not have to be contiguous. Linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, the synthetic oligonucleotide adaptors or linkers are used in accordance with conventional practice.

20 The term "antibody" is used in the broadest sense and specifically covers single anti-WISP polypeptide, such as anti-PRO261, monoclonal antibodies (including agonist, antagonist, and neutralizing antibodies), and anti-WISP polypeptide, such as anti-PRO261, and antibody compositions with polyepitopic specificity. The term "monoclonal antibody" as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, *i.e.*, the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts.

25 "Active" or "activity" or "WISP biological activity", for purposes herein, describes form(s) of a WISP polypeptide, such as PRO261, including its variants, or its antagonists, which retain the biologic and/or immunologic activities of a native or naturally occurring (native-sequence) WISP polypeptide, such as PRO261, or its antagonist. Preferred "activities" for a WISP polypeptide or its antagonist include the ability to inhibit proliferation of tumor cells or to stimulate proliferation of normal cells and to treat arteriosclerosis, including atherosclerosis, as well as to induce wound repair and hematopoiesis, prevent desmoplasia, prevent fibrotic lesions associated with skin disorders such as scleroderma, keloid, eosinophilic fasciitis, nodular fasciitis, and Dupuytren's contracture, to treat bone-related diseases such as osteoporosis, to regulate anabolism including promotion of growth, to treat immune disorders, to treat Wilms' tumor and kidney-related disorders, to treat testis-related disorders, to treat lung-related disorders, and to treat cardiac disorders.

30 35 An "antagonist" of a WISP polypeptide is a molecule that inhibits an activity of a WISP polypeptide. Preferred antagonists are those which interfere with or block an undesirable biological activity of a WISP polypeptide, such as where a WISP polypeptide might act to stimulate cancer cells and the antagonist would serve to inhibit the growth of those cells. In some cases, such as with WISP-1, WISP-2, and WISP-3, the

antagonist may be useful to inhibit the binding of a WISP polypeptide to an IGF. Such molecules include antibodies and small molecules that have such inhibitory capability, as well as WISP polypeptide variants of, and receptors for, WISP polypeptide (if available) or portions thereof that bind to WISP. For example, antagonists can be derived from receptors of WISP-1, WISP-2, and WISP-3 using the predicted family of receptors for WISPs-1, -2, and -3 (the CTGF receptors). Thus, the receptor can be expression cloned from the family; then a soluble form of the receptor is made by identifying the extracellular domain and excising the transmembrane domain therefrom. The soluble form of the receptor can then be used as an antagonist, or the receptor can be used to screen for small molecules that would antagonize WISP polypeptide activity.

5 Alternatively, using the murine sequences shown in Figures 1 and 2 (SEQ ID NOS:11, 12, 19, and 10 20, respectively) or the human sequences shown in Figures 3A-3B, 4, (SEQ ID NOS: 3, 4, 15, and 16, respectively), 6A-6B, and 7A-7B, variants of native WISP-1, WISP-2, or WISP-3, are made that act as antagonists. Using knowledge from the CTGF receptor family, the receptor binding sites of WISP-1, WISP-2, and WISP-3 polypeptides can be determined by binding studies and one of them eliminated by standard techniques (deletion or radical substitution) so that the molecule acts as an antagonist.

15 Antagonist activity can be determined by several means, including standard assays for induction of cell death such as that described herein, e.g., <sup>3</sup>H-thymidine proliferation assays, or other mitogenic assays, such as an assay measuring the capability of the candidate antagonist of inducing EGF-potentiated anchorage independent growth of target cell lines (Volckaert *et al.*, *Gene*, 15:215-223 (1981)) and/or growth inhibition of neoplastic cell lines. Roberts *et al.*, *Proc. Natl. Acad. Sci. U.S.A.*, 82:119-123 (1985). Anchorage- 20 independent growth refers to the ability of WISP polypeptide-treated, or TGF- $\beta$ -treated and EGF-treated non-neoplastic target cells to form colonies in soft agar, a characteristic ascribed to transformation of the cells. In this assay, the candidate is incubated together with an equimolar amount of a WISP polypeptide otherwise detectable in the EGF-potentiated anchorage-independent target cell growth assay, and the culture observed for failure to induce anchorage-independent growth. In addition, an antagonist may be an IGF such as IGF-I 25 or a peptide mimic of IGF-I or a receptor to IGF or a receptor to an IGFBP.

"Treatment" refers to both therapeutic treatment and prophylactic or preventative measures. Those in need of treatment include those already with the disorder or condition as well as those in which the disorder or condition is to be prevented.

30 "Mammal" for purposes of treatment refers to any animal classified as a mammal, including humans, domestic, and farm animals, and zoo, sports, or pet animals, such as dogs, horses, cats, sheep, pigs, etc. Preferably, the mammal is human.

35 A "disorder" or "WISP-related disorder" is any condition that would benefit from treatment with the WISP polypeptides or WISP antagonists herein. This includes chronic and acute disorders, as well as those pathological conditions which predispose the mammal to the disorder in question. Non-limiting examples of disorders to be treated herein include benign and malignant tumors; leukemias and lymphoid malignancies; neuronal, glial, astrocytal, hypothalamic and other glandular, macrophagal, epithelial, stromal, and blastocoelic disorders; hematopoiesis-related disorders; tissue-growth disorders; skin disorders; desmoplasia; fibrotic lesions; kidney disorders; bone-related disorders; trauma such as burns, incisions, and other wounds; catabolic states; testicular-related disorders; and inflammatory, angiogenic, and immunologic disorders.

including arteriosclerosis. A "Wnt-related disorder" is one caused at least by the upregulation of the Wnt gene pathway, including Wnt-1 and Wnt-4, but preferably Wnt-1, and may include cancer.

The terms "cancer", "cancerous", and "malignant" refer to or describe the physiological condition in mammals that is typically characterized by unregulated cell growth. Examples of cancer include but are not limited to, carcinoma including adenocarcinoma, lymphoma, blastoma, melanoma, sarcoma, and leukemia. More particular examples of such cancers include squamous cell cancer, small-cell lung cancer, non-small cell lung cancer, gastrointestinal cancer, Hodgkin's and non-Hodgkin's lymphoma, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer such as hepatic carcinoma and hepatoma, bladder cancer, breast cancer, colon cancer, colorectal cancer, endometrial carcinoma, salivary gland carcinoma, kidney cancer such as renal cell carcinoma and Wilms' tumors, basal cell carcinoma, melanoma, prostate cancer, vulval cancer, thyroid cancer, testicular cancer, esophageal cancer, and various types of head and neck cancer. The preferred cancers for treatment herein are breast, colon, lung, and melanoma.

10 The term "cytotoxic agent" as used herein refers to a substance that inhibits or prevents the function of cells and/or causes destruction of cells. The term is intended to include radioactive isotopes (e.g., <sup>131</sup>I, <sup>125</sup>I, <sup>90</sup>Y, and <sup>186</sup>Re), chemotherapeutic agents, and toxins such as enzymatically active toxins of bacterial, 15 fungal, plant, or animal origin, or fragments thereof.

20 A "chemotherapeutic agent" is a chemical compound useful in the treatment of cancer. Examples of chemotherapeutic agents include Adriamycin, Doxorubicin, 5-Fluorouracil, Cytosine arabinoside ("Ara-C"), Cyclophosphamide, Thiotapec, Busulfan, Cytoxin, Taxol, Taxotere, Methotrexate, Cisplatin, Melphalan, Vinblastine, Bleomycin, Etoposide, Ifosfamide, Mitomycin C, Mitoxantrone, Vinorelbine, 25 Carboplatin, Teniposide, Daunomycin, Carminomycin, Aminopterin, Dactinomycin, Mitomycins, Esperamicins (see U.S. Pat. No. 4,675,187), Melphalan, and other related nitrogen mustards. Also included in this definition are hormonal agents that act to regulate or inhibit hormone action on tumors, such as tamoxifen and onapristone.

25 A "growth-inhibitory agent" when used herein refers to a compound or composition which inhibits growth of a cell, such as an Wnt-overexpressing cancer cell, either *in vitro* or *in vivo*. Thus, the growth-inhibitory agent is one which significantly reduces the percentage of malignant cells in S phase. Examples of growth-inhibitory agents include agents that block cell cycle progression (at a place other than S phase), such as agents that induce G1 arrest and M-phase arrest. Classical M-phase blockers include the vincas (vincristine and vinblastine), taxol, and topo II inhibitors such as doxorubicin, daunorubicin, etoposide, and bleomycin. Those agents that arrest G1 also spill over into S-phase arrest, for example, DNA alkylating agents such as tamoxifen, prednisone, dacarbazine, mechlorethamine, cisplatin, methotrexate, 5-fluorouracil, and ara-C. Further information can be found in The Molecular Basis of Cancer, Mendelsohn and Israel, eds., 30 Chapter 1, entitled "Cell cycle regulation, oncogenes, and antineoplastic drugs" by Murakami *et al.* (WB Saunders: Philadelphia, 1995), especially p. 13. The 4D5 antibody (and functional equivalents thereof) can also be employed for this purpose if the cancer involves ErbB2-overexpressing cancer cells. See, e.g., WO 35 92/22653.

"Northern analysis" or "Northern blot" is a method used to identify RNA sequences that hybridize to a known probe such as an oligonucleotide, DNA fragment, cDNA or fragment thereof, or RNA fragment.

The probe is labeled with a radioisotope such as  $^{32}\text{P}$ , or by biotinylation, or with an enzyme. The RNA to be analyzed is usually electrophoretically separated on an agarose or polyacrylamide gel, transferred to nitrocellulose, nylon, or other suitable membrane, and hybridized with the probe, using standard techniques well known in the art such as those described in sections 7.39-7.52 of Sambrook et al., *supra*.

5 The technique of "polymerase chain reaction," or "PCR," as used herein generally refers to a procedure wherein minute amounts of a specific piece of nucleic acid, RNA and/or DNA, are amplified as described in U.S. Pat. No. 4,683,195 issued 28 July 1987. Generally, sequence information from the ends of the region of interest or beyond needs to be available, such that oligonucleotide primers can be designed; these primers will be identical or similar in sequence to opposite strands of the template to be amplified. The 10 5' terminal nucleotides of the two primers may coincide with the ends of the amplified material. PCR can be used to amplify specific RNA sequences, specific DNA sequences from total genomic DNA, and cDNA transcribed from total cellular RNA, bacteriophage, or plasmid sequences, etc. See generally Mullis et al., *Cold Spring Harbor Symp. Quant. Biol.*, 51: 263 (1987); Erlich, ed., *PCR Technology*, (Stockton Press, NY, 1989). As used herein, PCR is considered to be one, but not the only, example of a nucleic acid polymerase 15 reaction method for amplifying a nucleic acid test sample comprising the use of a known nucleic acid as a primer and a nucleic acid polymerase to amplify or generate a specific piece of nucleic acid.

## II. Compositions and Methods of the Invention

### A. Full-length WISP Polypeptide

20 The present invention provides newly-identified and isolated nucleotide sequences encoding a polypeptide referred to in the present application as a WISP polypeptide, including a WISP-1, WISP-2, or WISP-3 polypeptide. In particular, cDNAs have been identified and isolated encoding novel murine and human WISP-1 and WISP-2, and human WISP-3 splice variants as disclosed in further detail in the Examples below.

25 Using BLAST and FastA sequence alignment computer programs, it was found that the coding sequences of mouse and human WISP-1 and -2, as well as the two coding sequences of human WISP-3 disclosed herein, show significant homology to DNA sequences disclosed in the GenBank database, including those published by Adams et al., *Nature*, 377: 3-174 (1995).

30 Further, using BLAST and FastA sequence alignment computer programs, it was found that various portions of the coding sequences of mouse and human WISP-1 and WISP-2 show significant homology to CTGF, cef-10, Cyr61, and/or Nov protein. In this regard, mouse WISP-1 is 47% homologous to mouse CTGF and 46% homologous to human CTGF, mouse WISP-2 is 46% homologous to chick cef-10 protein precursor and 42% homologous to human Cyr61 protein, human WISP-1 is 47% homologous to mouse CTGF and 48% homologous to human CTGF, and human WISP-2 is 48% homologous to mouse CTGF, 49% homologous to human CTGF precursor, 46% homologous to mouse Nov protein homolog precursor, 49% homologous to human CTGF, and 48% homologous to mouse CTGF precursor. Further, apparently the amino acid sequences of mouse WISP-1 and mouse ELM1 (Hashimoto et al., *supra*) are identical, and the amino acid sequences of human WISP-1 and mouse ELM1 are 84% identical.

35 Since these factors have also been correlated with IGFBPs, it is presently believed that the WISP-1 and WISP-2 polypeptides disclosed in the present application are newly identified members of the CTGF or

IGFBP family and possess activity relating to development of normal, injured, and cancerous cells and tissue. More specifically, WISP-1 and WISP-2 may be involved in breast cancer, lung cancer, melanoma, and colon cancer, as well as in wound repair. Further, they may be involved in atherosclerosis.

Further, using BLAST and FastA sequence alignment computer programs, it was found that various portions of the coding sequences of the two splice variants of human WISP-3 show significant homology to mouse ELM1 and CTGF proteins. In this regard, both splice variants of WISP-3 are 45% homologous to mouse ELM1 and 42% homologous to mouse and human CTGF and its precursor, with the longer variant of Fig. 6 being 43% homologous to *Xenopus* CTGF and the shorter variant of Fig. 7 being 42% homologous to *Xenopus* CTGF.

10                   B. WISP Polypeptide Variants

In addition to the full-length native-sequence WISP polypeptides described herein, it is contemplated that variants of these sequences can be prepared. WISP variants can be prepared by introducing appropriate nucleotide changes into the WISP-encoding DNA, or by synthesis of the desired variant WISP polypeptides. Those skilled in the art will appreciate that amino acid changes may alter post-translational processes of the WISP polypeptide, such as changing the number or position of glycosylation sites or altering the membrane-anchoring characteristics, if the native WISP polypeptide is membrane bound.

Variations in the native full-length WISP sequences, or in various domains of the WISP polypeptides described herein, can be made, for example, using any of the techniques and guidelines for conservative and non-conservative mutations set forth, for instance, in U.S. Patent No. 5,364,934. Variations may be a substitution, deletion, or insertion of one or more codons encoding the WISP polypeptide that results in a change in the amino acid sequence as compared with the native-sequence WISP polypeptide. Optionally the variation is by substitution of at least one amino acid with any other amino acid in any portion of the WISP polypeptide. Guidance in determining which amino acid residue may be inserted, substituted, or deleted without adversely affecting the desired activity may be found by comparing the sequence of the WISP polypeptide with that of homologous known CTGF protein molecules, in the case of WISP-1, WISP-2, and WISP-3, and minimizing the number of amino acid sequence changes made in regions of high homology. Amino acid substitutions can be the result of replacing one amino acid with another amino acid having similar structural and/or chemical properties, such as the replacement of a leucine with a serine, *i.e.*, conservative amino acid replacements. Insertions or deletions may optionally be in the range of 1 to about 5 amino acids. The variation allowed may be determined by systematically making insertions, deletions, or substitutions of amino acids in the sequence and testing the resulting variants for activity in *in vitro* assays for gene upregulation or downregulation and in transgenic or knockout animals.

The variations can be made on the cloned DNA to produce the WISP DNA or WISP polypeptide variant DNA using methods known in the art such as oligonucleotide-mediated (site-directed) mutagenesis (Carter *et al.*, Nucl. Acids Res., 13:4331 (1986); Zoller *et al.*, Nucl. Acids Res., 10:6487 (1987)), cassette mutagenesis (Wells *et al.*, Gene, 34:315 (1985)), alanine scanning, PCR mutagenesis, restriction selection mutagenesis (Wells *et al.*, Philos. Trans. R. Soc. London SerA, 317:415 (1986)), or other known techniques.

Scanning amino acid analysis can also be employed to identify one or more amino acids along a contiguous sequence. Among the preferred scanning amino acids are relatively small, neutral amino acids.

Such amino acids include alanine, glycine, serine, and cysteine. Alanine is typically a preferred scanning amino acid among this group because it eliminates the side-chain beyond the beta-carbon and is less likely to alter the main-chain conformation of the variant. Alanine is also typically preferred because it is the most common amino acid. Further, it is frequently found in both buried and exposed positions. T.E. Creighton, Proteins: Structure and Molecular Properties (W.H. Freeman & Co., San Francisco, 1983); Chothia, J. Mol. Biol., 150:1 (1976). If alanine substitution does not yield adequate amounts of variant, an isoteric amino acid can be used.

Further deletional variants of the full-length WISP polypeptide include variants from which the N-terminal signal peptide, if any (such as, for example, those putatively identified as amino acids 1 to 22 for WISP-1, 1 to 23 for WISP-2, 1-33 for the WISP-3 of Fig. 6 and 1-15 for the WISP-3 of Fig. 7), and/or the initiating methionine has been deleted.

### C. Modifications of the WISP Polypeptide

Covalent modifications of the WISP polypeptides are included within the scope of this invention. One type of covalent modification includes reacting targeted amino acid residues of a WISP polypeptide with an organic derivatizing agent that is capable of reacting with selected side chains or the N- or C-terminal residues. Derivatization with bifunctional agents is useful, for instance, for crosslinking a WISP polypeptide to a water-insoluble support matrix or surface for use in the method for purifying anti-WISP antibodies, and vice-versa. Commonly used crosslinking agents include, e.g., 1,1-bis(diazoacetyl)-2-phenylethane, glutaraldehyde, N-hydroxysuccinimide esters, for example, esters with 4-azidosalicylic acid, homobifunctional imidoesters, including disuccinimidylesters such as 3,3'-dithiobis(succinimidylpropionate), bifunctional maleimides such as bis-N-maleimido-1,8-octane and agents such as methyl-3-((p-azidophenyl)-dithio)propioimide.

Other modifications include deamidation of glutaminyl and asparaginyl residues to the corresponding glutamyl and aspartyl residues, respectively, hydroxylation of proline and lysine, phosphorylation of hydroxyl groups of seryl or threonyl residues, methylation of the  $\alpha$ -amino groups of lysine, arginine, and histidine side chains (Creighton, *supra*, pp. 79-86), acetylation of the N-terminal amine, and amidation of any C-terminal carboxyl group. Another type of covalent modification of the WISP polypeptide included within the scope of this invention comprises altering the native glycosylation pattern of the polypeptide. "Altering the native glycosylation pattern" is intended for purposes herein to mean deleting one or more carbohydrate moieties found in the native sequence (either by deleting the underlying glycosylation site or by removing the glycosylation moieties by chemical and/or enzymatic means) and/or adding one or more glycosylation sites that are not present in the native sequence. In addition, the phrase includes qualitative changes in the glycosylation of the native proteins, involving a change in the nature and proportion of the various sugar residues present.

Addition of glycosylation sites to the WISP polypeptide herein may be accomplished by altering the amino acid sequence. The alteration may be made, for example, by the addition of, or substitution by, one or more serine or threonine residues to the native sequence (for O-linked glycosylation sites). The amino acid sequence may optionally be altered through changes at the DNA level, particularly by mutating the DNA

encoding the WISP polypeptide at preselected bases such that codons are generated that will translate into the desired amino acids. The DNA mutation(s) may be made using methods described above.

Another means of increasing the number of carbohydrate moieties on the WISP polypeptide is by chemical or enzymatic coupling of glycosides to the polypeptide. Such methods are described in the art, e.g., 5 in WO 87/05330 published 11 September 1987, and in Aplin and Wriston, CRC Crit. Rev. Biochem., pp. 259-306 (1981).

Removal of carbohydrate moieties present on the WISP polypeptide may be accomplished chemically or enzymatically or by mutational substitution of codons encoding amino acid residues that serve as targets for glycosylation. Chemical deglycosylation techniques are known in the art and described, for 10 instance, by Hakimuddin, *et al.*, Arch. Biochem. Biophys., 259:52 (1987) and by Edge *et al.*, Anal. Biochem., 118:131 (1981). Enzymatic cleavage of carbohydrate moieties on polypeptides can be achieved by the use 15 of a variety of endo- and exo-glycosidases described by Thotakura *et al.*, Meth. Enzymol., 138:350 (1987).

Another type of covalent modification comprises linking the WISP polypeptide to one of a variety of nonproteinaceous polymers, e.g., polyethylene glycol, polypropylene glycol, or polyoxyalkylenes, in the manner set forth, e.g., in U.S. Patent Nos. 4,640,835; 4,496,689; 4,301,144; 4,670,417; 4,791,192 or 4,179,337.

The WISP polypeptide of the present invention may also be modified in a way to form a chimeric molecule comprising a WISP polypeptide, or a fragment thereof, fused to a heterologous polypeptide or amino acid sequence. In one embodiment, such a chimeric molecule comprises a fusion of the WISP 20 polypeptide with a tag polypeptide which provides an epitope to which an anti-tag antibody can selectively bind. The epitope tag is generally placed at the amino- or carboxyl-terminus of a native or variant WISP molecule. The presence of such epitope-tagged forms can be detected using an antibody against the tag polypeptide. Also, provision of the epitope tag enables the WISP polypeptides to be readily purified by 25 affinity purification using an anti-tag antibody or another type of affinity matrix that binds to the epitope tag. In an alternative embodiment, the chimeric molecule may comprise a fusion of the WISP polypeptides, or fragments thereof, with an immunoglobulin or a particular region of an immunoglobulin. For a bivalent form 30 of the chimeric molecule, such a fusion could be to the Fc region of an Ig, such as an IgG molecule.

Various tag polypeptides and their respective antibodies are well known in the art. Examples include 35 poly-histidine (poly-His) or poly-histidine-glycine (poly-His-Gly) tags; the flu HA tag polypeptide and its antibody 12CA5 (Field *et al.*, Mol. Cell. Biol., 8:2159-2165 (1988)); the c-myc tag and the 8F9, 3C7, 6E10, G4, B7, and 9E10 antibodies thereto (Evan *et al.*, Molecular and Cellular Biology, 5:3610-3616 (1985)); and the Herpes Simplex virus glycoprotein D (gD) tag and its antibody. Paborsky *et al.*, Protein Engineering, 3(6):547-553 (1990). Other tag polypeptides include the Flag-peptide (Hopp *et al.*, BioTechnology, 6:1204-3(6):547-553 (1990). Other tag polypeptides include the Flag-peptide (Hopp *et al.*, BioTechnology, 6:1204-1210 (1988)); the KT3 epitope peptide (Martin *et al.*, Science, 255:192-194 (1992)); an  $\alpha$ -tubulin epitope 40 peptide (Skinner *et al.*, J. Biol. Chem., 266:15163-15166 (1991)); and the T7 gene 10 protein peptide tag. Lutz-Freyermuth *et al.*, Proc. Natl. Acad. Sci. USA, 87:6393-6397 (1990).

#### D. Preparation of WISP Polypeptide

The description below relates primarily to production of WISP polypeptides by culturing cells transformed or transfected with a vector containing at least DNA encoding the mature or full-length sequences

of human or mouse WISP-1 (SEQ ID NOS:3, 4, 11, or 12, respectively), or containing at least DNA encoding the mature or full-length sequences of human or mouse WISP-2 (SEQ ID NOS:15, 16, 19, or 20, respectively), or containing at least DNA encoding the mature or full-length sequences of human WISP-3 of Fig. 6 (SEQ ID NOS:32 or 33, respectively), or containing at least DNA encoding the mature or full-length sequences of human WISP-3 of Fig. 7 (SEQ ID NOS:36 or 37, respectively).

It is, of course, contemplated that alternative methods, which are well known in the art, may be employed to prepare WISP polypeptides. For instance, the WISP polypeptide sequence, or portions thereof, may be produced by direct peptide synthesis using solid-phase techniques. See, e.g., Stewart *et al.*, Solid-Phase Peptide Synthesis (W.H. Freeman Co.: San Francisco, CA, 1969); Merrifield, J. Am. Chem. Soc., 85:2149-2154 (1963). *In vitro* protein synthesis may be performed using manual techniques or by automation. Automated synthesis may be accomplished, for instance, using an Applied Biosystems peptide synthesizer (Foster City, CA) in accordance with manufacturer's instructions. Various portions of WISP polypeptides may be chemically synthesized separately and combined using chemical or enzymatic methods to produce a full-length WISP polypeptide.

15 1. Isolation of DNA Encoding WISP Polypeptide

DNA encoding a WISP polypeptide may be obtained from a cDNA library prepared from tissue believed to possess the mRNA for WISP polypeptide and to express it at a detectable level. Accordingly, DNA encoding human WISP polypeptide can be conveniently obtained from a cDNA library prepared from human tissue, such as a human fetal liver library or as otherwise described in the Examples. The gene encoding WISP polypeptide may also be obtained from a genomic library or by oligonucleotide synthesis.

20 A still alternative method of cloning WISP polypeptide is suppressive subtractive hybridization, which is a method for generating differentially regulated or tissue-specific cDNA probes and libraries. This is described, for example, in Diatchenko *et al.*, Proc. Natl. Acad. Sci. USA, 93: 6025-6030 (1996). The procedure is based primarily on a technique called suppression PCR and combines normalization and subtraction in a single procedure. The normalization step equalizes the abundance of cDNAs within the target population and the subtraction step excludes the common sequences between the target and driver populations.

25 Libraries can be screened with probes (such as antibodies to a WISP polypeptide or oligonucleotides of at least about 20-80 bases) designed to identify the gene of interest or the protein encoded by it. Screening the cDNA or genomic library with the selected probe may be conducted using standard procedures, such as described in Sambrook *et al.*, *supra*. An alternative means to isolate the gene encoding WISP polypeptide is to use PCR methodology. Sambrook *et al.*, *supra*; Dieffenbach *et al.*, PCR Primer: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1995).

30 The Examples below describe techniques for screening a cDNA library. The oligonucleotide sequences selected as probes should be of sufficient length and sufficiently unambiguous that false positives are minimized. The oligonucleotide is preferably labeled such that it can be detected upon hybridization to DNA in the library being screened. Methods of labeling are well known in the art, and include the use of radiolabels like <sup>32</sup>P-labeled ATP, biotinylation, or enzyme labeling. Hybridization conditions, including 35 moderate stringency and high stringency, are provided in Sambrook *et al.*, *supra*.

Sequences identified in such library screening methods can be compared and aligned to other known sequences deposited and available in public databases such as GenBank or other private sequence databases. Sequence identity (at either the amino acid or nucleotide level) within defined regions of the molecule or across the full-length sequence can be determined through sequence alignment using computer software programs such as ALIGN, DNASTAR, and INHERIT which employ various algorithms to measure homology.

5

Nucleic acid having polypeptide-coding sequence may be obtained by screening selected cDNA or genomic libraries using the deduced amino acid sequences disclosed herein for the first time, and, if necessary, using conventional primer extension procedures as described in Sambrook *et al.*, *supra*, to detect precursors and processing intermediates of mRNA that may not have been reverse-transcribed into cDNA.

10

## 2. Selection and Transformation of Host Cells

Host cells are transfected or transformed with expression or cloning vectors described herein for WISP polypeptide production and cultured in conventional nutrient media modified as appropriate for inducing promoters, selecting transformants, or amplifying the genes encoding the desired sequences. The culture conditions, such as media, temperature, pH, and the like, can be selected by the skilled artisan without undue experimentation. In general, principles, protocols, and practical techniques for maximizing the productivity of cell cultures can be found in Mammalian Cell Biotechnology: a Practical Approach, M. Butler, ed. (IRL Press, 1991) and Sambrook *et al.*, *supra*.

15

Methods of transfection are known to the ordinarily skilled artisan, for example, CaPO<sub>4</sub> and electroporation. Depending on the host cell used, transformation is performed using standard techniques appropriate to such cells. The calcium treatment employing calcium chloride, as described in Sambrook *et al.*, *supra*, or electroporation is generally used for prokaryotes or other cells that contain substantial cell-wall barriers. Infection with *Agrobacterium tumefaciens* is used for transformation of certain plant cells, as described by Shaw *et al.*, Gene, 23:315 (1983) and WO 89/05859 published 29 June 1989. For mammalian cells without such cell walls, the calcium phosphate precipitation method of Graham and van der Eb *Virology*, 52:456-457 (1978) can be employed. General aspects of mammalian cell host system transformations have been described in U.S. Patent No. 4,399,216. Transformations into yeast are typically carried out according to the method of Van Solingen *et al.*, J. Bact., 130:946 (1977) and Hsiao *et al.*, Proc. Natl. Acad. Sci. (USA), 76:3829 (1979). However, other methods for introducing DNA into cells, such as by nuclear microinjection, electroporation, bacterial protoplast fusion with intact cells, or polycations, e.g., polybrene or polyornithine, may also be used. For various techniques for transforming mammalian cells, see Keown *et al.*, Methods in Enzymology, 185:527-537 (1990) and Mansour *et al.*, Nature, 336:348-352 (1988).

20

25

30

35

Suitable host cells for cloning or expressing the DNA in the vectors herein include prokaryote, yeast, or higher eukaryote cells. Suitable prokaryotes include but are not limited to eubacteria, such as Gram-negative or Gram-positive organisms, for example, *Enterobacteriaceae* such as *Escherichia*, e.g., *E. coli*, *Enterobacter*, *Erwinia*, *Klebsiella*, *Proteus*, *Salmonella*, e.g., *Salmonella typhimurium*, *Serratia*, e.g., *Serratia marcescens*, and *Shigella*, as well as *Bacilli* such as *B. subtilis* and *B. licheniformis* (e.g., *B. licheniformis* 41P disclosed in DD 266,710 published 12 April 1989), *Pseudomonas* such as *P. aeruginosa*, and *Streptomyces*. Various *E. coli* strains are publicly available, such as *E. coli* K12 strain MM294 (ATCC 31,446); *E. coli* X1776 (ATCC 31,537); *E. coli* strain W3110 (ATCC 27,325); and K5 772 (ATCC 53,635). These examples

are illustrative rather than limiting. Strain W3110 is one particularly preferred host or parent host because it is a common host strain for recombinant DNA product fermentations. Preferably, the host cell secretes minimal amounts of proteolytic enzymes. For example, strain W3110 may be modified to effect a genetic mutation in the genes encoding proteins endogenous to the host, with examples of such hosts including *E. coli* W3110 strain 1A2, which has the complete genotype *tonA*; *E. coli* W3110 strain 9E4, which has the complete genotype *tonA pir3*; *E. coli* W3110 strain 27C7 (ATCC 55,244), which has the complete genotype *tonA pir3 phoA E15 (argF-lac)169 degP ompT kanr*; *E. coli* W3110 strain 37D6, which has the complete genotype *tonA pir3 phoA E15 (argF-lac)169 degP ompT rbs7 ilvG kanr*; *E. coli* W3110 strain 40B4, which is strain 37D6 with a non-kanamycin resistant *degP* deletion mutation; and an *E. coli* strain having mutant 10 periplasmic protease disclosed in U.S. Patent No. 4,946,783 issued 7 August 1990. Alternatively, *in vitro* methods of cloning, e.g., PCR or other nucleic acid polymerase reactions, are suitable.

In addition to prokaryotes, eukaryotic microbes such as filamentous fungi or yeast are suitable cloning or expression hosts for vectors containing nucleic acid encoding WISP polypeptide. *Saccharomyces cerevisiae* is a commonly used lower eukaryotic host microorganism. However, a number of other genera, species, and strains are commonly available and useful herein, such as *Schizosaccharomyces pombe* (Beach and Nurse, *Nature*, 290: 140 (1981); EP 139,383 published 2 May 1985); *Kluyveromyces* hosts (U.S. Patent No. 4,943,529; Fleer *et al.*, *Bio/Technology*, 9: 968-975 (1991)) such as, e.g., *K. lactis* (MW98-8C, CBS683, CBS4574; Louvencourt *et al.*, *J. Bacteriol.*, 737 (1983)), *K. fragilis* (ATCC 12,424), *K. bulgaricus* (ATCC 16,042), *K. wickeramii* (ATCC 24,178), *K. waltii* (ATCC 56,500), *K. drosophilae* (ATCC 36,905; Van den 15 Berg *et al.*, *Bio/Technology*, 8: 135 (1990)), *K. thermotolerans*, and *K. marxianus*; *yarrowiae* (EP 402,226); *Pichia pastoris* (EP 183,070; Sreekrishna *et al.*, *J. Basic Microbiol.*, 28: 265-278 (1988)); *Candida*; *Trichoderma reesiae* (EP 244,234); *Neurosporacrassa* (Case *et al.*, *Proc. Natl. Acad. Sci. USA*, 76: 5259-5263 (1979)); *Schwanniomyces* such as *Schwanniomyces occidentalis* (EP 394,538 published 31 October 1990); and filamentous fungi such as, e.g., *Neurospora*, *Penicillium*, *Tolypocladium* (WO 91/00357 published 10 January 1991), and *Aspergillus* hosts such as *A. nidulans* (Ballance *et al.*, *Biochem. Biophys. Res. Commun.*, 112: 284-289 (1983); Tilburn *et al.*, *Gene*, 26: 205-221 (1983); Yelton *et al.*, *Proc. Natl. Acad. Sci. USA*, 81: 1470-1474 (1984)) and *A. niger* Kelly and Hynes, *EMBO J.*, 4: 475-479 (1985). Methylotrophic yeasts are 20 genera consisting of *Hansenula*, *Candida*, *Kloeckera*, *Pichia*, *Saccharomyces*, *Torulopsis*, and *Rhodotorula*. A list of specific species that are exemplary of this class of yeasts may be found in C. Anthony, *The Biochemistry of Methylotrophs*, 269 (1982).

Suitable host cells for the expression of glycosylated WISP are derived from multicellular organisms. Examples of invertebrate cells include insect cells such as *Drosophila S2* and *Spodoptera Sf9*, as well as plant cells. Examples of useful mammalian host cell lines include Chinese hamster ovary (CHO) and COS cells. More specific examples include monkey kidney CV1 line transformed by SV40 (COS-7, ATCC CRL 1651); human embryonic kidney line (293 or 293 cells subcloned for growth in suspension culture (Graham *et al.*, *J. Gen. Virol.*, 36:59 (1977)); Chinese hamster ovary cells/-DHFR (CHO, Urlaub and Chasin, *Proc. Natl. Acad. Sci. USA*, 77:4216 (1980)); mouse sertoli cells (TM4, Mather, *Biol. Reprod.*, 23:243-251 (1980)); human lung cells (WI38, ATCC CCL 75); human liver cells (Hep G2, HB 8065); and mouse mammary tumor 35 human lung cells (WI38, ATCC CCL 75); human liver cells (Hep G2, HB 8065); and mouse mammary tumor

(MMT 060562, ATCC CCL51). The selection of the appropriate host cell is deemed to be within the skill in the art.

### 3. Selection and Use of a Replicable Vector

The nucleic acid (e.g., cDNA or genomic DNA) encoding the desired WISP polypeptide may be inserted into a replicable vector for cloning (amplification of the DNA) or for expression. Various vectors are publicly available. The vector may, for example, be in the form of a plasmid, cosmid, viral particle, or phage. The appropriate nucleic acid sequence may be inserted into the vector by a variety of procedures: In general, DNA is inserted into an appropriate restriction endonuclease site(s) using techniques known in the art. Vector components generally include, but are not limited to, one or more of a signal sequence, an origin of replication, one or more marker genes, an enhancer element, a promoter, and a transcription termination sequence. Construction of suitable vectors containing one or more of these components employs standard ligation techniques which are known to the skilled artisan.

The desired WISP polypeptide may be produced recombinantly not only directly, but also as a fusion polypeptide with a heterologous polypeptide, which may be a signal sequence, if the WISP polypeptide is conducive to being secreted, or other polypeptide having a specific cleavage site at the N-terminus of the mature or full-length protein or polypeptide. In general, the signal sequence may be a component of the vector, or it may be a part of the DNA encoding the WISP polypeptide that is inserted into the vector. The signal sequence may be a prokaryotic signal sequence such as, for example, the alkaline phosphatase, penicillinase, lpp, or heat-stable enterotoxin II leaders. For yeast secretion the signal sequence may be, e.g., the yeast invertase leader, alpha factor leader (including *Saccharomyces* and *Kluyveromyces*  $\alpha$ -factor leaders, the latter described in U.S. Patent No. 5,010,182), or acid phosphatase leader, the *C. albicans* glucoamylase leader (EP 362,179 published 4 April 1990), or the signal described in WO 90/13646 published 15 November 1990. In mammalian cell expression, mammalian signal sequences may be used to direct secretion of the protein, such as signal sequences from secreted polypeptides of the same or related species, as well as viral secretory leaders, and including signals from WISP polypeptides.

Both expression and cloning vectors contain a nucleic acid sequence that enables the vector to replicate in one or more selected host cells. Such sequences are well known for a variety of bacteria, yeast, and viruses. The origin of replication from the plasmid pBR322 is suitable for most Gram-negative bacteria, and the 2 $\mu$  plasmid origin is suitable for yeast, and various viral origins (SV40, polyoma, adenovirus, VSV, or BPV) are useful for cloning vectors in mammalian cells.

Expression and cloning vectors will typically contain a selection gene, also termed a selectable marker. Typical selection genes encode proteins that (a) confer resistance to antibiotics or other toxins, e.g., ampicillin, neomycin, methotrexate, or tetracycline, (b) complement auxotrophic deficiencies, or (c) supply critical nutrients not available from complex media, e.g., the gene encoding D-alanine racemase for *Bacilli*.

An example of suitable selectable markers for mammalian cells are those that enable the identification of cells competent to take up the nucleic acid encoding WISP polypeptide, such as DHFR or thymidine kinase. An appropriate host cell when wild-type DHFR is employed is the CHO cell line deficient in DHFR activity, prepared and propagated as described by Urlaub *et al.*, *Proc. Natl. Acad. Sci. USA*, 77:4216 (1980). A suitable selection gene for use in yeast is the *trp1* gene present in the yeast plasmid YRp7.

Stinchcomb *et al.*, Nature, 282:39 (1979); Kingsman *et al.*, Gene, 7:141 (1979); Tschemper *et al.*, Gene, 10:157 (1980). The *trp1* gene provides a selection marker for a mutant strain of yeast lacking the ability to grow in tryptophan, for example, ATCC No. 44076 or PEP4-1. Jones, Genetics, 85:12 (1977).

5 Expression and cloning vectors usually contain a promoter operably linked to the nucleic acid sequence encoding WISP polypeptide to direct mRNA synthesis. Promoters recognized by a variety of potential host cells are well known. Promoters suitable for use with prokaryotic hosts include the  $\beta$ -lactamase and lactose promoter systems (Chang *et al.*, Nature, 275:615 (1978); Goeddel *et al.*, Nature, 281:544 (1979)); and alkaline phosphatase, a tryptophan (*trp*) promoter system (Goeddel, Nucleic Acids Res., 8:4057 (1980); EP 36,776), and hybrid promoters such as the tac promoter, deBoer *et al.*, Proc. Natl. Acad. Sci. USA, 80:21-25 (1983). Promoters for use in bacterial systems also will contain a Shine-Dalgarno (S.D.) sequence operably linked to the DNA encoding the WISP polypeptide.

10 Examples of suitable promoting sequences for use with yeast hosts include the promoters for 3-phosphoglycerate kinase (Hitzeman *et al.*, J. Biol. Chem., 255:2073 (1980)) or other glycolytic enzymes (Hess *et al.*, J. Adv. Enzyme Reg., 7:149 (1968); Holland, Biochemistry, 17:4900 (1978)), such as enolase, 15 glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose-6-phosphate isomerase, 3-phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase, phosphoglucose isomerase, and glucokinase.

20 Other yeast promoters, which are inducible promoters having the additional advantage of transcription controlled by growth conditions, are the promoter regions for alcohol dehydrogenase 2, isocytchrome C, acid phosphatase, degradative enzymes associated with nitrogen metabolism, metallothionein, glyceraldehyde-3-phosphate dehydrogenase, and enzymes responsible for maltose and galactose utilization. Suitable vectors and promoters for use in yeast expression are further described in EP 73,657.

25 WISP transcription from vectors in mammalian host cells is controlled, for example, by promoters obtained from the genomes of viruses such as polyoma virus, fowlpox virus (UK 2,211,504 published 5 July 1989), adenovirus (such as Adenovirus 2), bovine papilloma virus, avian sarcoma virus, cytomegalovirus, a retrovirus, hepatitis-B virus, and Simian Virus 40 (SV40); from heterologous mammalian promoters, e.g., the actin promoter or an immunoglobulin promoter; and from heat-shock promoters, provided such promoters are compatible with the host cell systems.

30 Transcription of a DNA encoding a WISP polypeptide by higher eukaryotes may be increased by inserting an enhancer sequence into the vector. Enhancers are cis-acting elements of DNA, usually about from 10 to 300 bp, that act on a promoter to increase its transcription. Many enhancer sequences are now known from mammalian genes (globin, elastase, albumin,  $\alpha$ -fetoprotein, and insulin). Typically, however, one will use an enhancer from a eukaryotic cell virus. Examples include the SV40 enhancer on the late side of the replication origin (bp 100-270), the cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and adenovirus enhancers. The enhancer may be spliced into the vector at a position 5' or 3' to the sequence coding for a WISP polypeptide, but is preferably located at a site 5' from the promoter.

5 Expression vectors used in eukaryotic host cells (yeast, fungi, insect, plant, animal, human, or nucleated cells from other multicellular organisms) will also contain sequences necessary for the termination of transcription and for stabilizing the mRNA. Such sequences are commonly available from the 5' and occasionally 3', untranslated regions of eukaryotic or viral DNAs or cDNAs. These regions contain nucleotide segments transcribed as polyadenylated fragments in the untranslated portion of the mRNA encoding WISP polypeptide.

Still other methods, vectors, and host cells suitable for adaptation to the synthesis of WISP polypeptides in recombinant vertebrate cell culture are described in Gething *et al.*, Nature, 293:620-625 (1981); Mantei *et al.*, Nature, 281:40-46 (1979); EP 117.060; and EP 117.058.

10 4. Detecting Gene Amplification/Expression

Gene amplification and/or expression may be measured in a sample directly, for example, by conventional Southern blotting, Northern blotting to quantitate the transcription of mRNA (Thomas, Proc. Natl. Acad. Sci. USA, 77:5201-5205 (1980)), dot blotting (DNA analysis), or *in situ* hybridization, using an 15 appropriately labeled probe, based on the sequences provided herein. Alternatively, antibodies may be employed that can recognize specific duplexes, including DNA duplexes, RNA duplexes, and DNA-RNA hybrid duplexes or DNA-protein duplexes. The antibodies in turn may be labeled and the assay may be carried out where the duplex is bound to a surface, so that upon the formation of duplex on the surface, the presence of antibody bound to the duplex can be detected.

20 Gene expression, alternatively, may be measured by immunological methods, such as immunohistochemical staining of cells or tissue sections and assay of cell culture or body fluids, to quantitate directly the expression of gene product. Antibodies useful for immunohistochemical staining and/or assay of sample fluids may be either monoclonal or polyclonal, and may be prepared in any mammal. Conveniently, the antibodies may be prepared against a native-sequence WISP polypeptide or against a 25 synthetic peptide based on the DNA sequences provided herein or against exogenous sequence fused to DNA encoding WISP polypeptide and encoding a specific antibody epitope.

5. Purification of Polypeptide

Forms of WISP polypeptide may be recovered from culture medium or from host cell lysates. If 30 membrane-bound, it can be released from the membrane using a suitable detergent solution (e.g., Triton-X 100) or by enzymatic cleavage. Cells employed in expression of WISP polypeptides can be disrupted by various physical or chemical means, such as freeze-thaw cycling, sonication, mechanical disruption, or cell lysing agents.

35 It may be desired to purify WISP polypeptide from recombinant cell proteins or polypeptides. The following procedures are exemplary of suitable purification procedures: by fractionation on an ion-exchange column; ethanol precipitation; reverse phase HPLC; chromatography on silica or on a cation-exchange resin such as DEAE; chromatofocusing; SDS-PAGE; ammonium sulfate precipitation; gel filtration using, for example, SEPHADEX<sup>TM</sup> G-75; protein A SEPHAROSE<sup>TM</sup> columns to remove contaminants such as IgG; and metal chelating columns to bind epitope-tagged forms of the WISP polypeptide. Various methods of protein purification may be employed, and such methods are known in the art and described, for example,

in Deutscher, Methods in Enzymology, 182 (1990); and Scopes, Protein Purification: Principles and Practice (Springer-Verlag: New York, 1982).

In one specific example of purification, either a poly-His tag or the Fc portion of human IgG is added to the C-terminal coding region of the cDNA for WISP-1, WISP-2, or WISP-3 before expression. The conditioned media from the transfected cells are harvested by centrifugation to remove the cells and filtered.

5 For the poly-His-

tagged constructs, the protein may be purified using a Ni-NTA column. After loading, the column may be washed with additional equilibration buffer and the protein eluted with equilibration buffer containing 0.25 M imidazole. The highly purified protein may then be desalted into a storage buffer if desired.

10 Immunoadhesin (Fc-containing) constructs of the WISP-1, WISP-2, and WISP-3 proteins may be purified from the conditioned media by pumping them onto a 5-ml Protein A column which had been equilibrated in a phosphate buffer. After loading, the column may be washed extensively with equilibration buffer before elution with citric acid. The eluted protein may be immediately neutralized by collecting 1-ml fractions into tubes containing TRIS buffer. The highly purified protein may be subsequently desalted into 15 storage buffer as described above for the poly-His-tagged proteins. The homogeneity of the protein may be assessed by SDS polyacrylamide gels and by N-terminal amino acid sequencing by Edman degradation.

The purification step(s) selected will depend, for example, on the nature of the production process used and the particular WISP polypeptide produced.

#### E. Uses for WISP Polypeptide and Its Nucleic Acid

20 Nucleotide sequences (or their complement) encoding WISP polypeptides have various applications in the art of molecular biology, including uses as hybridization probes, in chromosome and gene mapping, and in the generation of anti-sense RNA and DNA. Nucleic acid encoding WISP polypeptide will also be useful for the preparation of WISP polypeptides by the recombinant techniques described herein.

The full-length nucleotide sequences for mouse and human WISP-1 or WISP-2 (SEQ ID NOS:9, 1, 25 17, and 13, respectively), or portions thereof, or the full-length nucleotide sequences for human WISP-3 of Fig. 6 (SEQ ID NO:30) or for WISP-3 of Fig. 7 (SEQ ID NO:34) may be used as hybridization probes for a cDNA library to isolate or detect the full-length gene encoding the WISP polypeptide of interest or to isolate 30 or detect still other genes (for instance, those encoding naturally occurring variants of WISP polypeptide, other WISP polypeptide family members, or WISP polypeptides from other species) which have a desired sequence identity to the WISP polypeptide sequences disclosed in Figures 1, 2, 3A and 3B, 4, 6A and 6B, and 7A and 7B (SEQ ID NOS:3, 4, 11, 12, 15, 16, 19, 20, 32, 33, 36, or 37). For example, such procedures as *in situ* hybridization, Northern and Southern blotting, and PCR analysis may be used to determine whether 35 DNA and/or RNA encoding a different WISP is present in the cell type(s) being evaluated. Optionally, the length of the probes will be about 20 to about 50 bases. For example, the hybridization probes may be derived from the UNQ228 (DNA33473-seq min) nucleotide sequence (SEQ ID NO:38) or the full-length human WISP-2 nucleotide sequence (SEQ ID NO:13) as shown in Figure 4 or from genomic sequences including promoters, enhancer elements, and introns of DNA encoding native-sequence WISP polypeptide.

By way of example, a screening method will comprise isolating the coding region of the WISP gene using the known DNA sequence to synthesize a selected probe of about 40 bases. Hybridization probes may be labeled by a variety of labels, including radionucleotides such as  $^{32}\text{P}$  or  $^{35}\text{S}$ , or enzymatic labels such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems. Labeled probes having a sequence complementary to that of any of the genes encoding WISP polypeptides of the present invention can be used to screen libraries of human cDNA, genomic DNA, or mRNA to determine to which members of such libraries the probe hybridizes. Hybridization techniques are described in further detail in the Examples below.

The probes may also be employed in PCR techniques to generate a pool of sequences for identification of closely related WISP sequences.

Nucleotide sequences encoding a WISP polypeptide can also be used to construct hybridization probes for mapping the gene which encodes that WISP polypeptide and for the genetic analysis of individuals with genetic disorders. The nucleotide sequences provided herein may be mapped to a chromosome and specific regions of a chromosome using known techniques, such as *in situ* hybridization, linkage analysis against known chromosomal markers, and hybridization screening with libraries. If the amplification of a given gene is functionally relevant, then that gene should be amplified more than neighboring genomic regions which are not important for tumor survival. To test this, the gene can be mapped to a particular chromosome, e.g., by radiation-hybrid analysis. The amplification level is then determined at the location identified, and at neighboring genomic region. Selective or preferential amplification at the genomic region to which the gene has been mapped is consistent with the possibility that the gene amplification observed promotes tumor growth or survival. Chromosome mapping includes both framework and epicenter mapping. For further details see e.g., Stewart *et al.*, Genome Research 7, 422-433 (1997).

Nucleic acid encoding a WISP polypeptide may be used as a diagnostic to determine the extent and rate of the expression of the DNA encoding the WISP polypeptide in the cells of a patient. To accomplish such an assay, a sample of a patient's cells is treated, via *in situ* hybridization, or by other suitable means, and analyzed to determine whether the sample contains mRNA molecules capable of hybridizing with the nucleic acid molecule.

Nucleic acids which encode WISP polypeptides or any of their modified forms can also be used to generate either transgenic animals or "knock-out" animals which, in turn, are useful in the development and screening of therapeutically useful reagents. A transgenic animal (e.g., a mouse or rat) is an animal having cells that contain a transgene, which transgene was introduced into the animal or an ancestor of the animal at a prenatal, e.g., an embryonic stage. A transgene is a DNA which is integrated into the genome of a cell from which a transgenic animal develops. In one embodiment, cDNA encoding a WISP polypeptide can be used to clone genomic DNA encoding the WISP polypeptide in accordance with established techniques and the genomic sequences used to generate transgenic animals that contain cells which express DNA encoding the WISP polypeptide.

Methods for generating transgenic animals, particularly animals such as mice or rats, have become conventional in the art and are described, for example, in U.S. Patent Nos. 4,736,866 and 4,870,009 and WO 97/38086. Typically, particular cells would be targeted for WISP transgene incorporation with tissue-specific

enhancers. Transgenic animals that include a copy of a transgene encoding the WISP polypeptide introduced into the germ line of the animal at an embryonic stage can be used to examine the effect of increased expression of DNA encoding the WISP polypeptide. Such animals can be used as tester animals for reagents thought to confer protection from, for example, pathological conditions associated with its overexpression. 5 In accordance with this facet of the invention, an animal is treated with the reagent and a reduced incidence of the pathological condition, compared to untreated animals bearing the transgene, would indicate a potential therapeutic intervention for the pathological condition.

Alternatively, non-human homologues of WISP polypeptides can be used to construct a WISP polypeptide "knock-out" animal which has a defective or altered gene encoding a WISP polypeptide as a 10 result of homologous recombination between the endogenous gene encoding the WISP polypeptide and altered genomic DNA encoding the WISP polypeptide introduced into an embryonic cell of the animal. For example, cDNA encoding the WISP polypeptide can be used to clone genomic DNA encoding the WISP polypeptide in accordance with established techniques. A portion of the genomic DNA encoding the WISP polypeptide can be deleted or replaced with another gene, such as a gene encoding a selectable marker which 15 can be used to monitor integration. Typically, several kilobases of unaltered flanking DNA (both at the 5' and 3' ends) are included in the vector. See e.g., Thomas and Capecchi, Cell, 51:503 (1987) for a description of homologous recombination vectors. The vector is introduced into an embryonic stem cell line (e.g., by electroporation) and cells in which the introduced DNA has homologously recombined with the endogenous 20 DNA are selected. See e.g., Li *et al.*, Cell, 69:915 (1992). The selected cells are then injected into a blastocyst of an animal (e.g., a mouse or rat) to form aggregation chimeras. See e.g., Bradley, in Teratocarcinomas and Embryonic Stem Cells: A Practical Approach, E. J. Robertson, ed. (IRL, Oxford, 1987), pp. 113-152. A chimeric embryo can then be implanted into a suitable pseudopregnant female foster 25 animal and the embryo brought to term to create a "knock-out" animal. Progeny harboring the homologously recombined DNA in their germ cells can be identified by standard techniques and used to breed animals in which all cells of the animal contain the homologously recombined DNA. Knockout animals can be characterized, for instance, by their ability to defend against certain pathological conditions and by their development of pathological conditions due to absence of the WISP polypeptide.

In particular, assays in which CTGF, IGFBPs, and other members of the CTGF superfamily and other growth factors are usually used are preferably performed with the WISP-1 and WISP-2 polypeptides. 30 For example, an assay to determine whether TGF- $\beta$  induces the WISP polypeptide, indicating a role in cancer, may be performed as known in the art, as well as assays involving induction of cell death and  $^3$ H-thymidine proliferation assays. Mitogenic and tissue growth assays are also performed with the WISP polypeptide as set forth above. The results are applied accordingly.

The WISP polypeptides of the present invention may also be used to induce the formation of anti-WISP polypeptide antibodies, which are identified by routine screening as detailed below.

In addition to their uses above, the WISP-1, WISP-2, and WISP-3 polypeptides of the present invention are useful as the basis for assays of IGF activity. Importantly, since such an assay measures a physiologically significant binding event, *i.e.*, that of an IGF to its IGFBP, triggering a detectable change (such as phosphorylation, cleavage, chemical modification, *etc.*), it is likely to be both more sensitive and

more accurate than immunoassays, which detect the physiologically non-significant binding of an IGF to anti-WISP polypeptide antibody. Although more sensitive and accurate than antibodies, the WISP-1, WISP-2, and WISP-3 molecules of the invention can be used to assay IGF (such as IGF-I or IGF-II) levels in a sample in the same ways in which antibodies are used.

5 For diagnostic purposes, the WISP-1, WISP-2, or WISP-3 polypeptide can be used in accordance with immunoassay technology. Examples of immunoassays are provided by Wide at pages 199-206 of Radioimmune Assay Method, Kirkham and Huner, ed., E & S. Livingstone, Edinburgh, 1970.

10 Thus, in one embodiment, WISP-1, WISP-2, and WISP-3 polypeptides can be detectably labeled and incubated with a test sample containing IGF molecules (such as biological fluids, e.g., serum, sputum, urine, etc.), and the amount of WISP-1, WISP-2, or WISP-3 molecule bound to the sample ascertained.

15 Immobilization of reagents is required for certain assay methods. Immobilization entails separating the WISP-1, WISP-2, or WISP-3 polypeptide from any analyte that remains free in solution. This conventionally is accomplished by either insolubilizing the WISP-1, WISP-2, or WISP-3 polypeptide before the assay procedure, as by adsorption to a water-insoluble matrix or surface (Bennich *et al.*, U.S. 3,720,760), by covalent coupling (for example, using glutaraldehyde cross-linking), or by insolubilizing the molecule afterward, e.g., by immunoprecipitation.

20 The foregoing are merely exemplary diagnostic assays for IGF. Other methods now or hereafter developed for the determination of these analytes are included within the scope hereof.

25 WISP-1, WISP-2, and WISP-3 polypeptides are also useful in radioimmunoassays to measure IGFs such as IGF-I or IGF-II. Such a radioimmunoassay would be conducted as described in the literature using the naturally purified or recombinant WISP-1, WISP-2, or WISP-3 as the WISP element.

30 In addition, WISP polypeptides are useful for screening for compounds that bind to them as defined above. Preferably, these compounds are small molecules such as organic or peptide molecules that exhibit one or more of the desired activities. Screening assays of this kind are conventional in the art, and any such screening procedure may be employed, whereby the test sample is contacted with the WISP polypeptide herein and the extent of binding and biological activity of the bound molecule are determined.

35 More specifically, this invention encompasses methods of screening compounds to identify those that mimic the WISP polypeptide (agonists) or prevent the effect of the WISP polypeptide (antagonists). Screening assays for antagonist drug candidates are designed to identify compounds that bind or complex with the WISP polypeptides encoded by the genes identified herein, or otherwise interfere with the interaction of the encoded polypeptides with other cellular proteins. Such screening assays will include assays amenable to high-throughput screening of chemical libraries, making them particularly suitable for identifying small molecule drug candidates.

40 The assays can be performed in a variety of formats, including protein-protein binding assays, biochemical screening assays, immunoassays, and cell-based assays, which are well characterized in the art.

45 All assays for antagonists are common in that they call for contacting the drug candidate with a WISP polypeptide encoded by a nucleic acid identified herein under conditions and for a time sufficient to allow these two components to interact.

In binding assays, the interaction is binding and the complex formed can be isolated or detected in the reaction mixture. In a particular embodiment, the WISP polypeptide encoded by the gene identified herein or the drug candidate is immobilized on a solid phase, e.g., on a microtiter plate, by covalent or non-covalent attachments. Non-covalent attachment generally is accomplished by coating the solid surface with a solution of the WISP polypeptide and drying. Alternatively, an immobilized antibody, e.g., a monoclonal antibody, specific for the WISP polypeptide to be immobilized can be used to anchor it to a solid surface. The assay is performed by adding the non-immobilized component, which may be labeled by a detectable label, to the immobilized component, e.g., the coated surface containing the anchored component. When the reaction is complete, the non-reacted components are removed, e.g., by washing, and complexes anchored on the solid surface are detected. When the originally non-immobilized component carries a detectable label, the detection of label immobilized on the surface indicates that complexing occurred. Where the originally non-immobilized component does not carry a label, complexing can be detected, for example, by using a labeled antibody specifically binding the immobilized complex.

If the candidate compound interacts with but does not bind to a particular WISP polypeptide encoded by a gene identified herein, its interaction with that polypeptide can be assayed by methods well known for detecting protein-protein interactions. Such assays include traditional approaches, such as, e.g., cross-linking, co-immunoprecipitation, and co-purification through gradients or chromatographic columns. In addition, protein-protein interactions can be monitored by using a yeast-based genetic system described by Fields and co-workers (Fields and Song, Nature (London), **340**: 245-246 (1989); Chien *et al.*, Proc. Natl. Acad. Sci. USA, **88**: 9578-9582 (1991)) as disclosed by Chevray and Nathans, Proc. Natl. Acad. Sci. USA, **89**: 5789-5793 (1991). Many transcriptional activators, such as yeast GAL4, consist of two physically discrete modular domains, one acting as the DNA-binding domain, the other one functioning as the transcription-activation domain. The yeast expression system described in the foregoing publications (generally referred to as the "two-hybrid system"); takes advantage of this property, and employs two hybrid proteins, one in which the target protein is fused to the DNA-binding domain of GAL4, and another, in which candidate activating proteins are fused to the activation domain. The expression of a GAL4-lucZ reporter gene under control of a GAL4-activated promoter depends on reconstitution of GAL4 activity via protein-protein interaction. Colonies containing interacting polypeptides are detected with a chromogenic substrate for  $\beta$ -galactosidase. A complete kit (MATCHMAKER<sup>TM</sup>) for identifying protein-protein interactions between two specific proteins using the two-hybrid technique is commercially available from Clontech. This system can also be extended to map protein domains involved in specific protein interactions as well as to pinpoint amino acid residues that are crucial for these interactions.

Compounds that interfere with the interaction of a gene encoding a WISP polypeptide identified herein and other intra- or extracellular components can be tested as follows: usually a reaction mixture is prepared containing the product of the gene and the intra- or extracellular component under conditions and for a time allowing for the interaction and binding of the two products. To test the ability of a candidate compound to inhibit binding, the reaction is run in the absence and in the presence of the test compound. In addition, a placebo may be added to a third reaction mixture, to serve as positive control. The binding (complex formation) between the test compound and the intra- or extracellular component present in the

mixture is monitored as described hereinabove. The formation of a complex in the control reaction(s) but not in the reaction mixture containing the test compound indicates that the test compound interferes with the interaction of the test compound and its reaction partner.

If the WISP polypeptide has the ability to stimulate the proliferation of endothelial cells in the presence of the co-mitogen ConA, then one example of a screening method takes advantage of this ability. Specifically, in the proliferation assay, human umbilical vein endothelial cells are obtained and cultured in 96-well flat-bottomed culture plates (Costar, Cambridge, MA) and supplemented with a reaction mixture appropriate for facilitating proliferation of the cells. the mixture containing Con-A (Calbiochem, La Jolla, CA). Con-A and the compound to be screened are added and after incubation at 37°C, cultures are pulsed with <sup>3</sup>H-thymidine and harvested onto glass fiber filters (pHD: Cambridge Technology, Watertown, MA). Mean <sup>3</sup>(H)thymidine incorporation (cpm) of triplicate cultures is determined using a liquid scintillation counter (Beckman Instruments, Irvine, CA). Significant <sup>3</sup>(H)thymidine incorporation indicates stimulation of endothelial cell proliferation.

To assay for antagonists, the assay described above is performed; however, in this assay the WISP polypeptide is added along with the compound to be screened and the ability of the compound to inhibit <sup>3</sup>(H)thymidine incorporation in the presence of the WISP polypeptide indicates that the compound is an antagonist to the WISP polypeptide. Alternatively, antagonists may be detected by combining the WISP polypeptide and a potential antagonist with membrane-bound WISP polypeptide receptors or recombinant receptors under appropriate conditions for a competitive inhibition assay. The WISP polypeptide can be labeled, such as by radioactivity, such that the number of WISP polypeptide molecules bound to the receptor can be used to determine the effectiveness of the potential antagonist. The gene encoding the receptor can be identified by numerous methods known to those of skill in the art, for example, ligand panning and FACS sorting. Coligan *et al.*, Current Protocols in Immun., 1(2): Chapter 5 (1991). Preferably, expression cloning is employed wherein polyadenylated RNA is prepared from a cell responsive to the WISP polypeptide and a cDNA library created from this RNA is divided into pools and used to transfect COS cells or other cells that are not responsive to the WISP polypeptide. Transfected cells that are grown on glass slides are exposed to labeled WISP polypeptide. The WISP polypeptide can be labeled by a variety of means including iodination or inclusion of a recognition site for a site-specific protein kinase. Following fixation and incubation, the slides are subjected to autoradiographic analysis. Positive pools are identified and sub-pools are prepared and re-transfected using an interactive sub-pooling and re-screening process, eventually yielding a single clone that encodes the putative receptor.

As an alternative approach for receptor identification, labeled WISP polypeptide can be cross-photoaffinity-linked with cell membrane or extract preparations that express the receptor molecule. Cross-linked material is resolved by PAGE and exposed to X-ray film. The labeled complex containing the receptor can be excised, resolved into peptide fragments, and subjected to protein micro-sequencing. The amino acid sequence obtained from micro-sequencing would be used to design a set of degenerate oligonucleotide probes to screen a cDNA library to identify the gene encoding the putative receptor.

In another assay for antagonists, mammalian cells or a membrane preparation expressing the receptor would be incubated with labeled WISP polypeptide in the presence of the candidate compound. The ability of the compound to enhance or block this interaction could then be measured.

5 The compositions useful in the treatment of WISP-related disorders include, without limitation, antibodies, small organic and inorganic molecules, peptides, phosphopeptides, antisense and ribozyme molecules, triple-helix molecules, etc., that inhibit the expression and/or activity of the target gene product.

10 More specific examples of potential antagonists include an oligonucleotide that binds to the WISP polypeptide, (poly)peptide-immunoglobulin fusions, and, in particular, antibodies including, without limitation, poly- and monoclonal antibodies and antibody fragments, single-chain antibodies, anti-idiotypic antibodies, and chimeric or humanized versions of such antibodies or fragments, as well as human antibodies 15 and antibody fragments. Alternatively, a potential antagonist may be a closely related protein, for example, a mutated form of the WISP polypeptide that recognizes the receptor but imparts no effect, thereby competitively inhibiting the action of the WISP polypeptide.

15 Another potential WISP polypeptide antagonist is an antisense RNA or DNA construct prepared using antisense technology, where, e.g., an antisense RNA or DNA molecule acts to block directly the translation of mRNA by hybridizing to targeted mRNA and preventing protein translation. Antisense technology can be used to control gene expression through triple-helix formation or antisense DNA or RNA, both of which methods are based on binding of a polynucleotide to DNA or RNA. For example, the 5' coding 20 portion of the polynucleotide sequence, which encodes the mature WISP polypeptides herein, is used to design an antisense RNA oligonucleotide of from about 10 to 40 base pairs in length. A DNA oligonucleotide is designed to be complementary to a region of the gene involved in transcription (triple helix - see Lee *et al.*, *Nucl. Acids Res.*, 6: 3073 (1979); Cooney *et al.*, *Science*, 241: 456 (1988); Dervan *et al.*, *Science*, 251: 1360 (1991)), thereby preventing transcription and the production of the WISP polypeptide. The antisense RNA oligonucleotide hybridizes to the mRNA *in vivo* and blocks translation of the mRNA molecule to the WISP 25 polypeptide (antisense - Okano, *Neurochem.*, 56: 560 (1991); Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression (CRC Press: Boca Raton, FL, 1988)). The oligonucleotides described above can also be delivered to cells such that the antisense RNA or DNA may be expressed *in vivo* to inhibit production of the WISP polypeptide. When antisense DNA is used, oligodeoxyribonucleotides derived from the translation- 30 initiation site, e.g., between about -10 and +10 positions of the target gene nucleotide sequence, are preferred.

Potential antagonists include small molecules that bind to the active site, the receptor binding site, or growth factor or other relevant binding site of the WISP polypeptide, thereby blocking the normal biological activity of the WISP polypeptide. Examples of small molecules include, but are not limited to, small peptides or peptide-like molecules, preferably soluble peptides, and synthetic non-peptidyl organic or inorganic compounds.

35 Ribozymes are enzymatic RNA molecules capable of catalyzing the specific cleavage of RNA. Ribozymes act by sequence-specific hybridization to the complementary target RNA, followed by endonucleolytic cleavage. Specific ribozyme cleavage sites within a potential RNA target can be identified by known techniques. For further details see, e.g., Rossi, *Current Biology*, 4: 469-471 (1994), and PCT publication No. WO 97/33551 (published September 18, 1997).

Nucleic acid molecules in triple-helix formation used to inhibit transcription should be single-stranded and composed of deoxynucleotides. The base composition of these oligonucleotides is designed such that it promotes triple-helix formation via Hoogsteen base-pairing rules, which generally require sizeable stretches of purines or pyrimidines on one strand of a duplex. For further details see, e.g., PCT publication No. WO 97/33551, *supra*.

5 These small molecules can be identified by any one or more of the screening assays discussed hereinabove and/or by any other screening techniques well known for those skilled in the art.

10 WISP-1, WISP-2, and WISP-3 polypeptides are additionally useful in affinity purification of an IGF that binds to WISP-1, WISP-2, or WISP-3 (such as, for example, IGF-I) and in purifying antibodies thereto. The WISP-1, WISP-2, or WISP-3 is typically coupled to an immobilized resin such as Affi-Gel 10<sup>TM</sup> (Bio-Rad, Richmond, CA) or other such resins (support matrices) by means well known in the art. The resin is equilibrated in a buffer (such as one containing 150 mM NaCl, 20 mM HEPES, pH 7.4 supplemented to contain 20% glycerol and 0.5% NP-40) and the preparation to be purified is placed in contact with the resin, whereby the molecules are selectively adsorbed to the WISP-1, WISP-2, or WISP-3 on the resin.

15 The resin is then sequentially washed with suitable buffers to remove non-adsorbed material, including unwanted contaminants, from the mixture to be purified, using, e.g., 150 mM NaCl, 20 mM HEPES, pH 7.4, containing 0.5% NP-40; 150 mM NaCl, 20 mM HEPES, pH 7.4 containing 0.5 M NaCl and 0.1% NP-40; 150 mM NaCl, 20 mM HEPES, pH 7.4 containing 0.1% deoxycholate; 150 mM NaCl, 20 mM HEPES, pH 7.4 containing 0.1% NP-40; and a solution of 0.1% NP-40, 20% glycerol and 50 mM glycine, pH 3. The resin is then treated so as to elute the IGF using a buffer that will break the bond between the IGF and WISP-1, WISP-2, or WISP-3 (using, e.g., 50 mM glycine, pH 3, 0.1% NP-40, 20% glycerol, and 100 mM NaCl).

20 It is contemplated that the WISP polypeptides of the present invention may be used to treat various conditions, including those characterized by overexpression and/or activation of at least the Wnt pathway. Further, since the WISP-1, WISP-2, and WISP-3 molecules respond to hormone-expressed breast cancer in mice and are abnormally expressed in human cancer, and are over-amplified in various colon cancer cell lines, they are useful in diagnosing cancer, for example, as a marker for increased susceptibility to cancer or for having cancer. Exemplary conditions or disorders to be treated with the WISP polypeptides include benign or malignant tumors (e.g., renal, liver, kidney, bladder, testicular, breast, gastric, ovarian, colorectal, prostate, 25 pancreatic, lung, esophageal, vulval, thyroid, hepatic carcinomas; sarcomas; glioblastomas; and various head and neck tumors); leukemias and lymphoid malignancies; other disorders such as neuronal, glial, astrocytal, hypothalamic, and other glandular, macrophagal, epithelial, stromal, and blastocoelic disorders; cardiac disorders; renal disorders; catabolic disorders; bone-related disorders such as osteoporosis; and inflammatory, angiogenic, and immunologic disorders, such as arteriosclerosis; as well as connective tissue disorders, 30 including wound healing.

35 The WISP polypeptides of the invention are administered to a mammal, preferably a human, in accord with known methods, such as intravenous administration as a bolus or by continuous infusion over a period of time, by intramuscular, intraperitoneal, intracerebrospinal, subcutaneous, intra-articular,

intrasynovial, intrathecal, oral, topical, or inhalation routes. Intravenous or subcutaneous administration of the polypeptide is preferred.

Therapeutic formulations of the WISP polypeptide are prepared for storage by mixing the polypeptide having the desired degree of purity with optional pharmaceutically acceptable carriers, excipients, or stabilizers (Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980)), in the form of lyophilized formulations or aqueous solutions. Acceptable carriers, excipients, or stabilizers are nontoxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride; benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose, or sorbitol; salt-forming counter-ions such as sodium; metal complexes (e.g., Zn-protein complexes); and/or non-ionic surfactants such as TWEEN™, PLURONICS™, or polyethylene glycol (PEG).

Other therapeutic regimens may be combined with the administration of the WISP polypeptides of the instant invention. For example, the patient to be treated with the polypeptides disclosed herein may also receive radiation therapy if the disorder is cancer. Alternatively, or in addition, a chemotherapeutic agent may be administered to the patient with cancer. Preparation and dosing schedules for such chemotherapeutic agents may be used according to manufacturers' instructions or as determined empirically by the skilled practitioner. Preparation and dosing schedules for such chemotherapy are also described in Chemotherapy Service, Ed., M.C. Perry (Williams & Wilkins: Baltimore, MD, 1992). The chemotherapeutic agent may precede or follow administration of the polypeptide or may be given simultaneously therewith. The polypeptide may be combined with an anti-oestrogen compound such as tamoxifen or an anti-progesterone such as onapristone (see, EP 616812) in dosages known for such molecules.

It may be desirable also to co-administer with the WISP polypeptide (or anti-WISP polypeptide) antibodies against other tumor-associated antigens, such as antibodies which bind to HER-2, EGFR, ErbB2, ErbB3, ErbB4, or vascular endothelial factor (VEGF). Alternatively, or in addition, two or more different anti-cancer antibodies, such as anti-ErbB2 antibodies, may be co-administered to the patient with the WISP polypeptide (or anti-WISP polypeptide antibody). Sometimes, it may be beneficial also to administer one or more cytokines to the patient.

In a preferred embodiment, the WISP polypeptide is co-administered with a growth-inhibitory agent to the cancer patient. For example, the growth-inhibitory agent may be administered first, followed by the WISP polypeptide. However, simultaneous administration or administration of the WISP polypeptide first is also contemplated. Suitable dosages for the growth-inhibitory agent are those presently used and may be lowered due to the combined action (synergy) of the growth-inhibitory agent and polypeptide. The

antibodies, cytotoxic agents, cytokines, or growth-inhibitory agents are suitably present in combination in amounts that are effective for the purpose intended.

The active ingredients may also be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin microcapsules and poly-(methylmethacrylate) microcapsules, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles, and nanocapsules) or in macroemulsions. Such techniques are disclosed in Remington's Pharmaceutical Sciences, 16th edition, Osol, A. Ed. (1980), *supra*.

5 The formulations to be used for *in vivo* administration must be sterile. This is readily accomplished by filtration through sterile filtration membranes.

10 Sustained-release preparations may be prepared. Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the polypeptide, which matrices are in the form of shaped articles, e.g., films, or microcapsules. Examples of sustained-release matrices include polyesters, hydrogels (for example, poly(2-hydroxyethyl-methacrylate), or poly(vinyl alcohol)), 15 polylactides (U.S. Pat. No. 3,773,919), copolymers of L-glutamic acid and  $\gamma$  ethyl-L-glutamate, non-degradable ethylene-vinyl acetate, degradable lactic acid-glycolic acid copolymers such as the LUPRON DEPOT<sup>TM</sup> (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate), and poly-D-(-)-3-hydroxybutyric acid. While polymers such as ethylene-vinyl acetate and lactic acid-glycolic acid enable release of molecules for over 100 days, certain hydrogels release proteins for shorter time periods. 20 When encapsulated polypeptides remain in the body for a long time, they may denature or aggregate as a result of exposure to moisture at 37°C, resulting in a loss of biological activity and possible changes in immunogenicity. Rational strategies can be devised for stabilization depending on the mechanism involved. For example, if the aggregation mechanism is discovered to be intermolecular S-S bond formation through thio-disulfide interchange, stabilization may be achieved by modifying sulphydryl residues, lyophilizing from 25 acidic solutions, controlling moisture content, using appropriate additives, and developing specific polymer matrix compositions.

30 For the prevention or treatment of disease or disorder, the appropriate dosage of WISP polypeptide will depend on the type of disorder to be treated, as defined above, the severity and course of the disorder, whether the polypeptide is administered for preventive or therapeutic purposes, previous therapy, the patient's clinical history and response to the polypeptide, the route of administration, the condition of the patient, and the discretion of the attending physician. The polypeptide is suitably administered to the patient at one time or over a series of treatments.

35 Depending on the type and severity of the disease, about 1  $\mu$ g/kg to 15 mg/kg (e.g., 0.1-20 mg/kg) of WISP polypeptide is an initial candidate dosage for administration to the patient, whether, for example, by one or more separate administrations, or by continuous infusion. A typical daily dosage might range from about 1  $\mu$ g/kg to 100 mg/kg or more, depending on the factors mentioned above. For repeated administrations over several days or longer, depending on the condition, the treatment is sustained until a desired suppression of symptoms of the disorder occurs. However, other dosage regimens may be useful. The progress of this therapy is easily monitored by conventional techniques and assays. In another

embodiment of the invention, an article of manufacture containing materials useful for the treatment of the disorders described above is provided. The article of manufacture comprises a container and a label. Suitable containers include, for example, bottles, vials, syringes, and test tubes. The containers may be formed from a variety of materials such as glass or plastic. The container holds a composition which is effective for treating the condition and may have a sterile access port (for example, the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle). The active agent in the composition is the WISP polypeptide. The label on, or associated with, the container indicates that the composition is used for treating the condition or disorder of choice. The article of manufacture may further comprise a second container comprising a pharmaceutically acceptable buffer, such as phosphate-buffered saline, Ringer's solution, and dextrose solution. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, syringes, and package inserts with instructions for use.

#### F. Anti-WISP Polypeptide Antibodies

The present invention further provides anti-WISP polypeptide antibodies. Exemplary antibodies include polyclonal, monoclonal, humanized, bispecific, and heteroconjugate antibodies.

##### 1. Polyclonal Antibodies

The anti-WISP polypeptide antibodies of the present invention may comprise polyclonal antibodies. Methods of preparing polyclonal antibodies are known to the skilled artisan. Polyclonal antibodies can be raised in a mammal, for example, by one or more injections of an immunizing agent and, if desired, an adjuvant. Typically, the immunizing agent and/or adjuvant will be injected in the mammal by multiple subcutaneous or intraperitoneal injections. The immunizing agent may include the WISP polypeptide or a fusion protein thereof. It may be useful to conjugate the immunizing agent to a protein known to be immunogenic in the mammal being immunized. Examples of such immunogenic proteins include but are not limited to keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, and soybean trypsin inhibitor. Examples of adjuvants which may be employed include Freund's complete adjuvant and MPL-TDM adjuvant (monophosphoryl Lipid A, synthetic trehalose dicorynomycolate). The immunization protocol may be selected by one skilled in the art without undue experimentation.

##### 2. Monoclonal Antibodies

The anti-WISP polypeptide antibodies may, alternatively, be monoclonal antibodies. Monoclonal antibodies may be prepared using hybridoma methods, such as those described by Kohler and Milstein, Nature, 256:495 (1975). In a hybridoma method, a mouse, hamster, or other appropriate host animal is typically immunized with an immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent. Alternatively, the lymphocytes may be immunized *in vitro*.

The immunizing agent will typically include the WISP polypeptide or a fusion protein thereof. Generally, either peripheral blood lymphocytes ("PBLs") are used if cells of human origin are desired, or spleen cells or lymph node cells are used if non-human mammalian sources are desired. The lymphocytes are then fused with an immortalized cell line using a suitable fusing agent, such as PEG, to form a hybridoma cell. Goding, Monoclonal Antibodies: Principles and Practice (Academic Press: New York, 1986) pp. 59-103.

5 Immortalized cell lines are usually transformed mammalian cells, particularly myeloma cells of rodent, bovine, and human origin. Usually, rat or mouse myeloma cell lines are employed. The hybridoma cells may be cultured in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, immortalized cells. For example, if the parental cells lack the enzyme hypoxanthine guanine phosphoribosyltransferase (HGPRT or HPRT), the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine ("HAT medium"), which substances prevent the growth of HGPRT-deficient cells.

10 Preferred immortalized cell lines are those that fuse efficiently, support stable high-level expression of antibody by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium. More preferred immortalized cell lines are murine myeloma lines, which can be obtained, for instance, from the Salk Institute Cell Distribution Center, San Diego, California, and the American Type Culture Collection, Manassas, Virginia. Human myeloma and mouse-human heteromyeloma cell lines also have been described for the production of human monoclonal antibodies. Kozbor, *J. Immunol.*, **133**:3001 (1984); Brodeur *et al.*, *Monoclonal Antibody Production Techniques and Applications* (Marcel Dekker, Inc.: New York, 1987) pp. 15 51-63.

20 The culture medium in which the hybridoma cells are cultured can then be assayed for the presence of monoclonal antibodies directed against a WISP polypeptide. Preferably, the binding specificity of monoclonal antibodies produced by the hybridoma cells is determined by immunoprecipitation or by an *in vitro* binding assay, such as radioimmunoassay (RIA) or enzyme-linked immunoabsorbent assay (ELISA). Such techniques and assays are known in the art. The binding affinity of the monoclonal antibody can, for example, be determined by the Scatchard analysis of Munson and Pollard, *Anal. Biochem.*, **107**:220 (1980).

25 After the desired hybridoma cells are identified, the clones may be subcloned by limiting dilution procedures and grown by standard methods. Goding, *supra*. Suitable culture media for this purpose include, for example, Dulbecco's Modified Eagle's Medium and RPMI-1640 medium. Alternatively, the hybridoma cells may be grown *in vivo* as ascites in a mammal.

30 The monoclonal antibodies secreted by the subclones may be isolated or purified from the culture medium or ascites fluid by conventional immunoglobulin purification procedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.

35 The monoclonal antibodies may also be made by recombinant DNA methods, such as those described in U.S. Patent No. 4,816,567. DNA encoding the monoclonal antibodies of the invention can be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies). The hybridoma cells of the invention serve as a preferred source of such DNA. Once isolated, the DNA may be placed into expression vectors, which are then transfected into host cells such as simian COS cells, CHO cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells. The DNA also may be modified, for example, by substituting the coding sequence for human heavy and light chain constant domains in place of the homologous murine sequences (U.S. Patent No. 4,816,567; Morrison *et al.*, *Proc. Natl. Acad. Sci. USA*, **81**:

6851-6855 (1984)) or by covalently joining to the immunoglobulin coding sequence all or part of the coding sequence for a non-immunoglobulin polypeptide. Such a non-immunoglobulin polypeptide can be substituted for the constant domains of an antibody of the invention, or can be substituted for the variable domains of one antigen-combining site of an antibody of the invention to create a chimeric bivalent antibody.

5 The antibodies may be monovalent antibodies. Methods for preparing monovalent antibodies are well known in the art. For example, one method involves recombinant expression of immunoglobulin light chain and modified heavy chain. The heavy chain is truncated generally at any point in the Fc region so as to prevent heavy-chain crosslinking. Alternatively, the relevant cysteine residues are substituted with another amino acid residue or are deleted so as to prevent crosslinking.

10 *In vitro* methods are also suitable for preparing monovalent antibodies. Digestion of antibodies to produce fragments thereof, particularly Fab fragments, can be accomplished using routine techniques known in the art.

### 3. Humanized Antibodies

15 The anti-WISP antibodies of the invention may further comprise humanized antibodies or human antibodies. Humanized forms of non-human (e.g., murine) antibodies are chimeric immunoglobulins, immunoglobulin chains, or fragments thereof (such as Fv, Fab, Fab', F(ab')<sub>2</sub>, or other antigen-binding subsequences of antibodies) which contain minimal sequence derived from non-human immunoglobulin. Humanized antibodies include human immunoglobulins (recipient antibody) in which residues from a 20 complementary-determining region (CDR) of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat, or rabbit having the desired specificity, affinity, and capacity. In some instances, Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues. Humanized antibodies may also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or 25 substantially all of the CDR regions correspond to those of a non-human immunoglobulin, and all or substantially all of the FR regions are those of a human immunoglobulin consensus sequence. The humanized antibody preferably also will comprise at least a portion of an Fc, typically that of a human immunoglobulin. Jones *et al.*, Nature, 321:522-525 (1986); Riechmann *et al.*, Nature, 332:323-329 (1988); Presta, Curr. Op. Struct. Biol., 2:593-596 (1992).

30 Methods for humanizing non-human antibodies are well known in the art. Generally, a humanized antibody has one or more amino acid residues introduced into it from a source which is non-human. These non-human amino acid residues are often referred to as "import" residues, which are typically taken from an "import" variable domain. Humanization can be essentially performed following the method of Winter and co-workers (Jones *et al.*, Nature, 321:522-525 (1986); Riechmann *et al.*, Nature, 332:323-327 (1988); 35 Verhoeyen *et al.*, Science, 239:1534-1536 (1988)), by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. Accordingly, such "humanized" antibodies are chimeric antibodies (U.S. Patent No. 4,816,567), wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species. In practice, humanized antibodies

are typically human antibodies in which some CDR residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies.

Human antibodies can also be produced using various techniques known in the art, including phage-display libraries. Hoogenboom and Winter, *J. Mol. Biol.*, 227:381 (1991); Marks *et al.*, *J. Mol. Biol.*, 222:581 (1991). The techniques of Cole *et al.* and Boerner *et al.* are also available for the preparation of human monoclonal antibodies. Cole *et al.*, *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, p. 77 (1985); Boerner *et al.*, *J. Immunol.*, 147(1):86-95 (1991).

#### 4. Bispecific Antibodies

Bispecific antibodies are monoclonal, preferably human or humanized, antibodies that have binding specificities for at least two different antigens. In the present case, one of the binding specificities is for a WISP polypeptide; the other one is for any other antigen, and preferably for a cell-surface protein or receptor or receptor subunit.

Methods for making bispecific antibodies are known in the art. Traditionally, the recombinant production of bispecific antibodies is based on the co-expression of two immunoglobulin heavy-chain/light-chain pairs, where the two heavy chains have different specificities. Milstein and Cuello, *Nature*, 305:537-539 (1983). Because of the random assortment of immunoglobulin heavy and light chains, these hybridomas (quadromas) produce a potential mixture of ten different antibody molecules, of which only one has the correct bispecific structure. The purification of the correct molecule is usually accomplished by affinity chromatography steps. Similar procedures are disclosed in WO 93/08829, published 13 May 1993, and in Traunecker *et al.*, *EMBO J.*, 10:3655-3659 (1991).

Antibody variable domains with the desired binding specificities (antibody-antigen combining sites) can be fused to immunoglobulin constant-domain sequences. The fusion preferably is with an immunoglobulin heavy-chain constant domain, comprising at least part of the hinge, CH2, and CH3 regions. It is preferred to have the first heavy chain constant region (CH1) containing the site necessary for light-chain binding present in at least one of the fusions. DNAs encoding the immunoglobulin heavy-chain fusions and, if desired, the immunoglobulin light chain, are inserted into separate expression vectors, and are co-transfected into a suitable host organism. For further details of generating bispecific antibodies see, for example, Suresh *et al.*, *Methods in Enzymology*, 121:210 (1986).

#### 5. Heteroconjugate Antibodies

Heteroconjugate antibodies are also within the scope of the present invention. Heteroconjugate antibodies are composed of two covalently joined antibodies. Such antibodies have, for example, been proposed to target immune system cells to unwanted cells (U.S. Patent No. 4,676,980), and for treatment of HIV infection. WO 91/00360; WO 92/200373; EP 03089. It is contemplated that the antibodies may be prepared *in vitro* using known methods in synthetic protein chemistry, including those involving cross-linking agents. For example, immunotoxins may be constructed using a disulfide-exchange reaction or by forming a thioether bond. Examples of suitable reagents for this purpose include iminothiolate and methyl-4-mercaptopbutyrimidate and those disclosed, for example, in U.S. Patent No. 4,676,980.

**G. Uses for anti-WISP Polypeptide Antibodies**

The antibodies of the invention may be used as affinity purification agents. In this process, the antibodies are immobilized on a solid phase such a SEPHADEX™ resin or filter paper, using methods well known in the art. The immobilized antibody is contacted with a sample containing the WISP polypeptide (or fragment thereof) to be purified, and thereafter the support is washed with a suitable solvent that will remove substantially all the material in the sample except the WISP protein, which is bound to the immobilized antibody. Finally, the support is washed with another suitable solvent, such as glycine buffer, pH 5.0, that will release the WISP polypeptide from the antibody.

Anti-WISP polypeptide antibodies may also be useful in diagnostic assays for WISP polypeptide, e.g., detecting its expression in specific cells, tissues, or serum. Thus, the antibodies may be used in the diagnosis of human malignancies (see, for example, U.S. Pat. No. 5,183,884).

For diagnostic applications, the antibody typically will be labeled with a detectable moiety. Numerous labels are available which can be preferably grouped into the following categories:

(a) Radioisotopes, such as  $^{35}\text{S}$ ,  $^{14}\text{C}$ ,  $^{125}\text{I}$ ,  $^{3}\text{H}$ , and  $^{131}\text{I}$ . The antibody can be labeled with the radioisotope using the techniques described in Current Protocols in Immunology, Volumes 1 and 2. Coligen *et al.*, Ed., (Wiley-Interscience: New York, 1991), for example, and radioactivity can be measured using scintillation counting.

(b) Fluorescent labels such as rare earth chelates (europium chelates) or fluorescein and its derivatives, rhodamine and its derivatives, dansyl, Lissamine, phycoerythrin, and Texas Red are available. The fluorescent labels can be conjugated to the antibody using the techniques disclosed in Current Protocols in Immunology, *supra*. Coligen, ed., for example. Fluorescence can be quantified using a fluorimeter.

(c) Various enzyme-substrate labels are available, and U.S. Patent No. 4,275,149 provides a review of some of these. The enzyme preferably catalyzes a chemical alteration of the chromogenic substrate which can be measured using various techniques. For example, the enzyme may catalyze a color change in a substrate, which can be measured spectrophotometrically. Alternatively, the enzyme may alter the fluorescence or chemiluminescence of the substrate. Techniques for quantifying a change in fluorescence are described above. The chemiluminescent substrate becomes electronically excited by a chemical reaction and may then emit light which can be measured (using a chemiluminometer, for example) or donates energy to a fluorescent acceptor. Examples of enzymatic labels include luciferases (e.g., firefly luciferase and bacterial luciferase; U.S. Patent No. 4,737,456), luciferin, 2,3-dihydrophthalazinediones, malate dehydrogenase, urease, peroxidase such as horseradish peroxidase (HRPO), alkaline phosphatase,  $\beta$ -galactosidase, glucoamylase, lysozyme, saccharide oxidases (e.g., glucose oxidase, galactose oxidase, and glucose-6-phosphate dehydrogenase), heterocyclic oxidases (such as uricase and xanthine oxidase), lactoperoxidase, microperoxidase, and the like. Techniques for conjugating enzymes to antibodies are described in O'Sullivan *et al.*, Methods for the Preparation of Enzyme-Antibody Conjugates for use in Enzyme Immunoassay, in Methods in Enzyme, Vol. 73, Langone and Van Yunakis, eds. (New York: Academic Press, 1981), pp. 147-166.

Examples of enzyme-substrate combinations include:

(i) Horseradish peroxidase (HRPO) with hydrogen peroxidase as a substrate, wherein the hydrogen peroxidase oxidizes a dye precursor (e.g., orthophenylenediamine (OPD) or 3,3',5,5'-tetramethyl benzidine hydrochloride (TMB));

(ii) alkaline phosphatase (AP) with para-nitrophenyl phosphate as chromogenic substrate; and

5 (iii)  $\beta$ -D-galactosidase ( $\beta$ -D-Gal) with a chromogenic substrate (e.g., p-nitrophenyl- $\beta$ -D-galactosidase) or fluorogenic substrate (4-methylumbelliferyl- $\beta$ -D-galactosidase).

Numerous other enzyme-substrate combinations are available to those skilled in the art. For a general review of these, see, for example, U.S. Patent Nos. 4,275,149 and 4,318,980.

Sometimes, the label is indirectly conjugated with the antibody. The skilled artisan will be aware of various techniques for achieving this. For example, the antibody can be conjugated with biotin and any of the three broad categories of labels mentioned above can be conjugated with avidin, or *vice versa*. Biotin binds selectively to avidin, and thus, the label can be conjugated with the antibody in this indirect manner. Alternatively, to achieve indirect conjugation of the label with the antibody, the antibody is conjugated with a small hapten (e.g., digoxin) and one of the different types of labels mentioned above is conjugated with an anti-hapten antibody (e.g., anti-digoxin antibody). Thus, indirect conjugation of the label with the antibody can be achieved.

In another embodiment of the invention, the anti-WISP polypeptide antibody need not be labeled, and the presence thereof can be detected using a labeled antibody which binds to the anti-WISP polypeptide antibody.

20 The antibodies of the present invention may be employed in any known assay method, such as competitive binding assays, direct and indirect sandwich assays, and immunoprecipitation assays. Zola, Monoclonal Antibodies: A Manual of Techniques (New York: CRC Press, Inc., 1987), pp.147-158.

25 Competitive binding assays rely on the ability of a labeled standard to compete with the test sample analyte for binding with a limited amount of antibody. The amount of WISP protein in the test sample is inversely proportional to the amount of standard that becomes bound to the antibodies. To facilitate determining the amount of standard that becomes bound, the antibodies preferably are insolubilized before or after the competition, so that the standard and analyte that are bound to the antibodies may conveniently be separated from the standard and analyte which remain unbound.

30 Sandwich assays involve the use of two antibodies, each capable of binding to a different immunogenic portion, or epitope, of the protein to be detected. In a sandwich assay, the test sample analyte is bound by a first antibody which is immobilized on a solid support, and thereafter a second antibody binds to the analyte, thus forming an insoluble three-part complex. See, e.g., U.S. Pat No. 4,376,110. The second antibody may itself be labeled with a detectable moiety (direct sandwich assays) or may be measured using an anti-immunoglobulin antibody that is labeled with a detectable moiety (indirect sandwich assay). For example, one type of sandwich assay is an ELISA assay, in which case the detectable moiety is an enzyme.

35 For immunohistochemistry, the tumor sample may be fresh or frozen or may be embedded in paraffin and fixed with a preservative such as formalin, for example.

The antibodies may also be used for *in vivo* diagnostic assays. Preferably, the antibody is labeled with a radionuclide (such as  $^{111}\text{In}$ ,  $^{99}\text{Tc}$ ,  $^{14}\text{C}$ ,  $^{131}\text{I}$ ,  $^{125}\text{I}$ ,  $^{3}\text{H}$ ,  $^{32}\text{P}$  or  $^{35}\text{S}$ ) so that the tumor can be localized using immunoscintigraphy.

5 Additionally, anti-WISP polypeptide antibodies may be useful as antagonists to WISP polypeptide functions where WISP polypeptide is upregulated in cancer cells or stimulates their proliferation or is upregulated in atherosclerotic tissue. Hence, for example, the anti-WISP polypeptide antibodies may by themselves or with a chemotherapeutic agent or other cancer treatment or drug such as anti-HER-2 antibodies be effective in treating certain forms of cancer such as breast cancer, colon cancer, lung cancer, and 10 melanoma. Further uses for the antibodies include inhibiting the binding of a WISP polypeptide to its receptor, if applicable, or to an IGF, if applicable. For therapeutic use, the antibodies can be used in the formulations, schedules, routes, and doses indicated above under uses for the WISP polypeptides. In addition, anti-WISP polypeptide antibody may be administered into the lymph as well as the blood stream.

15 As a matter of convenience, the anti-WISP antibody of the present invention can be provided as an article of manufacture such as a kit. An article of manufacture containing a WISP polypeptide or antagonists thereof useful for the diagnosis or treatment of the disorders described above comprises at least a container and a label. Suitable containers include, for example, bottles, vials, syringes, and test tubes. The containers may be formed from a variety of materials such as glass or plastic. The container holds a composition that is effective for diagnosing or treating the condition and may have a sterile access port (for example, the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection 20 needle).

25 The active agent in the composition is the WISP polypeptide or an agonist or antagonist thereto. The label on, or associated with, the container indicates that the composition is used for diagnosing or treating the condition of choice. The article of manufacture may further comprise a second container comprising a pharmaceutical-acceptable buffer, such as phosphate-buffered saline, Ringer's solution, and dextrose solution. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, syringes, and package inserts with instructions for use. The article of manufacture may also comprise a second or third container with another active agent as described above. A kit format generally is a packaged combination of reagents in predetermined amounts with instructions for 30 performing the diagnostic or treatment assay.

35 If the active agent is an antibody that is labeled with an enzyme, the kit will include substrates and cofactors required by the enzyme (e.g., a substrate precursor which provides the detectable chromophore or fluorophore). In addition, other additives may be included such as stabilizers, buffers (e.g., a block buffer or lysis buffer), and the like. The relative amounts of the various reagents may be varied widely to provide for concentrations in solution of the reagents which substantially maximize the sensitivity of the assay. Particularly, the reagents may be provided as dry powders, usually lyophilized, including excipients which on dissolution will provide a reagent solution having the appropriate concentration.

The following examples are offered for illustrative purposes only, and are not intended to limit the scope of the present invention in any way.

All patent and literature references cited in the present specification are hereby incorporated by reference in their entirety.

#### EXAMPLES

Commercially available reagents referred to in the examples were used according to manufacturer's instructions unless otherwise indicated. The source of those cells identified in the following examples, and throughout the specification, by ATCC accession numbers is the American Type Culture Collection, 10801 University Blvd., Manassas, Virginia.

##### EXAMPLE 1: Isolation of cDNA Clones Encoding Mouse WISP-1

Several putative WISP genes have been identified at the mRNA level in a high-throughput PCR-select cDNA subtraction experiment carried out using a mouse mammary cell line (C57MG), which has been transformed by a Wnt-1 retroviral vector and compared with the parental cell line. The WISP family disclosed herein, including the mouse WISP-1 gene, was induced only in the transformed cell line C57MGWnt-1.

###### 1. Suppression Subtractive Hybridization

Mouse WISP-1 was isolated independently by Wnt-1 differential screening using suppression subtractive hybridization (SSH), as described by Diatchenko *et al.*, Proc. Natl. Acad. Sci. USA, **93**: 6025-6030 (1996). SSH was carried out using the PCR-SELECT® cDNA Subtraction Kit (Clontech Laboratories, Inc.) according to the manufacturer's protocol. Driver double-stranded (ds) cDNA was synthesized from 2 micrograms of polyA+ RNA isolated from a mouse mammary cell line (C57MG), obtainable from a mouse breast cancer myoepithelial cell line. This cell line is described in Brown *et al.*, Cell, **46**: 1001-1009 (1986); Olson and Papkoff, Cell Growth and Differentiation, **5**: 197-206 (1994); Wong *et al.*, Mol. Cell. Biol., **14**: 6278-6286 (1994); and Jue *et al.*, Mol. Cell. Biol., **12**: 321-328 (1992), and is responsive to Wnt-1 but not to Wnt-4. Tester ds cDNA was synthesized from 2 micrograms of polyA+ RNA isolated from a transformed version of C57MG, called C57MG/wnt-1.

The C57MG/wnt-1 mouse mammary derivative cell line was prepared by first transforming the parent line with a Wnt-1 retroviral vector, pBabe Puro (5.1 kb). This vector has a 5' LTR, packaging elements, a multiple cloning site, the puromycin-resistance gene driven off the SV40 promoter, a 3' LTR, and the bacterial elements for replication and ampicillin selection. The vector was modified slightly for Wnt-1 cloning by removing the *Hind*III site after the SV40 promoter and adding a *Hind*III site to the multiple cloning site. Wnt-1 is cloned from *Eco*RI-*Hind*III in the multiple cloning site. Figure 13 shows a map of the vector.

The transformed derivative cells were grown up in a conventional fashion, and the final cell population was selected in DMEM + 10% FCS with 2.5 µg/ml puromycin to stabilize the expression vector.

PCR was performed using the Clontech kit, including the cDNA synthesis primer (SEQ ID NO:40), adaptors 1 and 2 (SEQ ID NOS:41 and 42, respectively) and complementary sequences for the adaptors (SEQ ID NOS:43 and 44, respectively). PCR primer 1 (SEQ ID NO:45), PCR primer 2 (SEQ ID NO:46), nested PCR primer 1 (SEQ ID NO:47), nested PCR primer 2 (SEQ ID NO:48), control primer G3PDHS' primer (SEQ ID NO:49), and control primer G3PDH3' primer (SEQ ID NO:50), shown in Figure 14.

Products generated from the secondary PCR reaction were inserted into the cloning site region of pGEM-T vector (Promega), shown in Figure 15 (SEQ ID NOS:51 and 52 for 5' and 3' sequences, respectively). Plasmid DNAs were prepared using the WIZARD MINIPREP™ Kit (Promega). DNA sequencing of the subcloned PCR fragments was performed manually by the chain termination reaction (SEQUENASE 2.0™ Kit, Pharmacia). Nucleic acid homology searches were performed using the BLAST 5 program noted above.

A total of 1384 clones were sequenced out of greater than 5000 found. A total of 1996 DNA templates were prepared. A program was used to trim the vector off, and a different program used to cluster the clones into two or more identical clones or with an overlap of 50 bases the same. Then a BLAST was 10 performed of a representative clone from the cluster. Primers were designed for RT-PCR to see if the clones were differentially expressed.

## 2. Semi-quantitative RT-PCR

One of the clones was clone 568 having 71 bp, which was identified as encoding mouse WISP-1. There were six clones in this cluster. The nucleotide sequence and putative amino acid sequence of full-length mouse WISP-1 are shown in Figure 1 (SEQ ID NOS:9 and 12, respectively). RT-PCR primers were 15 designed for confirming differential expression, screening for full-length mouse clone, and screening for the human clone. These primers were 568.PCR.top1 (nucleotides 909-932 of the full-length nucleotide sequence encoding mouse WISP-1 (SEQ ID NO:9 of Figure 1) and 568.PCR.bot1 (nucleotides 955-978 of the full-length complementary nucleotide sequence encoding mouse WISP-1 (SEQ ID NO:10 of Figure 1), which 20 are as follows:

568.PCR.top1: 5'-CCAGCCAGAGGAGGCCACGAAC (SEQ ID NO:100)

568.PCR.bot1: 3'-TGTGCGTGGATGGCTGGGTTCATG (SEQ ID NO:101)

For the RT-PCR procedure, cell lines were grown to subconfluence before extracting the RNA. Total RNA was extracted using Stat-60™ (TEL-TEST™ B) per manufacturer's instructions. First-strand 25 cDNA was prepared from 0.1 µg - 3 µg of total RNA with the SUPERSCRIPT™ RT kit (Gibco, BRL). PCR amplification of 5 µl of first-strand cDNA was performed in a 50-µl PCR reaction. The above primers were used to amplify first-strand cDNA. As controls, primers corresponding to nucleotide positions 707-729 (sense: 5'-GTGGCCCAGCTCTGGCAGAGGG (SEQ ID NO:102) or 836-859 (sense: 5'-GACTGGAGCAAGGTCGTCCCTCGCC (SEQ ID NO:103)) and 1048-1071 (anti-sense: 5'-GCACCACCCACAAGGAAGCCATCC (SEQ ID NO:104)) of human triosephosphate isomerase (huTPI) 30 (Maquat *et al.*, *J. Biol. Chem.*, **260**: 3748-3753 (1985); Brown *et al.*, *Mol. Cell. Biol.*, **5**: 1694-1706 (1985)) were used to amplify first-strand cDNA. For mouse triosephosphate isomerase, primers corresponding to nucleotide positions 433-456 (sense: 5'-GACGAAAGGGAAGCCGGCATCACQ (SEQ ID NO: 105)) or 457-480 bp (sense: 5'-GAGAAGGTCGTGTCGAGCAAACC (SEQ ID NO: 106)) and 577-600 bp (antisense: 5'-35 CTTCTCGTGTACTTCCTGTGCCTG (SEQ ID NO:107)) or 694-717 bp (antisense: 5'-CACGTCAGCTGGCGTTGCCAGCTC (SEQ ID NO:108)) were used for amplification.

Briefly, 4 µCi of (<sup>32</sup>P)-CTP (3000 Ci/mmol) was added to each reaction with 2.5 U of TAKARA EX TAQ™ (Panvera, Madison, WI) and 0.2 µM of each dNTP. The reactions were amplified in a 480 PCR THERMOCYCLER™ (Perkin Elmer) using the following conditions: 94°C for 1 min., 62°C for 30 sec..

72°C for 1 min. for 18-25 cycles. 5 µl of PCR products were electrophoresed on a 6% polyacrylamide gel. The gel was exposed to film. Densitometry measurements were obtained using ALPHA EASE VERSION 3.3a™ software (Alpha Innotech Corporation) to quantitate the WISP- or TPI-specific gene products.

#### 3. Northern Blot Analysis

5 Adult multiple-tissue Northern blots (Clontech) and the Northern blot of the C57MG parent and C57MG/Wnt-1 derivative polyA+RNA (2 µg/lane) were hybridized with a 70-bp mouse WISP-1 probe (amino acids 278 through 300 of Fig. 1; QPEEA TNFTLAGCVSTRTYRPKY; SEQ ID NO:109) generated using the primers 568.PCR.top1 and 568.pcr.bot1 noted above. The membranes were washed in 0.1 X SSC at 55-65°C and exposed for autoradiography. Blots were rehybridized with a 75-bp synthetic probe from the 10 human actin gene. See Godowski *et al.*, *Proc. Natl. Acad. Sci. USA*, **86**: 8083-8087 (1989) for a method for making a probe with overlapping oligos, which is how the actin probe was prepared.

#### 4. cDNA Library Screening

15 Clones encoding the full-length mouse WISP-1 were isolated by screening a λgt10 oligodT primed mouse embryo library (Clontech) with the primers 568.PCR.top1 and 568.PCR.bot1 noted above. The inserts of 13 of these clones were subcloned into pBLUESCRIPT™ II SK+ and their DNA sequences determined by dideoxy DNA sequencing on both strands.

#### 5. Results

20 The recently described technique of SSH combines a high subtraction efficiency with an equalized representation of differentially expressed sequences. This method is based on specific PCR reactions that permit exponential amplification of cDNAs which differ in abundance, whereas amplification of sequences of identical abundance in two populations is suppressed. The SSH technique was used herein to isolate genes expressed in a mouse mammary myoepithelial cell transformed with *Wnt-1* whose expression is reduced or absent in the parental myoepithelial cell. The polyA+RNA extracted from both types of cells was used to synthesize tester and driver cDNAs. The degree of subtraction efficiency was monitored by Southern blot 25 analysis of unsubtracted and subtracted PCR products using a β-actin probe. No β-actin mRNA was apparent in the subtracted PCR products, confirming the efficiency of the subtraction.

30 The subtracted cDNA library was subcloned into a pGEM-T vector for further analysis. A random sample of 1996 clones was sequenced from the transformed colonies obtained. To determine if the clones obtained were differentially expressed, PCR primers were designed for selected clones and semi-quantitative RT-PCR and Northern analyses were performed using mRNA from the mouse mammary cell line and its derivative. It was found that expression of *Wnt-1* in C57MG cells leads to elongated cell morphology and loss of contact inhibition.

35 One clone (m568.19A) of those that fulfilled the criteria for differential expression was found to encode full-length mouse WISP-1. By both RT-PCR analysis and Northern analysis, it was found that this clone provided an about three-fold induction in the Wnt-1 cell line over the parent cell line.

The cDNA sequence of this clone and deduced amino acid sequence of full-length mouse WISP-1 are shown in Figure 1 (SEQ ID NOS:9 and 12, respectively). The sequence alignment of human and mouse WISP-1 (SEQ ID NOS:4 and 12, respectively) is shown in Figure 8. *In-situ* analysis of the clone is presented below, along with thymidine incorporation assay and angiostatic assay results.

This clone was placed in pRK5E, an *E. coli*-derived cloning vector having a human cytomegalovirus intermediate early gene promoter, an SV40 origin and polyA site, an *sp6* transcription initiation site, a human immunoglobulin splice acceptor, and *Xba*I/*Nor*I cDNA cloning sites. It is a progeny of pRK5D that has an added *Sce*I site. Holmes *et al.*, *Science*, 253:1278-1280 (1991). Upon transformation into JM109 cells, the 5 plasmid rendered the cells ampicillin resistant. Upon digestion with *Xba*I and *Bam*HI, a 1140-bp fragment was obtained, and the mouse insert size was 1122 base pairs, from the ATG to the stop codon, including a 3' tag of six histidines.

EXAMPLE 2: Isolation of a cDNA Clone Encoding Mouse WISP-2

The cDNA for mouse WISP-2 was isolated independently by Wnt-1 differential screening using the 10 procedure described in Example 1. The initial clone isolated was 318 bp in length and was designated clone 1367. There were four clones in this cluster. The clone was sequenced as described above and RT-PCR primers were designed as follows:

1367.pcr.top1: nucleotides 1604-1627 of Figure 2:

3'-GGTGTGAAGACCGTCCGGTCCCGG (SEQ ID NO:110)

15 and

1367.pcr.bot1: nucleotides 1438-1461 of Figure 2:

5'-GTGTGCCTTCCTGATCTGAGAAC (SEQ ID NO:111)

After RT-PCR and Northern blot procedures were carried out as described in Example 1 to confirm differential expression, a five-fold induction in the Wnt-1 cell line was observed.

20 Clones encoding full-length mouse WISP-2 were isolated from RNA library 211: C57MG/Wnt-1. mRNA for construction of this library was isolated from the C57MG/Wnt-1 cell line described in Example 1. The RNA was used to generate an oligo-dT-primed cDNA library in the cloning vector pRK5E using reagents and protocols from Life Technologies, Gaithersburg, MD (SUPERSCRIPT PLASMID SYSTEM<sup>TM</sup>).

25 In this procedure, the double-stranded cDNA was primed with oligo dT containing a *Nor*I site, linked with blunt-to-*Sac*I hemikinased adaptors, cleaved with *Nor*I, sized to greater than 1000 bp appropriately by gel electrophoresis, and cloned in a defined orientation into the *Xba*I/*Nor*I-cleaved pRK5E vector. The library was screened by colony hybridization with a probe 1367.50mer, 1 of bases 1463-1512 of Figure 2:

3'-GGGACGGGCCGACCCTTCTAAAGACCCTGTACTTCTACCTTAGTG (SEQ ID NO:112).

30 The full-length mouse WISP-2 clone was obtained, designated clone 1367.3.

The cDNA for mouse WISP-2, like the mouse WISP-1 molecule, encodes a novel secreted protein 35 that belongs to the CTGF family and is the mouse homologue of SST DNA33473 of Example 4. (The alignment of human and mouse WISP-2 (SEQ ID NOS:16 and 20, respectively) is shown in Figure 9.) The mouse WISP-2 gene is 38% identical in sequence to mouse WISP-1, disclosed in Example 1, but lacks the C-terminal 95 amino acids thought to be involved in dimerization and receptor binding. Mouse WISP-2 was highly expressed in the lung. *In-situ* analysis of the clone is noted below. The nucleotide sequence and putative amino acid sequence of full-length mouse WISP-2 are shown in Figure 2 (SEQ ID NOS:17 and 20, respectively). The putative signal sequence is from amino acid positions 1 to 23 of SEQ ID:20.

The clone was inserted into pRK5E, described above. Upon transformation of JM109 cells, the plasmid rendered the cells ampicillin resistant. Upon digestion with *Bam*HI and *Nor*I, a 1770-bp fragment was obtained, having a mouse insert of 756 bp from ATG to the stop codon.

EXAMPLE 3: Isolation of a cDNA Clone Encoding Human WISP-1

5 To isolate the full-length human clone corresponding to m568.19A (mouse WISP-1), a human lung cDNA library (Clontech), treated with the SUPERSCRIPT™ kit using the pRK5E vector as described above, was screened with a 70-bp probe at low stringency (20% formamide, 1 X SSC, 55°C wash). The probe had the sequence from nucleotides 909-978 of the full-length mouse WISP-1 nucleotide sequence of Figure 1, i.e., the sequence:

10 5'-CCAGCCAGAGGAGGCCACGAACCTCACTCTCGCAGGCTGTGTCAGCACACGCACCTACC  
GACCCAAGTAC (SEQ ID NO:113)  
Only one clone was identified, hL.568.15A. The insert to this clone was subcloned into pBLUESCRIPT™ IISK+ and its DNA sequence determined by dideoxy DNA sequencing on both strands. This clone was found to be missing about 280 amino acids. Hence, a new probe (hu.568.50mer.1) was designed from clone 15A  
15 having the nucleotides 750-799 of the full-length human WISP-1 nucleotide sequence shown in Figures 3A and 3B, i.e.,

20 5'-GCCCTGGAGCCCTTGCTCCACCAGCTGCGGCCTGGGGTCTCCACTCGG (SEQ ID NO:114)  
This probe was used to screen a human fetal kidney cDNA library (Clontech), treated with the SUPERSCRIPT™ kit using the pRK5E vector as described above, by colony hybridization. A number of clones were obtained by screening this human fetal kidney cDNA library (clones without the A or B designation) or by screening a human fetal kidney λgt10 library (clones with the A or B designation) using  
25 the same probes described above. The inserts of these clones were subcloned into pBLUESCRIPT™ IISK+ and their DNA sequences determined by dideoxy DNA sequencing on both strands.

30 Two of these clones, designated as 568.1A and 568.4A, have their respective sequences (SEQ ID NOS:24 and 26) shown in Figures 27 and 29. These clones are missing the von Willebrand C1 domain, the variable domain, and the thrombospondin 1 domain, and have a frameshift. Other clones, designated as 568.13, 568.39, 568.5A, 568.6B, and 568.7 (SEQ ID NOS:23, 25, 27, 28, and 29, respectively; Figs. 26, 28, and 30-32, respectively), were obtained that lack one or more domains and/or short amino-acid stretches (e.g., an 8- amino-acid deletion) or contain additional short amino-acid stretches and may contain introns or alternative splice variants.

35 Two clones sharing a significant amount of sequence with the full-length clone 568.38 were identified: 568.23 and 568.35. Human clone 568.38 encoded the full-length human WISP-1. The nucleotide sequence and putative amino acid sequence for clone 568.38 are shown in Figures 3A and 3B (SEQ ID NOS:1 and 4, respectively). The aligning sequences of clones 568.38 and 568.35 differ from the corresponding aligning sequences of clones 568.15A and 568.23 in that the respective sequences of the latter two clones have an isoleucine residue at amino acid position 184 of Figs. 3A and 3B, whereas the respective corresponding sequences of clones 568.38 and 568.35 have a valine residue at this position. Further, the aligning sequences of clones 568.35 and 568.38 differ from each other in that the sequence of clone 568.35

has a serine residue at amino acid position 202 of Figs. 3A and 3B, whereas the corresponding sequence of clone 568.38 has an alanine residue at this position.

The human WISP-1 polypeptide, by homology searching, is also found to be a member of the CTGF family. The clone was placed in a pRK5E plasmid as described above and deposited with the ATCC. Upon 5 transformation into JM109 cells, the plasmid rendered the cells ampicillin resistant. Digestion with *Cla*I and *Eco*RV yielded a 1435-bp fragment with an insert size of 1104 basepairs from ATG to the stop codon.

*In situ* hybridization of human WISP-1 was performed, with the results given below. Northern analysis of human WISP-1 showed high expression in adult heart tissue and ovary tissue, and in fetal kidney tissue. Also presented below are thymidine incorporation assay, gene amplification assay, and angiostatic 10 assay results.

The chromosomal location of the human WISP genes was determined by radiation hybrid mapping using the Stanford G3<sup>TM</sup> and the MIT Genebridge 4 Radiation Hybrid<sup>TM</sup> panels. WISP-1 resides at approximately 3.48 cR from the meiotic marker AFM259xc5 (LOD score 16.31) on the Genebridge map. This places WISP-1 in band 8q24.1 to 8q24.3, roughly four megabases distal to *c-myc* located at chromosome 15 band 8q24.12-8q24.13. Takahashi *et al.*, *Cytogenet. Cell Genet.*, 57: 109-111 (1991). *c-myc* is a region that is a recurrent site of amplification in non-small cell lung carcinoma.

**EXAMPLE 4: Isolation of a cDNA Clone Encoding Human PRO261 (designated herein as human WISP-2)**

The extracellular domain (ECD) sequences (including the secretion signal, if any) of from about 950 known secreted proteins from the SWISS-PROT<sup>TM</sup> public protein database were used to search expressed 20 sequence tag (EST) databases. The EST databases included public EST databases (e.g., GenBank) and a proprietary EST DNA database (LIFESEQ<sup>TM</sup>, Incyte Pharmaceuticals, Palo Alto, CA). The search was performed using the computer program BLAST or BLAST2 (Altshul *et al.*, *Methods in Enzymology* 266:460-480 (1996)) as a comparison of the ECD protein sequences to a 6-frame translation of the EST sequence. Those comparisons resulting in a BLAST score of 70 (or in some cases 90) or greater that did not encode 25 known proteins were clustered and assembled into consensus DNA sequences with the program "phrap" (Phil Green, University of Washington, Seattle, Washington: <http://bozeman.mbt.washington.edu/phrap.docs/phrap.html>).

A consensus DNA sequence was assembled relative to other EST sequences using phrap. The EST sequences used (from Incyte) were Nos. 2633736, 2118874, 360014, 2316216, 1985573, 2599326, 1544634, 30 2659601, 1319684, 783649, 627240, 1962606, 2369125, 939761, 1666205, 692911, 984510, 1985843, 2104709, and 2120142. This consensus sequence is herein designated DNA30843 (see Fig. 5). Based on the DNA30843 consensus sequence, oligonucleotides were synthesized: 1) to identify by PCR a cDNA library that contained the sequence of interest, and 2) for use as probes to isolate a clone of the full-length coding sequence for PRO261 (human WISP-2). A pair of PCR primers, forward and reverse, were synthesized 35 having the respective sequences:

5'-AAAGGTGCGTACCCAGCTGTGCC (SEQ ID NO:115) and

3'-TCCAGTCGGCAGAACGGTTCTGG (SEQ ID NO:116).

Additionally, a synthetic oligonucleotide hybridization probe was constructed from the consensus DNA30843 sequence, which probe has the sequence:

5'-CCTGGTGCTGGATGGCTGTGGCTGCTGCCGGGTATGTGCACGGCGGCTGGG (SEQ ID NO:117).

For screening several libraries for a source of a full-length clone, DNA from the libraries was screened by PCR amplification, as per Ausubel *et al.* Current Protocols in Molecular Biology (Green Publishing Associates and Wiley Interscience, N.Y., 1989), with the PCR primer pair identified above. A 5 positive library was then screened by colony hybridization to isolate clones encoding PRO261 (human WISP-2) using the probe oligonucleotide and one of the PCR primers.

10 RNA for construction of the cDNA libraries was isolated from human fetal lung tissue. The cDNA libraries used to isolate the cDNA clones were constructed by standard methods using commercially available reagents such as those from Invitrogen, San Diego, CA. The cDNA was primed with oligo dT containing a *Nor*I site, linked with blunt-to-*Sac*I-hemikinased adaptors, cleaved with *Nor*I, sized appropriately by gel electrophoresis, and cloned in a defined orientation into a suitable cloning vector (such as pRK5B or pRK5D; pRK5B is a precursor of pRK5D that does not contain the *Sac*I site; see Holmes *et al.*, Science, 253:1278-1280 (1991)) in the unique *Xba*I and *Nor*I sites.

15 DNA sequencing of the clones isolated as described above gave the DNA sequence for PRO261 (herein designated as UNQ228 (DNA33473-seq min); SEQ ID NO:38), which begins at nucleotide 13 of SEQ ID NO:13 (Fig. 4) and the derived amino acid sequence for PRO261 (SEQ ID NO:16).

20 The entire nucleotide sequence encoding human WISP-2 is shown in Figure 4 (SEQ ID NO:13). This sequence contains a single open reading frame with an apparent translational initiation site at nucleotide positions 22-24 of SEQ ID NO:13 and ending at the stop codon after nucleotide 770 of SEQ ID NO:13 (Figure 4). The predicted polypeptide precursor is 250 amino acids long (Figure 4). The putative signal sequence spans from amino acid positions 1 to 23 of SEQ ID NO:16. Clone UNQ228 (DNA33473-seq min) has been deposited with ATCC and is assigned ATCC deposit no. 209391.

25 Analysis of the amino acid sequence of the full-length PRO261 polypeptide suggests that portions of it possess significant homology to CTGF, thereby indicating that PRO261 is a novel growth factor.

30 *In situ* hybridization of human WISP-2 is given below. The chromosomal location of the human WISP-2 gene was determined as described above for human WISP-1. Specifically, WISP-2 is linked to the marker SHGC-33922, with a LOD score of 1000. This places WISP-2 in band 20q12-20q13.1. Human chromosome 20q12 is a frequent site of DNA amplification in human breast cancer. In a *Xenopus* assay, injection of human WISP-2 RNA partially induced axis duplication (see Example 11). Also presented below are thymidine incorporation assay, gene amplification assay, and angiostatic assay results for human WISP-2.

#### EXAMPLE 5: Isolation of cDNA Clones Encoding Human WISP-3

35 In this example, the gene encoding WISP-3 was cloned twice essentially in parallel. First, it was determined whether the databases described above contained any new members of the WISP family. Two EST homologies to the WISPs were found and both were cloned. Full-length clones were isolated corresponding to each of these EST homologies. The efforts resulted in two full-length clones of the same gene (the original EST homologies had been from distinct regions of the same gene). The first clone obtained was designated as DNA56350 and the second as DNA58800.

DNAS6350

Based on the sequence of INCYTE 3208053, a virtual DNA 48917 was obtained and oligonucleotides were synthesized for use as probes to isolate a clone of the full-length coding sequence for PRO956 (human WISP-3). A pair of PCR primers, forward and reverse, were synthesized having the sequences:

5 5'-GTCTTGTGCAAGCAACAAAATGGACTCC (SEQ ID NO:118)

3'-GACACAATGTAAGTCGGAACGCTGTCG (SEQ ID NO:119)

Additionally, a synthetic oligonucleotide hybridization probe was constructed from the INCYTE sequence, which probe has the sequence:

10 5'-GCTCCAGAACATGTGGATGGAAATCTAACAGGGTGACCAATGAAAAQ (SEQ ID NO:120)

A human fetal kidney library primed with oligo dT containing a *Xba*I-*Not*I size cut greater than 3700 kb was screened for a source of a full-length clone by PCR amplification with the PCR primer pair identified above. The positive library was then used to isolate clones encoding PRO956 (human WISP-3) using the probe oligonucleotide and one of the PCR primers.

15 DNA sequencing of the clone isolated as described above gave the DNA sequence for PRO956 (herein designated as UNQ462 (SEQ ID NO:30), and the derived amino acid sequence for PRO956 (SEQ ID NO: 33).

20 The entire nucleotide sequence encoding human WISP-3 from this clone is shown in Figure 6 (SEQ ID NO:30). This sequence contains a single open reading frame with an apparent translational initiation site at nucleotide positions 46-48 of SEQ ID NO:30 and ending at the stop codon after nucleotide 1161 of SEQ ID NO:30 (Figure 6). The predicted polypeptide precursor is 372 amino acids long (Figure 6). The putative signal sequence is from amino acid positions 1 to 33 of SEQ ID NO:33. Clone UNQ462 (DNA56350-1176-2) has been deposited with ATCC and is assigned ATCC deposit no. 209706.

25 Analysis of the amino acid sequence of the full-length PRO956 polypeptide suggests that portions of it possess significant homology to CTGF, thereby indicating that PRO956 is a novel growth factor. This clone has an additional methionine just 5' of the first methionine in this clone. The amino acid sequence of this clone is 42% homologous to that of human WISP-1, and 32% homologous to that of human WISP-2.

30 *In situ* hybridization of human WISP-3 is shown below. Using the mapping techniques set forth above, it was found that human WISP-3 was localized to chromosome 6q22-6q23 and was linked to the marker AFM211ze5 with a LOD score of 1000. WISP-3 is approximately 18 megabases proximal to CTGF and 23 megabases proximal to the human cellular oncogene MYB, which are also located at 6q22-6q23. Martinerie *et al.*, *Oncogene*, 7: 2529-2534 (1992); Meese *et al.*, *Genes Chromosomes Cancer*, 1: 88-94 (1989).

35 The clone was inserted into pRK5E, described above. Upon transformation of JM109 cells, the plasmid rendered the cells ampicillin resistant. Upon digestion with *Bam*HI and *Not*I, a fragment was obtained having a human insert from ATG to the stop codon as indicated in Figure 6.

DNA58800

Based on the sequence of HS142L7, a virtual DNA 56506 was obtained and oligonucleotides were synthesized for use as probes to isolate a clone of the full-length coding sequence for PRO790 (human WISP-3). To this end, a pair of PCR primers, forward and reverse, were synthesized having the sequences:

5 5'-CCTGGAGTGAGCCTGGTGAGAGA (SEQ ID NO:121)  
3'-ACACTGGGTGTGTTCCCGACATAACA (SEQ ID NO:122)

Additionally, a synthetic oligonucleotide hybridization probe was constructed from the HS142L7 sequence, which probe has the sequence:

5'-TGGTTGCTTGGCACAGATTACAGCATCCACAGCCATCTCTCA (SEQ ID NO:123)

10 A human bone marrow library primed with oligo dT containing a *Xba*I-*Not*I size cut of 1-3 kb was screened for a source of a full-length clone by PCR amplification with the PCR primer pair identified above. The positive library was then used to isolate clones encoding PRO790 (human WISP-3) using the probe oligonucleotide and one of the PCR primers.

15 DNA sequencing of the clone isolated as described above gave the DNA sequence for PRO790 (SEQ ID NO:34), and the derived amino acid sequence for PRO790 (SEQ ID NO:37).

The entire nucleotide sequence encoding human WISP-3 from this clone is shown in Figure 7 (SEQ ID NO:34). This sequence contains a single open reading frame with an apparent translational initiation site at nucleotide positions 16-18 of SEQ ID NO:34 and ending at the stop codon after nucleotide 1077 of SEQ ID NO:34 (Figure 7). The predicted polypeptide precursor is 355 amino acids long (Figure 7). The putative signal sequence spans from amino acid positions 1 to 15 of SEQ ID NO:37. This clone DNA58800-1176-2 has been deposited with ATCC and is assigned ATCC deposit no. 209707.

20 Analysis of the amino acid sequence of the full-length PRO790 polypeptide suggests that portions of it possess significant homology to CTGF, thereby indicating that, like PRO956 which is a splice variant thereof, PRO790 is a novel growth factor.

25 *In situ* hybridization of human WISP-3 is shown below.

The clone was inserted into pRK5E, described above. Upon transformation of JM109 cells, the plasmid rendered the cells ampicillin resistant. Upon digestion with *Bam*HI and *Not*I, a fragment was obtained having a human insert from ATG to the stop codon as indicated in Figure 7.

EXAMPLE 6: Use of WISP-Encoding DNA as a Hybridization Probe

30 The following method describes use of a nucleotide sequence encoding a WISP polypeptide as a hybridization probe.

35 DNA comprising the coding sequence of full-length or mature human WISP-1 (as shown in Figures 3A and 3B, SEQ ID NOS:4 or 3, respectively), or full-length or mature mouse WISP-1 (as shown in Figure 1, SEQ ID NOS:12 or 11, respectively), or of full-length or putative mature human WISP-2 (as shown in Fig. 4, SEQ ID NOS:16 or 15, respectively), or full-length or putative mature mouse WISP-2 (as shown in Figure 2, SEQ ID NOS:20 or 19, respectively) is employed as a probe to screen for homologous DNAs (such as those encoding naturally occurring variants of these particular WISP proteins in human tissue cDNA libraries or human tissue genomic libraries.

Hybridization and washing of filters containing either library DNAs is performed under the following high-stringency conditions. Hybridization of radiolabeled WISP-polypeptide-derived probe (such as UNQ228 (DNA33473-seqmin)-derived probe) to the filters is performed in a solution of 50% formamide, 5x SSC, 0.1% SDS, 0.1% sodium pyrophosphate, 50 mM sodium phosphate, pH 6.8, 2x Denhardt's solution, and 10% dextran sulfate at 42°C for 20 hours. Washing of the filters is performed in an aqueous solution of 0.1x SSC and 0.1% SDS at 42°C.

5 DNAs having a desired sequence identity with the DNA encoding a full-length, native-sequence WISP polypeptide can then be identified using standard techniques known in the art.

EXAMPLE 7: Expression of WISP Polypeptide in *E. coli*

10 This example illustrates preparation of an unglycosylated form of WISP polypeptide by recombinant expression in *E. coli*.

15 The DNA sequence encoding WISP polypeptide is initially amplified using selected PCR primers. The primers should contain restriction enzyme sites which correspond to the restriction enzyme sites on the selected expression vector. A variety of expression vectors may be employed. An example of a suitable vector is pBR322 (derived from *E. coli*; see Bolivar *et al.*, *Gene*, 2:95 (1977)) which contains genes for ampicillin and tetracycline resistance. The vector is digested with restriction enzyme and dephosphorylated. The PCR-amplified sequences are then ligated into the vector. The vector will preferably include sequences which encode an antibiotic-resistance gene, a trp promoter, a polyhis leader (including the first six STII codons, polyhis sequence, and enterokinase cleavage site), the WISP-coding region, lambda transcriptional 20 terminator, and an *argU* gene.

25 The ligation mixture is then used to transform a selected *E. coli* strain using the methods described in Sambrook *et al.*, *supra*. Transformants are identified by their ability to grow on LB plates, and antibiotic-resistant colonies are then selected. Plasmid DNA can be isolated and confirmed by restriction analysis and DNA sequencing.

30 Selected clones can be grown overnight in liquid culture medium such as LB broth supplemented with antibiotics. The overnight culture may subsequently be used to inoculate a larger-scale culture. The cells are then grown to a desired optical density, during which the expression promoter is turned on.

35 After the cells are cultured for several more hours, the cells can be harvested by centrifugation. The cell pellet obtained by the centrifugation can be solubilized using various agents known in the art, and the WISP polypeptide can then be purified using a metal-chelating column under conditions that allow tight binding of the protein.

EXAMPLE 8: Expression of WISP Polypeptide in Mammalian Cells

This example illustrates preparation of a potentially glycosylated form of WISP polypeptide by recombinant expression in mammalian cells.

35 The vector, pRKSE, was employed as the expression vector. The appropriate DNA encoding WISP polypeptide was ligated into pRKSE with selected restriction enzymes to allow insertion of the DNA for WISP polypeptide using ligation methods as described in Sambrook *et al.*, *supra*. The resulting vectors were pRKSE.h.WIG-1.568.38, pRKSE.m.WIG-1.568.6his, pRKSE.m.WIG-2.1367.3, plasmid encoding human

WISP-2, DNA56350-1176-2, and DNA58800-1176-2, all deposited at the ATCC. These vectors are conveniently referred to collectively as pRK5E.WISP in the general description below.

In one embodiment, the selected host cells may be 293 cells. Human 293 cells (ATCC CCL 1573) are grown to confluence in tissue culture plates in medium such as DMEM supplemented with fetal calf serum and optionally, nutrient components and/or antibiotics. About 10 µg pRK5E.WISP DNA is mixed with about 5 µg DNA encoding the VA RNA gene (Thimmappaya *et al.*, Cell, 31:543 (1982)) and dissolved in 500 µl of 1 mM Tris-HCl, 0.1 mM EDTA, 0.227 M CaCl<sub>2</sub>. To this mixture is added, dropwise, 500 µl of 50 mM HEPES (pH 7.35), 280 mM NaCl, 1.5 mM NaPO<sub>4</sub>, and a precipitate is allowed to form for 10 minutes at 25°C. The precipitate is suspended and added to the 293 cells and allowed to settle for about four hours at 10 37°C. The culture medium is aspirated off and 2 ml of 20% glycerol in phosphate-buffered saline (PBS) is added for 30 seconds. The 293 cells are then washed with serum-free medium, fresh medium is added, and the cells are incubated for about 5 days.

Approximately 24 hours after the transfections, the culture medium is removed and replaced with culture medium (alone) or culture medium containing 200 µCi/ml <sup>35</sup>S-cysteine and 200 µCi/ml <sup>35</sup>S-methionine. After a 12-hour incubation, the conditioned medium is collected, concentrated on a spin filter, 15 and loaded onto a 15% SDS gel. The processed gel may be dried and exposed to film for a selected period of time to reveal the presence of the WISP polypeptide. The cultures containing transfected cells may undergo further incubation (in serum-free medium) and the medium is tested in selected bioassays.

In an alternative technique, the WISP polypeptide may be introduced into 293 cells transiently using 20 the dextran sulfate method described by Somparyrac *et al.*, Proc. Natl. Acad. Sci., 78:7575 (1981). 293 cells are grown to maximal density in a spinner flask and 700 µg pRK5E.WISP DNA is added. The cells are first 25 concentrated from the spinner flask by centrifugation and washed with PBS. The DNA-dextran precipitate is incubated on the cell pellet for four hours. The cells are treated with 20% glycerol for 90 seconds, washed with tissue culture medium, and re-introduced into the spinner flask containing tissue culture medium, 5 µg/ml bovine insulin, and 0.1 µg/ml bovine transferrin. After about four days, the conditioned media are centrifuged and filtered to remove cells and debris. The sample containing expressed WISP polypeptide can then be concentrated and purified by any selected method, such as dialysis and/or column chromatography.

In another embodiment, the WISP polypeptide can be expressed in CHO cells. The pRK5E.WISP can be transfected into CHO cells using known reagents such as CaPO<sub>4</sub> or DEAE-dextran. As described 30 above, the cell cultures can be incubated, and the medium replaced with culture medium (alone) or medium containing a radiolabel such as <sup>35</sup>S-methionine. After determining the presence of the WISP polypeptide, the culture medium may be replaced with serum-free medium. Preferably, the cultures are incubated for about 6 days, and then the conditioned medium is harvested. The medium containing the expressed WISP polypeptide can then be concentrated and purified by any selected method.

35 Epitope-tagged WISP polypeptide may also be expressed in host CHO cells. The WISP polypeptide may be subcloned out of the pRK5 vector. Suva *et al.*, Science, 237: 893-896 (1987); EP 307,247 published 3/15/89. The subclone insert can undergo PCR to fuse in-frame with a selected epitope tag such as a poly-his tag into a baculovirus expression vector. The poly-his-tagged WISP polypeptide insert can then be subcloned into a SV40-driven vector containing a selection marker such as DHFR for selection of stable clones. Finally,

the CHO cells can be transfected (as described above) with the SV40-driven vector. Labeling may be performed, as described above, to verify expression. The culture medium containing the expressed poly-His-tagged WISP can then be concentrated and purified by any selected method, such as by  $\text{Ni}^{2+}$ -chelate affinity chromatography.

5 In particular, mouse WISP-1 cDNA for insertion into mammalian expression vectors was created via PCR using clone m568.19A (see above) pure phage DNA as template and using as primers m.568.pcr.top4 (5'-TGACTTCCAGGCATGAGGTGGCTCTG: SEQ ID NO:124) and m.568.pcr.bot3 (5'-ATTGGCAATCTCTCGAAGTCAGGGTAAGATTCC: SEQ ID NO:125) for the 6-his version, or m.568.pcr.top4 (SEQ ID NO:124) and 568.pcr.bot5, which has a 3'-terminal *Xba*I site (5'-GGTACGTCTAGACTAATTGGCAATCTCTCGAAGTCAGGG: SEQ ID NO:126) for the non-his version. 10 The insert integrity was confirmed by sequencing and analyzed. The PCR was run using *Pfu* polymerase and the conditions were:

	<u>temp.</u>	<u>time</u>
denaturation	94°C	1 min
annealing	62°C	30 sec
extension	72°C	1.5 min

# of cycles: 25

For transient expression in 293 cells analyzed by Western blot, the above inserts were ligated into the pRK5 vector referred to above at the *Bam*H/*Xba*I site using the BOEHRINGER MANNHEIM™ rapid ligation kit. The resulting plasmids were designated pRK5.mu.WISP-1.6his and pRK5.mu.WISP-1.nohis for the His-tagged and non-His-tagged inserts, respectively. Then the 293 cells were plated and allowed to reach approximately 85% confluence overnight (37°C/5%  $\text{CO}_2$ ). The plated cells were transfected with plasmid DNA pRK5.mu.WISP-1.6his or pRK5.mu.WISP-1.nohis by using lipofectamine (Gibco BRL) at a 4.5:1 lipid:DNA ratio.

25 Transfection efficiency (>70% usually) was monitored using a GFP expression plasmid (pGREEN LANTERN™ from Gibco BRL). Approximately 5 hours post-transfection, the medium was changed to fresh SF media (50:50 with 1X L-Glu and 1X P/S) for protein production. The conditioned media was allowed to accumulate for specified amounts of time (depending on the experiment) before harvesting.

The medium was harvested and concentrated in the presence of 1 mM PMSF using the 30 CENTRICON-10™ concentrator. The concentrated, conditioned media (usually 1.5 ml) was then bound to  $\text{Ni}^{2+}$ -NTA agarose beads (Qiagen) for 2 hours (for the His-tagged version only). Protein was eluted from the beads by boiling for 10 minutes in 2X SDS loading buffer (Novex) with or without beta-mercaptoethanol for reduced vs. non-reduced protein, respectively.

The protein was visualized by SDS-PAGE using 4-20% gradient TRIS-glycine gels, 10-wells, 1 mm thickness (Novex). Gels ran at 125 volts (constant) for 95 minutes. Western transfer was achieved using a NOVEX™ transfer apparatus to PVDF membranes (Novex) at 200 mA (constant) for 45 minutes. The blots were blocked for a minimum of 1 hour at room temperature in blocking buffer (PBS + TWEEN-20™ (0.5%), 5% dry milk, and 3% goat serum). Blots were incubated in primary antibody (for His-tagged protein: INVITROGEN™ anti-his(C-terminal)-HRP-conjugated antibody or for the non-His version: polyclonal anti-

murine WISP-1 antibody prepared as described below) at a 1:2000 dilution in fresh blocking buffer for 1 hour at room temperature. The non-His-tagged protein blots were incubated in secondary antibody (PIERCE<sup>TM</sup> goat anti-rabbit IgG(H+L) HRP conjugated) diluted 1:2000 in fresh blocking buffer. The blots were incubated in chemiluminescent substrate (ECL<sup>TM</sup> from Amersham or SUPERSIGNAL<sup>TM</sup> from Pierce) for 5 minutes before exposing to film.

For transient expression analyzed by antibody staining, 293 cells were cultured, plated, and transfected as described above. The cells were fixed to culture dishes for 2 minutes in 1:1 methanol:acetone solution. Fixed cells were then incubated in primary antibody (for His-tagged protein: INVITROGEN<sup>TM</sup> anti-his(C-term)-HRP-conjugated antibody or for the non-His version: polyclonal anti-murine WISP-1 antibody prepared as described below) diluted 1:1000 in PBS with 10% fetal bovine serum for 2 hours. The 10 non-His-tagged protein blots were then incubated in secondary antibody (PIERCE<sup>TM</sup> goat anti-rabbit IgG(H+L) HRP conjugated) diluted 1:150 in PBS with 10% fetal bovine serum for 1 hour. The incubation was in color reagent substrate for HRP for up to 1 hour (1.0% O-dianisidine-saturated ETOH, 0.01% hydrogen peroxide in PBS).

15 For stable expression of mouse WISP-1 in mammalian cells, the starting vector employed was pRK5.CMV.puro-dhfR, the sequence of which is shown in Figures 16A-16D. This vector has two SAR sequences cloned into *Kpn*I, *Sap*I sites of the SV1DS splice-donor vector, and has the pSVI backbone with the pRK5 cloning linker (pSVI5) and the intron made from pSVI.WTSD.D by adding a linearization linker (LL) into the *Hpa*I site. The sequence is edited to include changes in vector puc118 backbone derived from 20 the sequence of pRK5 and includes a four-base insertion after MCS characteristic of the SVI vector.

25 The above inserts were ligated into pRK5.CMV.puro-dhfR at the *Bam*HI/*Xba*I site using the BOEHRINGER MANNHEIM<sup>TM</sup> rapid ligation kit, producing pRK5.CMV.puro-dhfR.mu.WISP-1.6his or pRK5.CMV.puro-dhfR.mu.WISP-1.nohis. This construct allows for stable selection of expressing cells using either puromycin (2 µg/ml in 293 cells or 10 µg/ml in CHO-DP12 cells) or the DHFR deletion in the CHO-DP12 line, which allows for subsequent amplification in methotrexate. Isolated colonies representative of 30 stably transfected cells were picked, cultured under selective pressure, and analyzed by antibody staining or Western blot as described above.

#### EXAMPLE 9: Expression of WISP Polypeptide in Yeast

30 The following method describes recombinant expression of a WISP polypeptide in yeast.

First, yeast expression vectors are constructed for intracellular production or secretion of a WISP 35 polypeptide from the ADH2/GAPDH promoter. DNA encoding a WISP polypeptide and the promoter is inserted into suitable restriction enzyme sites in the selected plasmid to direct intracellular expression. For secretion, DNA encoding a WISP polypeptide can be cloned into the selected plasmid, together with DNA encoding the ADH2/GAPDH promoter, a native WISP signal peptide or other mammalian signal peptide or yeast alpha-factor or invertase secretory signal/leader sequence, and linker sequences (if needed) for expression.

Yeast cells, such as yeast strain AB110, can then be transformed with the expression plasmids described above and cultured in selected fermentation media. The transformed yeast supernatants can be

analyzed by precipitation with 10% trichloroacetic acid and separation by SDS-PAGE, followed by staining of the gels with Coomassie Blue stain.

Recombinant WISP polypeptide can subsequently be isolated and purified by removing the yeast cells from the fermentation medium by centrifugation and then concentrating the medium using selected 5 cartridge filters. The concentrate containing the WISP polypeptide may further be purified using selected column chromatography resins.

EXAMPLE 10: Expression of WISP Polypeptide in Baculovirus-Infected Insect Cells and Purification Thereof

10 The following method describes recombinant expression of a WISP polypeptide in baculovirus-infected insect cells, and purification thereof.

General

15 The sequence coding for WISP polypeptide is fused upstream of an epitope tag contained within a baculovirus expression vector. Such epitope tags include poly-His tags and immunoglobulin tags (like Fc regions of IgG). A variety of plasmids may be employed, including plasmids derived from commercially 20 available plasmids such as pVL1393 (Novagen). Briefly, the sequence encoding WISP polypeptide or the desired portion of the coding sequence (such as the sequence encoding the mature protein if the protein is extracellular) is amplified by PCR with primers complementary to the 5' and 3' regions. The 5' primer may incorporate flanking (selected) restriction enzyme sites. The product is then digested with those selected 25 restriction enzymes and subcloned into the expression vector.

20 Recombinant baculovirus is generated by co-transfecting the above plasmid and BACULOGOLD<sup>TM</sup> virus DNA (Pharmingen) into *Spodoptera frugiperda* ("Sf9") cells (ATCC CRL 1711) using lipofectin (commercially available from Gibco-BRL). After 4 - 5 days of incubation at 28°C, the released viruses are harvested and used for further amplifications. Viral infection and protein expression are performed as described by O'Reilley *et al.*, Baculovirus Expression Vectors: A Laboratory Manual (Oxford: Oxford 25 University Press, 1994).

25 Expressed poly-His-tagged WISP polypeptide can then be purified, for example, by Ni<sup>2+</sup>-chelate affinity chromatography as follows. Extracts are prepared from recombinant virus-infected Sf9 cells as described by Rupert *et al.*, Nature, 362:175-179 (1993). Briefly, Sf9 cells are washed, resuspended in sonication buffer (25 mL HEPES, pH 7.9; 12.5 mM MgCl<sub>2</sub>; 0.1 mM EDTA; 10% glycerol; 0.1% NP-40; 0.4 M KCl), and sonicated twice for 20 seconds on ice. The sonicates are cleared by centrifugation, and the supernatant is diluted 50-fold in loading buffer (50 mM phosphate, 300 mM NaCl, 10% glycerol, pH 7.8), and filtered through a 0.45 µm filter. A Ni<sup>2+</sup>-NTA agarose column (commercially available from Qiagen) 30 is prepared with a bed volume of 5 mL, washed with 25 mL of water, and equilibrated with 25 mL of loading buffer. The filtered cell extract is loaded onto the column at 0.5 mL per minute. The column is washed to baseline A<sub>280</sub> with loading buffer, at which point fraction collection is started. Next, the column is washed with a secondary wash buffer (50 mM phosphate; 300 mM NaCl, 10% glycerol, pH 6.0), which elutes non-specifically bound protein. After reaching A<sub>280</sub> baseline again, the column is developed with a 0 to 500 mM 35 imidazole gradient in the secondary wash buffer. One-mL fractions are collected and analyzed by SDS-PAGE and silver staining or Western blot with Ni<sup>2+</sup>-NTA-conjugated to alkaline phosphatase (Qiagen).

Fractions containing the eluted His<sub>10</sub>-tagged WISP polypeptide are pooled and dialyzed against loading buffer.

Alternatively, purification of the IgG-tagged (or Fc-tagged) WISP polypeptide can be performed using known chromatography techniques, including, for instance, Protein A or protein G column chromatography.

Specific

1. Expression

In particular, mouse WISP-1 polypeptide was expressed in a baculovirus expression system similar to that described above using as the baculovirus transfer vector pb.PH.mu.568.9.IgG.baculo or pbPH.mu.568.8his.baculo. Figures 17A-17D show the sequence (SEQ ID NO:54) of plasmid pb.PH.IgG, which was used to prepare pb.PH.mu.568.9.IgG.baculo. Figures 18A-18D show the sequence (SEQ ID NO:55) of plasmid pbPH.His.c, which was used to prepare pbPH.mu.568.8his.baculo.

Both of these baculovirus transfer vectors are based on pVL1393 (Pharmingen), which has neither the His nor Fc tags. The pb.PH.IgG vector (Fig. 17) allows the expression of foreign proteins under control of the AcNPV polyhedrin promoter, which is active in the very late phase of virus infection. The foreign protein can be expressed as a C-terminal human IgG fusion protein. The His(8)-tag will not be translated as a result of the IgG stop codon just 5' of the His(8)-tag. The sequence encoding the foreign protein should be inserted as a 3' blunt-ended fragment into the unique *Stu*I site preceding the His-tag. In that case an additional proline residue will be added. The 5' site can be either *Bam*HI, *Eco*RI, *Nor*I, *Nco*I, and *Nhe*I.

The IgG vector was constructed by *Nde*I digestion of the pVL1393.IgG plasmid followed by Klenow treatment to fill in the sticky end site. This is followed by a *Nco*I digest and insertion into the pbPH.His.c x *Nco*I/*Smal*-digested vector.

The sequence of pbPH.His.c shown in Figs. 18A-18D contains the backbone sequence of the vector pVL1392, which contains approximately the *Eco*RI/*Xma*II fragment of AcMNPV C-6, from position 0.0 to 5.7 mu. Possee *et al.*, *Virology*, 185: 229-241 (1991). It allows the expression of foreign proteins under control of the *Autographa californica* nuclear polyhedrosis virus (AcNPV) polyhedrin gene promoter, which is active in the very late phase of virus infection.

The foreign protein can be expressed as a C-terminally His- or a IgG (Fc region only)-tagged protein. The sequence encoding the foreign protein should be inserted as a 3'-blunt-ended fragment into the unique *Smal* site preceding the His-tag or the *Stu*I site for IgG. In that case an additional glycine residue will be added for His tags and a proline will be added for IgG tags. The 5' site can be either *Bam*HI, *Nor*I, *Eco*RI, or *Nco*I. *Bam* HI was used for both.

The vectors were constructed by inserting a PCR insert into *Bam*HI/*Smal* for the His vector and *Bam*HI/*Stu*I for the IgG vector. The PCR insert was made using 5'-phosphorylated primers as follows: m.568.pcr.top6 (5'-TTTCCCTTGGATCCTAACCAACATGAGGTGGCTCTGCC; SEQ ID NO:127) and m.568.pcr.bot3 (SEQ ID NO:125), 5' phosphorylated. A twenty-cycle PCR reaction with Pfu polymerase enzyme was performed using the following conditions: 1 min at 95°C, 30 sec at 60°C, 3.5 min at 72°C. The PCR product was purified with QIAQUICK™ and digested with *Bam*HI at 37°C for 1 hr. The digested PCR insert was ligated into the digested vector using a 1:3 ratio of insert to vector with 1 μl T4 DNA ligase (Bio

Labs). ULTRA MAX<sup>TM</sup> DH5a FT competent cells, 100  $\mu$ L (Gibco BRL Cat #10643-013) were added to the ligation product, and the mixture was incubated on ice for 30 min, followed by a heat shock at 42°C for 45 sec. Individual colonies were picked and miniscreen DNA was prepared using QIA PREP<sup>TM</sup> (Qiagen). Construct sequencing was performed using ABI Prism's dRHODAMINE DYE<sup>TM</sup> terminator cycle sequencing.

5 The plasmid pb.PH.IgG has a polylinker *Bam*HI-*Not*I-*Eco*RI-*Nco*I-*Srf*I-*Sst*I-(IgG Fc region only)-Stop-*Xba*I-*Spe*I-*Pst*I-*Bgl*II. The location of particular regions in this plasmid is as follows: Insertion of polylinker/foreign gene: 4129-4912 (*Bam*HI-*Bgl*II), polh coding: 4913-5479, ORF 1629: 7134-4820; ORF 588 (PK1): 7133-7723; ColE1 origin of replication: 7973-8858, and ampicillin coding: 9779-8230. The 10 plasmid pbPH.His.c has a polylinker *Bam*HI-*Not*I-*Eco*RI-*Nco*I-*Srf*I-*Sma*I-(His8)-Stop-*Xba*I-*Spe*I-*Pst*I-*Bgl*II. The *Nco*I site of pbPH.His.c resides within a Kozak sequence. The location of particular regions in this plasmid is as follows: ORF 504 (PTP): 76-582, ORF 984 (ORF2): 1600-614, ORF 453 (ORF3): 2323-1868, conotoxin: 1818-1657, ORF 327 (ORF4): 2352-2681, ORF 630 (lef-2): 2662-3294, ORF 603: 3937-3332, ORF polh: 4093 (mutated codon ATG/ATT), insertion of polylinker/foreign gene: 4129-4218 (*Bam*HI-*Bgl*II), polh coding: 4224-4790, ORF 1629: 6445-4820. ORF 588 (PK1): 6444-7034. ColE1 origin of replication: 15 7284-8169, and ampicillin coding: 9090-8230.

20 The mouse WISP-1 cDNA disclosed herein was inserted into the vectors pbPH.His.c and pb.PH.IgG to produce the respective expression plasmids by creating a 3' blunt-ended fragment for cloning into the unique *Sma*I site preceding the His-tag or IgG-tag. An additional glycine residue was added to the His protein produced. An additional proline was added to the IgG protein. The 5' site of the cDNA insert was *Bam*HI.

## 2. Purification

25 For purification purposes, either a poly-His tag or the Fc portion of human IgG was added to the C-terminal coding region of the cDNA before expression. The conditioned media from the transfected cells (0.5 to 2 L) was harvested by centrifugation to remove the cells and filtered through 0.22 micron filters. For the poly-His-tagged constructs, the protein was purified using a Ni<sup>2+</sup>-NTA column (Qiagen). Before purification, imidazole was added to the conditioned media to a concentration of 5 mM. The conditioned media was pumped onto a 6-ml Ni<sup>2+</sup>-NTA column equilibrated in 20 mM HEPES, pH 7.4, buffer containing 0.3 M NaCl and 5 mM imidazole at a flow rate of 4-5 ml/min at 4°C. After loading, the column was washed 30 with additional equilibration buffer and the protein was eluted with equilibration buffer containing 0.25 M imidazole. The highly purified protein was subsequently desalted into a storage buffer containing 10 mM HEPES, 0.14 M NaCl, and 4% mannitol, pH 6.8, with a 25 ml G25 SUPERFINE<sup>TM</sup> (Pharmacia) column and stored at -80°C.

35 Immunoadhesin (Fc-containing) constructs of WISP-1 protein were purified from the conditioned media as follows. The conditioned media was pumped onto a 5-ml Protein A column (Pharmacia) which had been equilibrated in a 20 mM Na phosphate buffer, pH 6.8. After loading, the column was washed extensively with equilibration buffer before elution with 100 mM citric acid, pH 3.5. The eluted protein was immediately neutralized by collecting 1-ml fractions into tubes containing 275  $\mu$ L of 1 M Tris, pH 9, buffer. The highly purified protein was subsequently desalted into storage buffer as described above for the poly-His-

tagged proteins. The homogeneity of the protein was assessed by SDS polyacrylamide gels and by N-terminal amino acid sequencing by Edman degradation.

EXAMPLE 11: Axis Duplication Assay

5 *Xenopus* embryos were injected with human WISP-2 mRNA into either a presumptive ventral or presumptive dorsal vegetal blastomere at the 8- to 16-cell stage to overexpress locally the encoded protein and assay for its developmental effects. The methods used are described in Sokol *et al.*, *Cell*, 67: 741-752 (1991).

10 More specifically, for synthesis of capped RNA, human WISP-2 and mouse Wnt-1 cDNAs were cloned into the pGEMHE vector (gift of Dr. Todd Evans, AECOM) to prepare pGEMHE.hu.WISP-2.8H and pGEMHE.mu.Wnt-1, respectively. The constructs were linearized at the 3' end using the *Sph*I restriction enzyme. Capped RNAs were synthesized using AMBION's T7 MESSAGEMACHINE<sup>TM</sup> RNA synthesis kit.

15 For obtaining mature oocytes, an adult female *Xenopus laevis* was injected with 200 I.U pregnant mare serum 3 days before use. The night before the experiment, the female frog was injected with 800 I.U of human chorionic gonadotropin. Fresh oocytes were squeezed from female frogs the next morning. *In vitro* fertilization of oocytes was performed by mixing oocytes with minced testes from a sacrificed male frog. Fertilized eggs were dejellied with 2% cysteine (pH 7.8) for 10 minutes. Dejellied eggs were washed once with distilled water and transferred to 0.1 x Modified Barth's Solution (MBS) (Methods in Cell Biology, Volume 36, *Xenopus laevis: Practical uses in Cell and Molecular Biology*, Kay and Peng, Eds (New York: Academic Press, 1991)) with 5% Ficoll. Eggs were lined on injection trays which contained 0.1 x MBS with 5% Ficoll for injection. After injection, embryos were kept in 0.1X MBS in an 18°C incubator. Embryos were staged according to Nieuwkoop and Faber. Normal Table of Xenopus laevis: (Daudin) (Amsterdam: North-Holland, 1967).

20 For animal cap assays, embryos were injected at the 2-cell stage with 1 ng of capped RNA, and animal caps were isolated at stage 8 and cultured in 1 x MMR for another 24 hours for the RT-PCR assay. Total RNA was isolated from harvested animal caps using a RNEASY<sup>TM</sup> kit (Qiagen). RNA samples (approximately 1 µg) were reverse transcribed using random hexamer and GIBCO BRL SUPERSCRIPT II<sup>TM</sup> reverse transcriptase. The annealing temperature for the PCR reactions was 55°C unless noted otherwise.

25 For axis duplication assays, embryos at the 8-cell stage were injected with 1 ng capped RNA at either the dorsal or ventral vegetal blastomere and incubated in 0.1X MBS for 72 hours.

30 The sequences of PCR primers used in this experiment were:

EF-1a.U: 5'-CAGATTGGTGCTGGATATGC (SEQ ID NO:128)

EF-1a.D: 5'-ACTGCCTTGATTACTCCTAC (SEQ ID NO:129)

noggin.U: 5'-AGTTGCAGATGTGGCTCT (SEQ ID NO:130)

35 noggin.D: 5'-AGTCCAAGAGTCTCAGCA (SEQ ID NO:131)

goosecoid.U: 5'-ACAACCTGGAAGCACTGG (SEQ ID NO:132)

goosecoid.D: 5'-TCTTATTCCAGAGGAACC (SEQ ID NO:133)

cardiac-actin.U: 5'-TCCCTGTACGCTCTGGTCGTA (SEQ ID NO:134)

cardiac-actin.D: 5'-TCTCAAAGTCCAAAGCCACATA (SEQ ID NO:135)

NCAM.U: 5'-CACAGTTCCAGCAAATAC (SEQ ID NO:136)

NCAM.D: 5'-GGAATCAGGCGGTACAGT (SEQ ID NO:137)

It was found that human WISP-2 can partially induce axis duplication in this assay.

EXAMPLE 12: Thymidine Incorporation Assay

5 In a (<sup>3</sup>H)-thymidine incorporation assay, 19 different cell lines, including RAG (renal adenocarcinoma, mouse) and NRK-49F (normal kidney fibroblasts, rat) cells, identified in Table I below, were plated in 96-well plates at  $3 \times 10^4$  in HGDMEM with 10% serum. Twenty four hours after plating, the medium was changed to HGDMEM with 0.2% serum before adding the test proteins. WISP proteins were added to a final concentration of approximately 3.6 ng/ $\mu$ l. Serial dilutions were made in a total volume of 10  $\mu$ l/well of fresh media. After 18 hr incubation at 37°C, 5 $\mu$  Ci/ml (<sup>3</sup>H)thymidine was added for 5 hrs. Medium was aspirated and cells were removed with 1X trypsin onto a GF/C filter using Packard's<sup>TM</sup> 96-well FILTERMATE 196<sup>TM</sup>. The filters were dried and 40  $\mu$ l of scintillation fluid was added for counting on a top count, microplate scintillation counter (Packard).

The results are shown in Table I:

15

TABLE I

<sup>3</sup>H-Thymidine Incorporation Assay Results

Cell line	Type	ATCC No.	mWISP-1 - IgG	hWISP-1 - IgG	hWISP-2 - IgG
HT-29 (human colon)	adenocarcinoma moderately well-differentiated	HTB-38	No change	No change	
Wi-Dr (human colon)	adenocarcinoma	CCL-218	No change	No change	
Calu-1 (human lung)	epidermoid carcinoma grade III, metastasis to pleura	HTB-54	inhibits ~1.1X	inhibits ~1.2X	
Calu-6 (human lung)	anaplastic carcinoma, probably lung	HTB-56	No change	stimulates ~1.4X	
SK-MES-1 (human lung)	squamous carcinoma, pleural effusion	HTB-58	No change	No change	
A549 (human lung)	carcinoma	CCL-185	inhibits ~1.5X	inhibits ~1.7X	
H460 (human lung)	large cell carcinoma	HTB-177	inhibits ~1.4X	inhibits ~1.3X	
SW900 (human lung)	squamous cell carcinoma	HTB-59	no change	no change	
MRC5 (human lung)	normal diploid	CCL-171	no change	no change	

	IMR-90 (human lung)	normal diploid	CCL-186	stimulates ~1.1X	stimulates ~1.5X	
5	Wnt-1 C57mg (mouse mammary gland)	myo-epithelial		inhibits ~2X		
10	MLg (mouse lung)	lung		stimulates ~4X		
15	LL/2 (mouse lung)	lung carcinoma			inhibits ~2X	
20	JC (mouse mammary gland)	carcinoma		inhibits ~2X	inhibits ~3X	
25	N MuMG (mouse mammary gland)	normal		stimulates ~2X	stimulates ~1.4X	
30	NRK-49F (rat kidney)	normal fibroblast		stimulates ~3X	stimulates ~3.5X	
35	RAG (mouse kidney)	adenocarcinoma		stimulates ~4.5X	stimulates ~3X	stimulates ~4X
40	NIH/3T3 (mouse embryo)	fibroblast		stimulates ~3X		
	UCLA-P3 (human lung)	carcinoma		inhibits ~1.5X	inhibits ~2X	

It is seen that WISP-1 and WISP-2 exhibit both stimulatory and inhibitory effects on proliferation of normal and tumor cells, depending on the cell line employed.

30 EXAMPLE 13: Preparation of Antibodies that Bind WISP Polypeptide

1. Polyclonal Antibodies

35 Polyclonal antisera were generated in female New Zealand White rabbits against murine WISP-1 and human WISP-2. The antigens used were proteins fused with histidine for murine WISP-1 and proteins fused with the Fc portion of IgG for human WISP-2. The same protocol was used for both proteins. Each protein was homogenized with Freund's complete adjuvant for the primary injection and with Freund's incomplete adjuvant for all subsequent boosts. For the primary immunization and the first boost, 3.3 µg per kg body weight was injected directly into the popliteal lymph nodes as described in Bennett *et al.*, J. Biol. Chem., 266: 23060-23067 (1991) and "Production of Antibodies by Inoculation into Lymph Nodes" by Morton Sigel *et al.* in Methods in Enzymology, Vol. 93 (New York: Academic Press, 1983). For all subsequent boosts, 3.3 µg per kg body weight was injected into subcutaneous and intramuscular sites. Injections were done every 3 weeks with bleeds taken on the following two weeks.

40 2. Monoclonal Antibodies

Techniques for producing monoclonal antibodies that can specifically bind a WISP polypeptide are known in the art and are described, for instance, in Goding, *supra*. Immunogens that may be employed include purified WISP polypeptide, fusion proteins containing WISP polypeptide, and cells expressing recombinant WISP polypeptide on the cell surface. Selection of the immunogen can be made by the skilled artisan without undue experimentation.

Mice, such as Balb/c, are immunized with the WISP immunogen emulsified in complete Freund's adjuvant and injected subcutaneously or intraperitoneally in an amount from 1 to 100 micrograms. Alternatively, the immunogen is emulsified in MPL-TDM adjuvant (Ribi Immunochemical Research, Hamilton, MT) and injected into the animal's hind foot pads. The immunized mice are then boosted 10 to 12 days later with additional immunogen emulsified in the selected adjuvant. Thereafter, for several weeks, the mice may also be boosted with additional immunization injections. Serum samples may be periodically obtained from the mice by retro-orbital bleeding for testing in ELISA assays to detect antibodies to WISP polypeptide.

After a suitable antibody titer has been detected, the animals "positive" for antibodies can be injected with a final intravenous injection of a WISP polypeptide. Three to four days later, the mice are sacrificed and the spleen cells are harvested. The spleen cells are then fused (using 35% PEG) to a selected murine myeloma cell line such as P3X63AgU.1, available from ATCC, No. CRL 1597, or x63.Ag8.653 (Kearney *et al.*, Immunology, 123: 1548 (1979)). The fusions generate hybridoma cells which can then be plated in 96-well tissue culture plates containing HAT (hypoxanthine, aminopterin, and thymidine) medium to inhibit proliferation of non-fused cells, myeloma hybrids, and spleen cell hybrids.

The hybridoma cells will be screened in an ELISA for reactivity against a WISP polypeptide. Determination of "positive" hybridoma cells secreting the desired monoclonal antibodies against a WISP polypeptide is within the skill in the art.

The positive hybridoma cells can be injected intraperitoneally into syngeneic Balb/c mice to produce ascites containing the anti-WISP polypeptide monoclonal antibodies. Alternatively, the hybridoma cells can be grown in tissue culture flasks or roller bottles. Purification of the monoclonal antibodies produced in the ascites can be accomplished using ammonium sulfate precipitation, followed by gel-exclusion chromatography. Alternatively, affinity chromatography based upon binding of antibody to protein A or protein G can be employed.

Specifically, for each of the human WISP-1 antibodies, five female Balb-c mice were pre-bled and then injected via their hind foot pads with purified human WISP-1, tagged with the Fc portion of IgG and emulsified prior to injection in MPL-TDM adjuvant (Ribi Immunochemical Research, Hamilton, MT) in a 1:1 ratio of WISP antigen to adjuvant. The dosing schedule for the WISP-1 immunogen was as follows:

<u>Injection</u>	<u>Date</u>	<u>Dose/Site</u>	<u>Dose/Animal</u>	<u>Concentration</u>
35	Day 16 of month 1	50 µl/site	100 µl/animal	6 µg/animal
	Day 12 of month 2	50 µl/site	100 µl/animal	6 µg/animal
40	Day 21	50 µl/site	100 µl/animal	6 µg/animal

	of month 2		
5	Day 28 of month 2	50 µl/site	100 µl/animal
	Day 4 of month 3	50 µl/site	100 µl/animal
	Day 11 of month 3	50 µl/site	100 µl/animal
	Day 18 of month 3	50 µl/site	100 µl/animal
10	Day 25 of month 3	50 µl/site	100 µl/animal

For WISP-1, the mice were bled on Day 10 of month 4. After the mice were bled, the monoclonal antibodies were made by harvesting their spleens and by fusion as indicated above, using as the murine myeloma cell line X63.Ag8.653.

15 The five monoclonal antibodies generated to human WISP-1 are:

- 10F2.2A7 gamma 2b/kappa
- 10A9.2B1 gamma 2a/kappa
- 8F7.1B1 gamma 1/kappa
- 1H1.1D5 gamma 1/kappa
- 20G7.2H4 gamma 1/kappa

For WISP-2 monoclonal antibodies the same regimen is employed except that purified human WISP-2 is used as immunogen in the above protocol rather than purified human WISP-1 and the dosing schedule for the WISP-2 immunogen is as follows:

	<u>Injection Date</u>	<u>Dose/Site</u>	<u>Dose/Animal</u>	<u>Concentration</u>
25	Day 16 of month 1	50 µl/site	100 µl/animal	6 µg/animal
	Day 21 of month 2	50 µl/site	100 µl/animal	1 µg/animal
	Day 28 of month 2	50 µl/site	100 µl/animal	1 µg/animal
	Day 4 of month 3	50 µl/site	100 µl/animal	1 µg/animal
30	Day 11 of month 3	50 µl/site	100 µl/animal	1 µg/animal
	Day 18 of month 3	50 µl/site	100 µl/animal	1 µg/animal
	Day 25 of month 3	50 µl/site	100 µl/animal	1 µg/animal

EXAMPLE 14: Uses of Antibodies that Bind WISP Polypeptide1. Cell lines

The established human breast tumor cells BT474 and MDA-MB-231 (which are available from ATCC) are grown in minimum essential medium (Gibco, Grand Island, NY) supplemented with 10% heat-inactivated fetal bovine serum (FBS) (HyClone, Logan, UT), sodium pyruvate, L-glutamine (2mM), non-  
5 essential amino acids, and 2x vitamin solution and maintained at 37°C in 5% CO<sub>2</sub>. Zhang *et al.*, Invas. & Metas., 11:204-215 (1991); Price *et al.*, Cancer Res., 50:717-721 (1990).

2. Antibodies

Anti-WISP-1 or anti-WISP-2 monoclonal antibodies that may be prepared as described above are harvested with PBS containing 25mM EDTA and used to immunize BALB/c mice. The mice are given 10 injections i.p. of 10<sup>7</sup> cells in 0.5 ml PBS on weeks 0, 2, 5 and 7. The mice with antisera that immunoprecipitated <sup>32</sup>P-labeled Wnt-1 are given i.p. injections of a wheatgerm agglutinin-SEPHAROSE™ (WGA)-purified Wnt membrane extract on weeks 9 and 13. This is followed by an i.v. injection of 0.1 ml of the Wnt-1 preparation, and the splenocytes are fused with mouse myeloma line X63-Ag8.653. Hybridoma 15 supernatants are screened for Wnt-1 binding by ELISA and radioimmunoprecipitation. MOPC-21 (IgG1) (Cappell, Durham, NC) is used as an isotype-matched control.

Additionally, the anti-ErbB2 IgG<sub>1</sub>κ murine monoclonal antibodies 4D5 (ATCC CRL 10463 deposited May 24, 1990) and 7C2, specific for the extracellular domain of ErbB2, may be used with the above antibodies. They are produced as described in Fendly *et al.*, Cancer Research, 50:1550-1558 (1990) and 20 WO89/06692.

3. Analysis of cell cycle status and viability

Cells are simultaneously examined for viability and cell cycle status by flow cytometry on a FACSTAR PLUS™ (Becton Dickinson Immunocytometry Systems USA, San Jose, CA). Breast tumor cells 25 are harvested by washing the monolayer with PBS, incubating cells in 0.05% trypsin and 0.53 mM EDTA (Gibco), and resuspending them in culture medium. The cells are washed twice with PBS containing 1% FBS and the pellet is incubated for 30 minutes on ice with 50 µl of 400 µM 7-aminoactinomycin D (7AAD) (Molecular Probes, Eugene, OR), a vital dye which stains all permeable cells. Cells are then fixed with 1.0 ml of 0.5% paraformaldehyde in PBS and simultaneously permeabilized and stained for 16 hours at 4°C with 220 µl of 10 µg/ml HOECHST 33342™ dye (also a DNA binding dye) containing 5% TWEEN 20™.

30 The data from 1 x 10<sup>4</sup> cells are collected and stored using LYSYS II™ software and analyzed using PAINT-A-GATE™ software (Becton Dickinson). Darzynkiewica *et al.*, Cytometry, 13:795-808 (1992); Picker *et al.*, J. Immunol., 150:1105-1121 (1993). The viability and percentage of cells in each stage of the cell cycle are determined on gated single cells using 7AAD and Hoechst staining, respectively. (Cell doublets are excluded by pulse analysis of width vs. area of the Hoechst signal.) Cell numbers are determined using 35 a hemocytometer.

4. DNA synthesis ((<sup>3</sup>H)-Thymidine Incorporation Assay)

The assay was performed exactly as described in Example 12, except that the WISP polypeptides used as test proteins were replaced by the polyclonal antibodies generated in New Zealand White rabbits

against murine WISP-1 and human WISP-2 described in Example 13, and not all the cell lines in Example 12 were tested. The results are shown in Table II:

TABLE II  
<sup>3</sup>H-Thymidine Incorporation Assay Results

Cell line	Type	ATCC No.	pAB.mWISP-1	pAB.hWISP-2
HT-29 (human colon)	adenocarcinoma moderately well-differentiated	HTB-38	No change	No change
Wi-Dr (human colon)	adenocarcinoma	CCL-218	No change	No change
N MuMG (mouse mammary gland)	normal		inhibits ~3X	
NRK-49F (rat kidney)	normal fibroblast		stimulates ~2X	
RAG (mouse kidney)	adenocarcinoma		stimulates ~4X	
NIH/3T3 (mouse embryo)	fibroblast		inhibits ~2X	

It is seen that the polyclonal antibodies to mouse WISP-1 and to human WISP-2 exhibited both stimulatory and inhibitory effects on proliferation of normal and tumor cells, depending on the cell line employed.

5. Affinity of binding to putative receptor

Radioiodinated anti-WISP-1 and anti-WISP-2 antibodies are prepared by the IODOGEN<sup>TM</sup> method. Fracker *et al.*, *Biochem. Biophys. Res. Comm.*, 80:849-857 (1978). Binding assays are performed using appropriate receptor-expressing cells (such as, for mouse anti-WISP antibodies, MLG, a mouse lung cell line available from the ATCC) cultured in 96-well tissue culture plates (Falcon, Becton Dickinson Labware, Lincoln Park, N.J.). The cells are trypsinized and seeded in wells of 96-well plates at a density of 10<sup>4</sup> cells/well and allowed to adhere overnight. The monolayers are washed with cold culture medium supplemented with 0.1% sodium azide and then incubated in triplicate with 100 µl of serial dilutions of <sup>125</sup>I-anti-WISP-1 or WISP-2 antibodies in cold culture medium containing 0.1% sodium azide for 4 hours on ice. Non-specific binding is estimated by the preincubation of each sample with a 100-fold molar excess of nonradioactive antibodies in a total volume of 100 µl. Unbound radioactivity is removed by two washes with cold medium containing 0.1% sodium azide. The cell-associated radioactivity is detected in a gamma counter after solubilization of the cells with 150 µl of 0.1 M NaOH/well. The WISP-1 and WISP-2 binding constants ( $K_d$ ) and anti-WISP antibody binding affinities are determined by Scatchard analysis.

It is expected that the antibodies against WISP-1 and WISP-2 will affect the growth of these cells.

EXAMPLE 15: Further Uses of Antibodies that Bind WISP Polypeptide

1. WISP-1 and WISP-2

This example shows that the *WISP-1* and *WISP-2* genes are amplified in the genome of certain human lung, colon, and/or breast malignant tumors and/or cell lines. Amplification is associated with overexpression of the gene product, indicating that the WISP-1 and WISP-2 proteins are useful targets for

therapeutic intervention in certain cancers such as colon, lung, breast, and other cancers. A therapeutic agent may take the form of antagonists of WISP molecules, for example, murine-human, chimeric, humanized, or human antibodies against WISP-1 and WISP-2, such as the antibodies prepared as described above.

5 The starting material for the screen was genomic DNA isolated from a variety of cancers. The DNA is quantitated precisely, e.g., fluorometrically. As a negative control, DNA was isolated from the cells of ten normal healthy individuals, pooled, and used as an assay control for the gene copy in healthy individuals.

10 The 5' nuclease assay (for example, TAQMAN™) and real-time quantitative PCR (for example, ABI PRIZM 7700™ Sequence Detection System™ (Perkin Elmer, Applied Biosystems Division, Foster City, CA)), were used to find genes potentially amplified in certain cancers. The results were used to determine whether the DNAs encoding WISP-1 and WISP-2 are over-represented in any of the primary lung or colon cancers or cancer cell lines or breast cancer cell lines that were screened. The primary lung cancers were obtained from individuals with tumors of the type and stage as indicated in Table III. An explanation of the abbreviations used for the designation of the primary tumors listed in Table III and the primary tumors and cell lines referred to throughout this example is given below:

15 Human lung carcinoma cell lines include A549 (SRCC768), Calu-1 (SRCC769), Calu-6 (SRCC770), H157 (SRCC771), H441 (SRCC772), H460 (SRCC773), SKMES-1 (SRCC774) and SW900 (SRCC775), all available from ATCC. Primary human lung tumor cells usually derive from adenocarcinomas, squamous cell carcinomas, large cell carcinomas, non-small cell carcinomas, small cell carcinomas, and broncho alveolar carcinomas, and include, for example, SRCC724 (squamous cell carcinoma abbreviated as "SqCCa"), SRCC725 (non-small cell carcinoma, abbreviated as "NSCCa"), SRCC726 (adenocarcinoma, abbreviated as "AdenoCa"), SRCC727 (adenocarcinoma), SRCC728 (squamous cell carcinoma), SRCC729 (adenocarcinoma), SRCC730 (adeno/squamous cell carcinoma), SRCC731 (adenocarcinoma), SRCC732 (squamous cell carcinoma), SRCC733 (adenocarcinoma), SRCC734 (adenocarcinoma), SRCC735 (broncho alveolar carcinoma, abbreviated as "BAC"), SRCC736 (squamous cell carcinoma), SRCC738 (squamous cell carcinoma), SRCC739 (squamous cell carcinoma), SRCC740 (squamous cell carcinoma), and SRCC740 (lung cell carcinoma, abbreviated as "LCCa").

20 Colon cancer cell lines include, for example, ATCC cell lines SW480 (adenocarcinoma, SRCC776), SW620 (lymph node metastasis of colon adenocarcinoma, SRCC777), COLO320 (adenocarcinoma, SRCC778), HT29 (adenocarcinoma, SRCC779), HM7 (carcinoma, SRCC780), CaWiDr (adenocarcinoma, SRCC781), HCT116 (carcinoma, SRCC782), SKCO1 (adenocarcinoma, SRCC783), SW403 (adenocarcinoma, SRCC784), LS174T (carcinoma, SRCC785), and HM7 (a high mucin producing variant of ATCC colon adenocarcinoma cell line LS 174T, obtained from Dr. Robert Warren, UCSF). Primary colon tumors include colon adenocarcinomas designated CT2 (SRCC742), CT3 (SRCC743), CT8 (SRCC744), CT10 (SRCC745), CT12 (SRCC746), CT14 (SRCC747), CT15 (SRCC748), CT17 (SRCC750), CT1 (SRCC751), CT4 (SRCC752), CT5 (SRCC753), CT6 (SRCC754), CT7 (SRCC755), CT9 (SRCC756), CT11 (SRCC757), CT18 (SRCC758), and DcR3, BACrev, BACfwd, T160, and T159.

30 Human breast carcinoma cell lines include, for example, HBL100 (SRCC759), MB435s (SRCC760), T47D (SRCC761), MB468 (SRCC762), MB175 (SRCC763), MB361 (SRCC764), BT20 (SRCC765), MCF7 (SRCC766), and SKBR3 (SRCC767).

The results are reported in delta ( $\Delta$ ) CT units. One unit corresponds to one PCR cycle or approximately a 2-fold amplification relative to normal, two units corresponds to 4-fold, 3 units to 8-fold amplification and so on. Quantitation was obtained using primers derived from the 3'-untranslated regions of the *WISP-1* and *WISP-2* cDNAs and a TAQMAN<sup>TM</sup> fluorescent probe corresponding to the respective intervening sequences. Using the 3' region tends to avoid crossing intron-exon boundaries in the genomic DNA, an essential requirement for accurate assessment of gene amplification using this method. The sequences for the primers and probes (forward, reverse, and probe) used for the *WISP-1*-encoding and *WISP-2*-encoding gene amplification were as follows:

*WISP-1 probe and primers:*

- 10 hu.WISP1.TMP (probe) 5'-AGCCTTCCAAGTCACTAGAACGTCCTGCTGG (SEQ ID NO:138)  
hu.WISP1.TMF (forward primer) 5'-CTGGACTACACCCAAGCCTGA (SEQ ID NO:139)  
hu.WISP1.TMR (reverse primer) 5'-CATTCTGGGATTTAGGCAAGA (SEQ ID NO:140)

*WISP-2 probe and primers:*

- DNA33473.3utr-5 (forward primer) 5'-TCTAGCCCCTCCCTGCCT (SEQ ID NO:141)  
15 DNA33473.3utr-3 (reverse primer) 5'-GAAGTCGGAGAGAAAGCTCGC (SEQ ID NO:142)  
DNA33473.3utr-probe 5'-CACACACAGCCTATATCAAACATGCACACG (SEQ ID NO:143)

The 5' nuclease assay reaction is a fluorescent PCR-based technique which makes use of the 5' exonuclease activity of Taq DNA polymerase enzyme to monitor amplification in real time. Two oligonucleotide primers are used to generate an amplicon typical of a PCR reaction. A third oligonucleotide, 20 or probe, is designed to detect nucleotide sequence located between the two PCR primers. The probe is non-extendible by Taq DNA polymerase enzyme, and is labeled with a reporter fluorescent dye and a quencher fluorescent dye. Any laser-induced emission from the reporter dye is quenched by the quenching dye when the two dyes are located close together as they are on the probe. During the amplification reaction, the Taq DNA polymerase enzyme cleaves the probe in a template-dependent manner. The resultant probe fragments disassociate in solution, and signal from the released reporter dye is free from the quenching effect 25 of the second fluorophore. One molecule of reporter dye is liberated for each new molecule synthesized, and detection of the unquenched reporter dye provides the basis for quantitative interpretation of the data.

The 5' nuclease procedure is run on a real-time quantitative PCR device such as the ABI PRIZM 7700<sup>TM</sup> Sequence Detection System<sup>TM</sup>. The system consists of a thermocycler, laser, charge-coupled device (CCD), camera and computer. The system amplifies samples in a 96-well format on a thermocycler. During 30 amplification, laser-induced fluorescent signal is collected in real-time through fiber optics cables for all 96 wells, and detected at the CCD. The system includes software for running the instrument and for analyzing the data.

5'-Nuclease assay data are initially expressed as Ct, or the threshold cycle. This is defined as the 35 cycle at which the reporter signal accumulates above the background level of fluorescence. The  $\Delta$ Ct values are used as quantitative measurement of the relative number of starting copies of a particular target sequence in a nucleic acid sample when comparing cancer DNA results to normal human DNA results.

The results of the first run performed are shown in Figures 19A-D and 20A-D for *WISP-1* and *WISP-2*, respectively, and controls. Note the pattern shown in Fig. 19B (marked huWISP-1). The standard

deviation for two samples of normal human DNA is shown in the column marked Nor Hu. This was used as a quality control tool. If the standard deviation was unacceptably large, the entire run was repeated. The nine additional columns corresponded to the human colon cancer cell lines noted above. The delta CT's for HT29 and WIDr were >3, corresponding to an about 8-fold over-representation of the *WISP-1* gene in these samples compared to the normal samples. Similarly, Fig. 19B suggests an about 4-fold amplification of *WISP-1* in the HCT116, SKCo-1, and SW403 cell lines.

As a comparison, see Fig. 20B (marked huFASr). The generally small delta CT values indicate that this gene was not significantly amplified in any of the cell lines (the value of 1 for SW620 corresponding to 2-fold amplification is within the noise level for the assay).

The *WISP-1* result was confirmed in three replicate reactions. See Figures 21A-D, 22A-D, and 23A-C. The pattern and delta CT values obtained were very similar in Figures 21A-C (marked huWISP-1c, huWISP-1b, and huWISP-1a, respectively). The result was essentially identical to that obtained in the first run. HT29 and WIDr showed the highest levels of *WISP-1* amplification, while HCT116, SKCo-1, and SW403 cell lines showed somewhat lower levels of *WISP-1* gene amplification. Two additional reactions from a third run were confirmatory. See Figs. 25A and 25B.

The *WISP-1* gene is located on chromosome 8, in the general vicinity of the *myc* gene, which is known to be amplified in some colon cancer cell lines. The pattern obtained using primers and probe for the *myc* gene, namely,

hu.c-myc.tm.p 5'-CTTGAGA CTGAAAGATTTAGCCATAATGTAAACTGCCT (SEQ ID NO:144)  
hu.c-myc.tm.f 5'-CAAATGCAACCTCACAACTTG (SEQ ID NO:145), and  
hu.c-myc.tm.r 5'-TTCTTTTATGCCAAAGTCCAATT (SEQ ID NO:146),

is consistent with a published report (*Cancer Research*, 57: 1769-1775 (1997)), tending to validate the 5' nuclease assay method, but is clearly different from that obtained for *WISP-1*. These data prove that the *myc* gene is not the target of the amplification detected using the primers and probes for *WISP-1*.

The data using primers and probes based on the *WISP-2* DNA sequence suggest that this gene may be the target of low-level gene amplification in most of the cell lines examined. See Figs. 20C, 22A-D, and 25C and D. Hence, antibodies to both *WISP-1* and *WISP-2*, particularly humanized antibodies, are expected to be of benefit in combating certain types of cancer such as colon cancer, similar to the humanized anti-HER-2 antibody in clinical use.

## 30 2. WISP-2

### Description of Tumors and Cell Lines

Amplification using several different tumor types was performed for human *WISP-2* (PRO261), as described below. Table III describes the stage, T stage, and N stage of various primary tumors which were used to screen the *WISP-2* compound of the invention.

TABLE III  
Primary Lung and Colon Tumor Profiles

	Primary Tumor	Stage	Other Stage	Dukes Stage	T Stage	N Stage
5	Human lung tumor SqCCA (SRCC724) [LT1]	IB	--	--	T1	N1
	Human lung tumor NSCCa (SRCC725) [LT1a]	IA	--	--	T3	NO
	Human lung tumor AdenoCa (SRCC726) [LT2]	IB	--	--	T2	NO
	Human lung tumor AdenoCa (SRCC727) [LT3]	IB	--	--	T1	N2
	Human lung tumor SqCCq (SRCC728) [LT4]	IIB	--	--	T2	NO
10	Human lung tumor AdenoCa (SRCC729) [LT6]	IV	--	--	T1	NO
	Human lung tumor Aden/SqCCA (SRCC730) [LT7]	IB	--	--	T1	NO
	Human lung tumor AdenoCa (SRCC731) [LT9]	IIB	--	--	T2	NO
	Human lung tumor SqCCA (SRCC732) [LT10]	IA	--	--	T2	N1
	Human lung tumor AdenoCa (SRCC733) [LT11]	IB	--	--	T1	N1
15	Human lung tumor AdenoCa (SRCC734) [LT12]	IIA	--	--	T2	NO
	Human lung tumor BAC (SRCC735) [LT13]	IB	--	--	T2	NO
	Human lung tumor SqCCA (SRCC736) [LT15]	IB	--	--	T2	NO
	Human lung tumor SqCCA (SRCC737) [LT16]	IB	--	--	T2	NO
	Human lung tumor SqCCA (SRCC738) [LT17]	IIB	--	--	T2	N1
20	Human lung tumor SqCCA (SRCC739) [LT18]	IB	--	--	T2	NO
	Human lung tumor SqCCA (SRCC740) [LT19]	IB	--	--	T2	NO
	Human lung tumor LCCa (SRCC741) [LT21]	IIB	--	--	T3	N1
	Human colon AdenoCa (SRCC742) [CT2]	--	M1	D	pT4	NO
	Human colon AdenoCa (SRCC743) [CT3]		--	B	pT3	NO
25	Human colon AdenoCa (SRCC 744) [CT8]			B	T3	NO
	Human colon AdenoCa (SRCC745) [CT10]			A	pT2	NO
	Human colon AdenoCa (SRCC746) [CT12]		MO, RI	B	T3	NO

Human colon AdenoCa (SRCC747) [CT14]		pMO, RO	B	pT3	pNO
Human colon AdenoCa (SRCC748) [CT15]		M1, R2	D	T4	N2
Human colon AdenoCa (SRCC749) [CT16]		pMO	B	pT3	pNO
Human colon AdenoCa (SRCC750) [CT17]			C1	pT3	pNI
5 Human colon AdenoCa (SRCC751) [CT1]		MO, RI	B	pT3	NO
Human colon AdenoCa (SRCC752) [CT4]			B	pT3	MO
Human colon AdenoCa (SRCC753) [CT5]		G2	C1	pT3	pNO
Human colon AdenoCa (SRCC754) [CT6]		pMO, RO	B	pT3	pNO
Human colon AdenoCa (SRCC755) [CT7]		G1	A	pT2	pNO
10 Human colon AdenoCa (SRCC756) [CT9]		G3	D	pT4	pN2
Human colon AdenoCa (SRCC757) [CT11]			B	T3	NO
Human colon AdenoCa (SRCC758) [CT18]		MO, RO	B	pT3	pNO

DNA Preparation:

15 DNA was prepared from cultured cell lines, primary tumors, and normal human blood (controls and framework and epicenter mapping). The isolation was performed using purification kit #13362 (which includes 10 purification tips with a capacity of 400 µg genomic DNA each), buffer set #1960 and protease #19155 and #19101, all from Quiagen, according to the manufacturer's instructions and the description below.

Cell culture lysis:

20 Cells were washed and trypsinized at a concentration of  $7.5 \times 10^8$  per tip and pelleted by centrifuging at 1000 rpm for 5 minutes at 4°C, followed by washing again with 1/2 volume of PBS re-centrifugation. The pellets were washed a third time, and the suspended cells collected and washed 2x with PBS. The cells were then suspended into 10 mL PBS. Buffer C1 was equilibrated at 4°C. Protease #19155 (Quiagen) was diluted into 6.25 mL cold ddH<sub>2</sub>O to a final concentration of 20 mg/ml and equilibrated at 4°C. 10 mL of G2 Buffer was prepared by diluting RNase A stock (Quiagen) (100 mg/ml) to a final concentration of 200 µg/ml.

25 Buffer C1 (10 mL, 4°C) and ddH<sub>2</sub>O (40 mL, 4°C) were then added to the 10 mL of cell suspension, mixed by inverting and incubated on ice for 10 minutes. The cell nuclei were pelleted by centrifuging in a BECKMAN™ swinging bucket rotor at 2500 rpm at 4°C for 15 minutes. The supernatant was discarded and the nuclei were suspended with a vortex into 2 mL Buffer C1 (at 4°C) and 6 mL ddH<sub>2</sub>O, followed by a second 4°C centrifugation at 2500 rpm for 15 minutes. The nuclei were then resuspended into the residual buffer using 200 µL per tip. G2 buffer (10 mL) was added to the suspended nuclei while gentle vortexing was applied. Upon completion of buffer addition, vigorous vortexing was applied for 30 seconds. Quiagen protease (200 µL, prepared as indicated above) was added and incubated at 50°C for 60 minutes. The incubation and centrifugation were repeated until the lysates were clear (e.g., incubating an additional 30-60 minutes, pelleting at 3000 x g for 10 min., 4°C).

30 35 Solid human tumor sample preparation and lysis:

Tumor samples were weighed and placed into 50-ml conical tubes and held on ice. Processing was limited to no more than 250 mg tissue per preparation (1 tip/preparation). The protease solution was freshly prepared by diluting into 6.25 ml cold ddH<sub>2</sub>O to a final concentration of 20 mg/ml and stored at 4°C. G2 buffer (20 ml) was prepared by diluting DNase A to a final concentration of 200 mg/ml (from 100 mg/ml stock). The tumor tissue was homogenated in 19 ml G2 buffer for 60 seconds using the large tip of the 5 polytron in a laminar-flow TC hood to order to avoid inhalation of aerosols, and held at room temperature. Between samples, the polytron was cleaned by spinning at 2 x 30 seconds each in 2L ddH<sub>2</sub>O, followed by G2 buffer (50 ml). If tissue was still present on the generator tip, the apparatus was disassembled and cleaned.

10 Protease (Quiagen), prepared as indicated above, 1.0 ml, was added, followed by vortexing and incubation at 50°C for 3 hours. The incubation and centrifugation were repeated until the lysates were clear (e.g., incubating additional 30-60 minutes, pelleting at 3000 x g for 10 min.. 4°C).

*Human blood preparation and lysis:*

15 Blood was drawn from healthy volunteers using standard infectious agent protocols and citrated into 10 ml samples per tip. Protease (Quiagen) was freshly prepared by dilution into 6.25 ml cold ddH<sub>2</sub>O to a final concentration of 20 mg/ml and stored at 4°C. G2 buffer was prepared by diluting RNase A to a final concentration of 200 µg/ml from 100 mg/ml stock. The blood (10 ml) was placed into a 50-ml conical tube, and 10 ml C1 buffer and 30 ml ddH<sub>2</sub>O (both previously equilibrated to 4°C) were added, and the components 20 mixed by inverting and held on ice for 10 minutes. The nuclei were pelleted with a BECKMAN™ swinging bucket rotor at 2500 rpm, 4°C for 15 minutes and the supernatant was discarded. With a vortex, the nuclei were suspended into 2 ml C1 buffer (4°C) and 6 ml ddH<sub>2</sub>O (4°C). Vortexing was repeated until the pellet 25 was white. The nuclei were then suspended into the residual buffer using a 200-µl tip. G2 buffer (10 ml) was added to the suspended nuclei while gently vortexing, followed by vigorous vortexing for 30 seconds. Protease (Quiagen) was added (200 µl) and incubated at 50°C for 60 minutes. The incubation and centrifugation were repeated until the lysates were clear (e.g., incubating an additional 30-60 minutes, pelleting at 3000 x g for 10 min.. 4°C).

*Purification of cleared lysates: Isolation of genomic DNA:*

30 Genomic DNA was equilibrated (1 sample per maxi tip preparation) with 10 ml QBT buffer. QF elution buffer was equilibrated at 50°C. The samples were vortexed for 30 seconds, then loaded onto equilibrated tips and drained by gravity. The tips were washed with 2 x 15 ml QC buffer. The DNA was eluted into 30-ml silanized, autoclaved 30-ml COREX™ tubes with 15-ml QF buffer (50°C). Isopropanol (10.5 ml) was added to each sample, and the tubes were covered with paraffin and mixed by repeated 35 inversion until the DNA precipitated. Samples were pelleted by centrifugation in the SS-34 rotor at 15,000 rpm for 10 minutes at 4°C. The pellet location was marked, the supernatant discarded, and 10 ml 70% ethanol (4°C) was added. Samples were pelleted again by centrifugation on the SS-34 rotor at 10,000 rpm for 10 minutes at 4°C. The pellet location was marked and the supernatant discarded. The tubes were then placed on their side in a drying rack and dried 10 minutes at 37°C, taking care not to overdry the samples.

After drying, the pellets were dissolved into 1.0 ml TE (pH 8.5) and placed at 50°C for 1-2 hours. Samples were held overnight at 4°C as dissolution continued. The DNA solution was then transferred to 1.5-

ml tubes with a 26-gauge needle on a tuberculin syringe. The transfer was repeated 5x in order to shear the DNA. Samples were then placed at 50°C for 1-2 hours.

*Quantitation of genomic DNA and preparation for gene amplification assay:*

The DNA levels in each tube were quantified by standard A260/A280 spectrophotometry on a 1:20 dilution (5 µl DNA + 95 µl ddH<sub>2</sub>O) using the 0.1-ml quartz cuvettes in the BECKMAN DU640<sup>TM</sup> spectrophotometer. A260/A280 ratios were in the range of 1.8-1.9. Each DNA sample was then diluted further to approximately 200 ng/ml in TE (pH 8.5). If the original material was highly concentrated (about 700 ng/µl), the material was placed at 50°C for several hours until resuspended.

Fluorometric DNA quantitation was then performed on the diluted material (20-600 ng/ml) using the manufacturer's guidelines as modified below. This was accomplished by allowing a HOEFFER DYNQUANT 200<sup>TM</sup> fluorometer to warm up for about 15 minutes. The HOECHST<sup>TM</sup> dye working solution (#H33258, 10 µl, prepared within 12 hours of use) was diluted into 100 ml 1 x TNE buffer. A 2-ml cuvette was filled with the fluorometer solution, placed into the machine, and the machine was zeroed. pGEM 3Zf(+) (2 µl, lot #360851026) was added to 2 ml of fluorometer solution and calibrated at 200 units. A second 2 µl of pGEM 3Zf(+) DNA was then tested and the reading confirmed at 400 +/- 10 units. Each sample was then read at least in triplicate. When 3 samples were found to be within 10% of each other, their average was taken and this value was used as the quantification value.

The fluorometrically-determined concentration was then used to dilute each sample to 10 ng/µl in ddH<sub>2</sub>O. This was done simultaneously on all template samples for a single TAQMAN<sup>TM</sup> plate assay, and with enough material to run 500-1000 assays. The samples were tested in triplicate with both B-actin and GAPDH on a single plate with normal human DNA and no-template controls. The diluted samples were used, provided that the CT value of normal human DNA subtracted from test DNA was +/- 1 CT. The diluted, lot-qualified genomic DNA was stored in 1.0-ml aliquots at -80°C. Aliquots which were subsequently to be used in the gene amplification assay were stored at 4°C. Each 1-ml aliquot is enough for 8-9 plates or 64 tests.

Framework Mapping and Epicenter Marking:

Human WISP-1 was reexamined with both framework and epicenter mapping. Selected tumors from the above initial screen were reexamined with both framework and epicenter mapping. Table IV indicates the chromosomal mapping of the framework markers that were used in the present example. The framework markers are located approximately every 20 megabases along Chromosome 8 and were used to control for aneuploidy.

TABLE IV  
Framework Markers

Map Position on Chromosome 8	Stanford Human Genome Center Marker Name
H9	EST-00040
H59	WI-961
H121	SHGC-11323
H200	SHGC-7433
H256	AFMa183zf1

Table V describes the epicenter markers that were employed in association with WISP-1. These markers are located in close proximity to the gene for WISP-1 and are used to assess the amplification status of the region of chromosome 8 in which the gene for WISP-1 is located. The distance between individual markers is measured in centirays (cR), which is a radiation breakage unit approximately equal to a 1% chance of a breakage between two markers. One cR is very roughly equivalent to 20 kilobases. The marker SHGC-32958 is the marker found to be the closest to the location on chromosome 8 to which the gene encoding WISP-1 most closely maps.

TABLE V  
Epicenter Markers

	Map Position on Chromosome 8	Stanford Human Genome Center Marker Name	Distance to next Marker (cR)
10	H257	AFMa248tel	103(gap)
	H259	SHGC-36664	33
	H261	AFM259xc5	63
	H266	SHGC-32958	41
15	H267	AFMa175xc1	19
	H268	AFM337wg5	87
	H273	SHGC-33759	7i
	H274	SHGC-32752	5
	H275	WI-7711	21
20	H277	SHGC-34940	-

The framework markers for human WISP-2 are located approximately every 20 megabases along Chromosome 20, and are used to control for aneuploidy. The markers are shown in Table VI.

TABLE VI  
Framework Markers

	Map Position on Chromosome 20	Stanford Human Genome Center Marker Name
25	T10	SHGC-2797
	T48	UT759
	T73	AFMa339xf5
30	T115	SHGC-33922
	T159	SHGC-36268

The marker SHGC-33922 is the marker to which human WISP-2 DNA most closely maps. This marker is between the framework markers. Framework analysis showed that all markers were up in tumors; thus, chromosome 20 was aneuploid in many tumors. Since the markers were up due to aneuploidy, epicenter analysis was not done for human WISP-2 gene.

The  $\Delta Ct$  values of the above described framework markers along Chromosome 8 relative for WISP-1 are indicated for selected tumors in Tables VII and VIII.

TABLE VII

Amplification of framework markers relative to Human WISP-1 DNA Framework Markers ( $\Delta$ ct)

		Probe/Delta CT							
Template	c-myc (SD)	WISP-1 (SD)	WISP-2 (SD)	H9 (SD)	H59 (SD)	H121 (SD)	H200 (SD)	H256 (SD)	
5	Nor Hu	0.00 (0.91)	0.00 (0.01)	0.00 (0.20)	0.00 (0.13)	0.00 (0.20)	0.00 (0.14)	0.00 (0.16)	0.00 (0.04)
	SW480	1.86	0.84	1.92	-1.18	1.01	0.17	0.65	0.81
	SW620	1.45	0.98	1.60	0.45	0.75	1.00	0.81	0.52
	Colo320	3.73	0.65	1.88	0.69	0.70	0.89	0.60	0.40
	HT29	0.83	2.67	2.20	-1.13	-0.40	-0.55	1.00	2.42
10	HM7	-2.03	0.07	-0.28	-0.28	0.24	-0.48	0.12	-0.26
	WiDr	-0.13	2.91	1.67	-0.20	0.95	0.07	1.43	2.55
	HCT116	-0.57	1.82	1.04	1.24	1.56	0.84	1.76	1.53
	SKCO-1	0.19	1.68	0.97	-0.30	0.32	0.12	1.39	1.63
	SW403	-0.72	1.34	1.77	0.23	0.53	0.26	1.48	1.48
15	Nor Hu	----	0.00 (0.18)	0.00 (1.02)	0.00 (0.08)	0.00 (0.13)	0.00 (0.01)	0.00 (0.16)	0.00 (0.37)
	CT-2	----	0.65	0.44	-0.25	0.11	0.07	0.13	0.95
	CT-3	----	0.90	0.95	-0.27	0.05	-0.10	-0.11	0.32
	CT-8	----	0.47	-0.34	0.07	-0.20	0.00	-0.04	0.07
	CT-10	----	0.76	0.50	0.23	-0.36	-0.08	0.17	0.70
20	CT-12	----	1.30	2.14	-0.70	-0.45	0.24	0.47	1.75
	CT-14	----	1.17	-0.48	0.05	0.18	0.31	0.23	1.51
	CT-15	----	0.22	-0.13	0.13	-0.48	0.29	0.11	0.59
	CT-16	----	0.26	0.10	0.00	-0.15	-0.23	-0.09	0.95
	CT-17	----	0.57	-0.33	0.73	-0.11	-0.05	-0.11	0.25
25	Nor Hu	----	0.00(0.45)	0.00 (1.07)	0.000 (0.04)	0.00 (0.21)	0.00 (0.18)	0.00 (0.03)	0.00 (0.18)
	CT-1	----	0.84	-0.37	-0.36	0.19	0.68	0.01	0.66
	CT-4	----	0.15	-0.23	-1.00	0.24	-0.11	0.30	0.14
	CT-5	----	0.86	-1.23	-0.60	-0.25	0.22	0.51	0.62

5	CT-6	----	0.03	0.39	-0.24	0.61	0.70	0.01	0.19
	CT-7	----	-0.20	-1.36	-0.76	0.00	-0.09	-0.13	-0.18
	CT-9	----	0.30	-0.54	-0.50	0.29	0.54	0.11	0.18
	CT-11	----	0.48	0.14	-0.89	0.34	0.82	0.17	-0.06
	CT-18	----	-0.20	-1.37	-0.52	0.32	0.66	0.08	0.12

TABLE VIII

Amplification of framework markers relative to Human WISP-1 DNA Framework Markers ( $\Delta Ct$ )

	Probe/Delta CT						
	Template	WISP-2 (SD)	T10 (SD)	T48 (SD)	T73 (SD)	T115 (SD)	T159 (SD)
	Nor Hu	0.00 (0.05)	0.00 (0.16)	0.00 (0.09)	0.00 (0.21)	0.00 (3.22)	0.00 (0.09)
10	SW480	1.31	1.32	0.63	1.94	-5.66	1.61
	SW620	1.32	2.02	1.42	1.06	-10.95	1.48
	Colo320	0.43	1.35	1.37	0.61	0.30	1.37
	HT29	1.76	1.09	-2.23	1.26	-5.47	1.87
	HM7	-0.32	0.32	0.38	0.41	-6.3	0.48
15	WiDr	1.76	1.61	-1.38	1.04	-7.36	1.55
	HCT116	1.18	1.24	1.15	1.46	-8.38	1.49
	SKCO-1	1.40	1.17	1.19	1.13	-5.34	1.61
	SW403	1.92	2.24	-17.23	1.38	-3.66	2.12

Gene Amplification Assay Results:20 The human WISP-2 (PRO261) compound of the invention was screened in the following primary tumors and the resulting  $\Delta Ct$  values are reported in Table IX.TABLE IX  
 $\Delta Ct$  values in lung and colon primary tumor models

Primary Tumor	PRO261
LT1	0.41
LT1a	1.08
LT2	0.27
LT3	0.98
LT4	0.32

	LT6	0.45
	LT7	0.03
	LT9	0.18
	LT10	1.16
5	LT11	0.67, 1.59, 0.63, 0.19,
	LT12	0.80, 1.73, 1.08, 2.23
	LT13	1.02, 1.13, 1.01, 0.29
	LT15	0.97, 2.64, 0.56, 2.38
	LT16	0.80, 0.75, 0.82, 2.05
10	LT17	1.67, 2.01, 1.43, 0.93
	LT18	1.22, 0.46, 0.15, -0.17
	LT19	0.78, 1.38, 1.39, 2.33
	LT21	0.04, 1.14, 0.48, 3.40
	CT2	1.66
15	CT3	2.14
	CT8	0.55
	CT10	1.00
	CT12	0.34
	CT14	1.03
20	CT15	0.67
	CT16	0.87
	CT17	-0.19
	CT1	-0.06
	CT4	1.00
25	CT5	1.07
	CT6	-0.08
	CT7	0.15
	CT9	0.68
	CT11	0.59
30	CT18	0.73
	A549	--
	Calu-1	--
	Calu-6	--

	H157	--
	H441	--
	H460	--
	SKMES1	--
5	SW900	--
	SW480	0.62, 1.90, 1.20, 1.57, 1.68, 1.36, 1.59, 1.86, 1.91, 2.36, 1.68, 1.53, 2.50
	SW620	0.66, 1.65, 1.85, 1.63, 1.61, 1.24, 1.52, 1.98, 1.57, 1.83, 1.41, 1.42, 1.59
	Colo320	-0.33, 0.66, 0.48, 0.91, 0.72, 0.33, 2.49, 0.99, 1.06, 1.24, 1.04, 0.46, 0.27
	HT29	0.46, 1.95, 1.61, 2.58, 1.49, 1.38, 1.40, 2.00, 2.59, 2.59, 1.39, 1.32
10	HM7	-0.70, 0.74, -0.29, 0.66, 0.27, 0.08, 0.54, 0.67, 0.64, 0.34, 0.09, 0.29, 0.21
	WiDr	0.19, 1.64, 1.00, 1.71, 1.44, 1.57, 0.93, 1.84, 1.58, 0.91, 0.87
	HCT116	0.25, 1.29, 1.04, 2.01, 1.29, 1.07, 1.08, 2.05, 1.81, 1.56, 1.05, 1.09, 0.96
	SKCO1	0.73, 1.99, 1.33, 1.00, 1.33, 1.26, 1.19, 2.10, 1.50, 2.13, 1.33, 1.29
	SW403	0.26, 1.98, 1.42, 2.20, 2.40, 1.50, 1.43, 2.15, 1.52, 1.67, 2.19, 1.40, 1.29
15	LS174T	1.48
	HBL100	1.40
	MB435s	1.43
	T47D	0.38
	MB468	-0.08
20	MB175	0.23
	MB361	0.37
	BT20	1.66
	MCF7	0.53
	SKBR3	1.73

25 The  $\Delta Ct$  values for DNA33473 (PRO261; human WISP-2) in a variety of primary lung and colon tumors as well as lung tumor cell lines are reported in Table IX. A  $\Delta Ct$  value of  $> 1$  was typically used as the threshold value for amplification scoring, as this represents a doubling of the gene copy. Table IX indicates that significant amplification of DNA33474 occurred in: (1) primary lung tumors LT1a, LT10.

LT12, LT15, LT17 and LT19; (2) primary colon tumors CT2, CT3, CT14, and CT5; (3) colon tumor cell lines SW480, SW620, HT29, WiDr, HCT116, SKCO1, SW403, and LS174T and (4) breast tumor cell lines HBL100, MB435s, BT20 and SKBR3.

The  $\Delta Ct$  and average  $\Delta Ct$  values for the primary lung tumors were the following: 1.08, 1.16, 1.17, 5 1.64, 1.50 and 1.47, respectively; those for the primary colon tumors were 1.16, 2.14, 1.03 and 1.07, respectively; those for the colon tumor cell lines were 1.67, 1.54, 1.73, 1.24, 1.32, 1.35, 1.65, and 1.48, respectively; and those for the breast tumor cell lines were 1.40, 1.43, 1.66, and 1.73, respectively.

For the lung tumors, this represents approximately a 2.1-, 2.2-, 2.2-, 3.1-, 2.8-, and 2.8-, respectively, fold increase in gene copy relative to normal tissue. For the colon tumors, this represents a 10 2.2-, 4.4-, 2.0-, and 2.1-, respectively, fold increase in gene copy relative to normal tissue. For the colon tumor cell lines, this represents a 3.2-, 2.9-, 3.3-, 2.4-, 2.5-, 2.5-, 3.1-, and 2.8-, respectively, fold increase in gene copy relative to normal tissue. For the breast tumor cell lines, this represents a 2.6-, 2.7-, 3.2-, and 15 3.3-, respectively, fold increase in gene copy relative to normal tissue. Because amplification of DNA33473 (PRO261) occurs in various tumors, it is likely associated with tumor formation or growth. As a result, antagonists (e.g., antibodies) directed against the protein encoded by DNA33473 (PRO261) would be expected to be useful in cancer therapy.

#### EXAMPLE 16: *In Situ* Hybridization

*In situ* hybridization is a powerful and versatile technique for the detection and localization of 20 nucleic acid sequences within cell or tissue preparations. It may be useful, for example, in identifying sites of gene expression, analyzing the tissue distribution of transcription, identifying and localizing viral infection, following changes in specific mRNA synthesis, and aiding in chromosome mapping.

*In situ* hybridization was performed following an optimized version of the protocol by Lu and Gillett, Cell Vision 1: 169-176 (1994), using PCR-generated  $^{33}\text{P}$ -labeled riboprobes. Briefly, formalin-fixed, paraffin-embedded human tissues were sectioned, deparaffinized, deproteinized in proteinase K (20 g/ml) for 15 minutes at 37°C, and further processed for *in situ* hybridization as described by Lu and Gillett, 25 *supra*. A ( $^{33}\text{P}$ )UTP-labeled antisense riboprobe was generated from a PCR product and hybridized at 55°C overnight. The slides were dipped in KODAK NTB2<sup>TM</sup> nuclear track emulsion and exposed for 4 weeks.

#### $^{33}\text{P}$ -Riboprobe synthesis

30 6.0  $\mu\text{l}$  (125 mCi) of  $^{33}\text{P}$ -UTP (Amersham BF 1002, SA <2000 Ci/mmol) were speed-vacuum dried.

To each tube containing dried  $^{33}\text{P}$ -UTP, the following ingredients were added:

2.0  $\mu\text{l}$  5x transcription buffer  
1.0  $\mu\text{l}$  DTT (100 mM)  
2.0  $\mu\text{l}$  NTP mix (2.5 mM : 10  $\mu\text{l}$  each of 10 mM GTP, CTP & ATP + 10  $\mu\text{l}$  H<sub>2</sub>O)  
35 1.0  $\mu\text{l}$  UTP (50  $\mu\text{M}$ )  
1.0  $\mu\text{l}$  RNAsin  
1.0  $\mu\text{l}$  DNA template (1  $\mu\text{g}$ )

1.0  $\mu$ l  $H_2O$

1.0  $\mu$ l RNA polymerase (for PCR products T3 = AS, T7 = S, usually)

The tubes were incubated at 37°C for one hour. A total of 1.0  $\mu$ l RQ1 DNase was added, followed by incubation at 37°C for 15 minutes. A total of 90  $\mu$ l TE (10 mM Tris pH 7.6/1 mM EDTA, pH 8.0) was added, and the mixture was pipetted onto DE81 paper. The remaining solution was loaded in a MICROCON-50™ ultrafiltration unit, and spun using program 10 (6 minutes). The filtration unit was inverted over a second tube and spun using program 2 (3 minutes). After the final recovery spin, a total of 100  $\mu$ l TE was added. Then 1  $\mu$ l of the final product was pipetted on DE81 paper and counted in 6 ml of BIOFLUOR II™.

The probe was run on a TBE/urea gel. A total of 1-3  $\mu$ l of the probe or 5  $\mu$ l of RNA Mrk III was added to 3  $\mu$ l of loading buffer. After heating on a 95°C heat block for three minutes, the gel was immediately placed on ice. The wells of gel were flushed, and the sample was loaded and run at 180-250 volts for 45 minutes. The gel was wrapped in plastic wrap (SARAN™ brand) and exposed to XAR film with an intensifying screen in a -70°C freezer one hour to overnight.

15 **<sup>33</sup>P-Hybridization**

A. Pretreatment of frozen sections

The slides were removed from the freezer, placed on aluminum trays, and thawed at room temperature for 5 minutes. The trays were placed in a 55°C incubator for five minutes to reduce condensation. The slides were fixed for 10 minutes in 4% paraformaldehyde on ice in the fume hood, and washed in 0.5 x SSC for 5 minutes, at room temperature (25 ml 20 x SSC + 975 ml s.c.  $H_2O$ ). After deproteination in 0.5  $\mu$ g/ml proteinase K for 10 minutes at 37°C (12.5  $\mu$ l of 10 mg/ml stock in 250 ml prewarmed RNAse-free RNAse buffer), the sections were washed in 0.5 x SSC for 10 minutes at room temperature. The sections were dehydrated in 70%, 95%, and 100% ethanol, 2 minutes each.

B. Pretreatment of paraffin-embedded sections

25 The slides were deparaffinized, placed in s.c.  $H_2O$ , and rinsed twice in 2 x SSC at room temperature, for 5 minutes each time. The sections were deproteinated in 20  $\mu$ g/ml proteinase K (500  $\mu$ l of 10 mg/ml in 250 ml RNAse-free RNAse buffer; 37°C, 15 minutes) for human embryo tissue, or 8 x proteinase K (100  $\mu$ l in 250 ml RNAse buffer, 37°C, 30 minutes) for formalin tissues. Subsequent rinsing in 0.5 x SSC and dehydration were performed as described above.

30 C. Prehybridization

The slides were laid out in a plastic box lined with Box buffer (4 x SSC, 50% formamide) The filter paper was saturated. The tissue was covered with 50  $\mu$ l of hybridization buffer (3.75 g dextran sulfate + 6 ml s.c.  $H_2O$ ), vortexed, and heated in the microwave for 2 minutes with the cap loosened. After cooling on ice, 18.75 ml formamide, 3.75 ml 20 x SSC, and 9 ml s.c.  $H_2O$  were added, and the tissue was vortexed well and incubated at 42°C for 1-4 hours.

35 D. Hybridization

1.0 x 10<sup>6</sup> cpm probe and 1.0  $\mu$ l tRNA (50 mg/ml stock) per slide were heated at 95°C for 3 minutes. The slides were cooled on ice, and 48  $\mu$ l hybridization buffer was added per slide. After vortexing, 50  $\mu$ l <sup>33</sup>P mix was added to 50  $\mu$ l prehybridization on the slide. The slides were incubated overnight at 55°C.

5           E. Washes

Washing was done for 2x10 minutes with 2xSSC, EDTA at room temperature (400 ml 20 x SSC + 16 ml 0.25 M EDTA, V<sub>f</sub>=4L), followed by RNaseA treatment at 37°C for 30 minutes (500  $\mu$ l of 10 mg/ml in 250 ml RNase buffer = 20  $\mu$ g/ml). The slides were washed 2x10 minutes with 2 x SSC, EDTA at room temperature. The stringency wash conditions were as follows: 2 hours at 55°C, 0.1 x SSC, EDTA (20 ml 20 x SSC + 16 ml EDTA, V<sub>f</sub>=4L).

10           F. Oligonucleotides

*In situ* analysis was performed on DNA sequences disclosed herein. The oligonucleotides employed for these analyses are as follows.

(1) Mouse WISP-1 (Clone 568)

15           Notrim-p1: 5'-GGA TTC TAA TAC GAC TCA CTA TAG GGC GTC CCT GGC CAG TGC TGT GAG-3'  
(SEQ ID NO:147)

Notrim-p2: 5'-CTA TGA AAT TAA CCC TCA CTA AAG GGA GGG CCA GGC TTT GCT TCC ATT-3'  
(SEQ ID NO:148)

(2) Human WISP-1

20           hmWISP-1 p1: 5'-GGA TTC TAA TAC GAC TCA CTA TAG GGC TGG AGG CAT GGC ACA GGA  
AC-3' (SEQ ID NO:149)

hmWISP-1 p2: 5'-CTA TGA AAT TAA CCC TCA CTA AAG GGA TCC GGA TCA GGC TTG GGT  
GTA-3' (SEQ ID NO:150)

(3) Mouse WISP-2 (Clone 1367.3)

25           1367.p1: 5'-GGA TTC TAA TAC GAC TCA CTA TAG GGC AGC TTG GGA TGG AGG TCT TTC-3'  
(SEQ ID NO:151)

1367.p2: 5'-CTA TGA AAT TAA CCC TCA CTA AAG GGA GGG CAC TGG GGT GGT GT-3' (SEQ  
ID NO:152)

(4) Human WISP-2 (DNA33473)

30           DNA33473-p1: 5'-GGA TTC TAA TAC GAC TCA CTA TAG GGC GCG AGG ACG GCG GCT TCA-3'  
(SEQ ID NO:153)

DNA33473-p2: 5'-CTA TGA AAT TAA CCC TCA CTA AAG GGA AGA GTC GCG GCC GCC CTT  
TTT-3' (SEQ ID NO:154)

(5) Human WISP-3

35           WISP3-p1: 5'-GGA TTC TAA TAC GAC TCA CTA TAG GGC GGG GCT CCT CTT CTC CAC TCT-3'  
(SEQ ID NO:155)

WISP3-p2 5'-CTA TGA ATTAA CCC TCA CTA AAG GGA GCT GTC GCA AGG CTG AAT GTA-3'  
(SEQ ID NO:156)

5           G. Results

5           *In situ* analysis was performed on the above DNA sequences disclosed herein. The results from these analyses are as follows.

10           (1)    Mouse WISP-1

15           Expression in Mouse Tissues

10           Mouse Fetal Tissues: *In situ* hybridization of mouse WISP-1 showed strong expression in embryonic mesenchymal tissues. At E10.5 expression was observed in tissues that would develop into skeletal elements in the adult; this pattern was maintained at later stages of embryonic development. In later stages (E12.5 and E15.5), expression was highest in osteoblasts at the sites of bone formation. Expression was also observed in the embryonic heart, where the signal was particularly strong in the atria at E12.5 (atria were not included in sections at E15.5).

15           Mouse Adult Tissues: No expression was observed in any of the adult tissues examined, including heart, lung, kidney, adrenal, liver, pancreas, cerebrum, and cerebellum. These results do not correlate with the Northern data.

20           Additional sites of expression in the fetus were the walls of developing blood vessels and in fibroblast-like cells within the hepatic portal tract mesenchyme.

25           Expression in Normal and Wnt-1 Transgenic Tumors

20           Expression with the antisense probe was observed over fibroblast-like cells lying adjacent to the subcutaneous skeletal muscle in P10 (post-natal day 10 pups) and in pregnant females. Expression was not observed over breast epithelial cells at any of the time points examined in the study.

25           Expression of mouse WISP-1 was high in all three of the Wnt-1 transgenic tumors tested and appeared to be confined to the supporting fibroblast-like cells within the delicate connective tissue stroma. Some expression was seen over the tumor cells themselves; however, this likely represents overspill from tumor fibroblasts, rather than true expression by tumor cells.

30           In summary, mouse WISP-1 was expressed in embryonic skeletal mesenchyme and at sites of bone formation. It was additionally expressed in fibroblasts in the sub-cutus of growing pups and pregnant females. It is likely to play a role in osteogenesis, and may be involved in repair after injury. Expression was also observed in the embryonic heart.

35           (2) Human WISP-1

35           Expression in Human Tissues

35           Human Fetal Tissue The fetal tissues examined (E12-E16 weeks) included: placenta, umbilical cord, liver, kidney, adrenals, thyroid, lungs, heart, great vessels, oesophagus, stomach, small intestine, spleen, thymus, pancreas, brain, eye, spinal cord, body wall, pelvis, and lower limb.

35           Human WISP-1 exhibited expression at sites of connective tissue interfaces in the fetus, for example, developing portal tracts, fascial planes in muscle, and connective tissue surrounding developing

skeletal elements and tendons. Expression also was seen in the epithelium of the developing renal cortex and in spindle-shaped fibroblast-like cells in the fetal adrenal. Human WISP-1 was strongly expressed by osteoblasts at sites of bone formation in the fetal limb.

5 Human Adult Tissue The adult tissues examined were: liver, kidney, adrenal, myocardium, aorta, spleen, lung, skin, chondrosarcoma, eye, stomach, gastric carcinoma, colon, colonic carcinoma, renal cell carcinoma, prostate, bladder mucosa, and gall bladder, as well as tissue with acetaminophen-induced liver injury and hepatic cirrhosis.

No expression was seen in normal or diseased adult tissues in this study.

10 In summary, the overall pattern of expression of human WISP-1 was broadly similar to that observed for the mouse gene as noted above. The human WISP-1 probe did not cross react with the mouse embryo section.

Expression in Human Breast Carcinoma and Normal Breast Tissue

15 Human WISP-1 was negative on benign and malignant epithelial cells, but showed specific hybridization in mesenchymal cells, particularly in areas of tissue repair, including dystrophic ossification. Most positive cells had the morphology of fibroblasts; smooth muscle cells appeared to be negative.

20 In summary, this study shows expression of human WISP-1 RNA in mesenchymal cells involved in tissue repair and/or collagen deposition. The signal was particularly strong in benign fibroblast-like cells adjacent to either infiltrating breast carcinoma cells or tissue destruction due to benign, inflammatory conditions (duct rupture). Of note is the fact that deposition of benign osteoid seemed to correlate with strong expression of the RNA.

(3) Mouse WISP-2

Expression in Normal Mouse Tissues

Mouse Fetal Tissues: Expression of mouse WISP-2 was observed in osteoblasts in an E15.5 mouse embryo, within the developing mandible.

25 Mouse Adult Tissues: Expression of mouse WISP-2 was observed in stromal cells around the origin, and within the cusps of the mitral and tricuspid valves of the adult heart. Expression was also observed in the adventitial cells of the renal artery; expression was presumed to be present at this site in all arteries.

All other tissues were negative.

30 Expression in Wnt-1 Tumors

The results demonstrated specific expression of mouse WISP-2 in the stroma of all Wnt-1 tumors examined. There was a signal over mononuclear cells with open vesicular nuclei, possibly macrophages. No expression was observed in either the benign or the malignant epithelium.

(4) Human WISP-2

35 Expression in Human Tissues

Strong expression of the WISP-2-encoding gene was observed in dermal fibroblasts in normal adult skin. Additionally, strong expression was seen in two cirrhotic livers, at sites of active hepatic

fibrosis. Moderate expression was found over fasciculata cells of adrenal cortex. This localization supports a role for human WISP-2 in extracellular matrix formation or turnover.

Expression in Human Breast Carcinoma and Normal Breast Tissue, and in Lung Carcinoma

Human WISP-2 showed a similar hybridization pattern to human WISP-1 (described above) in the two breast tumors examined. It was negative on benign and malignant epithelial cells, but showed specific hybridization in mesenchymal cells, particularly in areas of tissue repair, including dystrophic ossification. The signal appeared to localize to the same cell population for both probes WISP-1 and WISP-2; however, in some areas (breast tumor 02), the signal for WISP-2 was significantly stronger than that for human WISP-1. Most positive cells had the morphology of fibroblasts; smooth muscle cells appeared to be negative. The signal for human WISP-2 was less intense in the lung tumor tissue; however, this section also showed less tissue repair compared with the breast tumor slides. Normal lung and kidney tissue were essentially negative for human WISP-2, as for human WISP-1.

In summary, this study shows expression of human WISP-2 RNA in mesenchymal cells involved in tissue repair and/or collagen deposition. The signal was particularly strong in benign fibroblast-like cells adjacent to either infiltrating breast carcinoma cells or tissue destruction due to benign, inflammatory conditions (duct rupture). Of note is the fact that deposition of benign osteoid seemed to correlate with strong expression of the RNA.

(5) Human WISP-3

Expression in Normal Adult and Fetal Tissues and in Human Breast Carcinoma and Normal Breast Tissue and in Colon Carcinoma

The analysis shows strong expression of human WISP-3 in dermal fibroblasts in normal adult skin and in cirrhotic livers at sites of active hepatic fibrosis. This localization pattern supports a role for this growth factor in extracellular matrix formation and turnover.

The probe for human WISP-3 was negative on most tissues examined. It showed a weak, diffuse positivity on sections of an osteosarcoma; some of the positive cells do represent malignant cells. WISP-3 was negative on all normal and fetal tissues examined.

EXAMPLE 17: Ability of WISP Polypeptides to Inhibit VEGF-Stimulated Proliferation of Endothelial Cell Growth

The ability of mouse and human WISP-1 and human WISP-2 polypeptides to inhibit VEGF-stimulated proliferation of endothelial cells was tested. Specifically, bovine adrenal cortical capillary endothelial (ACE) cells (from primary culture, maximum 12-14 passages) were plated on 96-well microtiter plates (Amersham Life Science) at a density of 500 cells/well per 100  $\mu$ L in low-glucose DMEM, 10% calf serum, 2 mM glutamine, 1x pen/strep, and fungizone, supplemented with 3 ng/mL VEGF. Controls were plated the same way but some did not include VEGF. A test sample of either mouse WISP-1, human WISP-1 conjugated to IgG, or human WISP-2 (PRO261) conjugated to poly-His was added in a 100- $\mu$ l volume for a 200- $\mu$ L final volume. Cells were incubated for 5-7 days at 37°C. The media were aspirated and the cells washed 1x with PBS. An acid phosphatase reaction mixture (100  $\mu$ L, 0.1 M sodium acetate, pH 5.5, 0.1% TRITON-100<sup>TM</sup>, 10 mM p-nitrophenylphosphate) was added. After incubation for 2 hours at 37°C.

the reaction was stopped by addition of 10  $\mu$ L 1 N NaOH. OD was measured on a microtiter plate reader at 405 nm. Controls were: no cells, cells alone, cells + FGF (5 ng/mL), cells + VEGF (3 ng/mL), cells + VEGF (3 ng/ml) + TGF- $\beta$  (1 ng/ml), and cells + VEGF (3 ng/mL) + LIF (5 ng/mL). (TGF- $\beta$  at a 1 ng/ml concentration is known to block 70-90% of VEGF-stimulated cell proliferation.)

5 The results were assessed by calculating the percentage inhibition of VEGF(3ng/ml)-stimulated cell proliferation, determined by measuring acid phosphatase activity at OD405 nm (1) relative to cells without stimulation, and (2) relative to the reference TGF- $\beta$  inhibition of VEGF-stimulated activity. The results, as shown in Table X below, are indicative of the utility of the WISP polypeptides in cancer therapy and specifically in inhibiting tumor angiogenesis. The numerical values (relative inhibition) shown in Table 10 X are determined by calculating the percent inhibition of VEGF-stimulated proliferation by the mouse WISP-1, human WISP-1-IgG, and human WISP-2-poly-His polypeptides relative to cells without stimulation and then dividing that percentage into the percent inhibition obtained by TGF- $\beta$  at 1 ng/ml, which is known to block 70-90% of VEGF-stimulated cell proliferation. Human WISP-1 and human WISP-2 appear to be particularly useful as angiostatic agents.

15 Table X

	<u>Polypeptide</u>	<u>Concentration (nM)</u>	<u>Relative Inhibition</u>
Mouse WISP-1	0.1	113	
	1.0	108	
	10.0	109	
20 Human WISP-1-IgG	1.1	1	
	11.0	0.95	
	110.0	0.9	
Human WISP-2-poly-His	0.01%	0.95	
	0.01%	1.1	
25	0.1	0.62	
	1.0	1.03	
	1.0	0.5	
	1.0	0.6	

Deposit of Material

30 The following materials have been deposited with the American Type Culture Collection, 10801 University Blvd., Manassas, VA, USA (ATCC):

	<u>Material</u>	<u>ATCC Dep. No.</u>	<u>Deposit Date</u>
	pRK5E.h.WIG-1.568.38	209533	December 10, 1997
	pRK5E.m.WIG-1.568.6his	209537	December 10, 1997
35	Plasmid (encoding human WISP-2)	209391	October 17, 1997
	pRKE.m.WIG-2.1367.3	209538	December 10, 1997

DNA56350-1176-2	209706	March 26, 1998
DNA58800-1176-2	209707	March 26, 1998

These deposits were made under the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purpose of Patent Procedure and the Regulations thereunder (Budapest Treaty). This assures maintenance of viable cultures of the deposits for 30 years from the date of deposit. The deposits will be made available by ATCC under the terms of the Budapest Treaty, and subject to an agreement between Genentech, Inc. and ATCC, which assures permanent and unrestricted availability of the progeny of the cultures of the deposits to the public upon issuance of the pertinent U.S. patent or upon laying open to the public of any U.S. or foreign patent application, whichever comes first, and assures availability of the progeny to one determined by the U.S. Commissioner of Patents and Trademarks to be entitled thereto according to 35 USC §122 and the Commissioner's rules pursuant thereto (including 37 CFR §1.14 with particular reference to 886 OG 638).

The assignee of the present application has agreed that if a culture of the materials on deposit should die or be lost or destroyed when cultivated under suitable conditions, the materials will be promptly replaced on notification with another of the same. Availability of the deposited materials is not to be construed as a license to practice the invention in contravention of the rights granted under the authority of any government in accordance with its patent laws.

The foregoing written specification is considered to be sufficient to enable one skilled in the art to practice the invention. The present invention is not to be limited in scope by the constructs deposited, since the deposited embodiment is intended as a single illustration of certain aspects of the invention and any constructs that are functionally equivalent are within the scope of this invention. The deposits of materials herein do not constitute an admission that the written description herein contained is inadequate to enable the practice of any aspect of the invention, including the best mode thereof, nor is it to be construed as limiting the scope of the claims to the specific illustrations that it represents. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and fall within the scope of the appended claims.

## WHAT IS CLAIMED IS:

1. Isolated nucleic acid comprising DNA having at least about 600 nucleotides and at least about a 75% sequence identity to (a) a DNA molecule encoding a human WISP-1 polypeptide comprising the sequence of amino acids 23 to 367 of Figures 3A and 3B (SEQ ID NO:3), or (b) a complement of the DNA molecule of (a).  
5
2. The nucleic acid of claim 1 having at least one WISP biological activity.
3. The nucleic acid of claim 1 comprising DNA having at least about a 95% sequence identity to (a) a DNA molecule encoding a human WISP-1 polypeptide comprising the sequence of amino acids 23 to 367 of Figures 3A and 3B (SEQ ID NO:3), or (b) a complement of the DNA molecule of (a).
- 10 4. The nucleic acid of claim 3 comprising DNA encoding a human WISP-1 polypeptide having amino acid residues 23 to 367 of Figures 3A and 3B (SEQ ID NO:3), or DNA encoding a human WISP-1 polypeptide having amino acid residues 1 to 367 of Figures 3A and 3B (SEQ ID NO:4), or a complement of either of the encoding DNAs.
- 15 5. The nucleic acid of claim 3 comprising DNA encoding a human WISP-1 polypeptide having amino acid residues 23 to 367 or 1 to 367 of Figures 3A and 3B except for an isoleucine residue at position 184 rather than a valine residue (SEQ ID NOS:5 and 6, respectively).
6. The nucleic acid of claim 3 comprising DNA encoding a human WISP-1 polypeptide having amino acid residues 23 to 367 or 1 to 367 of Figures 3A and 3B except for a serine residue at position 202 rather than an alanine residue (SEQ ID NOS:7 and 8, respectively).
- 20 7. The nucleic acid of claim 3 comprising DNA encoding a human WISP-1 polypeptide having amino acid residues 23 to 367 or 1 to 367 of Figures 3A and 3B except for an isoleucine residue at position 184 rather than a valine residue and except for a serine residue at position 202 rather than an alanine residue (SEQ ID NOS:21 and 22, respectively).
8. Isolated nucleic acid comprising SEQ ID NO:23, 24, 25, 26, 27, 28, or 29.
- 25 9. The nucleic acid of claim 1 comprising DNA encoding a mouse WISP-1 polypeptide having amino acid residues 23 to 367 of Figure 1 (SEQ ID NO:11), or DNA encoding a mouse WISP-1 polypeptide having

amino acid residues 1 to 367 of Figure 1 (SEQ ID NO:12), or a complement of either of the encoding DNAs.

10. Isolated nucleic acid comprising DNA having at least about 600 nucleotides and at least about a 85% sequence identity to (a) a DNA molecule encoding a mouse WISP-1 polypeptide comprising the sequence of amino acids 23 to 367 of Figure 1 (SEQ ID NO:11), or (b) a complement of the DNA molecule of (a).
- 5
11. The nucleic acid of claim 10 having at least one WISP biological activity.
12. The nucleic acid of claim 10 comprising DNA having at least about a 95% sequence identity to (a) a DNA molecule encoding a mouse WISP-1 polypeptide comprising the sequence of amino acids 23 to 367 of Figure 1 (SEQ ID NO:11), or (b) a complement of the DNA molecule of (a).
- 10 13. Isolated nucleic acid comprising DNA having at least about 600 nucleotides and at least about a 75% sequence identity to (a) a DNA molecule encoding the same full-length polypeptide encoded by the human WISP-1 polypeptide cDNA in ATCC Deposit No. 209533 (pRK5E.h.WISP-1.568.38), or (b) a complement of the DNA molecule of (a).
14. A vector comprising the nucleic acid of claim 1.
- 15 15. A host cell comprising the vector of claim 14.
16. A process for producing a WISP-1 polypeptide comprising culturing the host cell of claim 15 under conditions suitable for expression of the WISP-1 polypeptide and recovering the WISP-1 polypeptide from the cell culture.
17. Isolated WISP-1 polypeptide encoded by the nucleic acid of claim 1.
- 20 18. The polypeptide of claim 17 that is human WISP-1 or mouse WISP-1.
19. Isolated WISP-1 polypeptide encoded by a nucleic acid of claim 8.
20. A chimeric molecule comprising a WISP-1 polypeptide fused to a heterologous amino acid sequence.

21. The chimeric molecule of claim 20 wherein said heterologous amino acid sequence is an epitope tag sequence, a poly-amino acid sequence, or an Fc region.
22. An antibody which specifically binds to a WISP-1 polypeptide.
23. The antibody of claim 22 wherein said antibody is a monoclonal antibody.
- 5 24. Isolated nucleic acid having at least about 600 nucleotides and produced by hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a human WISP-1 polypeptide comprising the sequence of amino acids 23 to 367 of Figures 3A and 3B (SEQ ID NO:3), or (b) a complement of the DNA molecule of (a), and, if the test DNA molecule has at least about a 75% sequence identity to (a) or (b), isolating the test DNA molecule.
- 10 25. A polypeptide produced by (i) hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a human WISP-1 polypeptide comprising the sequence of amino acids 23 to 367 of Figures 3A and 3B (SEQ ID NO:3), or (b) a complement of the DNA molecule of (a), and if the test DNA molecule has at least about a 75% sequence identity to (a) or (b), (ii) culturing a host cell comprising the test DNA molecule under conditions suitable for expression of the polypeptide, and (iii) recovering the polypeptide from the cell culture.
- 15 26. Isolated nucleic acid comprising DNA having at least about an 80% sequence identity to (a) a DNA molecule encoding a human WISP-2 polypeptide comprising the sequence of amino acids 24 to 250 of Figure 4 (SEQ ID NO:15), or (b) a complement of the DNA molecule of (a).
27. The nucleic acid of claim 26 having at least one WISP biological activity.
- 20 28. The nucleic acid of claim 26 comprising DNA having at least about a 95% sequence identity to (a) a DNA molecule encoding a human WISP-2 polypeptide comprising the sequence of amino acids 24 to 250 of Figure 4 (SEQ ID NO:15), or (b) a complement of the DNA molecule of (a).
- 25 29. The nucleic acid of claim 26 comprising DNA encoding a human WISP-2 polypeptide having amino acid residues 24 to 250 of Figure 4 (SEQ ID NO:15), or DNA encoding a human WISP-2 polypeptide having amino acid residues 1 to 250 of Figure 4 (SEQ ID NO:16), or a complement of either of the encoding DNAs.

30. Isolated nucleic acid comprising DNA having at least about an 80% sequence identity to (a) a DNA molecule encoding a human WISP-2 polypeptide comprising the sequence of amino acids 1 to 250 of Figure 4 (SEQ ID NO:16), or (b) a complement of the DNA molecule of (a).
- 5 31. Isolated nucleic acid comprising DNA having at least about 500 nucleotides and at least about an 80% sequence identity to (a) a DNA molecule encoding a mouse WISP-2 polypeptide comprising the sequence of amino acids 24 to 251 of Figure 2 (SEQ ID NO:19), or (b) a complement of the DNA molecule of (a).
32. The isolated nucleic acid of claim 31 comprising DNA having at least about a 95% sequence identity to (a) a DNA molecule encoding a mouse WISP-2 polypeptide comprising the sequence of amino acids 24 to 251 of Figure 2 (SEQ ID NO:19), or (b) a complement of the DNA molecule of (a).
- 10 33. The nucleic acid of claim 32 comprising DNA encoding a mouse WISP-2 polypeptide having amino acid residues 24 to 251 of Figure 2 (SEQ ID NO:19), or DNA encoding a mouse WISP-2 polypeptide having amino acid residues 1 to 251 of Figure 2 (SEQ ID NO:20), or a complement of either of these encoding DNAs.
- 15 34. Isolated nucleic acid comprising DNA having at least about 500 nucleotides and at least about an 80% sequence identity to (a) a DNA molecule encoding a mouse WISP-2 polypeptide comprising the sequence of amino acids 1 to 251 of Figure 2 (SEQ ID NO:20), or (b) a complement of the DNA molecule of (a).
- 20 35. Isolated nucleic acid comprising DNA having at least about 400 nucleotides and at least about a 75% sequence identity to (a) a DNA molecule encoding the same full-length polypeptide encoded by the human WISP-2 polypeptide cDNA in ATCC Deposit No. 209391 (DNA33473), or (b) a complement of the DNA molecule of (a).
36. The nucleic acid of claim 35 comprising the nucleotide sequence of the full-length coding sequence of clone UNQ228 (DNA33473) deposited under accession number ATCC 209391.
37. A vector comprising the nucleic acid of claim 26.
38. A host cell comprising the vector of claim 37.
- 25 39. A process for producing a WISP-2 polypeptide comprising culturing the host cell of claim 38 under conditions suitable for expression of the WISP-2 polypeptide and recovering the WISP-2 polypeptide from the cell culture.

40. Isolated WISP-2 polypeptide encoded by the nucleic acid of claim 26.
41. The polypeptide of claim 40 that is isolated native-sequence human WISP-2 polypeptide comprising amino acid residues 1 to 250 of Figure 4 (SEQ ID NO:16) or comprising amino acid residues 24 to 250 of Figure 4 (SEQ ID NO:15).
- 5 42. A chimeric molecule comprising a WISP-2 polypeptide fused to a heterologous amino acid sequence.
43. An antibody which specifically binds to a WISP-2 polypeptide.
44. The antibody of claim 43 that is a monoclonal antibody.
- 10 45. Isolated nucleic acid having at least about 400 nucleotides and produced by hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a human WISP-2 polypeptide comprising the sequence of amino acids 24 to 250 of Figure 4 (SEQ ID NO:15), or (b) a complement of the DNA molecule of (a), and, if the test DNA molecule has at least about a 75% sequence identity to (a) or (b), isolating the test DNA molecule.
- 15 46. A polypeptide produced by (i) hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a human WISP-2 polypeptide comprising the sequence of amino acids 24 to 250 of Figure 4 (SEQ ID NO:15), or (b) a complement of the DNA molecule of (a), and if the test DNA molecule has at least about a 75% sequence identity to (a) or (b), (ii) culturing a host cell comprising the test DNA molecule under conditions suitable for expression of the polypeptide, and (iii) recovering the polypeptide from the cell culture.
- 20 47. Isolated nucleic acid comprising DNA having a 100% sequence identity in more than about 500 nucleotides to (a) a DNA molecule encoding a human WISP-3 polypeptide comprising the sequence of amino acids 34 to 372 of Figures 6A and 6B (SEQ ID NO:32), or (b) a complement of the DNA molecule of (a).
48. The nucleic acid of claim 47 having at least one WISP biological activity.
- 25 49. The nucleic acid of claim 47 comprising DNA encoding a human WISP-3 polypeptide having amino acid residues 34 to 372 of Figures 6A and 6B (SEQ ID NO:32) or amino acid residues 1 to 372 of Figures 6A and 6B (SEQ ID NO:33), or a complement thereof.

50. A vector comprising the nucleic acid of claim 47.
51. A host cell comprising the vector of claim 50.
52. A process for producing a WISP-3 polypeptide comprising culturing the host cell of claim 51 under conditions suitable for expression of the WISP-3 polypeptide and recovering the WISP-3 polypeptide from the cell culture.
53. Isolated WISP-3 polypeptide encoded by the nucleic acid of claim 47.
54. The polypeptide of claim 53 that is human WISP-3.
55. A chimeric molecule comprising the WISP-3 polypeptide of claim 53 fused to a heterologous amino acid sequence.
- 10 56. An antibody which specifically binds to the WISP-3 polypeptide of claim 53.
57. Isolated nucleic acid comprising DNA having a 100% sequence identity in more than about 500 nucleotides to (a) a DNA molecule encoding the same full-length polypeptide encoded by the human WISP-3 polypeptide cDNA in ATCC Deposit No. 209706 (DNA56350-1176-2), or (b) a complement of the DNA molecule of (a).
- 15 58. Isolated nucleic acid produced by hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a human WISP-3 polypeptide comprising the sequence of amino acids 34 to 372 of Figures 6A and 6B (SEQ ID NO:32), or (b) a complement of the DNA molecule of (a), and, if the test DNA molecule has a 100% sequence identity to (a) or (b) in more than about 500 nucleotides, isolating the test DNA molecule.
- 20 59. A polypeptide produced by (i) hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a human WISP-3 polypeptide comprising the sequence of amino acids 34 to 372 of Figures 6A and 6B (SEQ ID NO:32), or (b) a complement of the DNA molecule of (a), and if the test DNA molecule has a 100% sequence identity to (a) or (b) in more than about 500 nucleotides. (ii) culturing a host cell comprising the test DNA molecule under conditions suitable for expression of the polypeptide, and (iii) recovering the polypeptide from the cell culture.
- 25

60. Isolated nucleic acid comprising DNA having a 100% sequence identity in more than about 400 nucleotides to (a) a DNA molecule encoding a human WISP-3 polypeptide comprising the sequence of amino acids 16 to 355 of Figures 7A and 7B (SEQ ID NO:36), or (b) a complement of the DNA molecule of (a).
- 5 61. The nucleic acid of claim 60 having at least one WISP biological activity.
62. The nucleic acid of claim 60 comprising DNA encoding a human WISP-3 polypeptide having amino acid residues 16 to 355 of Figures 7A and 7B (SEQ ID NO:36) or amino acid residues 1 to 355 of Figures 7A and 7B (SEQ ID NO:37), or a complement thereof.
- 10 63. Isolated nucleic acid comprising DNA having a 100% sequence identity in more than about 400 nucleotides to (a) a DNA molecule encoding the same full-length polypeptide encoded by the human WISP-3 polypeptide cDNA in ATCC Deposit No. 209707 (DNA58800-1176-2), or (b) a complement of the DNA molecule of (a).
64. A vector comprising the nucleic acid of claim 60.
65. A host cell comprising the vector of claim 64.
- 15 66. A process for producing a WISP-3 polypeptide comprising culturing the host cell of claim 65 under conditions suitable for expression of the WISP-3 polypeptide and recovering the WISP-3 polypeptide from the cell culture.
67. Isolated WISP-3 polypeptide encoded by the nucleic acid of claim 60.
68. The polypeptide of claim 67 that is human WISP-3.
- 20 69. A chimeric molecule comprising the WISP-3 polypeptide of claim 67 fused to a heterologous amino acid sequence.
70. An antibody which specifically binds to the WISP-3 polypeptide of claim 67.
71. Isolated nucleic acid produced by hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a human WISP-3 polypeptide comprising the sequence of amino acids 16 to 355 of Figures 7A and 7B (SEQ ID NO:36), or (b) a complement of the DNA molecule of (a), and, if the test
- 25

DNA molecule has a 100% sequence identity to (a) or (b) in more than about 400 nucleotides. isolating the test DNA molecule.

5 72. A polypeptide produced by (i) hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a human WISP-3 polypeptide comprising the sequence of amino acids 16 to 355 of Figures 7A and 7B (SEQ ID NO:36), or (b) a complement of the DNA molecule of (a), and if the test DNA molecule has a 100% sequence identity to (a) or (b) in more than about 400 nucleotides.(ii) culturing a host cell comprising the test DNA molecule under conditions suitable for expression of the polypeptide. and (iii) recovering the polypeptide from the cell culture.

73. A composition comprising the polypeptide of claim 17 and a carrier therefor.

10 74. A composition comprising an antagonist to the polypeptide of claim 17 and a carrier therefor.

75. A composition comprising the polypeptide of claim 19 and a carrier therefor.

76. A composition comprising an antagonist to the polypeptide of claim 19 and a carrier therefor.

77. A composition comprising the polypeptide of claim 40 and a carrier therefor.

78. A composition comprising an antagonist to the polypeptide of claim 40 and a carrier therefor.

15 79. A composition comprising the polypeptide of claim 53 and a carrier therefor.

80. A composition comprising an antagonist to the polypeptide of claim 53 and a carrier therefor.

81. A composition comprising the polypeptide of claim 67 and a carrier therefor.

82. A composition comprising an antagonist to the polypeptide of claim 67 and a carrier therefor.

20 83. A composition comprising a WISP-1, WISP-2, or WISP-3 polypeptide and a pharmaceutically acceptable carrier.

84. The composition of claim 83 that further comprises a chemotherapeutic agent or growth-inhibitory agent.

85. The composition of claim 83 wherein the WISP-1, WISP-2, or WISP-3 polypeptide is a human polypeptide.

86. A pharmaceutical product comprising:

(a) a composition of claim 83;

5 (b) a container containing said composition; and

(c) a label affixed to said container, or a package insert included in said pharmaceutical product referring to the use of said WISP-1, WISP-2, or WISP-3 polypeptide in the treatment of a WISP-related disorder.

87. A process for diagnosing a disease or a susceptibility to a disease related to a mutation in a nucleic acid 10 sequence encoding a WISP-1, WISP-2, or WISP-3 polypeptide comprising:

(a) isolating a nucleic acid sequence encoding a WISP-1, WISP-2, or WISP-3 polypeptide from a sample derived from a host; and

(b) determining a mutation in the nucleic acid sequence encoding a WISP-1, WISP-2, or WISP-3 polypeptide.

15 88. A method of diagnosing a WISP-related disorder in a mammal comprising detecting the level of expression of a gene encoding a WISP-1, WISP-2, or WISP-3 polypeptide (a) in a test sample of tissue cells obtained from the mammal, and (b) in a control sample of known normal tissue cells of the same cell type, wherein a higher or lower expression level in the test sample indicates the presence of a WISP-related dysfunction in the mammal from which the test tissue cells were obtained.

20 89. A method for treating a WISP-related disorder in a mammal comprising administering to the mammal an effective amount of the composition of claim 83.

90. The method of claim 89 wherein the disorder is a malignant disorder or arteriosclerosis and the mammal is human.

25 91. The method of claim 90 wherein the malignant disorder is breast cancer, ovarian cancer, colon cancer, or melanoma.

92. An isolated antibody binding a WISP-1, WISP-2, or WISP-3 polypeptide.

93. The antibody of claim 92 that induces death of a cell overexpressing a WISP-1, WISP-2, or WISP-3 polypeptide.

94. The antibody of claim 93 wherein said cell is a cancer cell.
95. The antibody of claim 92 that binds to a human WISP-1, WISP-2, or WISP-3 polypeptide, and is a human or humanized antibody.
96. The antibody of claim 92 that is a monoclonal antibody.
- 5 97. The antibody of claim 96 that is an antibody fragment, a single-chain antibody, or an anti-idiotypic antibody.
98. A composition comprising an antibody of claim 92 in admixture with a pharmaceutically acceptable carrier.
99. The composition of claim 98 comprising a growth-inhibitory amount of said antibody.
- 10 100. A method for determining the presence of a WISP-1, WISP-2, or WISP-3 polypeptide comprising exposing a cell suspected of containing the WISP-1, WISP-2, or WISP-3 polypeptide to an anti-WISP-1, WISP-2, or WISP-3 antibody and determining binding of said antibody to said cell.
101. A method for treating a WISP-related disorder in a mammal comprising administering to the mammal an effective amount of a composition comprising an antagonist to a WISP-1, WISP-2, or WISP-3 polypeptide in a pharmaceutically acceptable carrier.
- 15 102. A method for inhibiting the growth of tumor cells comprising exposing a cell that overexpresses a Wnt-1-induced gene to an effective amount of an antagonist that inhibits the expression or activity of a WISP-1, WISP-2, or WISP-3 polypeptide.
- 20 103. A method for inhibiting the growth of tumor cells comprising exposing said cells to an effective amount of the composition of claim 99.
104. The method of claim 103 wherein the tumor cells are colon cancer cells, the antibody is against human WISP-1 and is a humanized or human monoclonal antibody, and the mammal is human.
- 25 105. A kit comprising a WISP-1, WISP-2, or WISP-3 polypeptide or antagonist and instructions for using the polypeptide or antagonist to detect or treat a WISP-related disorder.

106. The kit of claim 105 comprising an anti-WISP-1, WISP-2, or WISP-3 antibody and a carrier in suitable packaging.

107. A method for inducing cell death comprising exposing a cell that is induced by Wnt to an effective amount of a WISP-1, WISP-2, or WISP-3 polypeptide or antagonist.

5 108. An article of manufacture comprising:

a container;

a label on the container; and

10 a composition comprising an active agent contained within the container; wherein the composition is effective for inducing cell death or inhibiting the growth of tumor cells, the label on the container indicates that the composition can be used for treating conditions characterized by overinduction of Wnt or a WISP-related disorder or by overexpression of a WISP-1, WISP-2, or WISP-3 polypeptide, and the active agent in the composition is an antagonist that inhibits the expression or activity of the WISP-1, WISP-2, or WISP-3 polypeptide.

15 109. The article of manufacture of claim 108 wherein the active agent is an anti-WISP-1, anti-WISP-2, or anti-WISP-3 antibody, and wherein the label on the container indicates that the composition can be used for treating a WISP-related disorder.

110. A process for identifying agonists to a WISP-1, WISP-2, or WISP-3 polypeptide comprising:

18 (a) contacting cells and a compound to be screened under conditions suitable for the stimulation of cell proliferation by the polypeptide; and

20 (b) measuring the proliferation of the cells to determine if the compound is an effective agonist.

111. An agonist to a WISP-1, WISP-2, or WISP-3 polypeptide identified by the process of claim 110.

112. A method for identifying a compound that inhibits the expression or activity of a WISP-1, WISP-2, or WISP-3 polypeptide, comprising contacting a candidate compound with a WISP-1, WISP-2, or WISP-3 polypeptide under conditions and for a time sufficient to allow the compound and polypeptide to interact.

25

113. The method of claim 112 comprising the steps of:

(a) contacting cells and a compound to be screened in the presence of the WISP-1, WISP-2, or WISP-3 polypeptide under conditions suitable for the stimulation of cell proliferation by polypeptide; and

(b) measuring the proliferation of the cells to determine if the compound is an effective antagonist.

114. A compound identified by the method of claim 112.

115. A compound that inhibits the expression or activity of a WISP-1, WISP-2, or WISP-3 polypeptide.

116. A method of diagnosing a WISP-related disorder in a mammal comprising (a) contacting an anti-WISP-1, anti-WISP-2, or anti-WISP-3 antibody with a test sample of tissue cells obtained from the mammal, and (b) detecting the formation of a complex between the anti-WISP-1, anti-WISP-2, or anti-WISP-3 antibody and the WISP-1, WISP-2, or WISP-3 polypeptide in the test sample.

117. The method of claim 116 wherein said test sample is obtained from an individual suspected to have neoplastic cell growth or proliferation.

1 TAACAAGGCN GTCCTGCTTG GAGAGGCATC CGCATCCTCT GGGCTGAGCC GTAGCCTCCTG TGACGGCTGAC TTCCAGGCAT GAGGTGGCTC CTGCCCTGGA  
 ATTGTTCCGN CAGGACGAACTCCTCGTAG GCGTAGGAGA CCCGACTCGG ACTCGAGGAC M R W L L P W T  
 1

101 CGCTGGCAGC CGTGGCAGTC CTGAGGGTGG GCAACATCCTT GGCCACGGCC CTCTCTCCAA CCCCCACAAAC AATGACCTTC ACCCGCAC CACTAGAGGA  
 GCGACCGTCG GCACCGTCG GACTCCACCG CGTGTAGGA CGGGTGGGG GAGAGGGTT TTACTGGAAAG TGGGGTCTG GTGATCTCCT  
 9 L A A V A V L R V N I L A T A L S P T P T M T F T P A P L E E

201 AACGACTACA CGCCCCGAAT TCTGCAAGTG GCCATGTTAGG TGCCCCACAAT CCCCACCTCG CTGCCCCACTG GGGGTCAGCC TAATCACAGA TGGCTGTGAA  
 TTGCTGTATGT GCGGGGTTA AGACGTTCAC CGGTACACTC ACGGGTCTTA GGGGGGAGC GACGGTGGAC CGGAGTCGG ATTAGTGTCT ACCGACACTT  
 42 T T T R P E F C K W P C E C P Q S P P R C P L G V S L I T D G C E

301 TGCTGTAAGA TATGTCGCCA GCAGCTGGG GACAACCTGCA CAGAGGCTGC CATTCTGTGAC CCACACGGG GCCTCTACTG CGATTACAGT GGGGATGCC  
 ACCACATCTT ATACACGGGT CGTGAACCC CGTGTGACGGT GTAGACACTG GGTGTGGCC CGGAGATGAC GCTAATGTC ACCCTAGGG  
 75 C C K I C A Q Q L G D N C T E A A I C D P H R G L Y C D Y S G D R P

401 CGAGGTAACGC AATAGGAGGT TGTGACAGG TGGTGGGTT GGGGTGGTC CGTGTGGCC TAAGGCCCCAG TAGCTACAC CAATGGCAG TCCTCTCCAAAC CCAACTGGCAG  
 GCTCCATGCG TTATCCTCAC ACACGTGTC ACCAGCCACA CCCGACACAG GACCTACCGC ATGCGATGT GTTACCGCCTC AGGAGGTGT GGTGTGACGTC  
 109 R Y A I G V C A Q V V G V G C V L D G V R Y T N G E S F Q P N C R

501 GTACAACCTGT ACCTGCAATTG ATGGCACGGT GGGGTGGACA CCGCTGTGCC TAAGGCCCCAG GCCAGCCCCGCC CTCTGGTGGCC GCACGGCCCG  
 CATGGTGACA TGGAGTAAC TACCGTGCCTCAC CGCGACGTGT GGGCACACGG ATTCGGGGTC CGGGGGTGGC GAGACCCACGG CGGTGGGGC CGTGCACCT  
 142 Y N C T C I D G T V G C T P L C L S P R P P R L W C R Q P R H V R

601 GTCCCTGGCC AGTGTGTGTA GCAGTGGGGT TGTGATGATG ACGCAAGGAG ACCACGCCAG ACTGCACTGT TGGACACCCAG AGCCCTTTGCA GCGTCAGGGCG  
 CAGGGACCGG TCACGACACT CGTCACCCAC ACACATCAAC TGCGTGTCCCTC TGCGTGTGCC TGACGTGACA ACCTGTGGTC TCGGAAAGT CGCACTGGCG  
 175 V P G Q C C E Q W V C D D A R R P R Q T A L L D T R A F A A S G A

701 CCGGGAGCA ACGGTATGAG AACTGCACTAG CCTACACTAG TCCCTGGAGC CCCTGCTCTA CCACCTGTGG CCTAGGTATC TCCACTCGGA TCTCTAACGT  
 GGACACCTCGT TGCCATACTC TGACGTGATC GGATGTGATC AGGGACCTCG GGACGAGAT GGAGACACC GGATCCATAG AGGTGAGCCT AGAGATGTGCA  
 209 V E Q R Y E N C I A Y T S P W S P C S T T C G L G I S T R I S N V

801 CAATGCCGG TGCTGGCCAG AGCAGGAAAG TCGCCTCTGC AACCTGGGGC CATGTGATGT GGACATCCAA CTACACATCA AGGAGGGAA GAMATGCCCTG  
 GTACGGGGCC ACGACGGTC TCGCCCTTC AGGGAGACG TTGGAGGCC GTACACTACA CCTGTGGTT GATGTGTAGT TCCGTCCCTT CTTTACGGAC  
 242 N A R C W P E Q E S R L C N L R P C D V D I Q L H I K A G K K C L

**FIG.- 1A**

901 GCTGTGTACC AGCCAGAGGA GGCCACGAAC TTCACTCTCG CAGGCTGTGT CAGCACACGC ACCTACCGAC CCAAGTACTG CGGAGTCTGT ACTGACAATA  
 CGACACATGG TCGGTCTCCT CCGGTGCTTG AAGTGAGAGC GTCCGACACA GTGCGACACA GTGCGTGTGG TCGGTGCTG GGTTCATGAC GCCTCATGAC TGACTGTTAT  
 275 A V Y Q P E E A T N F T L A G C V S T R T Y R P K Y C G V C T D N R

1001 GGTGTTGCAT CCCCTACAGA TCCAAGACCA TCAGTGTGGA TTTCAGTGTGT CCAGGAGGGC CAGGGTTCTC CCGGAGGTC TATGGATA ATGCTTGCTT  
 CCAACAGTA GGGGATGTC AGGTCTGGT AGTCACACCT AAAGGTACA GTTCTCCCG GTCCAAGAG GGCGTCCAG GATAACCTATA TACGAACGAA

309 C C I P Y K S K T I S V D F Q C P E G P F S R Q V L W I N A C F

1101 CTGCAACCTG AGCTGGAGGA ATCCAAACGA TATCTTTGCT GACTTGAAT CTTACCTGA CTTCGAAAGAG ATTGCCAATT AGGTGGGTG GTGGCTCAGG  
 GACGTTGGAC TCGACGTCT TAGGATTGCT ATAGAAACGA CTGAACCTTA GAATGGACT TAACGGTTAA TCCACCCACA CACCGAGTCC

342 C N L S C R N P N D I F A D L E S Y P D F E E I A N O

1201 GAAAGTTC ATGCTGCAA GCAGGCCAGCC CTTTGTGGTC CAGGACTCTCA CAATTGAGCC TTATTCTAC TACTTCCTAC TCGATTCTGA ATTCCAGTT  
 CATTCAAGG TAGACGTTT CGTGGTGG GAAACACAG GTCCTGAGT GTTAACCTGG AATAAAGTAG ATGAAGGATG AGCTAAGACT TAAGGGTCAA

1301 TCTGTTCCCTG TTTGACAAAT CGTAATGCC CAGGAGCTG CTGCTCAGGC TCAGACAATG GGTTCCTCCT TGGGACATT CTACATCATT CCAAGAAAA  
 AGACAAGGAC AAAACTGTTA GCATTAACGG GTCCCTCTCAC GACGAGTCGG AGTCCTGTTAC CCAAGGGGA ACCCTGTAA GATGAGTAA GTTCTCTTT

1401 CACATCTCTG ACTGTTACA ATGAGCAA AGCCTGGCC AGCTAGTCTG GCTCCAGGCC GGGCAAGTT TCAGAAAGTT TGATGGATT GTCCAAGGAA  
 GTGTAGAGAC TGACAAGTGT TACCTTCGTT TCGGACCGGG TCGATAGAC CGAGGTGGGA CCGTTCAAC AGTCTCAAC ACTACCCCAA CAGGTCTCTT

1501 AAGCATCAGC TGAAGAACCA GTATCATGAA GTCCTCTCCTC AGATGCCAAG CCTAGGGATG CTGGGATCCT TTICAGACAGA TGGATGGGAT TGGGACACA  
 TTCTGTAGTCG ACTTCTGGT CATAGTACTT CAGGAAGGAG TCTACGGTC GGATCCCTAC GACCCCTAGGA AAGTCTGTCT ACCTACCCAA ACCCTGTGT

1601 GGAATAAGCT ATTATTTCAC CCTTGCCAAA TGATACTATC CTGGTATT CTGGGATCCT ACATACCAA AGTGTCTG TTCCACTGAT CTGTATATCA  
 CCTTATTGCA TAATAAATG GGAAACGGTTT ACTATGATAG GACCCATAAA GACGGATTGTT TGTATGGTT TCACAAAGAAC AAGGTGACTA GACATATAGT

1701 CAAGTCACCA AACATTTCAC AGGTGAGGAC CCATAGTGT GTCATCTGT TTGCCAATT GAAAAA  
 GTTCAGTGGT TTGAAAAGG TCCACTCCCTG GGTATCAACA CAGTAAGACA AAACGGTTAA CTTTTT

**FIG.-1B**

3 / 49

1 CCCACGGTC CGGGCTCCTG ATCTCCAGAG GACCCGGGC TGGGACAGGG GCCCTTGGCGA GGCTGCAGCT GCTGTGGCAG TAGCTGGGA TGGAGGTCTT  
GGTGGCGAG GGGCGAG TAGAGGTCTC CTGGGGCCG ACCCTGTCCC CGAACCGGT CCGACGTGA CGACACGGTC ATCGAACCT ACCTCAGAA

101 TCTGCTGGG AACTGAGGAG CTGAGGGCT CTTGTCAGGC TCCTGTCTTA AACTCTTGGC ACTTGTGGT GCTTGGCTT CACACACTGT CAGACACCTT  
AGAACGACCC TTGACTCTTC GACTCTCGA GACAGTCG AGGACAGGGAT TTGAGAACCC TGAAACGCAC CGAACCGAA GTCTGTGAA

201 CTGGTGGCC TCCTCGGGCT CAGGTTGAA GCTGGCTCCA CAAGGGACAC GGTGACATGA GGGGAAACCC ACTGATCCAT CTTCCTGGCA TTTCCTTCT  
GAACCACGG AGGAGCGGA GTCCAAACTT GACCGAGGT GTTCCCTGTG TGACTGTACT CCCCGTTGG TGACTAGGTA GAAGACCGGT AAAGGAAGGA  
16 C I L S M V Y S Q L C P A P C A C P W T P P Q C P P G V P L V L D  
49 G C G C C R V C A R R L G E S C D H L V C D P S Q G L V C Q P G A  
83 G P S G R G A V C L F E E D D G S C E V N G R R Y L D G E T F K P  
116 N C R V L C R C D D G G F T C L P L C S E D V R L P S W D C P R P  
149 R R I Q V P G R C C P E W V C D Q A V M Q P A I Q P S S A Q G H Q L  
183 S A L V T P A S A D G P C P N W S T A W G P C S T T C G L G I A T  
216 R V S N Q N R F C Q L E I Q R R L C L S R P C L A S R S H G S W N

301 CTGGATTCTC TCAATGGTGT ATTCCAGCT GTGGCCAGCA CCCTGTGGCT GTCCCTGGAC ACCACCCAG TGCCACCCAG GGGTACCCCT GGTGCTGGAT  
GACGTAAGAG AGTTACACCA TAAGGGTGA CACGGGTGTT GGGACACCGGA CAGGAACCTG TGTTGGGGGTC ACGGTGGGCC CCCATGGGA CCACGACCTA  
401 GGCTGTGGCT GCTGTGAGT GTGTGACGG AGGCTGGGG AGTCCGTGCA CCACCTGCAT GTCTGCAC CCAGCCAGGG CCTGGTTGT CAGCCTGGGG  
CCGACACCGA CGACAGCTCA CACAGCTCA TCCGACCCCC TCAGGAGCT GGTGGACGTA CAGACGCTGG GTGGTGGTCCC GGACCAAAACA GTCGGACCCC  
501 CAGGGCCAG TGGCCGGT GCTGTGTGCC TCTTCGAAGA GGATGACGGG AGCTGTGAGG TGAATGGGG CAGGTACCTG GATGGGGAGA CCTTTAACCC  
GTCCGGGGTC ACCGGACCA CGACACACGG AGAACGCTCT CCTACTGCC TGACACTCC ACTTACGGC GTCCATGGAC CTACCCCTCT GGAAATTGG  
83 G P S G R G A V C L F E E D D G S C E V N G R R Y L D G E T F K P  
601 CAATTGCAAG GTTTGTGCC GCTGTGATGA CGGTGGTTTC ACCTGCCTGC CGCTGTGCAG TGAGGATGTG CGGGTGCCTA GCTGGGACTG CCCACGCC  
GTAAACGTCC CAAACACGG CGACACTACT GCCACCAAAG TGGACGGACG GCGACACGTC ACTCCTACAC GCGACACGGGT CGACCCCTGAC GGGTGGGG  
116 N C R V L C R C D D G G F T C L P L C S E D V R L P S W D C P R P  
701 AGGAGAATAAC AGGTGCOAGG AAGGTGCTGC CCCGAGTGGG TGTGTGACCA GGAGTGTGATG CAGGGCCCAA TCCAGCCCTC CTCAGCCCAA GGACACCCAA  
TCCTCTTATG TCCACGGTCC TCCACGAGC GGGCTCACCC ACACACTGGT CGTCACTAC GTGGCCCGTT AGGTGGGGAG GAGTGGTTT CCTGTGGTTG  
149 R R I Q V P G R C C P E W V C D Q A V M Q P A I Q P S S A Q G H Q L  
183 S A L V T P A S A D G P C P N W S T A W G P C S T T C G L G I A T  
216 R V S N Q N R F C Q L E I Q R R L C L S R P C L A S R S H G S W N

**FIG.-2A**

1001	AGTGCCTCTT	AGAGCCATTTG	CGGGGATGTG	GATACAGGGC	CTGCCATTCT	CAGCAATGT	CCCTAGGACC	AGGCCCTGGA	CTGATGGTAG	ATGCCCTCT
1002	TCACGGAAGA	TCTCGGTAAAC	GCCCCTACAC	CTATGTCGG	GACGGTAAGA	GTCGTTTACA	GGGATCTGG	TCCGGGACCT	GACTACCATC	TACGGGGAGA
249	S	A	F	O						
1101	CCATGCTCTT	GGCTGCGAGTT	AAC TGTCCTG	GGTGGATTCA	GTGTCAGAG	CCTCTGAGG	ATCCCTGCTC	TGTCTGAGGT	GGGGGAGGA	GGTGACCCAGC
1102	GGTACGAGAA	CCGACGTCAA	TTGACAGGAC	CCACCTAAGT	CACAGGTCTC	GGAGACTCGC	TAGGGACGAG	ACAGACTCCA	CCCCCTTCTGT	CCACTGGTCG
1201	TCCATTTCCTC	TGGATTCTGA	CCCAGGGCTTC	TGGGTTCTCC	TGGCTAGTTTC	CTCAAAACTT	CCCTGTATGA	AAAGGACAAC	AAAAGGACCC	TTAAAGCTA
1202	AGGTAAGAG	ACCTAAGACT	GGGTCCGAAG	ACCCAAAGGG	ACCGATCAAG	GAGTTTTGAA	GGGACATACT	TTTCCTGTG	GTTCCTGG	AAATTTCGAT
1301	AGCTGTACTG	GGCAAGGCCTG	GGCACCATGC	TGGGATAGT	GACAGTATA	GGTACCAAGGC	AGCAGATGTC	CTGAAACATC	CAGGTCCCTT	CTTGGACTTC
1302	TCGACATGAC	CCGGTTCGGAC	CGGTGGTACG	ACCCCTATCA	CTGTCATTAT	CCATGGTCCG	TGGTCTAAGC	GACTTGTAG	GTCAGGGAA	GAACCTGAAG
1401	TATGTGCTTG	TCCCCAAAGAT	TATGGGTGAC	CTTGTAAGTG	TGCCTTCCCT	GATCTGAGAA	CACCCGTGCC	GGCTGGGAAG	ATTTTTCTGG	GAACATGAAG
1402	ATACACGAAAC	AGGGTTCTA	ATACCCACTG	GAACATTCAAC	ACGGAAAGGA	CTTAGACTCTT	GTGGGACGGG	CGAACCCCTTC	TTAAAGACC	CTTGTACTTC
1501	AGATGGAATC	ACACTATCT	TAAGAGGGTT	TGCCAAGTCC	AGGAACCTGA	CCCTTGTATT	TGTAAAAATA	CACATCTCTT	AAATGCTCAC	AAAGCAAGAG
1502	TCTACCTTAG	TGTGATAAGA	ATTCTCGCAA	ACGGTTCAAGG	TCCTTGAACT	GGAAACATAAA	ACATTTTTAT	GTGTAGAGAA	TTTACGAGTG	TTTCGTTCTC
1601	GCTCCACACT	TCTGGCAGGC	CAGGGCCTT	CTCTTCAGGA	TGAGAGAGAC	AGGAACAGT	AGAGTACCT	CCTCTGGAGG	ACTGGCCCGG	TCTGGAAATA
1602	CGAGGGTGTGA	AGACCGTCCG	GTCCGGAAA	GAGAAAGTGT	ACTCTCTCTG	TTCCTTGTCA	TCTCATGGGA	GGAGACCTCC	TGACCCGGGGC	AGACCTTATT
1701	ACCCCCAAAT	CAAGTGTGGA	AAAAAAA	AAAAA						

**FIG.\_2B**

1 CCCACGGCTC CGCTGGCCCC AGCTCCCCG AGAGGTGGTC GGATCCCTCG GGCTGTCTG TCGATGCCAT TGCCACTGAC GTCCACGGAT GAGGTGGCTTC  
 GGGTGGCAG GCGACCCGGG TCGAGGGGG TCTCCACAG CCTAGGAGAC CCGACGAGCC AGCTACGGAC ACGGTGACTG CAGGTCCGTA CTCCACCAAG  
 M R W F

5 L P W T L A A V T A A A S T V L A T A L S P A P T T M D F T P A P

101 CTCGCCCTGGA CGCTGGCAGC AGTGACAGCA GCAGCCGCCA GCACCCGCC GCACCGCTCCT GGCACAGGGCC CTCCTCTCCAG CCCCTACGAC CATGGACCTT ACTCCAGCTC  
 GACGGACCT GCGACCGTGT TCACGTGCTG CGTGGGGGT CGTGGGGAGA CCGGGGGGG GAGAGGGTC GGGGATGCTG GTACCTGAAAG TGAGGTGAG  
 39 L E D T S S R P Q F C K W P C E C P P S P P R C P L G V S L I T D

201 CACTGGAGGA CACCTCCCTCA CGCCCCAAT TCTGCAAGTG GCCATGTGAG TGCCCGCCAT CCCCACCCCG CTGCCCCGCTG GGGGTCAAGCA  
 GTGACCTCT GTGGAGGGAGT GCGGGGTTA AGACGTTCA CGGTACACTC ACGGGGGGTA GGGGGGGGG GACGGGGAC CCCCACTGCG AGTAGGTGCT  
 72 G C E C C K M C A Q Q L G D N C T E A A I C D P H R G L Y C D Y S

301 TGGCTGTGAG TGTGCGCTCA CGAGCTTCGG GACAACGTGCA CGGAGGGCTGC CATCTGTGAC CCCAACCGGG GCTCTCTACTG TGACTACAGC  
 ACCGACACTC ACGACATCT ACACGGAGT CGTGAACACC CGTGTGACGT GCTCGACAG GTAGACACTG GGGGGCCC CGGAGATGAC ACTGATGTG  
 105 G D R P R Y A I G V C A Q V V G C V L D G V R Y N N G Q S F Q P

401 GGGGACCGCC CGAGGTACGC AATAGGAGTG TGTGACAGG TGGTGGGTG GGGCTGGTC CTGGATGGGG TGCGCTACAA CAAACGGCCAG TCCTTCCAGC  
 CCCCTGGGG GCTCCATGCG TTATCCTCAC ACACGTGTC ACCAGCCACA CCCGACGCCAG GACCTACCCC AGCGATGTT GTTGGCCGGTC AGGAAGGTG  
 139 N C K Y N C T C I D G A V G C T P L C L R V R P P R L W C P H P R

501 CTAAC TGCAA GTACAAACTGC ACGTGCATCG ACTGCTGCC ACCAGCCACA CCCGACGCCAG GGGGACACGG AGGCTCACGC AGGCTCACGG  
 GATTGACGTTT CATGTTGACG TGCACTGAG TGCCGGCCCA CCCGACGTGT GGTGACACGG AGGCTCACGC AGGCTCACGG CCCACCCGG  
 172 R V S I P G H C C E Q W V C E D D A K R P R K T A P R D T G A F D

601 GCGCGTGAGC ATACCTGCC ACTGCTGTGA GCAGTGGGTA TGTGAGGGACG ACCGCAAGAG GCCACGCAAG ACCGCAACCC GTGACACAGG AGCCTTCGAT  
 CGCGCACTCG TATGGACCGG TGACGACACT CGTACCTCTGC ACACCTCCAT CCTACACAAG CCGCTGGAGC CCTTGCTCCA CCAGCTGGGG  
 205 A V G E V E A W H R N C I A Y T S P W S P C S T S C G L G V S T R I

701 GCGTGTGGGTG AGGTGGGGC ATGGCACAGG AACTGCAATAG CCTACACAAG CGTACCTCTGC TGCGGTTCTC CGGTGCGTT TGGCGTGGGG  
 CGACACCCAC TCCACCTCCG TACCGTGTCC TGTGACGTATC GGATGTGTT GGAAACGAGGT GGTCGACGCC GGACCCCCAG AGGTGAGCT  
 239 S N V N A Q C W P E Q E S R L C N L R P C D V D I H T L I K A G K

901 GAAGTGTCTG GCTGTGTAAGGAGGC ATCCATGAAAC TTCAACACTTG CGGGCTGCAT CAGCACACGC TCCTATCACAC CCAAGTACTG TGGACTTTGC  
 CTTACAGAC CGACATGG CGGGTCTCCG TAGTTACTTG AAGTGTGAAAC GCCCAGCTA GTCGTGTCGG AGGATAGTGT GTTCTCATGAC ACCTCAAAAC  
 272 K C L A V Y Q P E A S M N F T L A G C I S T R S Y Q P K Y C G V C  
  
 1001 ATGGACAATA GGTGCTGAT CCCCTACAAG TCTAAAGACTA TCGACGTGTC CTTCCAGGT CCTGATGGGC TTGGCTTCTC CGGCCAGGT CTATGGATA  
 TACCTGTTAT CCACGACGTA GGGGATGTC AGATTCTGT AGCTGCACAG GAAGGTCAAA GGACTACCCG AACCGAAGAG GGCGGTCCAG GATACTTAAT  
 305 M D N R C C I P Y K S K T I D V S F Q C P D G L G F S R Q V L W I N  
  
 1101 ATGCCCTGCTT CTGTAACCTG AGCTGTAGGA ATCCCAATGA CATCTTGCT GACTTGAAT CCTAACCTGA CTTTCAGAA ATTGCCAACT AGGCAGGCAC  
 TACGGACAA GACATTGGAC TCGACATCCT TAGGGTTACT GTAGAAACGA CTGAACTTA GGATGGACT GAAGAGTCTT TAACGGTTGA TCCGTTGGTG  
 339 A C F C N L S C R N P N D I F A D L E S Y P D F S E I A N O  
  
 1201 AAATCTTGGG TCTTGGGAC TAACCCAATG CCTGTGAAGC AGTCAGCCCT TATGGCCAAT AACTTTCAC CAATGAGCCT TAGTTACCT GATCTGGACC  
 TTTAGAACCC AGAACCCCTG ATTGGTTAC GGACACTTC TCAGTCGGG ATACCGGTTA TTGAAAAGTG GTTACTCGGA ATCAATGGG CTAGACCTGG  
  
 1301 CTTGGCTCC ATTTCCTGCT CTAACCAATTC AAATGACGCC TGATGGCT GCTCAGCCCTT GATGCTATGAG TTTCCTCCCT GATATCATTC AGCATCTACT  
 GAACCGGAGG TAAAGACAGA GATTGGTAAG TTTACTGCG ACTACACGA CGACTCCGGG TACGATACG AAAGAGGAA CTATAGTAAG TCGTAGATGA  
  
 1401 CTAAGAAAAA ATGCCCTGCTT CTAGCTGTTG TGGACTACAC CCAAGCCTGA TCCAGCCCTT GATGCTGCTG CCTAAATCCC  
 GATTTCCTTT TACGGACAGA GATGGACAAG ACCTGTGTTG GGTCGGACT AGCTCGGAA AGGTCAAGTA TCCTCAGGAC GACCTAGAAC GGATTTAGGG  
  
 1501 AAGAAATGGA ATCAGGTTAGA CTTTAATAT CACTAATTTC TTCTTAGAT GCCAAACCC AAGACTCTT GGGTCCATTG AGATGAATAG ATGGAATTG  
 TTCTTACCT TAGTCCACT GAAATTATA GTGATTAAG AAGAAATCTA CGGTTGGGTG TTCTGAGAA CCCAGGTAAG TCTACTTAC TACCTAAAC  
  
 1601 GAAACAATAGA ATAATCTATT ATTGGAGCC TGCCAAGAGG TACTGTAATG GGTAAATTCTG ACGTCAGGC ACCAAAACCA TCCGTGATTCC AAATATGTAT  
 CTTGTATCT TATTAGATAA TAAACCTCGG ACGGTTCTC ATGACATTAC CCATTAAGAC TGGTGTGG TGTTTTGAT AGGACTAAGG TTATACATA  
  
 1701 GCACCTCAAG GTCATCAAC ATTGCCAAG TGAGTTGAAT AGTTGCTTAA TTGGTATT TAATGAAAG TTGTATCCAT TAACCTGGGC ATTGTTGAGG  
 CGTGGAGTTC CAGTAGTTG TAAACGGTT ACTCAACTTA TCAACGAAATT AAAACTAAA ATTACCTTC AACATAGGTA ATTGGACCCG TAACAACCTCC  
  
 1801 TTAAAGTCTCT CTTCACCCCT ACACGTGAA GGGTACAGAT TAGGGTGTGTC CCAGTCAGAA ATAAAATTG ATAAACATTIC CTGTTGATGG GAAAAGCCCC  
 ATTCAAGA GAAGTGGGA TGTGACATT CCCATGTTA ATCCAACAG GGTCAGTCTT TATTGAAAC TATTGAAAG GACAACCTAAC CTTTTCGGGG  
  
 1901 CAGTTAATAC TCCAGAGACA GGGAAAGGTC AGCCCAATTIC AGAAGGACCA ATGACTCTC ACATGAAATC AGCTGCTGAC TGGCAGGGCT TTGGCAGTT  
 GTCATTATG AGGTCTCTGT CCCTTCCAG TCGACGACTAG TGTGACTTAG TGTGACTAG TGTGACTAG TGTGACTAG AACCGTCAA

**FIG.-3B**

2001 GGCAGGCTC TTCTTGAAAT CTTCTCCCTT GTCCTGCTTG GGTCATAGG ATTTGTAAG GCCTCTGGAC TGGCTGTCT GCCTCCTGAG AGTGGGGGCC  
 CCGTCCGAG AAGGAACCTT GAAGGGAA CAGGACGAA CCAAGTATCC TTACCATTC CGGAGACCTG ACCGACAGA CGGGGACTC TCACCAACGGG  
  
 2101 TGGAAACACTC CTCTACTCTT ACAGAGCCTT GAGAGACCA GCTGCAGACC ATGCCAGACC CACTGAATG ACCAAGACAG GTTCAGGTAG GGGTGTGGGT  
 ACCTTGTGAG GAGATGAGAA TGTCTCGGAA CTCTCTGGGT CGACGTCTGG TACCGCTCTGG GTGACTTAC TGGTCTGTG CAACTCCAT CCCACACCCA  
  
 2201 CAAACCAAGA AGTGGGGGCC CTTGGTAGCA GCCTGGGGTG ACCTCTAGAG CTGGAGGCTG TGGGACTCCA GGGCCCCCG TGTTCAGGAC ACATCTATTG  
 GTTGGTTCT TCACCCACGG GAACATCGT GGACATCTC GACGAGTCTC GACCTGGGT ACCCTGAGGT CCCGGGGC ACAAGTCTGT TGAGATAAC  
  
 2301 CAGAGACTCA TTTCACAGCC TTTCGTTCTG CTGACCAAAT GGCCAGTTT CTGGTAGGAA GATGGAGTT TACCAAGTT TTAGAAACAG AAATAGACTT  
 GTCTCTGAGT AAAGTGTGG AAAGCAAGAC GACTGGTTA CGGGTCAAAA GACCATCCTT CTACCTCCAA ATGGTCAAACA ATCTTGTG TTTATCTGAA  
  
 2401 AATAAAGGTT TAAAGCTGAA GAGGTGAAAG CTTAAAGGAA AAGGGTGTG TTAAATGAATA TCAGGGTATT ATTATTTGTA TTAGGAAAT ATAAATTTA  
 TTATTCCTAA ATTTGCACTT CTCCAACTTC GATTTCCTT TTCCAAACAC AATTACTTT AGTCGATAAA TAAATAACAT ATCCCTTTA TATTATAAT  
  
 2501 CTGTTAGAAT TCTTTTTT AGGGCTTTT CTGTCAGA CATTGCTCTC AGTGTCTTG ATGTTAGC TCACGAAATC TTACCGACAA TGTGAGAAG  
 GACAACTTA AGAAAATAAA TCCCGAAAAA GACACGGCTC GTAACGGAG TCACGAAAC AGTCAATCG AGTCAATCG AGTCAATCG AGTCAATCG  
  
 2601 TTCCCAATTAT TATTTCGTT CTTACAAATG TGAAACGGAA GCTCATAGG GTGAGAAAAAC TCAACCGAG TCACCCAGTT GGTGACTGGG AAAGTAGGA  
 AAGGGTAATA ATAAAGACAA GAATGTTAC ACTTTGCTT CGAGTATCTC CACTCTTTG AGTGGGTCTC AGTGGTCAA CCACGTACCC TTTCATCCT  
  
 2701 TTCAAGATCGA AATTGGACTG TCTTATAAAC CCATATTTC TAGAGCTTT GAATAGAAA ACATGGCAAT AAATGGCTTC  
 AAGTCTAGCT TAAACCTGAC AGAAATATTG GGTATAAAAAG GGGGACAAA ATCTCGAAGG TTACACAGT CTTACCTTT TGAAACGTTA TTACCGAAC

**FIG.-3C**

1 CCCACCGGTC CGGCTGGGA CATGAGGG ACACCGAAGA CCCACCTCCT GGCTCTGCC CTCCTCTGCC TCCTCTCAA GTTGGTAC CAGCTGCC  
 GGGTGCAG GCCGACCT GTACTCTCG TGTGGCTCT GGTTGGAGGA CGGGAAAGGG  
 1 M R G T P K T H L L A F S L L C L S K V R T Q L C P  
  
 101 CGACACCAG TACCTGCC CGGCTACCTC CCCGATGCC GCTGGGAGTA CCCCTGGTC TGGATGGCTG TGGGTGCTGC CGGGTATGTG CACGGGGCT  
 GCTGGTAC ATGGACGGG ACCGGTGGAG GGGCTACGGG CGACCCATCG GGGACCAAC ACCTACCGAC ACCGAGCAG GCCCATACAC GTGGCCCGA  
 28 T P C T C P W P P R C P L G V P L V L D G C G C C R V C A R R L  
  
 201 GGGGAGCCC TGGGACCAAC TCCACGCTG CGACGCCAGC CAGGGCCTGG TCTGCCAGGC CGGGGAGGA CCCGGTGGCC GGGGGCCCT GTGGCTCTTG  
 CCCCTCGGG AGCGTGGTAC AGGTGAGAC GCTGGGGTGC GTCCCGGACC AGACGGTGG GCCCCGTCCT GGGCACCGG CCCCCGGG CACGGAGAAC  
 61 G E P C D Q L H V C D A S Q G L V C Q P G A G P G G R G A L C L L  
  
 301 GCAGGAGCG ACAGGAGCTG TGAGGTGAAAC GGCCGGCTGT ATCGGGAAAGG GGAGACCTTC CAGGCCCACT GCAGGATCCG CTGGCGCTGC GAGGAGGGCG  
 CGTCTCTGC TGTCGTGAC ACTCACTTG CGGGGGGACA TAGCCCTTC CCGGGGGAAAG GTCGGGGTGA CGTCGTAGGC GACGGGAGC CTCCCTGCCGC  
 94 A E D D S S C E V N G R L Y R E G E T F Q P H C S I R C R C E D G G  
  
 401 GCTTCACCTG CGTGGCCGCTG TGCAGCGAGG ATGTGGGGT GCCCAGCTGG GACTGGCCCC ACCCCAGGAG GTTCGAGGTC CTGGGAAAGT GCTGCCCTGA  
 CGAAGTGGAC GCACGGGAGC ACGTGCTCC TACACGCCA CGGGTGCACC CTGACGGGG TAGCCCTTC CCTGGGGTCTC CCAGGTCAG GACGGGACT  
 128 F T C V P L C S E D V R L P S W D C P H P R R F S E V L G K C C P E  
  
 501 GTGGGTGTC GGCCAGGG GGGGACTGGG GACCCAGCCC CTTCCAGGCC AAGGACCCCC GTTTCTGGC CTTGTCCTT CCCTGCCCT TGTTGCC  
 CACCCACAG CGGGTCTC CCCCAGCC CTGGTGCGG GAAGGCTGGG TCTCTGGGT CAAAGACCG GAACAGAGAA GGGACGGGG ACCACAGGG  
 161 W V C G Q G G G L G T Q P L P A Q G P Q F S G L V S S L P P G V P  
  
 601 TGCCCCAGAAT GGAGCACGGC CTGGGGACCC TGTCTGCCA CCTGGGGCTT GGGCATGGCC ACCGGGGTGT CCAACCAGAA CGCGCTCTGC CGACTGGAGA  
 ACCGGGCTTA CCTCGTGCAG GACCCCTGGG AGGAGCTGGT GGACACCCGA CCCGTACCGG TGGGCCACA GTGGGGTCTT GGGGAAGAGC GCTGACCTCT  
 194 C P E W S T A W G P C S T T C G L G M A T R V S N Q N R F C R L E T  
  
 701 CCCAGGCCCG CCTGTGCTG TCCAGGCCCT GCCCCACCTC CAGGGGCTCG AGTCCACAAA ACAGTGCCT CTAGAGCCGG GCTGGGAAATG GGGACACGGT  
 GGTGCGGCC GGACACGGAC AGGTCGGGA CGGGGGAG GTCCCCAGCG TCAGGGTGTGTT TGTCAGGAA GATCTCGGGCC CGACCCCTAAC CCCTGTGCCA  
 228 Q R R L C L S R P C P P S R G R S P Q N S A F O  
  
 801 GTCCACCATC CCCAGCTGGT GGGCCTGTC CTGGGCCCTG GGCTGATGGA AGATGGTCCG TGCCAGGGC CTTGGCTGCA GGCAACACTT TAGCTGGGT  
 CAGGTGGTAG GGGTGCAGCA CGGGACACAG GACCCGGGAC CGGACTACCT TCTACCGGGC ACGGTCCGG GAACCGACGT CGGTGTGAA ATCGAACCCA

**FIG.-4A**

901 CCACCATGCA GAACACCAAT ATAACACCGC TGCCTGGTCT GTCTGGATCC CGAGGTATGG CAGAGGTGCA AGACCTAGTC CCCTTTCCTC TAACTCACTG  
GGTGGTAGCT CTTGGTGTAA TAATTGTTA ACGGACCGAA CAGACCTAGG GCTCCATACC GCTCCACGT TCTGGATCAG GGGAAAGGAG ATTGAGTGAC

1001 CCTAGGAGGC TGGCCAAGGT GTCCAGGGTC CTCTAGCCCA CTCCCTGCCT ACACACACAG CCTATATCAA ACATGCACAC GGGCGAGCTT TCCTCCGAC  
GGATCCCTCG ACCGGTTCA CAGGTCCAG GAGATCGGGT GAGGGACGGA TGTGTGTGTC GGATATAGTT TGTACGTGTG CCCGCTCGAA AGAGGGCTG

1101 TTCCCCCTGGG CAAGAGATGG GACAAGGAGT CCCTTAATAAT TGAGGCTGCA GCAGGTGCTG GGCTGGACTG GCCATTTTC TGGGGTAGG ATGAAGAGAA  
AAGGGACCC GTTCTCTAACCT CGTGTGTCA GGGAAATTATA ACTCCGACGT CGTCCACGAC CGAACCTGAC CGGTAAGG ACCCCCATCC TACTTCTT

1201 GGCACACAGA GATTCTGGAT CTCCCTGCTGC CTTTTCTGGA GTTTGTAATAA TGTGTCTGA ATACAAGGCT ATGCGTGAAA AAAAAAAA AAA  
CCGGTGTCT CTAAGACCTA GAGGACGACG GAAAAGACCT CAAACATTG AACAGGACT TATGTTGGAA TACGGACTTT TTTTTTTTTT TTT

## FIG.\_ 4B

1        5' -CTGCAGGGGACATGAGAGGCACACCGAAGACCCACCTCCTGGCCTTCTC  
51        CCTCCTCTGCCTCCTCTCAAAGGTGCGTACCCAGCTGTGCCCGACACCAT  
101        GTACCTGCCCTGGCCACCTCCCCGATGCCCGCTGGGAGTACCCCTGGTG  
151        GTGGATGGCTGTGGCTGCTGCCGGGTATGTGCACGGCGGCTGGGGAGCC  
201        CTGCGACCAACTCCACGTCTGCGACGCCAGCCAGGGCCTGGTCTGCCAGC  
251        CCGGGGCAGGACCCGGTGGCCGGGGGGCCCTGTGCCTCTTGGCAGAGGAC  
301        GACAGCAGCTGTGAGGTGAACGGCCGCTGTATCGGAAGGGGAGACCTT  
351        CCAGCCCCACTGCAGCATCCGCTGCCGCTGCGAGGAACGGCGGCTTCACCT  
401        GCGTGCCGCTGTGCAGCGAGGATGTGCCGCTGCCAGCTGGGACTGCC  
451        CACCCCAGGAGGGTCGAGGTCTGGCAAGTGCTGCCCTGAGTGGGTGTG  
501        CGGCCAAGGAGGGGACTGGGACCAAGCCCTCCAGCCCCAAGGACCCC  
551        AGTTTCTGGCCTTGTCTCTTCCCTGCCCTGGTGTCCCCTGCCAGAA  
601        TGGAGCACGGCCTGGGACCCCTGCTCGACCACCTGTGGCTGGCATGGC  
651        CACCCGGGTGTCCAACCAGAACCGCTTCTGCCGACTGGAGACCCAGCGCC  
701        GCCTGTGCCCTGTCCAGGCCCTGCCACCCCTCCAGGGTCCAGTCCACAA  
751        AACAGTGCCTTCTAGAGCCGGCTGGGAATGGGACACGGTGTCCACCAT  
801        CCCCAGCTGGTGGCCCTGTGCCTGGGCCCTGGCTGATGGAAGA

**FIG.\_5**

1 GTGGGGTTGCAGGGAGACAGGGAGCTTGTGTACCCGGAGCAATGAAACAGCGGGGACTTCTCTTACCC  
 CACCCCAAACGTCCTCTGCCCCCTCGAAACACATGGCCCTCGTGAAGAGATGG  
 1  
 71 CCTCAGGGGGCTCCACGGTCCAGCGACA  
 10 S G W L H P S D M  
 101 TGCAGGGGCTCCACACTCTCTGCTGCTGGCAGCTTGCTGCAGGGTACAGGGCAC  
 ACGTCCCCGAGGAGAAGGGTGAAGAGCAACGACCGGACCGTGTCAAGACGACTCCCGTG  
 20 Q G L L F S T L L A G L A Q F C C R V Q G T  
 171 TGGACCAATTAGATAACAACACCTGAAGGAAG  
 ACCTGGTAATCTATGTTGGACTTCCCTC  
 43 G P L D T T P E G R  
 201 GCCTGGAGAAGTGTCAAGTGCACCTCAGCTTGTCAACTGCCCTTGCAAAATGCCCTCAGCAG  
 CGGACCTCTTCACAGTCTACGTGGACTACGTGGAGTCGCATTGTC  
 53 P G E V S D A P Q R K Q F C H W P C X C P Q Q  
 271 AAGCCCCCTGGCCCTCCTGGAGTGGCCCTG  
 76 K P R C P P G V S L  
 301 GTGAGAGATGGCTGGATGGCTGTAATCTGTGCCAAGCAACCAGGGAAATCTGCAATGAAGCTGAC  
 CACTCTCTACCGACACCTACGACATTAGACACGGTTGGTCCCTTAGACGTTACTTCGACTGG  
 86 V R D G C C K I C A K Q P G E I C N E A D L  
 371 TCTGTGACCCACACAAAGGGCTGTATTGTG  
 AGACACTGGGTGTGTTCCCGACATAACAC  
 110 C D P H K G L Y C D  
 401 ACTACTCAGTAGACAGGGCTTAGGTACGGAGACTGGAGTGTGTGCATACCTTGTAGCTGTGGGTGGCAGT  
 TGATGAGTCATGTCGGATCCATGCTCTGACCTCACACAGTATGGAAACATCGACAACCCACGCTCAA  
 120 Y S V D R P R Y E T G V C A Y L V A V G C E F  
 471 CAACCAAGGTACATTATCATATGGCCAAGT  
 GTGGTCCATGTAATACTTACCGGGTCA  
 143 N Q V H Y H N G Q V

**FIG.-6A**

501 GTTTCAGCCCCAACCCCTTGTTCAGCTGCCCTCTGTGAGTGGGGCCATTGGATGCACACCTCTGTTCTA  
 CAAAGTGGGGTGGGAAACAAGTCAGGGAGACACACTCACCCGGTAACCTACGTGTGGAGACAAGTAT  
 153 F Q P N P L F S C L C V S G A I G C T P L F I

571 CCAAAGCTGGCAGTCAGTGCCTGGAA  
 GGTTTCGACCGACGGTCAGTGACGGAGACCT  
 176 P K L A G S H C S G

601 GCTAAAGGTGAAAGAAGTCTGATCAGTCAGTCAGCTGGAAACCAATTACTACAGCAGCTTCAACAA  
 CGATTTCACCTTCTTCAGACTAGTCAGTCAGTCAGTCAGTCAGTCAGTCAGTCAGTCAGTCAGTCAG  
 186 A K G G K K S D Q S N C S L E P L L Q Q L S T S

671 GCTACAAACAAATGCCAGCTTATAGAGATC  
 CGATGTTTGTGTACGGTCGAATATCTCTAG  
 210 Y K T M P A Y R D L

701 TCCCACTTATTGGAAAAAAATGTCCTGTGCAAGCAACAAAATGGACTCCCTGGCTCCAGAACATGTTGG  
 AGGGTGAATAAACCTTTTTTACAGAACACGTGTTACCTGAGGGACGGGTCTGTACACCC  
 220 P L I W K K C L V Q A T K W T P C S R T C G

771 GATGGGAATATCTAACAGGGTGACCAATGA  
 CTACCCCTTATAGATTGTCCCACTGGTTACT  
 243 M G I S N R V T N E

801 AACACGCAACTGTGAAATGAGAAAAGACTGTGTTACATTGACAGCAATATATTA  
 TTGTCGTTGACACTTACTCTTCTCTGACACAATGTAAGTCGGAACGGTGTGTATATAAT  
 253 N S N C E M R K E K R L C Y I Q P C D S N I L

871 AAGACAAATAAAGATTCCAAAGGAAACAA  
 TTCTGTTATTCTTAAGGGTTCCCTTTTGT  
 276 K T I K I P K G K T

901 TGCCAAACCTTCAACTCTCCAAAGCTGAAAAAATTGTCCTTCTGGATGCTCAAGTACTCAGAGT  
 ACGGTTGGATGAAAGGGTTGAGGGTTCCGACTTTAACAGAAAAGACCTACGGATTCATGGTCTCAA  
 286 C Q P T F Q L S K A E K F V F S G C S S T Q S Y

971 ACAAAACCCACTTTGTGGAAATATGCTGG  
 TGTTGGGTGAAACACCTTATACGAAACC  
 310 K P T F C G I C L D

**FIG.\_ 6B**

1001 ATAAGAGATGGCTATCCCTATAAAGTCTAAAATGATTACTTCAATTGATTGGCCAAATGAGGGTC  
 TATTCTCTACGACATAAGGGATTATTCAAGATTACTAATGATAAAGTTAAACTAACGGGTTACTCCCAAG  
 320 K R C C I P N K S K M I T I Q F D C P N E G S

1071 ATTAAATGGAAAGATGGCTGGATTACATC  
 TAAATTACCTTCTACGACACCTAATGTAG  
 343 F K W K M L W I T S

1101 TTGTTGTTGTCAGAGAAACTGCAGAGAACCTGGAGATATTTCTGAGGCTCAAGATTCTGTAAACCAA  
 AACACACACAGTCTCTTGACGTCCTGTGACCTCTATAAAAGACTCGAGTTCTAAGACATTGGTT  
 353 C V C Q R N C R E P G D I F S E L K I L O

1171 GCAAATGGGGAAAAGTTAGTCAATCCTGT  
 CGTTAACCCCTTTCAATCAGTAGGACA

1201 CATANATAAAAATTAAGTGGACTATAAAATGGTGGCAAACTACTTTGTTAAAACAGTATGAATGCCCT  
 GTATNTTATTTTTAATCCTCATATTTACCCGGTTAGTGAACAAATTTGTCTACCTTACGGA

1271 ATTCTCAAGATCACTACATTAGGCATAG  
 TAAGAGTCAGTGTAGTGAATTCCGTATTC

1301 AAACTTTAAAAGTTANCTAAAAATATACATAA  
 TTTGAAATTTCAATNGAATTATATGTAT

**FIG.\_ 6C**

1 CACGGTCCAGCAGATGCAGGGCTCCTTCTCCACTCTGTGGCACAGTTCTGCT  
 1 GTGCCAGGGTCCGGTGTACGTCCCCGGAGAAGAGGTGAGAACGACGGACAGA  
 1 M Q G L F S T L L A G L A Q F C C

71 GCAGGGTACAGGGCACTGGACCATTAGATA  
 CGTCCCATGTCGGTGCACCTGGTAATCTAT  
 20 R V Q G T G P L D T

101 CAAACACTGAAGGAAGGCCCTGGAGAAGTCAGATGCACCTCAGCGTAAACAGTTGTCACTGGCCCTG  
 GTTGTGACTTCCTTCCGGACCTCTCACAGTCTACGTGGAGTGCATTGTCAAACAGTGACCGGGAC  
 30 T P E G R P G E V S D A P Q R K Q F C H W P C

171 CAAATGCCCTCAGCAGAAGGCCCGTGGCC  
 GTTTACGGGAGTGTGTCGGGCAACGGG  
 53 K C P Q K P R C P

201 TCCTGGAGTGGCTGGTGAAGATGGCTGTGGATGGCTGTAAGAACCGGAAACCAGGAAATC  
 AGGACCTCACTGGACCACTCTACCGACACCTACGACATTAGACACGGTTGGTCCCTTTAG  
 63 P G V S L V R D G C C K I C A K Q P G E I

271 TGCAATGAAGCTGACCTCTGTGACCCAC  
 ACGTTACTTCGACTGGAGAACACTGGGTGTG  
 86 C N E A D L C D P H

301 AAAGGGCTGTATTGTGACTACTCAGTAGACAGGGCTTAGGTACGAGACTGGAGTGTGCATAACCTTGTA  
 GTTCCCGACATACACTGATGAGTCATCTGTCCGGATCCATGCTCACACACGTATGGAACATC  
 96 K G L Y C D Y S V D R P R Y E T G V C A Y L V A

371 CTGTTGGGTGAGTCAACCAGGTACATT  
 GACAACCCACGCTCAAGTGGTCCATGTA  
 120 V G C E F N Q V H Y

401 ATCATTAATGGCCZAAGTGTTCAGGCCAACCCCTTGTTCAGCTGCCCTGTGTGAGGGCCATTGGATG  
 TAGTATTACGGTTACAAAGTGGGTGGGAAACAAGTCAGGGAGACACACTCACCCGGTAACCTAC  
 130 H N G Q V F Q P N P L F S C L C V S G A I G C

471 CACACCTCTGTTCATACCAAAAGCTGGCTGG  
 GTGTGGAGACAAAGTATGGTTGCACGGACC  
 153 T P L F I P K L A G

**FIG.-7A**

501 CAGTCACTGCTCTGGAGCTAAAGGTGGAAAGAAGTCTGATCAGTCAAACTGTAGCCTGGAACCCATTACTA  
 163 S H C S G A K G K S D Q S N C S L E P L L  
 GTCAGTGCAGGAGACCTCGATTTCCACCTTCTTCAGACTAGTCAGTTGACATCGGACCTGGTAATGAT  
 571 CAGCAGCTTCAACAAAGCTACAAACAAATG  
 GTCGTGAAAGTTGTTGATGTTGTTAC  
 186 Q Q L S T S Y K T M  
 GGTGAAATATCTTCAACCTTATTGGAAAAAAATGTCCTGTGCAAGCAACAAAATGGACTCCCT  
 601 CCAGCTTATAGAAATCTCCACCTTATTAGGGTGAATAAACCTTTTACAGAACACGTTGTTTACACTGAGGGA  
 196 P A Y R N L P L I W K K C L V Q A T K W T P C  
 GCTCCAGAACATGTGGATGGGAATATCTA  
 671 CGAGGTCTTGTACACCCCTAACCTTATAGAT  
 220 S R T C G M G I S N  
 ACAGGGTGACCAATGAAACAGCAACTGTGAATGAGAAAAAGACTGTGTTACATTAGCCTTG  
 701 TGTCCCACGTGGTACTTTGTGTTGACACTTACTCTTTCTCTTGACACAACTGTAAGTCGGAAC  
 230 R V T N E N S N C E M R K E K R L C Y I Q P C  
 CGACAGCAATATAAGACAATAAGAT  
 771 GCTGTCGTTATAATTCTGTATTCTA  
 253 D S N I L K T I K I  
 TCCCAAAGGAAAMACATGCCAACCTACTTCCAAACTCTCCAAAGCTGAAAAATTGTCTTTCTGGATGC  
 801 AGGGTTCCCTTTGTACGGTGGATGAAAGGTTGAGGGTTGACTTTAACAGAAAACGACTACG  
 263 P K G K T C Q P T F Q L S K A E K F V S G C  
 TCAAGTACTCAGAGTTACAAACCCACTTT  
 871 AGTTCATGAGTCATGTTGGGTGAAAAA  
 286 S S T Q S Y K P T F

**FIG.-7B**

FIG.-7C

mouse.wisp-1	1	M R W L L P W T L A A V A V L R V G N I L A T A L S P T P T T M T F T P A P L E E T T T R P E F C K
human.wisp-1	1	M R W F L P W T L A A V T A A A S T V L A T A L S P A P T T M D F T P A P L E D T T S S R P Q F C K
mouse.wisp-1	51	W P C E C P Q S P P R C P L G V S L I T D G C E C C K I C A Q Q L G D N C T E A A I C D P H R G L Y
human.wisp-1	51	W P C E C P P S P P R C P L G V S L I T D G C E C C K M C A Q Q L G D N C T E A A I C D P H R G L Y
mouse.wisp-1	101	C D Y S G D R P R Y A I G V C A Q V V G V G C V L D G V R Y T N G E S F Q P N C R Y N C T C I D G T
human.wisp-1	101	C D Y S G D R P R Y A I G V C A Q V V G V G C V L D G V R Y N N G Q S F Q P N C K Y N C T C I D G A
mouse.wisp-1	151	V G C T P L C L S P R P P R L W C R Q P R H V A R V P G Q C C E Q W V C D D D A R P R Q T A L L D T
human.wisp-1	151	V G C T P L C L R V R P P R L W C P H P R A V S I P G H C C E Q W V C E D D A K P R K T A P R D T
mouse.wisp-1	201	R A F A A S G A V E Q R Y E N C I A Y T S P W S P C S T T C G L G I S T R I S N V N A R C W P E Q E
human.wisp-1	201	G A F D A V G E V E A W H R N C I A Y T S P W S P C S T S C G L G V S T R I S N V N A Q C W P E Q E
mouse.wisp-1	251	S R L C N L R P C D V D I Q L H I K A G K K C L A V Y Q P E E A T N F T L A G C V S T R T Y R P K Y
human.wisp-1	251	S R L C N L R P C D V D I H T L I K A G K K C L A V Y Q P E A S M N F T L A G C I S T R S Y Q P K Y
mouse.wisp-1	301	C G V C T D N R C C I P Y K S K T I S V D F Q C P E G P G F S R Q V L W I N A C F C N L S C R N P N
human.wisp-1	301	C G V C M D N R C C I P Y K S K T I D V S F Q C P D G L G F S R Q V L W I N A C F C N L S C R N P N
mouse.wisp-1	351	D I F A D L E S Y P D F E E I A N
human.wisp-1	351	D I F A D L E S Y P D F S E I A N

18 / 49

mouse.wisp-2 1 M R G N P L I H L L A I S F L C I L S M V Y S Q L C P A P C A C P W T P P Q C P P G V P L V L D G C  
human.wisp-2 1 M R G T P K T H L L A F S L C L S K Y R T Q L C P T P C T C P W P P P R C P L G V P L V L D G C

mouse.wisp-2 51 G C C R V C A R R L G E S C D H L H V C D P S Q G L V C Q P G A G P S G R G A V C L F E E D D G S C  
human.wisp-2 51 G C C R V C A R R L G E P C D Q L H V C D A S Q G L V C Q P G A G P G G R G A L C L L A E D D S C

mouse.wisp-2 101 E V N G R R Y L D G E T F K P N C R V L C R C D D G G F T C L P L C S E D V R L P S W D C P R P R A  
human.wisp-2 101 E V N G R L Y R E G E T F Q P H C S I R C R C E D G G F T C V P L C S E D V R L P S W D C P H P R R

mouse.wisp-2 151 I Q V P G R C C P E W V C D Q A V M Q P A I Q P S S A Q G H Q L S A L V T P A S S A D G P C P N W S T  
human.wisp-2 151 V E V L G K C C P E W V C G Q G G . G L G T Q P L P A Q G P Q F S G L V S S L P P G V P C P E W S T

mouse.wisp-2 201 A W G P C S T T C G L G I A T R V S N Q N A F C Q L E I Q R R L C L S R P C L A S R S H G S W N S A  
human.wisp-2 200 A W G P C S T T C G L G M A T R V S N Q N R F C R L E T Q R R L C L S R P C P P S R G R S P Q N S A

mouse.wisp-2 251 F  
human.wisp-2 250 F

**FIG.\_9**

hWISP-3.DNA56350	10	20	30	40	50
	MNKRRLLYPSGWLHGPSDMQGLLFSTLLLAGLAQFCCRVQGTGPLDTTPE				
	*****				
hWISP-3.DNA58800	MQGLLFSTLLLAGLAQFCCRVQGTGPLDTTPE				
	10	20	30		
hWISP-3.DNA56350	60	70	80	90	100
	GRPGEVSDAPQRKQFCHWPCCKCPQQKPRCPPGVSLVRDGCCKICAKQP				
	*****				
hWISP-3.DNA58800	GRPGEVSDAPQRKQFCHWPCCKCPQQKPRCPPGVSLVRDGCCKICAKQP				
	40	50	60	70	80
hWISP-3.DNA56350	110	120	130	140	150
	GEICNEADLCDPHKGLYCDYSVDRPRYETGVCAVLVAVGCEFNQVHYHNG				
	*****				
hWISP-3.DNA58800	GEICNEADLCDPHKGLYCDYSVDRPRYETGVCAVLVAVGCEFNQVHYHNG				
	90	100	110	120	130
hWISP-3.DNA56350	160	170	180	190	200
	QVFQPQPLFSCLCVSGAIGCTPLFIPKLAGSHCSGAKGGKKSDQSNCSLE				
	*****				
hWISP-3.DNA58800	QVFQPQPLFSCLCVSGAIGCTPLFIPKLAGSHCSGAKGGKKSDQSNCSLE				
	140	150	160	170	180
hWISP-3.DNA56350	210	220	230	240	250
	PLLQQLSTSYYKTMPAYRDLPLIWKKKCLVQATKWTPCSRTCGMGIISNRVT				
	*****				
hWISP-3.DNA58800	PLLQQLSTSYYKTMPAYRNLPLIWKKKCLVQATKWTPCSRTCGMGIISNRVT				
	190	200	210	220	230
hWISP-3.DNA56350	260	270	280	290	300
	NENSNCEMRKEKRLCYIQPCDSNILKTIKIPKGKTCQPTFQLSKAEKFVF				
	*****				
hWISP-3.DNA58800	NENSNCEMRKEKRLCYIQPCDSNILKTIKIPKGKTCQPTFQLSKAEKFVF				
	240	250	260	270	280
hWISP-3.DNA56350	310	320	330	340	350
	SGCSSTQSYKPTFCGICLDKRCCIPNKSXMITIQFDCPNEGSFKWKMLWI				
	*****				
hWISP-3.DNA58800	SGCSSTQSYKPTFCGICLDKRCCIPNKSXMITIQFDCPNEGSFKWKMLWI				
	290	300	310	320	330
hWISP-3.DNA56350	360	370			
	TSCVCQRNCREP GDPIFSELKIL				
	*****				
hWISP-3.DNA58800	TSCVCQRNCREP GDPIFSELKIL				
	340	350			

**FIG.\_10**

20 / 49

hwISP-3.DNA56350	GTGGGGTTGCAGAGGAGACAGGGAGCTTGTGTACCCGGAGCAATGAA				
	10	20	30	40	50
huWISP-1	A *				
hwISP-3.DNA56350	CAAGCGGCGACTTCTCTACCCCTCAGGGTGGCTCCACGGTCCCAGCGACA				
	60	70	80	90	100
huWISP-1	TGAGGTGGTTCTGCCCTGGAC---GCTGGCAGCAGTGACAGCAGCAGCC *** * *** ***** ** * *** *** * *** * *** *				
hwISP-3.DNA56350	TGCAGGGGCTCCTCTTCTCCACTCTCTGCTGGCTGGCACAGTTC				
	110	120	130	140	150
huWISP-1	50 60 70 80 90 GCCAGCACCGTCTGGCCACGGCCCTCTCCAGCCCCTACGACCATGGA * *** * *** * *** * *** * *** * *** * *** *				
hwISP-3.DNA56350	TGCTGCAGGGTACAGGGCACTG-----GACCATTAGATACAACACCTGA				
	160	170	180	190	
huWISP-1	100 110 120 130 140 CTTTACTCCAGCTCCACTGGAGGACACCTCCTCACGCCCAATTCTGCA * *** * *** * *** * *** * *** * *** * *** *				
hwISP-3.DNA56350	AGGAAGGCCTGGAGAAGTGTAGATGCACCTCAGCGTAAACAGTTTGTC				
	200	210	220	230	240
huWISP-1	150 160 170 180 190 AGTGGCCATGTGAGTGCCGCCATCCCCACCCCGCTGCCGCTGGGGGTC * ***** * * * ***** * ***** * ***** * * *** *				
hwISP-3.DNA56350	ACTGGCCCTGCAAATGCCCTCAGCAGAACGCCCCGTTGCCCTCTGGAGTG				
	250	260	270	280	290
huWISP-1	200 210 220 230 240 AGCCTCATCACAGATGGCTGTGAGTGCTGTAAGATGTGGCTCAGCAGCT ***** * * ***** * ***** * ***** * * *** * *** * *** *				
hwISP-3.DNA56350	AGCCTGGTGAGAGATGGCTGTGGATGCTGTAAAATCTGTGCCAACGAAACC				
	300	310	320	330	340
huWISP-1	250 260 270 280 290 TGGGGACAACCTGCACGGAGGCTGCCATCTGTGACCCCCACCGGGGCTCT ***** * ***** * * * * * ***** * ***** * *** * *** *				
hwISP-3.DNA56350	AGGGGAAATCTGCAATGAAGCTGACCTCTGTGACCCACACAAAGGGCTGT				
	350	360	370	380	390
huWISP-1	300 310 320 330 340 ACTGTGACTACAGCGGGGACCGCCCGAGGTACGCAATAGGAGTGTGTGCA * ***** * * * * * ***** * * * * * ***** * * ***** * ***				
hwISP-3.DNA56350	ATTGTGACTACTCAGTAGACAGGCCTAGGTACGAGACTGGAGTGTGTGCA				
	400	410	420	430	440
huWISP-1	350 360 370 380 390 CAGGTGGTCGGTGTGGGCTGCGTCCTGGATGGGGTGCCTACAAACACGG * * *** * *** * * * * * *** * * *** * *** * *** *				
hwISP-3.DNA56350	TACCTTGTAGCTGTTGGGTGCGAGTTCAACCAGGTACATTATCATAATGG				
	450	460	470	480	490

**FIG. 11A**  
SUBSTITUTE SHEET ( rule 26 )

21 / 49

huWISP-1	400	410	420	430	440
	CCAGTCCTTCCAGCCTAACTGCAAGTACAACGTGCACGTGCATCGACGGCG				
	***	**	*****	***	***
hWISP-3.DNA56350	500	510	520	530	540
	CCAAGTGGTTCAGCCAAACCCCTTGGTCAGCTGCCTCTGTGAGTGGGG				
huWISP-1	450	460	470	480	490
	CGGTGGGCTGCACACCACTGTGCCTCCGAGTGCACGCCCCCGCGTCTCTGG				
	***	***	*****	***	***
hWISP-3.DNA56350	550	560	570		580
	CCATTGGATGCACACCTCTGTTCATACCAAAGC-----TGGCTGG				
huWISP-1	500	510	520	530	540
	TGCCCCCACCCGGCGCGTGAGC-ATACCTGCCACTGCTGTGAGCAGT				
	***	***	***	***	***
hWISP-3.DNA56350	590	600	610	620	
	-----CAGTCACTGCTCTGGAGCTAAAGGTGAAAGAAGTCTGATCAGT				
huWISP-1	550	560	570	580	590
	GGGTATGTGAGGACGACGCCAACAGAGGCCACGCAGACCGCACCCGTGAC				
	***	***	***	***	***
hWISP-3.DNA56350	630	640	650	660	670
	CAAACGTG-AGCCTGGAACCATTA--CTACAGCAGCTTCAACAAGCTAC				
huWISP-1	600	610	620	630	640
	ACAGGAGCCTTCGATGCTGTGGGTGAGGTGGAGGCATGGCACAGGAACGTG				
	***	***	***	***	***
hWISP-3.DNA56350	680	690	700	710	720
	AAAACAATGCCAGCTTATAGAGATCTCCACTTATTGGAAAAAAAATG				
huWISP-1	650	660	670	680	690
	CATAGCCTACACAAGCCCCTGGAGGCCCTTGCTCCACCAGCTGCAGGCGCTGG				
	***	***	***	***	***
hWISP-3.DNA56350	730	740	750	760	770
	TCTTGTGCAAGCAACAAAATGGACTCCCTGCTCCAGAACATGTGGATGG				
huWISP-1	700	710	720	730	740
	GGGTCTCCACTCGGATCTCAATGTTAACGCCAGTGCTGGCTGAGCAA				
	***	***	***	***	***
hWISP-3.DNA56350	780	790	800	810	820
	GAATATCTAACAGGGTGACCAATGAAAACAGCAACTGTGAAATGAGAAAA				
huWISP-1	750	760	770	780	790
	GAGAGCCGCCTCTGCAACTTGCAGGCCATGCGATGTGGACATCCACACT				
	****	***	***	***	***
hWISP-3.DNA56350	830	840	850	860	870
	GAGAAAAGACTGTGTTACATTGCAGCCTTGCGACAGCAATATATTAAAGAC				
huWISP-1	800	810	820	830	840
	CATTAAG-----GCAGGGAAAGAAGTGTCTGGCTGTGTACCGCCAGAGG				
	***	***	***	***	***
hWISP-3.DNA56350	880	890	900	910	920
	AATAAAAGATTCCCAAAGGAAAAACATGCCAACCTACTTCCAACCTCCA				
huWISP-1	850	860	870	880	890
	CATCCATGAACCTCACACTTGCAGGCCATGCGATGTGGACATCCACCGCTCCTATCAA				
	***	***	***	***	***
hWISP-3.DNA56350	930	940	950	960	970
	AAGCTGAAAAATTGTCTTTCTGGATGCTCAAGTACTCAGAGTTACAAA				

**FIG.\_11B**


SUBSTITUTE SHEET (RULE 26)

huWISP-1	900	910	920	930	940
	CCCAAGTACTGTGGAGTTGCATGGACAATAGGTGCTGCATCCCCAACAA				
	*****	*****	*****	*****	*****
hWISP-3.DNA56350	980	990	1000	1010	1020
	CCCACTTTGTGGAATATGCTTGGATAAGAGATGCTGTATCCCTAATAA				
	980	990	1000	1010	1020
huWISP-1	950	960	970	980	990
	GTCTAAGACTATCGACGTGTCCTCCAGTGTCCCTGATGGGCTTGGCTTCT				
	*****	**	**	**	**
hWISP-3.DNA56350	1030	1040	1050	1060	1070
	GTCTAAAATGATTACTATTCAATTGATTGCCAAATGAGGGTCATTTA				
	1030	1040	1050	1060	1070
huWISP-1	1000	1010	1020	1030	1040
	CCCGCCAGGTCTATGGATTAATGCCCTGCTCTGTAAACCTGAGCTGTAGG				
	* ***	* ****	* ***	* ***	* ***
hWISP-3.DNA56350	1080	1090	1100	1110	1120
	AATGGAAGATGCTGTGGATTACATCTTGTGTGTCAAGAGAAACTGCAGA				
	1080	1090	1100	1110	1120
huWISP-1	1050	1060	1070	1080	1090
	AATCCAATGACATCTTGCTGACTTGGAACTCCTACCCCTGACTTCAGA				
	* **	* ***	* ***	* **	* **
hWISP-3.DNA56350	1130	1140	1150	1160	1170
	GAACCTGGAGATATATTCTGAGCTCAAGATTCTGTAAAACCAAGCAA				
	1130	1140	1150	1160	1170
huWISP-1	1100				
	AATTGCCAAC				
	* **				
hWISP-3.DNA56350	1180	1190	1200	1210	1220
	TGGGGAAAAGTTAGTCATCCTGTCATANAATAAAAAAATTAGTGAGTA				
	1180	1190	1200	1210	1220
hWISP-3.DNA56350	1230	1240	1250	1260	1270
	TAAAATGGTGGCAAATCTACTTTGTTAAAACAGTATGAATGCCTATTCT				
	1230	1240	1250	1260	1270
hWISP-3.DNA56350	1280	1290	1300	1310	1320
	CAGATCACTACATTAAGGCATTAGAAACTTTAAAAAGTTANCTTAAAA				
	1280	1290	1300	1310	1320
hWISP-3.DNA56350	1330				
	ATATACATAA				

**FIG.\_ 11C**


	10	20	30	40	
hWISP-3.DNA56350	MNKRRLLYPSGWLHGPSDMQGLLFSTL-LLAGLAQFCCRVQGTGPLDTPP				
huWISP-1	MRWFLPWTLAAVTAAAATVLATALSPAPTTM				
	10	20	30	40	
	50	60	70	80	90
hWISP-3.DNA56350	EGRPGEVSDAPQRKQFCWPKCPQQKPRCPGVSLVRDGCGCKICAKQ				
huWISP-1	DFTPAPLEDTSSRPQFCWKPCCEPPSPPRCPLGVSLITDGCECCKMCAQQ				
	40	50	60	70	80
	100	110	120	130	140
hWISP-3.DNA56350	PGEICNEADLCDPHKGLYCDYSVDRPRYETGVCAVLVAVGCEFNQVHYHN				
huWISP-1	LGDNCTEAAICDPHRLGLYCDYSGDRPRYAIGVCAQVVGVCVLGVRYNN				
	90	100	110	120	130
	150	160	170	180	190
hWISP-3.DNA56350	GQVFQPNPLFSCLCVSGAIGCTPL-FIPKLAGSHCSGAK---GGKKSDQ				
huWISP-1	GQSFQPNCKYNCTCIDGAVGCTPLCLRVRPPRLWCPHRRVSIPGHCEQ				
	140	150	160	170	180
	200	210	220	230	240
hWISP-3.DNA56350	SNCSLEPLLQQLSTSYKTMPAYRDLPLI--WKKKCLVQATKWTPCSRTCG				
huWISP-1	WVCEDDAKRPRKTAP-RDTGAFDAVGEVEAHRNCIAYTSPWSPCSTSCG				
	190	200	210	220	230
	250	260	270	280	290
hWISP-3.DNA56350	MGISNRVTNENSNCMRKEKRLCYIQPCDSNILKTIKIPKGKTCQPTFQL				
huWISP-1	LGVSTRISNVNAQCWCPEQESRLCNLRPCDVDIHTLIK--AGKKCLAVYQP				
	240	250	260	270	270
	300	310	320	330	340
hWISP-3.DNA56350	SKAEKFVFSGCSSTQSYKPTFCGICLDRCCIPNKSCKMITIQFDCPNEGS				
huWISP-1	EASMNFTLAGCISTRSYQPKYCGVCMNDNRCICIPYKSKTIDVSFQCPDGLG				
	280	290	300	310	320
	350	360	370		
hWISP-3.DNA56350	FKWKMLWITSCVCQRNCREP GDPIFSELKIL				
huWISP-1	FSRQVLWINACFCNLSCRNPNDIFADLESYPDFSEIAN				
	330	340	350	360	

**FIG.\_ 12**



**SUBSTITUTE SHEET ( rule 26 )**

**FIG.- 13**






FIG.- 15

TTCGAGCTCGCCGACATTGATTATTGACTAGAGTCGATCACCGGTTATTAATAGTAATC  
 AATTACGGGGTCATAGTCATAGCCCATATGGAGTCCCGCTTACATAACTTACGGTA  
 AATGGCCCGCCTGGCTGACCGCCAAACGACCCCCGCCATTGACGTCAATAATGACGTAT  
 GTTCCCAGTAGTAACGCCAATAGGGACTTCCATTGACGTCAATGGTGGAGTATTTACGG  
 TAAACTGCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCTATTGAC  
 GTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCAAGTACATGACCTTATGGGACTTT  
 CCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGGTGTGCGGTTTGG  
 CAGTACATCAATGGCGTGGATAGCGGTTGACTCACGGGATTCCAAGTCTCCACCCCC  
 ATTGACGTCAATGGGAGTTGTTGGCACCAAAATCAACGGACTTTCCAAAATGTCGT  
 AACAACTCCGCCATTGACGAAATGGCGTAGGCGTAGGCGTACGGTGGGAGGTCTATATA  
 AGCAGAGCTCGTTAGTGAACCGTCAGATGCCCTGGAGACGCCATCCACGCTGTTTGAC  
 CTGGGCCCGGCCAGGCCCTCGGCCTTGAGCTATTCCAGAAGTAGTGAGGAGGCTTT  
 TTGAGGCCTAGGCTTTGCAAAAGCTAGCTTATCCGGCGGGAACGGTGCATTGGAA  
 CGCGGATTCCCCGTGCCAAGAGT  
 ><splice donor>  
 GACGTAAGTACCGCCTATAGAGCGACTAGTCCACC  
 ><PUR>  
 ATGACCGAGTACAAGCCCACGGTGCCTCGCCACCCGCACGACGTCCCAGGGCGTA  
 CGCACCCCTCGCCGCCGCTTCGCCACTACCCGCCACCGCCACACCGTAGACCCGGAC  
 CGCCACATCGAGCGGGTCACCGAGCTGCAAGAACTCTCCTCACGCCGTGGCTCGAC  
 ATCGGCAAGGTGTGGTCGGACGGACGGCGCCGGTGGCGCTGGACCAAGCCGGAG  
 AGCGTCAAGCGGGGGCGGTGTTCCCGAGATGGCCCGCATGGCGAGTTGAGCGGT  
 TCCCGGCTGGCCCGCAGAACAGATGGAAGGCCTCTGGCGCCGCACCGGCCAAGGAG  
 CCCGCGTGGTCTGGCACCGTCGGCGTCTGCCCGACCAACAGGGCAAGGGTCTGGC  
 AGCGCCGTCGTGCTCCCCGAGTGGAGGCGGCCAGCGCCGGGTGCCCGCTTCCTG  
 GAGACCTCCGCCCGCAACCTCCCTCTACGAGCGGCTGGCTTACCGTCACCGCC  
 GACGTCGAGTCCCCGAAGGACCGCGACCTGGTGCATGACCCGAAGCCGGTGCCAAC  
 ><DHFR ATG>  
 ATGGTTGACCAATTGAACTGCATCGTCGGTGTCCAAAATATGGGATTGGCAAGAAC  
 GGAGACCTACCCCTGCCCTCCGCTCAGGAACCGCTCAAGTACTCCAAAGAATGACCA  
 ACCTCTTCAGTGGAAAGTAAACAGAAATCTGGTATTATGGTAGGAAAACCTGGTTCTCC  
 ATTCTGAGAACATGACCTTAAAGGACAGAAATTAAATATAGTTCTCAGTAGAGAACTC  
 AAAGAACCAACGAGGAGCTATTCTGCCAAAAGTTGGATGATGCCCTAACGACTT  
 ATTGAACAAACCGGAATTGCAAGTAAAGTAGACATGGTTGGATAGTCGGAGGCAGTCT  
 GTTTACCAGGAAGCCATGAATCAACCAGGCCACCTTAGACTCTTGTGACAAGGATCATG  
 CAGGAATTGAAAGTGACACGTTTCCAGAAATTGATTGGGAAATATAAACCTCTC  
 CCAGAACATCCAGGCCTCTCTGAGGTCCAGGAGGAAAAGGCATCAAGTATAAGTT  
 GAAGTCTACGAGAACAGACTAA  
 ><End DHFR>  
 CGTTAACTGCTCCCTCTAAAGCTATGCATTTATAAGACCATGGGACTTTGCTGGC  
 TTTAGATCCCTGGCTTCGTTAGAACGCACTACAATTAAACATAACCTTATGTATCA  
 TACACATACGATTTAGGTGACACTATAGATAAACATCCACTTGCCTTCCTCACAGGT  
 GTCCACTCCAGGTCCAACGACCTCGGTCTATCGATTGAATTCCCCGGGATCCTCT  
 AGAGTCGACCTGCAGAAGCTCGATGGCCGCATGGCCAACCTGTTATTGCAGCTTAT  
 AATGGTTACAAATAAGCAATAGCATCACAAATTCAACAAATAAGCATTTTCACTG  
 CATTCTAGTTGTGGTTGTCCAAACTCATCAATGTATCTTATCATGTCGGATCGATCGG  
 <sv40 origin>  
 GAATTAATTGGCGCAGCACCATGGCCTGAAATAACCTCTGAAAGAGGAACCTGGTTA  
 <Kpn-SAR-Kpn insert here>  
 GGTACCGACTAGTCGCGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAA

## FIG.\_ 16A

CGACCCCCGCCATTGACGTCAATAATGACGTATGTTCCCAGTAGAACGCCAATAGGGAC  
TTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCACTTGGCAGTACATCA  
AGTGTATCATATGCCAAGTACGCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTG  
GCATTATGCCAGTACATGACCTTATGGACTTCTACTTGGCAGTACATCTACGTATT  
AGTCATCGCTATTACCATGGTATGCCAGTCTCCACCCATTGACGTCAATGGGAGTTGTTTG  
GTTTGACTCACGGGATTCCAAGTCTCCACCCATTGACGTCAATGGGAGTTGTTTG  
ACTAGTAGCAAGGTGCCACGCACAAGATCAATTTAACATCACTAGTCATCTCTTTAGC  
AATAAAAAGGTGAAAATACATTAAAAATGACACCATTAGACGATGTATGAAAAAAT  
CTACTTGGAAATAATCTAGGCAAAGAAGTCAAGACTGTTACCCAGAAAACTTACAAT  
TGTAAATGAGAGGTTAGTGAAGATTAAATGAATGAAGATCTAAATAAAACTTATAAATTG  
TGAGAGAAATTAAATGAATGTCTAAGTTAATGCAGAACGGAGAGACATACTATTCATG  
AACTAAAAGACTTAATATTGTGAAGGTATACTTCTTTACACATAATTGTAGTCAATA  
TGTTCACCCAAAAAAGCTGTTGTAATTGTCAACCTCATTCAAAATGTATATAGAA  
AGCCCAAAGACAATAACAAAAATATTCTGTAGAACAAAATGGGAAAGAATGTTCCACTA  
AATATCAAGATTAGAGCAAAGCATGAGATGTGTTGGGATAGACAGTGAGGCTGATAAAA  
TAGAGTAGAGCTCAGAACAGACCCATTGATATATGTAAGTGACCTATGAAAAAAATATG  
GCATTTACAATGGGAAATGATGATCTTTCTTTAGAAAAACAGGGAAATATATT  
TATATGAAAAAATAAAAGGGAACCCATATGTCATACACACACACACACACACAC  
GAATTATAAGTCTAAATGGAGAAGCAAAACCTTAAATCTTAAAGGAAATATAGAAG  
CATGCCATCATGACTTCAGTAGAGAAAAATTCTTATGACTCAAAGTCTAACACACAA  
AGAAAAGATTGTTAATTAGATTGCAATGAATTTAAAGACTTATTCTTAAAGGAAAC  
ATTAAGAAAAGTCAGGCCATAGAATGACAGAAAATTTGCAACACCCCCAGTAAAGAGAA  
TTGTAATATGCAGATTATAAAAGAAGTCTTACAAATCAGTAAAAAATAAAATAGACAA  
AAATTGAAACAGATGAAAGAGAAAACCTAAATAATCATTACACATGAGAAACTCAATCTC  
AGAAATCAGAGAACTATCATTGCAATACACTAAATTAGAGAAATATTAAAAGGCTAAGT  
AACATCTGTGGCAATATTGATGGTATATAACCTTGTATGATGTGAGAACAGTACTT  
TACCCCATGGGCTTCCTCCCCAACCCCTACCCAGTATAAATCATGACAATATACTTT  
AAAAACATTACCCATTCTAACAGTACTCCTCAAAACTGTCAAGGTCTACAAAAATA  
AGAAAAGTCTGAGGAACCTGTCAAAACTAAGAGGAACCCAAGGGAGACATGAGAATTATATG  
TAATGTGGCATTCTGAATGAGATCCCAGAACAGAAAAGAACAGTAGCTAAAAACTAAT  
GAAATATAAATAAAAGTTGAACCTTAGTTTTTAAAGAGTAGCTAAACACGGCA  
AAGTCATTTCATATTCTTGTAACTTAAAGTACAAGTCTATAATTAAAATTTTAA  
ATGTAGTCTGGAACATTGCCAGAACAGAACAGTACAGCAGCTATCTGTGCTGCTAAC  
TATCCATAGCTGATTGGCTAAATGAGATACATCAACGCTCCATGTTTTGTTT  
CTTTTAAATGAAAACCTTATTGTTAAGAGGAGTTCAAGGTTCATAGCAAAATTGAGA  
GGAAGGTACATTCAAGCTGAGGAAGTTCTCTATTCTAGTTACTGAGAGATTGCAT  
CATGAATGGGTGTTAAATTGTCATGCTTTCTGTGTCTATCAATATGACCATGTG  
ATTTCCTCTTAAACCTGTTGATGGGACAATTACGTTAATTGATTTCAAACGTTGAAC  
CACCCCTACATATCTGGAATAAATTCTACTGGTTGGGTGTATATTGATACATTC  
TTGGATTCTTTGCTAATATTGTTGAAAATGTTGTATCTTGTGTTCATGAGAGATAT  
TGGCTGTTGTTCTTGTAAATGTCATTCTAGTTCCGGTATTAAGGTAATGCT  
GGCCTAGTTGAATGATTAGGAAGTATTCCCTCTGCTTCTGTCTGAGGTACCGCGGC  
CGCCCGTCGTTTAC

## FIG.\_ 16B

<start pUC118>  
 <linearization linker inserted into Hpa1 site>  
 AACGTCGTGACTGGAAAACCCTGGCGTTACCCAACCTTAATCGCCTTGCGAGCACATCCCC  
 CTTTCGCCAGCTGGCGTAAAGCGAAGAGGCCGCACCGATGCCCTCCAAACAGTTGC  
 GCAGCCTGAATGGCGAATGGC  
 <start M13>  
 GCCTGATGCGGTATTTCTCCTTACGCATCTGTGCGGTATTCACACCGCATACGTCAA  
 GCAACCATACTGCGCCCTGTAGCGGCGCATTAGCGCGGGTGTGGTGGTTACGCG  
 CAGCGTACCGCTACACTGCCAGCGCCCTAGCGCCCGCTCTTCGCTTCTCCCTTC  
 CTTTCGCCACGTTGCCGGTTCCCGTCAAGCTCTAAATCGGGGGCTCCCTTAGG  
 GTTCCGATTTAGTGTCTTACGGCACCTCGACCCCCAAAAACTTGATTTGGGTGATGGTT  
 ACGTAGTGGGCCATGCCCTGATAGACGGTTTCGCCCTTGACGTTGGAGTCCACGTT  
 CTTTAATAGTGGACTCTTGTCCAAACTGGAACAACACTCAACCCATCTCGGGCTATT  
 TTTTGATTTATAAGGGATTTGCCGATTCGGCTATTGGTTAAAAAATGAGCTGATTTA  
 AAAAAAATTAACCGAATTTAACAAAATATTAACGTTACAATTATGGTGCACTCT  
 CAGTACAATCTGCTCTGATGCCGATAGTTAACGCCAGCCCCGACACCCGCCAACACCCGC  
 TGACGCCCTGACGGGCTTGTCTGCCCTACAGACAAGCTGTGACCGT  
 CTCCGGGAGCTGCATGTGTCAGAGGTTTCACCGTCATACCGAAACGCCGAG  
 < Hinc II (2271) to GTCATC>  
 < Pst I (1973) to CTGCTG>  
 < Acc I (183) delete 6 bp>  
 < Arbitrarily change EcoRI (1) to GAATAC>  
 <pUCx 83.11.25 sequence not fully known>  
 ACGAAAGGGCCTCGTGTACGCCATTTCATAGGTTAATGTCATGATAATAATGGTTTC  
 TTAGACGTCAGGTGGCACTTTGCCGGAAATGTGCGCGGAACCCCTATTGTTTATTTT  
 CTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCGATAAATGCTTCATA  
 ATATTGAAAAAGGAAGAGTATGAGTATTCAACATTCCGTTGTCGCCCTATTCCCTTT  
 TGC GGCACTTGCCTTCTGTTTGCTCACCCAGAAACGCTGGTAAAGTAAAGATGC  
 TGAAGATCAGTTGGGTGACGGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAAGAT  
 CCTTGAGAGTTTCGCCCGAAGAACGTTTCAATGATGAGCACTTTAAAGTTCTGCT  
 ATGTGGCGGGTATTATCCGTATTGACGCCGGCAAGAGCACTCGGTGCCGATACA  
 CTATTCTCAGAATGACTTGGTTGAGTACTCACCACTCACAGAAAAGCATCTACGGATGG  
 CATGACAGTAAGAGAATTATGCACTGCTGCATAACCATGAGTGATAACACTGCC  
 CTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACGTTTGCACAACATGG  
 GGATCATGTAACCGCCTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACAAACGA  
 CGAGCGTGACACCACGATGCCGTAGCAATGGCAACACGTTGCGCAAACATTAACTGG  
 CGAACTACTTACTCTAGCTTCCGGCAACAAATTATAGACTGGATGGAGGCGGATAAAAGT  
 TGCAGGACCACTCTGCCCTGGCCCTCCGGCTGGCTGGTTATTGCTGATAATCTGG  
 AGCCGGTGAGCGTGGGTCTCGGGTATCTGAGCACTGGGCCAGATGGTAAGCCCTC  
 CCGTATCGTAGTTATCTACACGACGGGAGTCAGGCAACTATGGATGAAAGAAATAGACA  
 GATCGCTGAGATAGGTGCCACTGATTAAGCATTGTAACTGTCAGACCAAGTTACTC  
 ATATATACTTAGATTGATTAAAACCTCATTTAATTAAAAGGATCTAGGTAAAGAT  
 CCTTTTGATAATCTCATGACCAAAATCCCTTAACGTGAGTTTCGTTCCACTGAGCGTC  
 AGACCCCGTAGAAAAGATCAAAGGATCTTCTGAGATCCTTTCTGCGCGTAATCTG  
 CTGCTGCAAACAAAAACCCGCTACCAAGCGGTGGTTGTTGCCGGATCAAGAGCT  
 ACCAACTCTTTCCGAAGGTAACGGCTTCAGCAGAGCGCAGATACCAAATACTGCT  
 TCTAGTGTAGCCGTAGTTAGGCCACCACTCAAGAACTCTGTAGCACCACCTACATACCT  
 CGCTCTGCTAACTCTGTACCAAGTGGCTGCTGCCAGGGCATAAGTCGTCTTACCGG  
 GTTGGACTCAAGACGATAAGTACCGGATAAGGCGCAGCGGTGGCTGAACGGGGGTTTC

**FIG.\_ 16C**

**SUBSTITUTE SHEET ( rule 26 )**

GTGCACACAGCCCAGCTGGAGCGAACGACCTACACCGAACGTGAGATACCTACAGCGTGA  
 GCTATGAGAAAGGCCACGCCCTCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGG  
 CAGGGTCGGAACAGGAGAGCGCACAGGAGGGCTCCAGGGGAAACGCCCTGGTATCTTA  
 TAGTCTCTGCGGGTTGCCACCTCTGACTTGAGCGTCATTGTGATGCTCGTCAGG  
 GGGGCGGAGCCTATGGAAAACGCCAGCAACCGCCCTTTACGGTCTGGCCTTTG  
 CTGGCCTTTGCTCACATGTTCTTCCTGCGTTACCCCTGATTCTGTGGATAACCGTAT  
 TACCGCCTTGAGTGAGCTGATACCGCTGCCAGCCGAACGACCGAGCGCAGCGAGTC  
 AGTGAGCGAGGAAGCG

<Sap-SAR-Sap insert here>

GAAGAGCCCGCGGGCAAGGTCGCCACGCCAACAGATCAATTAAACAATCAGTCATCTCTC  
 TTTAGCAATAAAAAGGTGAAAATACATTAAAAATGACACCATAGACGATGTATGAA  
 AATAATCTACTTGAAATAATCTAGGCAAAGAAGTGCAAGACTGTTACCCAGAAAACCTT  
 ACAAAATTGTAATGAGAGGTTAGTGAGATTAAATGAATGAAGATCTAAATAACTTAT  
 AAATTGTGAGAGAAATTAAATGAATGTCTAAGTTAATGCAAGAACGGAGAGACATACTATA  
 TTCACTGAACTAAAAGACTTAATATTGTGAAGGTATACTTTCTTTACATAAATTGTAG  
 TCAATATGTTCACCCAAAAAGCTGTTGTTACTTGTCAACCTCATTCAAAATGTAT  
 ATAGAAAGCCCAAAGACAATAACAAAAATTCTGTAGAACAAAATGGAAAGAATGTT  
 CCACTAAATATCAAGATTAGAGCAAAGCATGAGATGTGAGGGATAGACAGTGAGGCTG  
 ATAAAATAGAGTAGAGCTCAGAAACAGACCCATTGATATATGTAAGTGACCTATGAAAAA  
 AATATGGCATTACAATGGAAATGATGATCTTTCTTTAGAAAAACAGGGAAA  
 TATATTATATGAAAAAATGGAAACCCATTGTCATACACACACACAAAAAAT  
 TCCAGTGAATTATAAGTCTAAATGGAGAAGGCAAAACTTAAATCTTTAGAAAATAA  
 TAGAACGATGCCATCATGACTTCAGTGTAGAGAAAATTCTATGACTCAAAGTCCTAA  
 CCACAAAGAAAAGATTGTTAATTAGATTGCAATTAAAGACTTATTAAATTAA  
 AAAACCAATTAAAGAAAAGTCAGGCCATAGAACAGAAAATTGTCAACACCCAGTAA  
 AGAGAATTGTAATATGCAGATTATAAAAGAAGTCTACAAATCAGTAAAAAATAAA  
 AGACAAAAATTGAAACAGATGAAAGAGAAAATCTAAATAATCATTACACATGAGAAACTC  
 AATCTCAGAAATCAGAGAACTATCATTGCAATTACACTAAATTAGAGAAATTAAAAGG  
 CTAAGTAACATCTGTCAGGCCATTGATGGTATATAACCTTGTATATGATGTGAGAAC  
 GTACTTTACCCATTGGCTCTCCCAACCCCTACCCAGTATAAATCATGACAATA  
 TACTTTAAACCAATTACCCATTATCTAACAGTACTCCTCAAAACTGTCAAGGTCTAA  
 AAAATAAGAAAAGTCTGAGGAACCTGCTAAACTAACAGAGAACCCAGGAGACATGAGAAT  
 TATATGTAATGTGGCATTCTGAATTGAGATCCCAGAACAGAAAAGAAGTAGCTAAAAA  
 ACTAATGAAATATAAAAGTTGAACATTGAACTTGTAGTTTTTAAAGAGTAGCTTAAC  
 ACGGCAAAGTCATTTCATATTCTTGTGAAACATTAGTACAAGTCTATAATTAAAATT  
 TTTAAATGTAGTCTGGAACATTGCCAGAACAGAACAGTACAGCAGCTATCTGTGCTGTCG  
 CCTAACTATCCATAGCTGATTGGTCTAAATGAGATACATCAACGCTCCATGTTTT  
 TGTTTCTTTAAATGAAAAACTTATTGTTAAGAGGAGTTCAAGGTTCTAGGTTCTAGCAGAAA  
 TTGAGAGGAAGGTACATTCAAGCTGAGGAAGTTCTCTATTCTAGTTACTGAGAGA  
 TTGCATCATGAATGGGTGTTAAATTGTCTAAATGCTTTCTGTGTCTATCAATTATGAC  
 CATGTGATTCTCTTAAACCTGTTGATGGGACAAATTACGTTAATTGATTTCAAACG  
 TTGAACCACCCATTACATATCTGGAATAAAATTCTACTTGGTGTGGTGTATATTGAT  
 ACATTCTGGATTCTTTGCTAAATTGTTGAAATGTTGTATCTTGTGAG  
 AGATATTGGCTGTTGTTCTTCTGTAATGTCATTCTAGTTCCGGTATTAAGGT  
 AATGCTGGCCTAGTTGAATGATTAGGAAGTATTCCCTCTGCTTCTGTCTGAAGCGG  
 AAGAGC  
 <end M13>  
 GCCCAATACGAAACGCCCTCTCCCGCGCGTGGCCGATTCAATTAAATGCAAGCTGGCACG  
 ACAGGTTCCGACTGGAAAGCGGGCAGTGAGCGCAACGCAATTAAATGAGTTAGCTCA  
 CTCATTAGGCACCCAGGCTTACACTTATGCTTCCGGCTCGTATGTTGTGGAATTG  
 TGAGCGGATAACAATTACACAGGAAACAGCTATGACATGATTACGAATTAA

## FIG.\_ 16D

SUBSTITUTE SHEET ( rule 26 )

AAGCTTACTCGTAAAGCGAGTTGAAGGATCATATTAGTTGCGTTATGAGATAAGATT  
 GAAAGCACGTGTAAA  
 ><start ORF504 (PTP)>  
 ATGTTCCCGCGCGTGGACAACATTTACAATGCGGCCAAGTTATAAAAGATTCTAAT  
 CTGATATGTTTAAACACCTTGCAGGCGAGTTGCTACGTGACTAGCGAAGAA  
 GATGTGTGGACCGCAGAACAGATAGTAAACAAACCTAGTATTGGAGCAATAATCGAT  
 TTAACCAACACGTCTAAATATTATGATGGTGTGCATTGCGGGCGGGCTGTTATAC  
 AAAAAAATTCAAGTACCTGGCCAGACTTGGCCCTGAAAGCATAGTTCAAGAATTATT  
 GACACGGTAAAAGAATTACAGAAAAGTGTCCCGGCATGTTGGTGGCGTGCACGTGACA  
 CACGGTATTAATCGCACCGGTTACATGGTGTGCAGATATTAAATGCACACCCCTGGGTATT  
 GCGCCGAGGAAGCCATAGATAGATTGAAAGGCAAGGTCACAAAATTGAAAGACAA  
 AATTACGTTCAAGATTATTAAATTAAATTAAATTATTATTGATCTTAAACAAATACTT  
 ATCCTATTTCAAATTGTCGCTTCTCCAGCGAACCAAAACTATGCTTCGCTGCTCC  
 GTTTAGCTTGTAGCCGATCAGTGGCGTTGTTCCAATCGACGGTAGGATTAGGCCGGATAT  
 TCTCCACCAATGTTGGCAACGTTGATGTTACGTTATGCTTTGGTTTCCACGTACG  
 TCTTTGGCCGGTAATAGCCGTAACCGTAGTGCCTGCGCGTCACGCACAAACACCCGGAT  
 GTTTGCCTTGTCCCGGGGTATTGAACCGCGCAGTCCGACAAATCCACCAACTTGGCAA  
 CTAAATCGGTGACCTGCGCGTCTTTCTGCATTATTCGTCCTTCTTGCATGGTT  
 CCTGGAAGCCGGTGTACATGCGGTTAGATCAGTCATGACGCGCGTACCTGCAAATCTT  
 TGGCCTCGATCTGCTGCTTGTGATGGCAACGATGCGTTCAATAAAACTCTGTTTTAA  
 CAAGTTCCCTCGGTTTTTGCGCCACCCACGCGTTGCGAGCGCTTGTGCTCGGTGAATG  
 TCGCAATCAGCTTAGTCACCAACTGTTGCTCTCCCTCCGTTGTTGATCGCGGGAT  
 CGTACTTGGCGGTGCAGAGCACTTGAGGAATTACTTCTCTAAAGCATTCTGTAATT  
 CTATGGCGTAAGGCAATTGGACTTCATAATCAGCTGAATCAGCCGGATTAGTAATGA  
 GCACTGTATGCGGCTGCAAATACAGCGGGTCGCCCCTTTCAGACGCTGTTAGAGGTAG  
 GGCCCCCATTGGATGGCTGCTCAAATAACGATTGTTGATTTATGCTACATGAACAC  
 GTATAGCTTATCACAAACTGTATATTAAACTGTTAGCGACGTCCTGGCCACCGAAC  
 GGACCTGTTGGTCGCGCTAGCACGTACCGCAGGTTGAACGTATCTCTCCAAATTAA  
 ATTCTCCAATTAAACGCGAGCCA  
 ><start ORF984 (ORF2)>  
 TTTTGATACACGTGTGCGATTGGCAACAACATTGTTTTAACGCAAACAACTAACTTA  
 TTGTGGTAAGCAATAATTAAATATGGGGGACATGCGCCGCTACAACACTCGTGTATG  
 AACCGAGACGGCGCCGGTCTGGCGCAAGGGCTAAACGTGTGCGCGTTCAACCGCGC  
 AAACATCGCAAAGCCAATAGTACAGTTGATTTGCA  
 ><start conotoxin>  
 TATTAACGGCGATTAAATTATCTTATTAAATAAAAGTTATGACGCCCTACAACCTCC  
 CCGCCCGCGTTGACTCGCTGCACCTCGAGCAGTTGTTGACGCCCTCCCTCCGTTGGCG  
 AACACGTCGAGCGGGTGGTCGATGACCAGCGCGTGCACGCGACAAGTATCTG  
 TACACCGAATGATCGTCCGGCGAAGGCACGTCGGCTCCAAGTGGCAATATTGGCAAATT  
 CGAAAATATATACAGTTGGGTTGTTGCGCATATCTATCGTGGCGTTGGCATGTCAGTC  
 CGAACGTTGATTGCAAGCCAAATTAAATCATTGCGATTAGTGCAGTAAACGTT  
 TGTACATCCTCGCTTTAATCATGCCGCTGATTAAATCGCGCAATCGAGTCAGTGTAC  
 AAGTGTGGAATAATGTTCTTGATTCGGAGTCAAGCGCAGCGCGTATTAAACAAA  
 CTAGCCATCTTGTAAAGTTAGTTCA  
 ><start ORF453>  
 TTTAATGCAACTTATCCAATAATATATT  
 ><start ORF327>  
 ATGTATCGCACGTCAAGAATTAAACAATGCGCCCGTTGTCGCATCTCAACACGACTATGAT  
 AGAGATCAAATAAGCGCAATTAAATAGCTTGCACGCAACGTGACGATCTGTGACG  
 CGTCCGGCACCGAGCTTGTATTGATAAGTTTACGAAGCGATGACATGACCCCCGTA  
 GTGACAAACGATCACGCCAAAAGAACACTGCCACTACAAAATTACCGAGTATGTCGGTGAC  
 GTTAAAACATTAAAGCCATCCAATCGACCGTTAGTCGAATCAGGACCGCTGGTGCAGAAC  
 GCCCGCGAAGT  
 ><start ORF630>

ATGGCGAATGCATCGTATAACGTGTGGAGTCGCTCATTAGAGCGTCATGTTAGACAAG  
 AAAGCTACATATTTAATTGATCCCGATGATTATTGATAAAATGACCCTAACCCATAC  
 ACGGTATTCTACAATGGCGGGTTTGGTCAAAATTTCCGGACTGCGATGTACATGCTG  
 TTAACGGCTCCGCCACTATTAATGAAATTAAAAATTCCAATTAAACGCAGCAAG  
 AGAAACATTGTATGAAAGAATGCGTAGAAGGAAGAAAAATGTCGTCGACATGCTGAAC  
 AACAGATTAAATATGCCTCCGTATAAAAAAAATTGAACGATTGAAAGAAAACAAT  
 GTACCGCGCGCGTATGTACAGGAAGAGGTTTACTAAACTGTTACATTGCAAACGTG  
 GTTCTGTGCCAAGTGTGAAACCGATGTTAATCAAGGCTCTGACGCATTCTACAAAC  
 CACGACTCCAAGTGTGTGGGTGAAGTCATGCATCTTAAATCAAATCCAAGATGTTAT  
 AAACCAACAAACTGCCAAAAATGAAAATGTCGACAAGCTCTGCGTTGCTGCCAAC  
 TGCAAGGGTCTCAATCCTATTGTAATTGAAATAATAAAACATTATAAAATGCTAAAT  
 TTGTTTTTATTAAACGATACAAACCAACGCAACAAGAACATTGTAGTATTATCTATAA  
 TTGAAACCGCTAGTTATAATCGCTGAGGTAATATTAAATCATTCAAATGATTCAAC  
 AGTTAATTGCGACAATATAATTATTATTTACATAAAACTAGACGCCCTGTCGCTTCTT  
 CTTCTGATTCTCTCTTTCATTTCTCCTCATAAAAATTAAACATAGTTATTATCGT  
 ATCCATATATGTATCTATCGTATAGAGTAAATTGTTGTCATAAAATATATGTCCTT  
 TTTTAATGGGGTGTATAGTACCGCTGCCATAGTTCTGTAATTACAACAGTGTCTAT  
 TTTCTGGTAGTTCTCGGAGTGTGTTAATTATAAAATTATATAATCAATGAATT  
 TGGGATCGCGGTTTGTACAATATGTTGCCGGCATAGTACGCCAGCTCTCTAGTTCAA  
 TTACACCATTTTAGCAGCACCGGATTAACATAACTTCCAAAATGTTGTACGAACCGT  
 TAAACAAAAACAGTTCACCTCCCTTTCTATACTATTGTCGAGCAGTTGTTGTTGTT  
 TAAAAATAACAGCCA  
 ><start ORF603>  
 TTGTAATGAGACGCACAAACTAATATCACAAACTGGAAATGTCTATCAATATATAGTTGC  
 TGATATCATGGAGATAATTAAATGATAACCCTCGCAAATAAA  
 ><start of polh transcription>  
 TAAGTATTCTACTGTTCTGTAACAGTTGTAATAAAAAACCTATAAAT  
 ><mutated polh start codon>  
 ATTCCGGATTATTCATACCGTCCCACCATGGGCGC  
 ><start polylinker>  
 GGATCCGGCGCGGAATTCTAAACACCAGGCTAGCAGGCCT  
 ><start of IgG>  
 GACAAAACACATGCCACCGTCCCCAGCACCTGAACTCCTGGGGGACCGTCAGTC  
 TTCTCTTCCCCCAAAACCAAGGACACCCTCATGATCTCCGGACCCCTGAGGTACA  
 TGCGTGGTGGTGGACGTGAGCCACGAAGACCTGAGGTCAAGTTCAACTGGTACGTGGAC  
 GGCCTGGAGGTGCATAATGCCAAGACAAAGCCGCCGGAGGAGCAGTACAACAGCACGTAC  
 CGTGTGGTCAGCGTCCTCACCGTCCTGCACCAAGACTGGCTGAATGGCAAGGAGTACAAG  
 TGCAAGGTCTCCAACAAAGCCCTCCAGCCCCATCGAGAAAACCATCTCCAAAGCCAAA  
 GGGCAGCCCCGAGAACACAGGTGTACACCTGCCCCATCCCGGGAAAGAGATGACCAAG  
 AACCAAGGTCAAGCTGACCTGCCCTGGTCAAAGGCTTCTATCCAGCGACATGCCGTGGAG  
 TGGGAGAGCAATGGGCAGCCGGAGAACAAACTACAAGACCACGCCCTCCGTGCTGGACTCC  
 GACGGCTCTTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGG  
 AACGTCTTCTCATGTCCTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGC  
 CTCTCCCTGTCCTGGGTAAA  
 ><end of IgG>  
 TGACATAGGG  
 ><untranslated His tag>  
 CATCATCATCATCATCATCATATTAAATTCTAGACTAGTCTGCAGATC  
 ><end polylinker>  
 T

## FIG.\_ 17B

><polh coding sequences>

GATCCTTCTGGGACCCGGCAAGAACCAAAACTCACTCTCAAGGAAATCCGTAAT  
 GTTAAACCCGACACGATGAAGCTGTCGTTGGATGAAAGGAAAGAGTTCTACAGGGAA  
 ACTTGACCCGTTCATGGAAGACAGCTTCCCATTGTTAACGACCAAGAAGTGTG  
 GTTTTCTTGTGTCACCATGCGTCCCACTAGACCCAACCCTGTTACAAATTCTGGCC  
 CAACACGCTCTGCGTGGACCCGACTATGTACCTCATGACGTGATTAGGATGTCGAG  
 CCTTCATGGGTGGCAGCAACAACGAGTACCGCATCAGCCTGGCTAAGAAGGGCGGC  
 TGCCCAATAATGAACCTCACTGAGTACACCAACTCGTTGAAACAGTTCTGCTGAAGAG  
 GTCATCTGGGAGAACCTCTACAAGCCCATCGTTACATCGGTACCGACTCTGCTGAAGAG  
 GAGGAAATTCTCCTTGAAGTTCCCTGGTGGTCAAAGTAAAGGAGTTGCACCAAGC  
 CCTCTGTTACTGGTCCCGTATTAAACACGATACATTGTTATTAGTACATTATTAA  
 GCGCTAGATTCTGTGCGTTGTTACAGACAATTGTTGTAACGTTAGAGC  
 GAAAATCAAATGATTTCAGCGTCT  
 TTAAATTATAATCTTAAAGGTGGTATGTTAGAGC  
 GAAAATCAAATGATTTCAGCGTCT  
 TTATATCTGAATTAAATATTAAACCTCAATAGATTGTTAAAGGTTGATTAGTT  
 TCAAACAAGGGTGTGTTTCCGAACCGATGGCTGGACTATCTAATGGATTTCGCTCAAC  
 GCCACAAAATGCCAAATCTTGTAGCAGCAATCTAGCTTGTGATATTGTTGTT  
 TTGTTTGTAATAAAGGTTGACGTCGTTCAAATATTATGCCCTTGTATTCTTCA  
 TCACTGTCGTTAGTGTACAATTGACTCGACGTTAAACACGTTAAATAAGCTGGACATAT  
 TTAACATCGGGCGTGTAGCTTATTAGGCCGATTATCGTCGTCGCCCCAACCTCGTCG  
 TTAGAAGTTGCTTCCGAAGACGATTTCGCCATAGCCACACGACGCCATTAAATTGTCG  
 GCTAACACGTCGCGATCAAATTGTTAGTGTAGCTTGTGAAATTATTCTGATTGCGGG  
 CGTTTTGGGCGGGTTCAATCTAATGTCGCCCCGATTAAATTGAGACAAACACGTTAGAA  
 AGCGATGGTGCAGGCGGTGGTAACATTCAAGACGGCAAATCTACTAATGGCGCGGTT  
 GGAGCTGATGATAAAATCTACCATCGGTGGAGGCGCAGGCGGGCTGGCGGGAGGCGGA  
 GGCAGGAGGTGGTGGCGGTGATGCAAGACGGCGTTAGGCTCAAATGTCCTTAGGCAAC  
 ACAGTCGGCACCTCAACTATTGTAATGGTTCCGGCGCCGTTTGTTGACCGGTCTG  
 AGACGAGTGCAGTTTCTAATAGCTTCAACAAATTGTTGTCGTCGTCGTC  
 GGTGCAAGCGGGTTGAGGTTCCGTCGGCATGGTGGAGCAGGCGGGCAATTCAAGACATCGAT  
 GGTGGTGGTGGTGGAGGCGCTGGAATGTTAGGCACGGGAGAAGGTGGTGGCGCGGT  
 GCGCCGGTATAATTGTTCTGGTTAGTTGTTGCGCAGATTGTCGGGCACCGGGCGCA  
 GGCAGGCGCTGGCTGCACAACGGAAGGTCGTCGTCGAGGCGCAGGCGCTGGGGTGGTGGC  
 AATTCAATATTATAATTGGAATACAATCGAAAAATCTGCTATAAGCATTGTAATTTCG  
 CTATCGTTACCGTGGCGATATTAAACAACCGCTCAATGTAAGCAATTGTTATTGAAAGA  
 GATTGTCGTCAGCTCCGCACGCCATAACAAGCCTTTCAATTAACTACAGCATTGTC  
 TGGCGAGACACTTCGCTGTCGTCGACGTCATGTTGTCGTCGTC  
 GCAAGCTTTAAATATTAAAAGAACATCTCTGTTGCAAGCACCAGTGTGTCGAAATG  
 TTGTTTTGATAATTGCGCTTCCGAGTATGACACGTTCAAATTGATGCCATCA  
 ATTTGTTGTTCTATTATTGAATAAAATAAGATTGACAGATTCTACGATTGTC  
 ><start ORF588>

A

><start ORF1629>

TGGCCACCAAAATGCTACGCTGCAAACGCTGGTACAATTGAAACTGCAAAACG  
 TCAAAACTCGGTATAAAATAATCAACGGCGCTTGGCAAATATCTATTGTC  
 AGCCCCACTAGCAAATTGTTGAGAAAACAATTGCGCACAATTAAACGTC  
 AAATAAAAGTCACCAAGTTAATGAGCGACCCAAATTGTTATAAAATCTATTGTC  
 ACGGTTCCATCAACAACCAAGTGTGATGGACTACATTGACTGTC  
 AAACACTACAAATTAAAGGCAGGTTGTCACCAACTGTTAGCAATTATTAGACAGC  
 TGTGTGAAGCGCTCAACGATTGCAAGCACAAGCACAATTTC  
 AACACGAAACTCACTTAGCGTGCACGACGGCACGTTGGAGTATTGTC  
 TTGACACACAATTGCACTGTTGACTGGTACGCGCGTGTAAACATACAAGTT  
 GCTAACCGGGCG

**FIG. 17C**

**SUBSTITUTE SHEET ( rule 26 )**

><end of polh locus fragment>

TTCGTAATCATGGTCATAGCTGTTCTGTGAAATTGTTATCCGCTACAATTCCACA  
 CAACATACGAGCCGGAAGCATAAAGTGTAAAGCCTGGGTGCCAATGAGTGAGCTA  
 CACATTAATTGCGTTGCGCTCACTGCCGTTCCAGTCGGGAAACCTGTCGTGCCAGCT  
 GCATTAATGAATCGGCCAACGCGGGGAGAGGCAGTTGCGTATTG

><border Cole1 origin>

GGCGCTCTCCGCTTCGCTCACTGACTCGCTGCCCTCGGTCGGCTGCCAGAG  
 CGGTATCAGCTCACTAAAGCGGTAAATACGGTTATCCACAGAATCAGGGATAACGCAG  
 GAAAGAACATGTGAGCAAAGGCCAGCAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGC  
 TGGCGTTTCCATAGGCTCCGCCCTGACGAGCATCACAAAAATCGACGCTCAAGTC  
 AGAGGTGGCGAAACCGACAGGACTATAAAGATAACCAGGCCTCCCCCTGGAAGCTCCC  
 TCGTGCCTCTCCTGTTCCGACCTGCCGTTACCGGATACCTGTCGCCCTTCTCCCTT  
 CGGGAAAGCGTGGCGCTTCTCATAGCTCACCGCTGTAGGTATCTCAGTCCGTGTAGGTG  
 TTCGCTCCAAGCTGGCTGTGCAACGAAACCCCGTTAGCCGACCCTGCGCCTTAT  
 CCGGTAACTATCGTCTTGAGTCAACCCGGTAAGACACGACTTATGCCACTGGCAGCAG  
 CCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCAGCTACAGAGTTCTGAAGT  
 GGTGGCTAACTACGGCTACACTAGAAGGACAGTATTGGTATCTGCGCTCTGCTGAAGC  
 CAGTTACCTCGAAAAAGAGTTGGTAGCTCTGATCCGGAAACAAACCACCGCTGGTA  
 GCGGTGGTTTTTGTTGCAAGCAGATTACGCCAGAAAAAAAGGATCTCAAGAAG  
 ATCCTTGATCTTCTACGGGTCTGACGCTCAGTGAACGAAAACACGTTAAGGGA  
 TTTGGTCATGAGATTATCAAAAGGATCTCACCTAGATCCTT

><border Cole1 origin>

AAATTAAAAATGAAGTTTAAATCAATCTAAAGTATATGAGTAAACTGGTCTGACAG  
 TTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGCTATTTCGTTATCCAT  
 AGTTGCCTGACTCCCCGTCGTAGATAACTACGATAACGGGAGGGCTTACCATCTGGCC  
 CAGTGCCTGCAATGATAACCGCGAGACCCACGCTCACCGGCTCCAGATTATCAGCAATAA  
 CCAGCCAGCCGGAAGGGCCAGCGCAGAAGTGGCTCTGCAACTTATCCGCTCCATCCA  
 GTCTATTAAATTGTTGCCGGGAAGCTAGAGTAAGTAGTTGCCAGTTAATAGTTGCGCAA  
 CGTTGTTGCCATTGCTACAGGCATCGTGGTGTACGCTCGTCTGGTATGGCTTCATT  
 CAGCTCCGGTCCCAACGATCAAGGCAGTTACATGATCCCCATGTTGCAAAAAAGC  
 GGTTAGCTCTCGGTCTCCGATCGTTGTCAGAAGTAAGTTGGCCGAGTGTATCACT  
 CATGGTTATGGCAGCACTGCATAATTCTCTACTGTCATGCCATCCGTAAGATGCTTTTC  
 TGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGTGTATGCCGAGCTTG  
 CTCTTGCCCGCGTCATAACGGGATAATACCGGCCACATAGCAGAACTTAAAGTGCT  
 CATATTGAAAACGTTCTCGGGCGAAAACCTCTCAAGGATCTTACCGCTGTTGAGATC  
 CAGTTCGATGTAACCCACTCGCACCCAACTGATCTCAGCATTTACTTCACCAG  
 CGTTCTGGGTGAGCAAAACAGGAAGGAAAATGCCGAAAAAGGAATAAGGGCAG  
 ACGGAAATGTTGAATACTCA

><Start Amp>

TAATCTCTTTCAATATTATTGAAGCATTATCAGGGTTATTGTCATGAGCGGAT  
 ACATATTGAATGTATTAGAAAATAACAAATAGGGGTTCCGCGCACATTCCCGAA  
 AAGTGCCACCTGACGTCTAAGAAACCAATTATCATGACATTAACCTATAAAATAGGC  
 GTATCACGAGGCCCTTCGTCGCGCTTCGGTGATGACGGTAAAACCTCTGACACA  
 TGCAGCTCCGGAGACGGTCACAGCTTGTCTGTAAGCGGATGCCGGAGCAGACAAGCCC  
 GTCAGGGCGCGTCAGCGGTGTTGGCGGGTGTGCGGGCTGGCTTAACATGCCGATCAG  
 AGCAGATTGTAAGAGGTGACCATATATGCGGTGTGAAATACCGCACAGATGCGTAAG  
 GAGAAAATACCGCATCAGGCCATTGCCATTAGCTGCGCAACTGTTGGGAAGGGCG  
 ATCGGTGCGGGCTTTCGCTATTAGCCAGCTGGGAAAGGGGATGTGCTGCAAGGCG  
 ATTAAGTTGGGTAACGCCAGGGTTTCCAGTCACGACGTTGAAACGACGCCAGTGC  
 C

**FIG.\_17D**  
 SUBSTITUTE SHEET ( rule 26 )

AAGCTTTACTCGTAAAGCGAGTTGAAGGATCATATTAGTTGCGTTATGAGATAAGATT  
 GAAAGCACGTGTAAA  
 ><start ORF504 (PTP)>  
 ATGTTTCCCGCGCTGGCACAACTATTTACAATGCGGCCAAGTTATAAAAGATTCTAAT  
 CTGATATGTTTAAACACCTTGCAGGGCCAGTTGCGTACGTGACTAGCGAAGAA  
 GATGTGTGGACCGCAGAACAGATAGTAAAACAAAACCTAGTATTGGAGCAATAATCGAT  
 TTAACCAACACGTCTAAATATTATGATGGTGTGCATTTCGCGGCCTGTATAC  
 AAAAAAAATTCAAGTACCTGGCCAGACTTGCAGGCATGTTGGTGGCGTGCACGTGACA  
 GACACGGTAAAAGAACAGATAGTCCCAGCATGTTGGTGGCGTGCACGTGACA  
 CACGGTATTAATCGCACCGTTACATGGTGTGCAGATATTAAATGCACACCCCTGGGTATT  
 GCGCCGCAGGAAGCCATAGATAGATTGAAAGCCAGAGGTACAAAAATTGAAAGACAA  
 AATTACGTTCAAGATTATTAAATTAAATTATTGATCTTAAACAAATACCTT  
 ATCCTATTTCAAATTGTTGCGCTCTTCAGCGAACCAAACATGCTTCGCTGCTCC  
 GTTTAGCTTGTAGCCGATCAGTGGCGTTCCAATCGACGGTAGGATTAGGCCGGATAT  
 TCTCCACCACAAATGTTGCCAACGTTGATGTTACGTTATGCTTTGGTTTCCACGTACG  
 TCTTTGGCCGGAATAGCCGTAACGTTAGTGCGTCGCGTCACGCACAACACCCGAT  
 GTTTGCCTTGTCCGGGGTATTGAAACCGCGCAGCCGACAAATCCACCACTTGGCAA  
 CTAAAATCGGTGACCTGCGCTCTTCTGCAATTTCGTCCTTCTTGCATGGTTT  
 CCTGGAAGCCGGTGTACATGCGTTAGATCAGTCATGACGCGCGTGCACCTGCAAATCTT  
 TGGCCTCGATCTGCTTGTCTGATGGCAACGATGCGTTCAATAAACTCTGTTTTAA  
 CAAGTTCCCTCGGTTTTGCGCCACCACCGCTTGCAGCGCGTTGTGCTCGGTGAATG  
 TCGCAATCAGCTTAGTCACCAACTGTTGCTCTCCTCCGTTGATCGCGGAT  
 CGTACTTGCCTGGTGCAGAGCACTTGAGGAATTACTCTTCTAAAGCCATTCTGTAATT

CTATGGCGTAAGGCAATTGGACTTCATAATCAGCTGAATCACGCCGGATTAGTAATGA  
 GCACTGTATGCCGCTGCAAATACAGCGGGTCGCCCTTTCACGACGCTGTTAGAGGTAG  
 GGCCCCCATTTGGATGGTCTGCTCAAATAACGATTGTATTATTGTCTACATGAACAC  
 GTATAGCTTATCACAAACTGTATATTAAACTGTTAGCGACGTCCTGGCACGAAAC  
 GGACCTGTTGGTCGCGCTAGCACGTACCGCAGGTGAACGTATCTCTCCAAATTAA  
 ATTCTCAATTAAACGCGAGCCA  
 ><start ORF984 (ORF2)>  
 TTTTGATACACGTGTGTCGATTGCAACAACTATTGTTTAACGCAAACAACTAACTTA  
 TTGTTGTAAGCAATAATTAAATATGGGGAACATGCGCCGCTACAACACTCGTCGTTATG  
 AACGCAAGACGGCGCCGGTCTCGCGCAAGCGGCTAAACGTGTTGCGCGTTCAACGCGGC  
 AAACATCGCAAAGCCAATAGTACAGTTGATTTGCA  
 ><start conotoxin>  
 TATTAACGGCGATTAAATTATCTTATTAAATAAATAGTTATGACGCCCTACAACCTCC  
 CCGCCCGCTTGAACCGCTGACCGTGCAGCTGAGCAGTCGTTGACGCCCTCCCGTGTGGCCG  
 AACACGTCGAGCGGGTGGTCGATGACCGAGCGCGTGCACGCGACAAGTATCTG  
 TACACCGAATGATCGTGGCGAAGGCACGTCGGCTCCAAGTGGCAATATTGGCAAATT  
 CGAAAATATACAGTTGGTTGTTGCGCATATCTATCGTGGCGTTGGCATGTC  
 CGAACGTTGATTTGCATGCAAGCCGAAATTAAATCATTGCGATTAGTGCAGTAAACGT  
 TGTACATCCTCGCTTTAATCATGCCGTCGATTAAATCGCGCAATCGAGTCAGTGATCA  
 AAGTGTGGAATAATGTTCTTGTATTCCGAGTCAGCGCAGCGCGTATTAAACAAA  
 CTAGCCATTTGTAAGTTAGTTCA

## FIG.\_ 18A

```

><start ORF453>
TTTAATGCAACTTATCCAATAATATATT
><start ORF327>
ATGTATCGCACGTCAAGAATTACAATGCGCCCGTTGTCGCATCTCAACACGACTATGAT
AGAGATCAAATAAAGCGCGAATTAAATAGCTTGCACGCAACGTGCACGATCTGTGCACG
CGTTCCGGCACGAGCTTGATTGATAATAAGTTTACGAAGCGATGACATGACCCCCGTA
GTGACAAACGATCACGCCAAAAGAACTGCCGACTACAAAATTACCGAGTATGTCGGTGAC
GTTAAAACATTAAAGCCATCCAATCGACCGTTAGTCGAATCAGGACCGCTGGTGCAGAA
GCCGCGAAGT
><start ORF630>
ATGGCGAATGCATCGTATAACGTGGAGTCCGCTCATTAGAGCGTCATGTTAGACAAG
AAAGCTACATATTAAATTGATCCCGATGATTGATAAAATTGACCCCTAACTCCATAC
ACGGTATTCTACAATGGGGGGTTTGGTCAAAATTCCGGACTCGGATTGTACATGCTG
TTAACGGCTCCGCCACTATTAAATGAAATTAAAATTCCAATTAAAACGCAAG
AGAAACATTGTATGAAAGAATGCGTAGAAGGAAAGAAAATGTCGTGACATGCTGAAC
AACAAAGATTAATATGCCTCCGTATAAAAAAAATTGAACGATTGAAAGAAAACAAT
GTACCGCGCGGCGGTATGTACAGGAAGAGGTTTAACTAAACTGTTACATTGCAAACGTG
GTTTCGTGTGCCAAGTGTGAAAACCGATGTTAATCAAGGCTCTGACGCATTCTACAAC
CACGACTCCAAGTGTGGGTGAAGTCATGCATTTAATCAAATCCCAAGATGTGTAT
AAACCAACCAAATGCCAAAAACTGCGACAAGCTCTGCGTTGCTGGCAAC
TGCAAGGGTCTCAATCCTATTGTAATTATTGAAATAAAACAAATTATAATGCTAAAT
TTGTTTTTATTAAACGATACAAACCAACGCAACAAGAACATTGTTAGTATTATCTATAA
TTGAAAACGCGTAGTTATAATCGCTGAGGTAATTAAATTTCAAATGATTCAC
AGTTAATTGCGACAATATAATTTCACATAACTAGACGCCTGTCGTCTTCTT
CTTCGTATTCCCTCTCTTTCATTTCTCCCTATAAAATTAAACATAGTTATTATCGT
ATCCATATATGTATCTATCGTATAGAGTAAATTGTTGTCATAAATATATGTCCTT
TTTAATGGGGTGTATAGTACCGCTGCGCATAGTTTCTGTAATTACAACAGTGTCT
TTCTGGTAGTTCTCGGAGTGTGTTGCTTAATTATTAAATTATAATCAATGAATT
TGGGATCGCGGTTTGTACAATATGTCGCGCATAGTACGCAGCTCTCTAGTTCAA
TTACACCATTAGCAGCACCGGATTAACATAACTTCCAAAATGTTGACGAACCGT
TAAACAAAAACAGTTCACCTCCCTTTCTATAACTATTGTCGAGCAGTTGTTGT
AAAAATAACAGCCA
><start ORF603>
TTGTAATGAGACGCACAAACTAATATCACAAACTGGAAATGTCATCAATATATAGTTGC
TGATATCATGGAGATAATTAAATGATAACCCTCGCAAATAA
><start of polh transcription>
TAAGTATTTACTGTTCTGTAACAGTTGTAATAAAAAACCTATAAAT
><mutated polh start codon>
ATTCCGGATTATTCATACCGTCCCACCATCGGGCGC
><start polylinker >
GGATCCCGCGGCCCGAATTCTAAACCAACCATGGCAGCTGCCCGGG
><His tag>
CATCATCATCATCATCATCATATTAGACTAGTCTGCAGATC
><end polylinker>
T

```

## FIG.\_ 18B

><polh coding sequences>

GATCCTTCTGGGACCCGGCAAGAACCAAAACTCACTCTCAAGGAAATCCGTAAT  
 GTTAAACCCGACACGATGAAGCTGCGTTGGATGAAAGGAAAAGAGTCTACAGGGAA  
 ACTTGGACCCGCTTCATGGAAGACAGCTCCCCATTGTTAACGACCAAGAAGTGTGATGGAT  
 GTTTCTTGTGTCACATGCGTCCACTAGACCAACCGTTACAAATTCCCTGGCC  
 CAACACGCTCTGCGTTGCGACCCGACTATGTACCTCATGACGTGATTAGGATCGAG  
 CCTTCATGGTGGCAGCAACAACGAGTACCGCATCAGCCTGGCTAAGAAGGGCGCGGC  
 TGCCCAATAATGAACCTTCACTCTGAGTACACCAACTCGTCAACAGTGTGATCGT  
 GTCATCTGGGAGAACTTCTACAAGCCCACCGTTACATCGGTACCGACTCTGCTGAAGAG  
 GAGGAAATTCTCCTTGAAGTTCCCTGGTGTCAAAGTAAAGGAGTTGACCCAGACGCA  
 CCTCTGTTCACTGGTCCGGTATTAAAACACGATACATTGTTATTAGTACATTATTAA  
 GCGCTAGATTCTGTGCGTGTGATTACAGACAATTGTTGTACGTATTAAATAATTCA  
 TTAAATTATAATCTTGTAGGGTGGTATGTTAGAGCAAAATCAAATGATTTCAGCGTCT  
 TTATATCTGAATTAAATTAAATCCTCAATAGATTGTAAGGTTAGGTTGATTAGTT  
 TCAAAACAAGGGTTGTTTCCGAACCGATGGCTGGACTATCTAATGGATTTCGCTCAAC  
 GCCACAAAATCTGCAAATCTGTAGCAGCAATCTAGCTTGTGATATTGTTGTT  
 TTGTTTGTAAATAAGGTCGACGTTGACGTTGACGTTGTTAGGCTTTGTTGTT  
 TCACTGTCGTTAGTGTACAATTGACTCGACGTAACACGTTAAATAAGCTTGGACATAT  
 TTAACATCGGGCGTGTAGCTTATTAGGCCGATTATCGTCGTCGCCCCAACCTCGT  
 TTAGAAGTTGCTCCGAAGACGATTTGCCATAGCCACACGACGCCTATTAAATTGTCG  
 GCTAACACGTCGGCGATCAAATTGTTAGGCTGAGCTTTGGAATTATTCTGATTGCGGG  
 CGTGTGTTGGCGGGTTCAACTCTAATGTCGCCCCGATTAAATTCAAGACAACACGTAGAA  
 AGCGATGGTGCAGGGCGTGGTAACATTTCAGACGGCAAATCTACTAATGGCGGGCGTGGT  
 GGAGCTGATGATAAAATCTACCATCGGTGGAGGCGCAGGCGGGCTGGCGCGAGGCGGA  
 GCGGAGGTGGTGGCGGTGATGCAAGACGGCGTTAGGCTCAAATGTCCTTAGGCAAC  
 ACAGTCGGCACCTCAACTATTGTTAGGTTGCGCCGTTTTGGTTGACCGGTCTG  
 AGACGAGTGCATTTTCTGTTCTAATAGCTTCAAACAAATTGTTGTCTGTCGCTAAA  
 GGTGCAGCGGGTTGAGGTTCCGTCGGCATTGGTGGAGCGGGCGGCAATTCAAGACATCGAT  
 GGTGGTGGTGGTGGAGGCGCTGGAAATGTTAGGCACGGGAGAAGGTGGTGGCGGG  
 GCCGCCGGTATAATTGTTCTGGTTAGTTGTTGCGCAGCATTGTGGAGCACCAGC  
 GGCGCCGCTGGCTGCACAACGGAAGGTCGTCGTTGAGGCAAGCCTGGGTGG  
 AATTCAATATTATAATTGGAATACAAATCGAAAAATCTGCTATAAGCATTGTAATTTCG  
 CTATCGTTACCGTGCCTGATATTAAACAACCGCTCAATGTAAGCAATTGTTGAAAGA  
 GATTGTCAGCTCCGACGCCATAACAAGCCTTTCAATTAACTACAGCATTGTTAG  
 TGGCGAGACACTCGCTGTCGTCGACGTACATGTTGTTGTCACAAACGTCGTTG  
 GCAAGCTTAAATATTAAAAGAACATCTCTGTCAGCACCAGTGTGTTGTCGAAATG  
 TTGTTTGTGATAATTGCGCTCCGAGTATGACACGTTCAAAAATTGATGCGCATCA  
 ATTGTTGTTGTTCTATTATTGAATAAAAGATTGACATTGATCATATCTACGATTGTC

><start ORF588>

A

><start ORF1629>

TGGCCACCACAAATGCTACGCTGCAAACGCTGGTACAATTGAAAGTCAAAACG  
 TCAAAACTCGGTATAAAATAATCAACGGGCGTTGGCAAATATCTATTATCGCACA  
 AGCCCACTAGCAAATTGTTGAGAAAACAATTGCGCAGCATTAAACGCTGACG  
 AAATAAAAGTTCACCAAGTTAATGAGCGACCACCCAAATTGTTATAAAATCTATTAAATC  
 ACGGTTCCATCAACAACCAAGTGTGATGGACTACATTGACTGTCCGATTATTG  
 AAACACTACAAATTAAAGGCAGGCTTGTACCAACTGTTAGCAATTATTAGACAGC  
 TGTGTGAAGCGCTCAACGATTGTCACAAGCACAATTTCATACACAACGACATAAAACTCG  
 AAAATGTCTTATATTGAAAGCACTGATCGCGTATGTTGCGATTACGGATTGTGCA

## FIG.\_ 18C

AACACGAAA ACTCACTTAGCGTGCACGACGGCACGTTGGAGTATTTAGTCGGAAAAAA  
 TTCGACACACA ACTATGCACGTTCGTTGACTGGTACGCCGGTGTAAACATACAAGTT  
 GCTAACCGGGCGG  
 ><end of polh locus fragment>  
 TTCGTAATCATGGTCATAGCTGTTCCCTGTTGAAATTGTTATCCGCTCACAAATTCCACA  
 CAACATACGAGGCCGGAACGATAAAAGTAAAGCCTGGGGCTTAATGAGTGAGCTAACT  
 CACATTAATTGCGTGCCTCACTGCCGCTTCCAGTCGGGAAACCTGTCGTGCCAGCT  
 GCATTAATGAATCGGCCAACGCGCGGGAGAGGCGGTTGCGTATTG  
 ><border Cole1 origin>  
 GGCCTCTTCGCTTCGCTCACTGACTCGCTGCCCGTTCGGCTGCCAGGAG  
 CGGTATCAGCTCACTCAAAGGCGGTAAACGGTTATCCACAGAATCAGGGATAACGCAG  
 GAAAGAACATGTGAGCAAAGGCCAGCAAAGGCCAGGAACCGTAAAAGGCCGCGTTGC  
 TGGCGTTTTCATAGGCTCCGCCCTGACGAGCATCACAAAATGACGCTCAAGTC  
 AGAGGTGGCGAAACCCGACAGGACTATAAGATAACCAAGGCGTTCCCGCTTGGAAAGCTCCC  
 TCGTGCCTCTCCTGTTCCGACCCCTGCCGTTACCGGATACCTGTCGCCCTTCTCC  
 CGGGAAAGCGTGGCGCTTCTCATAGCTCACGCTGTAGGTATCTCAGTTGGTAGGTG  
 TTCGCTCCAAGCTGGCTGTGCAAGAACCCCCGTTCACGCCGACCGCTGCCCTTAT  
 CCGTAACATCGTCTGAGTCCAACCCGGTAAGACACGACTATCGCCACTGGCAGCAG  
 CCACTGGTAACAGGATTAGCAGAGCAGGTATGTAGGCAGTACAGAGTTCTGAAGT  
 GGTGGCCTAACTACGGCTACACTAGAAGGACAGTATTGGTATCTGCGCTCTGCTGAAGC  
 CAGTTACCTCGGAAAAGAGTTGGTAGCTTGTGATCCGGCAAACAAACCACCGCTGGTA  
 GCGGTGGTTTTTGTTGCAAGCAGCAGATTACGCCAGAAAAAAAGGATCTAAGAAG  
 ATCCTTGATCTTCTACGGGTCTGACGCTCAGTGGAACGAAAACACGTTAAGGGA  
 TTTGGTCATGAGATTATCAAAAGGATCTCACCTAGATCCTT  
 ><border Cole1 origin>  
 AAATTAAAAATGAAGTTAAATCAATCTAAAGTATATGAGTAAACTTGGTCTGACAG  
 TTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGCTATTGTTCATCCAT  
 AGTTGCCCTGACTCCCCGTCGTAGATAACTACGATAACGGGAGGGCTTACCATCTGGCC  
 CAGTGCCTGCAATGATACCGCGAGAACCCACGCTCACCCGCTCCAGATTATCAGCAATAAA  
 CCAGCCAGCCGGAAAGGGCCGAGCGCAGAAGTGGCTTGCAACTTATCCGCTCCATCCA  
 GTCTATTAAATTGTTGCCGGGAAGCTAGAGTAAGTAGTTGCGCAGTTAATAGTTGGCAA  
 CGTTGTTGCCATTGCTACAGGCATCGTGGTGTACGCTCGTCTGGTATGGCTTCAATT  
 CAGCTCCGGTTCCAACGGATCAAGGCAGTTACATGATCCCCATGTTGCAAAAAAGC  
 GGTAGCTCCTCGGTCTCCGATCGTTGTCAGAAGTAAGTGGCCGAGTGTATCACT  
 CATGGTTATGGCAGCACTGCATAATTCTCTACTGTCATGCCATCCGTAAGATGCTTT  
 TGTGACTGGTAGACTCAACCAAGTCATTGAGAATAGTGTATGCGGCGACCGAGTTG  
 CTCTTGCCCGCGTCAATACGGGATAATACCGCCACATAGCAGAACTTTAAAGTGT  
 CATCATTGGAAAACGTTCTCGGGCGAAAACCTCAAGGATCTTACCGCTGTTGAGATC  
 CAGTTCGATGTAACCCACTCGTCACCCACTGATCTCAGCATTTTACTTACCCAG  
 CGTTCTGGGTGAGCAAACAGGAAGGCAAATGCCGAAAAAAGGAAATAAGGGCGAC  
 ACGGAAATGTTGAATACTCA  
 ><Start Amp>  
 TACTCTCCTTTCAATATTATTGAAGCATTATCAGGGTTATTGTCATGAGCGGAT  
 ACATATTGAATGTTAGAAAAATAACAAATAGGGGTTCCGCGCACATTCCCCGAA  
 AAGTGCCACCTGACGCTAAAGAAACATTATTATCATGACATTAAACCTATAAAATAGGC  
 GTATCACGAGGCCCTTCGTCCTCGCGCTTCCGGTGTACGGTAAAGCGGATGCCGGGAGCAGACAAGGCC  
 TGCAGCTCCGGAGACGGTCACAGCTTGTGTAAGCGGATGCCGGGAGCAGACAAGGCC  
 GTCAGGGCGCGTCAGCGGGTGTGGCGGGCTGGCTTAACATGCGGCATCAG  
 AGCAGATTGACTGAGAGTGCACCATATATGCGGTGTAAATACCGCACAGATGCGTAAG  
 GAGAAAATACCGCATCAGGCCATTGCCATTAGCTGCGCAACTGTTGGGAAGGGCG  
 ATCGGTGCGGGCTTCTCGTATTACGCCAGCTGGCAAAGGGGATGTGCTGCAAGGCG  
 ATTAAGTTGGGTAACGCCAGGGTTTCCCAGTCACGACGTTGAAACGACGCCAGTGC  
 C

**FIG.\_18D**

**SUBSTITUTE SHEET (RULE 26)**




FIG.-19B




FIG.-19D




FIG.-19A




FIG.-19C

40 / 49




FIG.\_20B




FIG.\_20D




FIG.\_20A




FIG.\_20C

SUBSTITUTE SHEET ( rule 26 )




FIG. 21B




FIG. 21D




FIG. 21A




FIG. 21C




FIG.\_22B




FIG.\_22D




FIG.\_22A




FIG.\_22C




FIG. 23B





FIG. 23A






FIG.-24B




FIG.-24D




FIG.-24A




FIG.-24C




FIG.\_25B




FIG.\_25D




FIG.\_25A




FIG.\_25C

5' -GCCAGTCTGGGCCAGCTCCCCGAGAGGTGGTCGGATCCTCTGGCTGCTCGTCGATG  
 CCTGTGCCACTGACGTCCAGGCATGAGGTGGTCTGCCCTGGACGCTGGCAGCAGTGAC  
 AGCAGCAGCCGCCAGCACCGTCTGGCCACGCCCTCTCCAGCCCTACGACCATGGA  
 CTTTACCCAGCTCCACTGGAGGACACCTCCTCACGCCCAATTCTGCAAGTGGCCATG  
 TGAGTGCCGCCATCCCCACCCGCTGCCCGTGGGGTCAGCCTCATCACAGATGGCTG  
 TGAGTGCTGTAAGATGTGCGCTCAGCAGCTGGGGACAAC TGACGGAGGCTGCCATCTG  
 TGACCCCCACCGGGGCTCTACTGTGACTACAGGGGACCGCCGAGAGGTGGTCGGTG  
 TGGGCTGGTCTGGATGGGGTGCCTACAACAACGCCAGTCCTCCAGCCTAAC TGCA  
 AGTACAAC TGACGTGCATCGACGGCGGTGGGCTGCACACCAC TGCCCTCCGAGTGC  
 GCCCCCCCGGTCTGGGCCCCACCCGCGCGTGAGCATACTGGCACTGCTGTG  
 AGCAGTGGGTATGTGAGGACGCCAAGAGGCCACGCCAAGACCGCACCCGTGACACAG  
 GAGCCTCGATGCTGTGGGTGAGGTGGAGGCATGGCACAGGAAC TGCAATGCCAAC  
 GCCCCTGGAGCCCTTGCTCCACCAGCTGCCCTGGGGTCTCCACTGGATCTCCAATG  
 TTAACGCCAGTGCTGGCCTGAGCAAGAGAGGCCCTTGCAACTTGCGGCCATGCGATG  
 TGGACATCCATACACTCATTAAGGCAGGGAAAGAAGTGTCTGGCTGTGTACCGCCAGAGG  
 CATCCATGAACCTCACACTTGCGGGCTGCATCAGCACACGCCCTATCAACCCAAGTACT  
 GTGGAGTTGCATGGACAATAGGTGCTGCATCCCTACAAGTCTAACAGACTATGACGTGT  
 CCTTCCAGTGTCTGATGGCTTGCTCTCCGCCAGGTCTATGGATTAAATGCCCTGCT  
 TCTGTAACCTGAGCTGTAGGAATCCAATGACATCTTGCTGACTTGGAAATCCTACCCCTG  
 ACTTCTCAGAAATTGCCAACTAGGCAGGCACAAATCTTGGGTCTTGGGACTAACCAAT  
 GCCTGTGAAGCAGTCAGCCCTATGGCAATAACTTTCACCAATGAGCCTTAGTTACCC  
 TGATCTGGACCCCTGGCCTCCATTCCTGCTCTAACCATCAAATGACGCCATGGTGC  
 TGCTCAGGCCATGCTATGAGTTCTCCTGATATCAGCATCTACTCTAAAGAAA  
 AATGCCCTGTCTAGCTGTTCTG

## FIG.\_26

5' -TTTAATTAAACCCCAAGGGCTGCCAGGAGCATATCTGGTCTCTGATGGCCGGCC  
 AGTCTGGGCCAGCTCCCCGAGAGGTGGTCGGATCCTCTGGCTGCTCGTCGATGCT  
 GTGCCACTGACGTCCAGGCATGAGGTGGTCTGCCCTGGACGCTGGCAGCAGTGACAGC  
 AGCAGCCGCCAGCACCGTCTGCCACGCCCTCTCCAGCCCTACGACCATGGACTT  
 TACCCAGCTCCACTGGAGGACACCTCCTCACGCCCAATTCTGCAAGTGGCATGTGA  
 GTGCCGCCATCCCCACCCGCTGCCGCTGGGGTCAGCCTCATCACAGATGGCTGTGA  
 GTGCTGTAAGATGTGCGCTCAGCAGCTTGGGACAAC TGCACTGGAGGCTGCCATCTGTGA  
 CCCCCACCGGGGCTCTACTGTGACTACAGCGGGACGCCGAGGTACGCAATAGGAGT  
 GTGTGCACGCAGGGAAAGAAGTGTCTGGCTGTGTACAGCCAGAGGCATCCATGAACCTCA  
 CACTTGCGGGCTGCATCAGCACACGCCCTATCAACCCAAGTACTGTGGAGTTGCATGG  
 ACAACAGGTGCTGCATCCCTACAAGTCTAACAGACTATGACGTGTCTCCAGTGTCTG  
 ATGGGCTTGGCTCTCCGCCAGGTCTATGGAA

## FIG.\_27

SUBSTITUTE SHEET ( rule 26 )

47 / 49

5' -CAGAATTGAACTGGGATCCACCTGTCTAAAGATGGGTTCTCCATGCTTCCACAC  
 TGCCTCTCTGATCAGAAACATACAAGGAGCTGAGAACATGTCCTCACTCCCTGGGTAC  
 CTTGCTGGTTAGAAGCCAACCTGCTGTCCTGTGGGGAGGTACAGCCAATTCTGTGTT  
 CTCTGAGTTCTGGGGACCGCAGACCTAGTGTGGTAAAGTGAGCGTTGGGGCTGGTGG  
 GAGCTGTAGATTCATGCAGATTCTGTTCCCCACACACAGATGCTGTGGTGAGGTGGAGG  
 CATGGCACAGGAACGTGCATAGCCTACACAAGCCCTGGAGCCCTGCTCCACCAGCTGCC  
 GCCTGGGGTCTCCACTCGGATCTCAAATGTTAACGCCAGTGCTGGCCTGAGCAAGAGA  
 GCCGCCTCTGCAACTTGCAGGCATGCGATGTGGACATCCATACACTCATTAGGCAGGG  
 AGAAGTGTCTGGCTGTGTACAGCCAGGGCATCCATGAACCTCACACTTGCGGGCTGCA  
 TCAGCACACGCTCCTATCAACCCAAGTACTGTGGAGTTGCATGGACAATAGTGCTGCA  
 TCCCCTACAAGTCTAAGACTATCGACGTGCTCCAGTGTCTGATGGCTGGCTTCT  
 CCCGCCAGGTGATGGATTAAT

**FIG.\_28**

5' -GTCCTGGGCCAGCTCCCCGAGAGGTGGTCGGATCCTCTGGCTGCTCGGTGATGCCCTG  
 TGCCACTGACGTCCAGGCATGAGGTGGTCTGCCCTGGACGCTGGCAGCAGTGACAGCA  
 GCAGCCGCCAGCACCGTCCCTGGCCACGGCCCTCTCCAGCCCTACGACCATGGACTTT  
 ACCCCAGCTCCACTGGAGGACACCTCCTCACGCCCAATTCTGCAAGTGGCATGTGAG  
 TGCCCGCCATCCCCACCCGCTGCCCTGGGGTCAGCCTCATCACAGATGGCTGTGAG  
 TGCTGTAAGATGTGCGCTCAGCAGCTGGGACAACTGACGGAGGCTGCCATCTGTGAC  
 CCCCACCGGGGCTCTACTGTGACTACAGCGGGACCGCCCGAGGTACGCAATAGGAGTG  
 TGTGCACCGAGGAAGAAGTGTCTGGCTGTGACCGCCAGGGCATCCATGAACCTCAC  
 ACTTGCGGGCTGCATCAGCACACGCTCCTATCAACCCAAGTACTGTGGAGTTGCATGGA  
 CAACAGGTGCTGCATCCCTACAAGTCTAAGACTATCGACGTGCTCCAGTGTCTGA  
 TGGGCTTGGCTTCTCCGCCAGGTCTATGGATTAATGCCCTGCTCTGTAACCTGAGCTG  
 TAGGAATCCAATGACATTTGCTGACTTGGAAATCCTACCCCTGACTTCTCAGAAATTGC  
 CAACTAGGCAGGCACAAATCTGGGCTTGGGACTAACCAATGCCCTGTGAAGCAGTCA  
 GCCCTATGCCAATAACTTTACCAATGAGCCTTAGTTACCCCTGATCTGGACCCCTGG  
 CCTCCATTCTGCTCTAACCAATTGACGCCCTGATGGTGCTGCTCAGGCCATGCT  
 ATGAGTTTCTCCTGATATCATTGACATCTACTCTAAAGAAAATGCCCTGTCTAGC  
 TGTCTGGACTACACCAAGCCTGATCCAGCCTTCAAGTCACTAGAAGTCTGCTGGA  
 TCTTGCTTAAATCCAAGAAATGGAATCAGGTAGACTTTAATATCACTAATTCTTCTT  
 TAGATGCCAAACCACAAAGACTCTTGGGCTCATTGAGATGAAATAGATGGAATTGGAACA  
 ATAGAATAATCTATTATGGAGCCTGCCAAGAGGTACTGTAATGGTAATTCTGACGTC  
 AG

**FIG.\_29**

5' - CAGAACAGCTAGAGACAGGCATTTCTTAGAGTAGATGCTGAATGATATCAAGGAGAA  
 AACTCATAGCATGGGCCTGAGCAGCACCATCAGCGTCATTGAATGGTTAGAGACAGAA  
 ATGGAGGCCAAGGGTCCAGATCAGGGTAACTAAGGCTATTGGTAAAAGTTATTGCCA  
 TAAGGGCTGACTGCTTCACAGGCATTGGGTTAGTCCCAGACCCAAGACAGATTGTGCCTGC  
 CTAGTTGGCAATTCTGAGAAGTCAGGGTAGGATTCCAAGTCAGCAAAGATGTCATTGGG  
 ATTCCCTACAGCTCAGGTTACAGAACGGCATTAAATCCATAGGACCTGGCGGGAGAACCC  
 AAGCCCATCAGGACACTGGAAGGACACGTCGATAGTCTTAGACTTGAGGGATGCAGCA  
 CCTATTGTCCATGCAAACACTCCACAGTACTTGGGTTGATAGGAGCGTGTGCTGATGCAGCC  
 CGCAAGTGTGAAGTTATGGATGCCTCTGGCTGGTACACAGCCAGACACTTCTCCCTGC  
 CTTAATGAGTGTATGGATGTCACATCGCATGGCGCAAGTTGCAGAGGCGGCTCTTTG  
 CTCAGGCCAGCACTGGCGTTAACATTGGAGATCCGAGTGGAGACCCCCAGGCCAGCT  
 GGTGGAGCAAGGGCTCCAGGGGCTTGTGTAGGCTATGCAGTTCTGTGCCATGCCTCCAC  
 CTCACCCACAGCATTGTGTGGGAACAGAAATCTGCATGAATCTACAGCTCCACCAAG  
 CCCCCAACGCTCACTTCACCACACTAAGGTCTGGCTCCCAGAACTCAGAGGAACACA  
 GAAATTGGCTGTACCTCCCCACAGGACAGCAAGTTGGCTCTAACCAGCAAAGGTACCCA  
 GGGAGTGGAGGACATGTTCTCAGCTCCTGTATGTTCTGATCAAGAGAGGCAGTGTGGA  
 AGCATGGGAGGAAACCCATCTTAGAGACAGGTGGATCCAGTTCAAATTCTGCTCTACC  
 ACCTACAAGCTGTGTGATCTTAGATAACCCACCCCTGGGCTGTCTCCCCATTAGAACAAAT  
 AACACCTGCCTGTGGCGCTGGCAACACAATAATAAGGGCTAGATTTTACTGAGTATGC  
 ATCAATCATCCTTGCTAAGTGTGGAAATGGACTTTTTTTT

### FIG.\_30

5' - CCTGATCTGGACCCTTGGCCTCCAATTCTGTCGTAAACCATTCAAATGACGCCCTGGTGGT  
 GCTGCTCAGGCCATAGCAAGGTTAGCAGCCTGGTTAAGTCCAAGCTGAATTAGCGGCCGCG  
 TCGACAGTAGGAGTGTGCACATGCTGTGGGTGAGGTGGAGGCATGGCACAGGAACCTGC  
 ATAGCCTACACAAGCCCTGGAGCCCTGCTCCACCAGCTGCCCTGGGGCTCTCCACT  
 CGGATCTCCAATGTTAACGCCAGTGCTGGCCTGAGCAAGAGAGCCCTTGCAACTTG  
 CGGCCATGCGATGTGGACATCCATACACTCATTAAGGCAGGGAAAGAAGTGTCTGGCTGTG  
 TACCAAGGCCAGAGGCATCCATGAACCTCACACTTGCTGGGCTGCATCAGCACACGCTCCTAT  
 CAACCCAAAGTACTGTGGAGTTGCATGGACAATAGGTGCTGCATCCCTACAAAGTCTAAG  
 ACTATCGACGTGTCCCTCCAGTGTCCCTGATGGGCTTGGCTCTCCGCCAGGTCTATGG  
 ATTAAT

### FIG.\_31

5' -GGCCAGCTCCCCGAGAGGTGGTCGGATCCTCTGGCTGCTCGTCGATGCCTGTGCCA  
CTGACGTCAGGCATGAGGTGGTCTGCCCTGGACGCTGGCAGCAGTGACAGCAGCAGC  
CGCCAGCACCGTCTGGCCACGGCCCTCTCTCCAGCCCCTACGACCATGGACTTACCCC  
AGCTCCACTGGAGGACACCTCCTCACGCCCAATTCTGCAAGTGGCCATGTGAGTGCCC  
GCCATCCCCACCCCGCTGCCGCTGGGGTCAGCCTCATCACAGATGGCTGTGAGTGCTG  
TAAGATGTGCGCTCAGCAGCTGGGACAACACTGCACGGAGGCTGCCATCTGTGACCCCC  
CCGGGGCCTCTACTGTGACTACAGCGGGGACCGCCGAGAGGTGGTCGGTGTGGCTGG  
TCCTGGATGGGTGCGCTACAACAACGGCCAGTCCTCCAGCCTAACTGCAAGTACAAC  
GCACGTGCATCGACGGCGGGTGGCTGCACACCAACTGTGCCTCCAGTGCACCCCCCG  
GTCCTGGTGCACCCACCCGGCGCGTGAACATACCTGCCACTGCTGTGAGCAGTGG  
TATGTGAGGACGACGCCAAGAGGCCACGCAAGACCGCACCCGTGACACAGGAGCCTCG  
ATGCCAGAAGGCCGCTCCCTCAGAGATGTGACAACAAAATCATCTCCAGACCTTCC  
AAATACACCCCTAGGAGACAAAATTGCTCGGTGGAGAAGCAGTCCTGTGAGGACAGGAGGA  
GGCGTGGAGGAAAGCTTGCTCCAGCAGCCCCAGGGAAAGCAAGGAGCTCTCCACAC  
CACCTCCCCAGGAGGGCACACGAGGGTCACGGGGGAGCAGGGAGGCGGAAGCTGTCTG  
CCATTGTGTCTGGCCAGTGACCTGTTCTGACCGAGCACAAGCGAGGCCCTGCCTAGC  
CGAGATGCTGTGGGTGAGGTGGAGGCATGGCACAGGAACGTGCATAGCCTACACAAGCCCC  
TGGAGCCCTTGCTCCACCAAGCTGCACGGCTGGGGTCTCCACTCGGATCTCCAATGTTAAC  
GCCAGTGCTGGCCTGAGCAA

**FIG.\_32**

## Sequence Listing

<110> Genentech, Inc.

<120> WISP POLYPEPTIDES AND NUCLEIC ACIDS ENCODING SAME

<130> P1176R2PCT

5 <141> 1998-10-29

<160> 156

<210> 1

<211> 2830

<212> DNA

10 <213> Human

<400> 1

cccacgcgtc cgctggggcc agctcccccg agaggtggtc ggatcctctg 50

ggctgctcggt tcgatgcctg tgccactgac gtccaggcat gaggtgggtc 100

ctgccttggc cgctggcagc agtgacagca gcagccgcca gcaccgtcct 150

15 ggccacggcc ctctctccag cccctacgac catggacttt actccagtc 200

cactggagga cacctcttca cgcccccaat tctgcaagtg gccatgtgag 250

tgcccgccat ccccaccccg ctgcccgtg ggggtcagcc tcatacacaga 300

tggctgtgag tgctgtttaa tgtgcgtca gcagtttggg gacaactgca 350

cggaggctgc catctgtgac ccccacccggg gcctctactg tgactacagc 400

20 ggggaccggcc cgaggtacgc aataggagtg tgtgcacagg tggtcgggt 450

gggctgcgtc ctggatgggg tgcgctacaa caacggccag tccttccagc 500

ctaactgcaa gtacaactgc acgtgcacgt acggcgccgt gggctgcaca 550

ccactgtgcc tccgagtgcg ccccccgtgt ctctggtgcc cccaccccg 600

gcgctgtgagc atacctggcc actgtgtga gcagtgggtt tgtgaggacg 650

25 acgccaagag gccacgcaga accgcacccgttgcacacagg agccttcgtat 700

gctgtgggtg aggtggaggc atggcacagg aactgcatacg cctacacaag 750

ccccctggagc ccttgctcca ccagctgcgg cctgggggtc tccactcgga 800

tctccaatgt taacgcccag tgctggctgt agcaagagag cccgcctctgc 850

aacttgccgc catgcgtatgt ggacatccat acactcatta aggcaggaa 900

30 gaagtgtctg gctgtgttacc agccagaggc atccatgaac ttcacacttg 950

cgggctgcgtc cagcacacgc tcctatcaac ccaagtactg tggagtttgc 1000

atggacaata ggtgctgcgtc cccctacaag tctaagacta tcgacgtgtc 1050

cttccagtgt cccgatgggc ttggcttctc ccgccaggc ctagggat 1100  
atgcctgctt ctgtAACCTG agctgttagga atcccaatga catctttgt 1150  
gacttggaat cctaccctga cttctcagaa attgccaact aggcaggcac 1200  
aaatcttggg tcttggggac taacccaatg cctgtgaagc agtcagccct 1250  
5 tatggccaat aactttcac caatgagccct tagttaccct gatctggacc 1300  
cttggcctcc atttctgtct ctaaccattc aaatgacgac tgatgggtct 1350  
gctcaggccc atgctatgag ttttctcctt gatatcattc agcatctact 1400  
ctaaagaaaa atgcctgtct ctagctgttc tggactacac ccaagcctga 1450  
tccagccttt ccaagtcact agaagtccctg ctggatcttgc cctaaatccc 1500  
10 aagaaatgga atcaggtaga cttttaatat cactaatttc ttcttttagat 1550  
gccaaccac aagactcttt gggtccattc agatgaatag atggaatttg 1600  
gaacaataga ataatctatt atttggagcc tgccaagagg tactgtaatg 1650  
ggtaattctg acgtcagcgc accaaaacta tcctgattcc aaatatgtat 1700  
gcacctcaag gtcataaacc atttgcaag tgagttgaat agttgctaa 1750  
15 ttttatttt taatggaaag ttgtatccat taacctgggc attgttgagg 1800  
ttaagttctt cttcacccctt acactgtgaa gggtacagat taggtttgtc 1850  
ccagtcagaa ataaaatttg ataaacattc ctgttgatgg gaaaagcccc 1900  
cagttataac tccagagaca gggaaaggc agcccatattc agaaggacca 1950  
attgactctc acactgaatc agctgctgac tggcaggcgt ttggcagtt 2000  
20 ggccaggcgtc ttcccttgaat cttctccctt gtcctgcttgc ggttcatagg 2050  
aattggtaag gcctctggac tggcctgtct ggccctgtgag agtgggtcccc 2100  
tggaacactc ctctactctt acagagcctt gagagaccca gctgcagacc 2150  
atgccagacc cactgaaatg accaagacag gttcaggttag ggggtgggt 2200  
caaaccaaga agtgggtgcc cttggtagca gcctgggtg acctcttagag 2250  
25 ctggaggctg tgggactcca ggggcccccg tgttcaggac acatctattg 2300  
cagagactca tttcacagcc tttcggtctg ctgacccaaat ggccagtttt 2350  
ctggtaggaa gatggaggtt taccagttgt ttagaaacag aaatagactt 2400  
aataaagggtt taaagctgaa gaggttgaag ctaaaaggaa aaggttgg 2450  
ttaatgaata tcaggctattt atttattgtt ttagggaaat ataatattt 2500  
30 ctggttagaat tcttttattt agggcctttt ctgtgccaga cattgctctc 2550

agtgcgttgc atgtattagc tcactgaatc ttcacgacaa tggtgagaag 2600  
ttccccattat tatttctgtt cttacaaatg tgaaacggaa gctcatagag 2650  
gtgagaaaac tcaaccagag tcacccagtt ggtgactggg aaagtttagga 2700  
ttcagatcga aattggactg tctttataac ccatatttc cccctgttt 2750  
5 tagagcttcc aaatgtgtca gaataggaaa acattgcaat aaatggctt 2800  
atttttaaa aaaaaaaaaa aaaaaaaaaa 2830  
  
<210> 2  
<211> 1101  
<212> DNA  
10 <213> Human  
  
<400> 2  
gttggcaatt tctgagaagt cagggtagga ttccaagtca gcaaagatgt 50  
cattgggatt cctacagctc aggttacaga agcaggcatt aatccatagg 100  
acctggcggg agaagccaag cccatcagga cactggaagg acacgtcgat 150  
15 agtcttagac ttgttagggg tgcagcacct attgtccatg caaactccac 200  
agtacttggg ttgataggag cgtgtgctga tgcagccgc aagtgtgaag 250  
ttcatggatg cctctggctg gtacacagcc agacacttct tccctgcctt 300  
aatgagtgtta tggatgtcca catcgcatgg ccgcaagttg cagaggcggc 350  
tctcttgcac aggcagcac tggcgtaa cattggagat ccgagtggag 400  
20 acccccaggc cgcaagctggt ggagcaaggg ctccaggggc ttgtgttaggc 450  
tatgcagttc ctgtgccatg cctccacctc acccacagca tcgaaggctc 500  
ctgtgtcacg gggcgccgtc ttgcgtggcc tcttggcgtc gtcctcacat 550  
acccactgct cacagcagtg gccaggatg ctcacgcgc gcgggtgggg 600  
gcaccagaga cgccgggggc gcactcggag gcacagtggt gtgcagccca 650  
25 ccgcgcgcgc gatgcacgtg cagtttact tgcagttagg ctggaaggac 700  
tggccgttgt ttagcgcac cccatccagg acgcagccca caccgaccac 750  
ctgtgcacac actccttattg cgtacccctgg gcggtccccg ctgttagtcac 800  
agtagaggcc ccgggtgggg tcacagatgg cagcctccgt gcagttgtcc 850  
ccaaagctgct gagcgcacat cttacagcac tcacagccat ctgtgtatgag 900  
30 gctgacccccc agcggggcagc ggggtggggta tggcgccac tcacatggcc 950  
acttgcagaa ttggggcggt gaggaggtgt cctccagtg agctggagta 1000  
aagtccatgg tcgttagggc tggagagagg gccgtggcca ggacggtgct 1050

ggcggctgct gctgtcactg ctgccagcgt ccagggcagg aaccacctca 1100  
 t 1101  
 <210> 3  
 <211> 345  
 5 <212> PRT  
 <213> Human  
 <400> 3  
 Thr Ala Leu Ser Pro Ala Pro Thr Thr Met Asp Phe Thr Pro Ala  
 23 25 30 35  
 10 Pro Leu Glu Asp Thr Ser Ser Arg Pro Gln Phe Cys Lys Trp Pro  
 40 45 50  
 Cys Glu Cys Pro Pro Ser Pro Pro Arg Cys Pro Leu Gly Val Ser  
 55 60 65  
 15 Leu Ile Thr Asp Gly Cys Glu Cys Cys Lys Met Cys Ala Gln Gln  
 70 75 80  
 Leu Gly Asp Asn Cys Thr Glu Ala Ala Ile Cys Asp Pro His Arg  
 85 90 95  
 Gly Leu Tyr Cys Asp Tyr Ser Gly Asp Arg Pro Arg Tyr Ala Ile  
 100 105 110  
 20 Gly Val Cys Ala Gln Val Val Gly Val Gly Cys Val Leu Asp Gly  
 115 120 125  
 Val Arg Tyr Asn Asn Gly Gln Ser Phe Gln Pro Asn Cys Lys Tyr  
 130 135 140  
 25 Asn Cys Thr Cys Ile Asp Gly Ala Val Gly Cys Thr Pro Leu Cys  
 145 150 155  
 Leu Arg Val Arg Pro Pro Arg Leu Trp Cys Pro His Pro Arg Arg  
 160 165 170  
 Val Ser Ile Pro Gly His Cys Cys Glu Gln Trp Val Cys Glu Asp  
 175 180 185  
 30 Asp Ala Lys Arg Pro Arg Lys Thr Ala Pro Arg Asp Thr Gly Ala  
 190 195 200  
 Phe Asp Ala Val Gly Glu Val Glu Ala Trp His Arg Asn Cys Ile  
 205 210 215  
 Ala Tyr Thr Ser Pro Trp Ser Pro Cys Ser Thr Ser Cys Gly Leu  
 220 225 230  
 35 Gly Val Ser Thr Arg Ile Ser Asn Val Asn Ala Gln Cys Trp Pro  
 235 240 245  
 Glu Gln Glu Ser Arg Leu Cys Asn Leu Arg Pro Cys Asp Val Asp  
 250 255 260  
 40 Ile His Thr Leu Ile Lys Ala Gly Lys Lys Cys Leu Ala Val Tyr

	265	270	275
	Gln Pro Glu Ala Ser Met Asn Phe Thr Leu Ala Gly Cys Ile Ser		
	280	285	290
	Thr Arg Ser Tyr Gln Pro Lys Tyr Cys Gly Val Cys Met Asp Asn		
5	295	300	305
	Arg Cys Cys Ile Pro Tyr Lys Ser Lys Thr Ile Asp Val Ser Phe		
	310	315	320
	Gln Cys Pro Asp Gly Leu Gly Phe Ser Arg Gln Val Leu Trp Ile		
	325	330	335
10	Asn Ala Cys Phe Cys Asn Leu Ser Cys Arg Asn Pro Asn Asp Ile		
	340	345	350
	Phe Ala Asp Leu Glu Ser Tyr Pro Asp Phe Ser Glu Ile Ala Asn		
	355	360	365
	367		367
15	<210> 4		
	<211> 367		
	<212> PRT		
	<213> Human		
	<400> 4		
	Met Arg Trp Phe Leu Pro Trp Thr Leu Ala Ala Val Thr Ala Ala		
20	1	5	10
	Ala Ala Ser Thr Val Leu Ala Thr Ala Leu Ser Pro Ala Pro Thr		
	20	25	30
	Thr Met Asp Phe Thr Pro Ala Pro Leu Glu Asp Thr Ser Ser Arg		
	35	40	45
25	Pro Gln Phe Cys Lys Trp Pro Cys Glu Cys Pro Pro Ser Pro Pro		
	50	55	60
	Arg Cys Pro Leu Gly Val Ser Leu Ile Thr Asp Gly Cys Glu Cys		
	65	70	75
30	Cys Lys Met Cys Ala Gln Gln Leu Gly Asp Asn Cys Thr Glu Ala		
	80	85	90
	Ala Ile Cys Asp Pro His Arg Gly Leu Tyr Cys Asp Tyr Ser Gly		
	95	100	105
	Asp Arg Pro Arg Tyr Ala Ile Gly Val Cys Ala Gln Val Val Gly		
	110	115	120
35	Val Gly Cys Val Leu Asp Gly Val Arg Tyr Asn Asn Gly Gln Ser		
	125	130	135
	Phe Gln Pro Asn Cys Lys Tyr Asn Cys Thr Cys Ile Asp Gly Ala		
	140	145	150
40	Val Gly Cys Thr Pro Leu Cys Leu Arg Val Arg Pro Pro Arg Leu		
	155	160	165

	Trp Cys Pro His Pro Arg Arg Val Ser Ile Pro Gly His Cys Cys			
	170	175	180	
	Glu Gln Trp Val Cys Glu Asp Asp Ala Lys Arg Pro Arg Lys Thr			
	185	190	195	
5	Ala Pro Arg Asp Thr Gly Ala Phe Asp Ala Val Gly Glu Val Glu			
	200	205	210	
	Ala Trp His Arg Asn Cys Ile Ala Tyr Thr Ser Pro Trp Ser Pro			
	215	220	225	
10	Cys Ser Thr Ser Cys Gly Leu Gly Val Ser Thr Arg Ile Ser Asn			
	230	235	240	
	Val Asn Ala Gln Cys Trp Pro Glu Gln Glu Ser Arg Leu Cys Asn			
	245	250	255	
	Leu Arg Pro Cys Asp Val Asp Ile His Thr Leu Ile Lys Ala Gly			
	260	265	270	
15	Lys Lys Cys Leu Ala Val Tyr Gln Pro Glu Ala Ser Met Asn Phe			
	275	280	285	
	Thr Leu Ala Gly Cys Ile Ser Thr Arg Ser Tyr Gln Pro Lys Tyr			
	290	295	300	
20	Cys Gly Val Cys Met Asp Asn Arg Cys Cys Ile Pro Tyr Lys Ser			
	305	310	315	
	Lys Thr Ile Asp Val Ser Phe Gln Cys Pro Asp Gly Leu Gly Phe			
	320	325	330	
	Ser Arg Gln Val Leu Trp Ile Asn Ala Cys Phe Cys Asn Leu Ser			
	335	340	345	
25	Cys Arg Asn Pro Asn Asp Ile Phe Ala Asp Leu Glu Ser Tyr Pro			
	350	355	360	
	Asp Phe Ser Glu Ile Ala Asn			
	365	367		
	<210> 5			
30	<211> 345			
	<212> PRT			
	<213> Human			
	<400> 5			
35	Thr Ala Leu Ser Pro Ala Pro Thr Thr Met Asp Phe Thr Pro Ala			
	1	5	10	15
	Pro Leu Glu Asp Thr Ser Ser Arg Pro Gln Phe Cys Lys Trp Pro			
	20	25	30	
	Cys Glu Cys Pro Pro Ser Pro Pro Arg Cys Pro Leu Gly Val Ser			
	35	40	45	
40	Leu Ile Thr Asp Gly Cys Glu Cys Cys Lys Met Cys Ala Gln Gln			
	50	55	60	

	Leu	Gly	Asp	Asn	Cys	Thr	Glu	Ala	Ala	Ile	Cys	Asp	Pro	His	Arg
							65					70			75
	Gly	Leu	Tyr	Cys	Asp	Tyr	Ser	Gly	Asp	Arg	Pro	Arg	Tyr	Ala	Ile
							80					85			90
5	Gly	Val	Cys	Ala	Gln	Val	Val	Gly	Val	Gly	Cys	Val	Leu	Asp	Gly
							95					100			105
	Val	Arg	Tyr	Asn	Asn	Gly	Gln	Ser	Phe	Gln	Pro	Asn	Cys	Lys	Tyr
							110					115			120
10	Asn	Cys	Thr	Cys	Ile	Asp	Gly	Ala	Val	Gly	Cys	Thr	Pro	Leu	Cys
							125					130			135
	Leu	Arg	Val	Arg	Pro	Pro	Arg	Leu	Trp	Cys	Pro	His	Pro	Arg	Arg
							140					145			150
	Val	Ser	Ile	Pro	Gly	His	Cys	Cys	Glu	Gln	Trp	Ile	Cys	Glu	Asp
							155					160			165
15	Asp	Ala	Lys	Arg	Pro	Arg	Lys	Thr	Ala	Pro	Arg	Asp	Thr	Gly	Ala
							170					175			180
	Phe	Asp	Ala	Val	Gly	Glu	Val	Glu	Ala	Trp	His	Arg	Asn	Cys	Ile
							185					190			195
20	Ala	Tyr	Thr	Ser	Pro	Trp	Ser	Pro	Cys	Ser	Thr	Ser	Cys	Gly	Leu
							200					205			210
	Gly	Val	Ser	Thr	Arg	Ile	Ser	Asn	Val	Asn	Ala	Gln	Cys	Trp	Pro
							215					220			225
	Glu	Gln	Glu	Ser	Arg	Leu	Cys	Asn	Leu	Arg	Pro	Cys	Asp	Val	Asp
							230					235			240
25	Ile	His	Thr	Leu	Ile	Lys	Ala	Gly	Lys	Lys	Cys	Leu	Ala	Val	Tyr
							245					250			255
	Gln	Pro	Glu	Ala	Ser	Met	Asn	Phe	Thr	Leu	Ala	Gly	Cys	Ile	Ser
							260					265			270
30	Thr	Arg	Ser	Tyr	Gln	Pro	Lys	Tyr	Cys	Gly	Val	Cys	Met	Asp	Asn
							275					280			285
	Arg	Cys	Cys	Ile	Pro	Tyr	Lys	Ser	Lys	Thr	Ile	Asp	Val	Ser	Phe
							290					295			300
	Gln	Cys	Pro	Asp	Gly	Leu	Gly	Phe	Ser	Arg	Gln	Val	Leu	Trp	Ile
							305					310			315
35	Asn	Ala	Cys	Phe	Cys	Asn	Leu	Ser	Cys	Arg	Asn	Pro	Asn	Asp	Ile
							320					325			330
	Phe	Ala	Asp	Leu	Glu	Ser	Tyr	Pro	Asp	Phe	Ser	Glu	Ile	Ala	Asn
							335					340			345
40	<210> 6														
	<211> 345														

<212> PRT  
 <213> Human

<400> 6  
 Thr Ala Leu Ser Pro Ala Pro Thr Thr Met Asp Phe Thr Pro Ala  
 5 1 5 10 15  
 Pro Leu Glu Asp Thr Ser Ser Arg Pro Gln Phe Cys Lys Trp Pro  
 20 25 30  
 Cys Glu Cys Pro Pro Ser Pro Pro Arg Cys Pro Leu Gly Val Ser  
 35 40 45  
 10 Leu Ile Thr Asp Gly Cys Glu Cys Cys Lys Met Cys Ala Gln Gln  
 50 55 60  
 Leu Gly Asp Asn Cys Thr Glu Ala Ala Ile Cys Asp Pro His Arg  
 65 70 75  
 Gly Leu Tyr Cys Asp Tyr Ser Gly Asp Arg Pro Arg Tyr Ala Ile  
 15 80 85 90  
 Gly Val Cys Ala Gln Val Val Gly Val Gly Cys Val Leu Asp Gly  
 95 100 105  
 Val Arg Tyr Asn Asn Gly Gln Ser Phe Gln Pro Asn Cys Lys Tyr  
 110 115 120  
 20 Asn Cys Thr Cys Ile Asp Gly Ala Val Gly Cys Thr Pro Leu Cys  
 125 130 135  
 Leu Arg Val Arg Pro Pro Arg Leu Trp Cys Pro His Pro Arg Arg  
 140 145 150  
 Val Ser Ile Pro Gly His Cys Cys Glu Gln Trp Val Cys Glu Asp  
 25 155 160 165  
 Asp Ala Lys Arg Pro Arg Lys Thr Ala Pro Arg Asp Thr Gly Ser  
 170 175 180  
 Phe Asp Ala Val Gly Glu Val Glu Ala Trp His Arg Asn Cys Ile  
 185 190 195  
 30 Ala Tyr Thr Ser Pro Trp Ser Pro Cys Ser Thr Ser Cys Gly Leu  
 200 205 210  
 Gly Val Ser Thr Arg Ile Ser Asn Val Asn Ala Gln Cys Trp Pro  
 215 220 225  
 Glu Gln Glu Ser Arg Leu Cys Asn Leu Arg Pro Cys Asp Val Asp  
 35 230 235 240  
 Ile His Thr Leu Ile Lys Ala Gly Lys Lys Cys Leu Ala Val Tyr  
 245 250 255  
 Gln Pro Glu Ala Ser Met Asn Phe Thr Leu Ala Gly Cys Ile Ser  
 260 265 270  
 40 Thr Arg Ser Tyr Gln Pro Lys Tyr Cys Gly Val Cys Met Asp Asn

	275	280	285
	Arg Cys Cys Ile Pro Tyr Lys Ser Lys Thr Ile Asp Val Ser Phe		
	290	295	300
5	Gln Cys Pro Asp Gly Leu Gly Phe Ser Arg Gln Val Leu Trp Ile		
	305	310	315
	Asn Ala Cys Phe Cys Asn Leu Ser Cys Arg Asn Pro Asn Asp Ile		
	320	325	330
	Phe Ala Asp Leu Glu Ser Tyr Pro Asp Phe Ser Glu Ile Ala Asn		
	335	340	345
10	<210> 7		
	<211> 367		
	<212> PRT		
	<213> Human		
	<400> 7		
15	Met Arg Trp Phe Leu Pro Trp Thr Leu Ala Ala Val Thr Ala Ala		
	1	5	10
	Ala Ala Ser Thr Val Leu Ala Thr Ala Leu Ser Pro Ala Pro Thr		
	20	25	30
20	Thr Met Asp Phe Thr Pro Ala Pro Leu Glu Asp Thr Ser Ser Arg		
	35	40	45
	Pro Gln Phe Cys Lys Trp Pro Cys Glu Cys Pro Pro Ser Pro Pro		
	50	55	60
	Arg Cys Pro Leu Gly Val Ser Leu Ile Thr Asp Gly Cys Glu Cys		
	65	70	75
25	Cys Lys Met Cys Ala Gln Gln Leu Gly Asp Asn Cys Thr Glu Ala		
	80	85	90
	Ala Ile Cys Asp Pro His Arg Gly Leu Tyr Cys Asp Tyr Ser Gly		
	95	100	105
30	Asp Arg Pro Arg Tyr Ala Ile Gly Val Cys Ala Gln Val Val Gly		
	110	115	120
	Val Gly Cys Val Leu Asp Gly Val Arg Tyr Asn Asn Gly Gln Ser		
	125	130	135
	Phe Gln Pro Asn Cys Lys Tyr Asn Cys Thr Cys Ile Asp Gly Ala		
	140	145	150
35	Val Gly Cys Thr Pro Leu Cys Leu Arg Val Arg Pro Pro Arg Leu		
	155	160	165
	Trp Cys Pro His Pro Arg Arg Val Ser Ile Pro Gly His Cys Cys		
	170	175	180
40	Glu Gln Trp Ile Cys Glu Asp Asp Ala Lys Arg Pro Arg Lys Thr		
	185	190	195

Ala Pro Arg Asp Thr Gly Ala Phe Asp Ala Val Gly Val Glu  
 200 205 210  
 Ala Trp His Arg Asn Cys Ile Ala Tyr Thr Ser Pro Trp Ser Pro  
 215 220 225  
 5 Cys Ser Thr Ser Cys Gly Leu Gly Val Ser Thr Arg Ile Ser Asn  
 230 235 240  
 Val Asn Ala Gln Cys Trp Pro Glu Gln Glu Ser Arg Leu Cys Asn  
 245 250 255  
 Leu Arg Pro Cys Asp Val Asp Ile His Thr Leu Ile Lys Ala Gly  
 10 260 265 270  
 Lys Lys Cys Leu Ala Val Tyr Gln Pro Glu Ala Ser Met Asn Phe  
 275 280 285  
 Thr Leu Ala Gly Cys Ile Ser Thr Arg Ser Tyr Gln Pro Lys Tyr  
 290 295 300  
 15 Cys Gly Val Cys Met Asp Asn Arg Cys Cys Ile Pro Tyr Lys Ser  
 305 310 315  
 Lys Thr Ile Asp Val Ser Phe Gln Cys Pro Asp Gly Leu Gly Phe  
 320 325 330  
 Ser Arg Gln Val Leu Trp Ile Asn Ala Cys Phe Cys Asn Leu Ser  
 20 335 340 345  
 Cys Arg Asn Pro Asn Asp Ile Phe Ala Asp Leu Glu Ser Tyr Pro  
 350 355 360  
 Asp Phe Ser Glu Ile Ala Asn  
 365 367  
 25 <210> 8  
 <211> 367  
 <212> PRT  
 <213> Human  
 30 <400> 8  
 Met Arg Trp Phe Leu Pro Trp Thr Leu Ala Ala Val Thr Ala Ala  
 1 5 10 15  
 Ala Ala Ser Thr Val Leu Ala Thr Ala Leu Ser Pro Ala Pro Thr  
 20 25 30  
 35 Thr Met Asp Phe Thr Pro Ala Pro Leu Glu Asp Thr Ser Ser Arg  
 35 40 45  
 Pro Gln Phe Cys Lys Trp Pro Cys Glu Cys Pro Pro Ser Pro Pro  
 50 55 60  
 Arg Cys Pro Leu Gly Val Ser Leu Ile Thr Asp Gly Cys Glu Cys  
 65 70 75  
 40 Cys Lys Met Cys Ala Gln Gln Leu Gly Asp Asn Cys Thr Glu Ala  
 80 85 90

	Ala Ile Cys Asp Pro His Arg Gly Leu Tyr Cys Asp Tyr Ser Gly		
	95	100	105
	Asp Arg Pro Arg Tyr Ala Ile Gly Val Cys Ala Gln Val Val Gly		
	110	115	120
5	Val Gly Cys Val Leu Asp Gly Val Arg Tyr Asn Asn Gly Gln Ser		
	125	130	135
	Phe Gln Pro Asn Cys Lys Tyr Asn Cys Thr Cys Ile Asp Gly Ala		
	140	145	150
10	Val Gly Cys Thr Pro Leu Cys Leu Arg Val Arg Pro Pro Arg Leu		
	155	160	165
	Trp Cys Pro His Pro Arg Arg Val Ser Ile Pro Gly His Cys Cys		
	170	175	180
	Glu Gln Trp Val Cys Glu Asp Asp Ala Lys Arg Pro Arg Lys Thr		
	185	190	195
15	Ala Pro Arg Asp Thr Gly Ser Phe Asp Ala Val Gly Glu Val Glu		
	200	205	210
	Ala Trp His Arg Asn Cys Ile Ala Tyr Thr Ser Pro Trp Ser Pro		
	215	220	225
20	Cys Ser Thr Ser Cys Gly Leu Gly Val Ser Thr Arg Ile Ser Asn		
	230	235	240
	Val Asn Ala Gln Cys Trp Pro Glu Gln Glu Ser Arg Leu Cys Asn		
	245	250	255
	Leu Arg Pro Cys Asp Val Asp Ile His Thr Leu Ile Lys Ala Gly		
	260	265	270
25	Lys Lys Cys Leu Ala Val Tyr Gln Pro Glu Ala Ser Met Asn Phe		
	275	280	285
	Thr Leu Ala Gly Cys Ile Ser Thr Arg Ser Tyr Gln Pro Lys Tyr		
	290	295	300
30	Cys Gly Val Cys Met Asp Asn Arg Cys Cys Ile Pro Tyr Lys Ser		
	305	310	315
	Lys Thr Ile Asp Val Ser Phe Gln Cys Pro Asp Gly Leu Gly Phe		
	320	325	330
	Ser Arg Gln Val Leu Trp Ile Asn Ala Cys Phe Cys Asn Leu Ser		
	335	340	345
35	Cys Arg Asn Pro Asn Asp Ile Phe Ala Asp Leu Glu Ser Tyr Pro		
	350	355	360
	Asp Phe Ser Glu Ile Ala Asn		
	365	367	
40	<210> 9		
	<211> 1766		

<212> DNA  
<213> Mouse

<220>  
<221> Unknown  
5 <222> 10  
<223> Any nucleotide

<400> 9  
taacaaggcn gtcctgcttg gagaggcatc cgcatcctct gggctgagcc 50  
gtagctcctg tgacgctgac ttccaggcat gaggtggctc ctgccctgga 100  
10 cgctggcagc cgtggcagtc ctgagggtgg gcaacatcct gccacacggcc 150  
ctctctccaa cccccacaac aatgacacctc accccagcac cactagagga 200  
aacgactaca ccccccaaat tctgcaagtg gccatgtgag tgcccacaat 250  
ccccacctcg ctgcccactg ggcgtcagcc taatcacaga tggctgtgaa 300  
tgctgtaaga tatgtgccc gcagcttggg gacaactgca cagaggctgc 350  
15 catctgtgac ccacaccggg gcctctactg cgattacagt ggggatcgcc 400  
cgaggtacgc aataggagtg tgtgcacagg tggtcggtgt gggctgtgac 450  
ctggatggcg tacgctacac caatggcgag tccttccaac ccaactgcag 500  
gtacaactgt acctgcattt atggcacggg gggctgcaca ccgctgtgcc 550  
taagccccag gcccccacgc ctctggtgcc gccagccccg gcacgtgaga 600  
20 gtccctggcc agtgctgtga gcagtgggtg tgtgatgatg acgcaaggag 650  
accacgcccag actgcactgt tggacaccag agcctttgca ggcgtcaggcg 700  
ccgtggagca acggtatgag aactgcatac cctacactag tccctggagc 750  
ccctgctcta ccacctgtgg cctaggtatc tccactcgga tctctaacgt 800  
caatgcccgg tgctggccag agcagggaaag tcgcctctgc aacctgcggc 850  
25 catgtgatgt ggacatccaa ctacacatca aggcagggaa gaaatgcctg 900  
gctgtgtacc agccagagga ggccacgaac ttcactctcg caggctgtgt 950  
cagcacacgc acctaccgac ccaagtactg cggagtctgt actgacaata 1000  
ggtgttgcatt cccctacaag tccaagacca tcagtgtgga tttccagtgt 1050  
ccagaggggc caggtttctc cggcaggtc ctatggatta atgcttgctt 1100  
30 ctgcaacctg agctgcagga atcctaacga tatctttgct gacttggaaat 1150  
cttaccctga cttcgaagag attgccaatt aggtgggtgt gtggctcagg 1200  
gtaaagttcc atgctgcaaa gcagccagcc ctttgtggtc caggacttca 1250

caattgagcc ttatttcatc tacttcctac tcgattctga attcccaagtt 1300  
tctgttcctg tttgacaat cgtaatggcc caggagagtgc tgctcaggc 1350  
tcagacaatg ggttcctcct tggggacatt ctacatcatt ccaaggaaaa 1400  
cacatctctg actgttcaca atgaaagcaa agcctggccc agctagtcg 1450  
5 gctccagcct gggcaagttg tcagaagttg tgatggatt gtccaaggaa 1500  
aagcatcagc tgaagaacca gtatcatgaa gtccttcctc agatgccaag 1550  
cctagggatg ctgggatcct ttcagacaga tggatggat tggggacaca 1600  
ggaataagct attatttac ctttgcacaa tgatactatc ctgggtat 1650  
ctgcctaaaa acataccaaa agtgttcttg ttccactgat ctgtatatca 1700  
10 caagtcacca aacattttcc aggtgaggac ccatagttgt gtcattctgt 1750  
tttgcattt gaaaaa 1766

<210> 10  
<211> 1140  
<212> DNA  
15 <213> Mouse

<400> 10  
attggcaatc tcttcgaagt cagggtaaga ttccaagtc gcaaagat 50  
cgtaggatt cctgcagctc aggtgcaga agcaaggcatt aatccatagg 100  
acctgcccggg agaaacctgg cccctctgga cactggaaat ccacactgat 150  
20 ggtcttggac ttgttagggta tgcaacacct attgtcagta cagactccgc 200  
agtacttggg tcggtaggtg cgtgtgctga cacagcctgc gagagtgaag 250  
ttcgtggcct cctctggctg gtacacagcc aggcatttct tccctgcctt 300  
gatgtgtagt tggatgtcca catcacatgg ccgcaggttg cagaggcgac 350  
tttcctgctc tggccagcac cgggcattga cgtagagat ccgagtggag 400  
25 ataccttaggc cacaggttgt agagcagggg ctccaggac tagtgttaggc 450  
tatgcagttc tcataaccgtt gctccacggc gcctgacgct gcaaaggctc 500  
tggtgtccaa cagtgcagtc tggcgtggc tcctgcgtc atcatcacac 550  
acccactgct cacagcactg gccaggact ctcacgtgcc ggggctggcg 600  
gcaccagagg cgtggggcc tggggcttag gcacagcggt gtgcagccca 650  
30 ccgtgccatc aatgcaggtt cagttgtacc tgcaaggatggg ttggaaggac 700  
tcgcccattgg tggtagcgtac gccatccagg acacagccca caccgaccac 750  
ctgtgcacac actccatattt cgtacccctgg ggcgcgtccca ctgtatcg 800

agtagaggcc ccgggtgtggg tcacagatgg cagcctctgt gcagttgtcc 850  
 ccaagctgct gggcacatat cttacagcat tcacagccat ctgtgattag 900  
 gctgacgccc agtgggcagc gaggtgggga ttgtgggcac tcacatggcc 950  
 acttgcagaa ttccgggcgt gtagtcgtt cctctagtgg tgctgggtg 1000  
 5 aaggtcattg ttccggaatc ctctagtggt gctgggtga aggtcattgt 1050  
 tgtggggtt ggagagaggg ccgtggccag gatgttgc 1100  
 ctgccacggc tgccagcg 1140  
 ctgccacggc tgccagcg 1140  
 <210> 11  
 <211> 345  
 10 <212> PRT  
 <213> Mouse  
 <400> 11  
 Thr Ala Leu Ser Pro Thr Pro Thr Thr Met Thr Phe Thr Pro Ala  
 1 5 10 15  
 15 Pro Leu Glu Glu Thr Thr Arg Pro Glu Phe Cys Lys Trp Pro  
 20 25 30  
 Cys Glu Cys Pro Gln Ser Pro Pro Arg Cys Pro Leu Gly Val Ser  
 35 40 45  
 Leu Ile Thr Asp Gly Cys Glu Cys Cys Lys Ile Cys Ala Gln Gln  
 50 55 60  
 20 Leu Gly Asp Asn Cys Thr Glu Ala Ala Ile Cys Asp Pro His Arg  
 65 70 75  
 Gly Leu Tyr Cys Asp Tyr Ser Gly Asp Arg Pro Arg Tyr Ala Ile  
 80 85 90  
 25 Gly Val Cys Ala Gln Val Val Gly Val Gly Cys Val Leu Asp Gly  
 95 100 105  
 Val Arg Tyr Thr Asn Gly Glu Ser Phe Gln Pro Asn Cys Arg Tyr  
 110 115 120  
 Asn Cys Thr Cys Ile Asp Gly Thr Val Gly Cys Thr Pro Leu Cys  
 30 125 130 135  
 Leu Ser Pro Arg Pro Pro Arg Leu Trp Cys Arg Gln Pro Arg His  
 140 145 150  
 Val Arg Val Pro Gly Gln Cys Cys Glu Gln Trp Val Cys Asp Asp  
 155 160 165  
 35 Asp Ala Arg Arg Pro Arg Gln Thr Ala Leu Leu Asp Thr Arg Ala  
 170 175 180  
 Phe Ala Ala Ser Gly Ala Val Glu Gln Arg Tyr Glu Asn Cys Ile  
 185 190 195

	Ala Tyr Thr Ser Pro Trp Ser Pro Cys Ser Thr Thr Cys Gly Leu			
	200	205	210	
	Gly Ile Ser Thr Arg Ile Ser Asn Val Asn Ala Arg Cys Trp Pro			
	215	220	225	
5	Glu Gln Glu Ser Arg Leu Cys Asn Leu Arg Pro Cys Asp Val Asp			
	230	235	240	
	Ile Gln Leu His Ile Lys Ala Gly Lys Lys Cys Leu Ala Val Tyr			
	245	250	255	
10	Gln Pro Glu Glu Ala Thr Asn Phe Thr Leu Ala Gly Cys Val Ser			
	260	265	270	
	Thr Arg Thr Tyr Arg Pro Lys Tyr Cys Gly Val Cys Thr Asp Asn			
	275	280	285	
	Arg Cys Cys Ile Pro Tyr Lys Ser Lys Thr Ile Ser Val Asp Phe			
	290	295	300	
15	Gln Cys Pro Glu Gly Pro Gly Phe Ser Arg Gln Val Leu Trp Ile			
	305	310	315	
	Asn Ala Cys Phe Cys Asn Leu Ser Cys Arg Asn Pro Asn Asp Ile			
	320	325	330	
20	Phe Ala Asp Leu Glu Ser Tyr Pro Asp Phe Glu Glu Ile Ala Asn			
	335	340	345	
	<210> 12			
	<211> 367			
	<212> PRT			
	<213> Mouse			
25	<400> 12			
	Met Arg Trp Leu Leu Pro Trp Thr Leu Ala Ala Val Ala Val Leu			
	1	5	10	15
	Arg Val Gly Asn Ile Leu Ala Thr Ala Leu Ser Pro Thr Pro Thr			
	20	25	30	
30	Thr Met Thr Phe Thr Pro Ala Pro Leu Glu Glu Thr Thr Thr Arg			
	35	40	45	
	Pro Glu Phe Cys Lys Trp Pro Cys Glu Cys Pro Gln Ser Pro Pro			
	50	55	60	
35	Arg Cys Pro Leu Gly Val Ser Leu Ile Thr Asp Gly Cys Glu Cys			
	65	70	75	
	Cys Lys Ile Cys Ala Gln Gln Leu Gly Asp Asn Cys Thr Glu Ala			
	80	85	90	
	Ala Ile Cys Asp Pro His Arg Gly Leu Tyr Cys Asp Tyr Ser Gly			
	95	100	105	
40	Asp Arg Pro Arg Tyr Ala Ile Gly Val Cys Ala Gln Val Val Gly			
	110	115	120	



ggccttctcc ctctctgcc tcctctcaaa gggtgcgtacc cagctgtgcc 100  
 cgacaccatg tacctgcccc tggccacctc cccgatgccc gctgggagta 150  
 cccctggtgc tggatggctg tggctgctgc cgggtatgtg cacggcgct 200  
 gggggagccc tgcgaccaac tccacgtctg cgacgccagc cagggcctgg 250  
 5 tctgccagcc cggggcagga cccggtggcc ggggggcctt gtgcctcttg 300  
 gcagaggacg acagcagctg tgaggtgaac ggccgcctgt atcgggaagg 350  
 ggagaccttc cagccccact gcagcatccg ctgcccgtgc gaggacggcg 400  
 gttcacctg cgtgccgtg tgcagcgagg atgtgcggct gcccagctgg 450  
 gactgcccccc accccaggag ggtcgagggtc ctgggcaagt getgccctga 500  
 10 gtgggtgtgc ggccaaggag ggggactggg gacccagccc cttccagccc 550  
 aaggacccca gtttctggc cttgtctttt ccctgcccccc tggtgtcccc 600  
 tgcccagaat ggagcacggc ctggggaccc tgctcgacca cctgtgggct 650  
 gggcatggcc acccggtgtt ccaaccagaa ccgtttctgc cgactggaga 700  
 cccagcgccg cctgtgcctg tccagggccct gcccacccctc caggggtcgc 750  
 15 agtccacaaa acagtgcctt ctagagccgg gctgggaatg gggacacgg 800  
 gtccaccatc cccagctggt ggccctgtgc ctggggccctg ggctgtatgga 850  
 agatggtccg tgcccaggcc cttggctgca ggcaacactt tagcttgggt 900  
 ccaccatgca gaacaccaat attaacacgc tgccatggct gtctggatcc 950  
 cgaggtatgg cagaggtgca agaccttagtc cccttcctc taactcactg 1000  
 20 cctaggaggc tggccaaggt gtccagggtc ctctagccca ctccctgcct 1050  
 acacacacag cctatatcaa acatgcacac gggcgagctt tctctccgac 1100  
 ttccccctggg caagagatgg gacaagcagt cccttaatat tgaggctgca 1150  
 gcaggtgctg ggctggactg gccattttc tgggggttagg atgaagagaa 1200  
 ggcacacaga gattctggat ctccatgtgc cttttctgga gtttgtaaaa 1250  
 25 ttgttcctga atacaaggct atgcgtgaaa aaaaaaaaaaaa aaa 1293  
  
 <210> 14  
 <211> 750  
 <212> DNA  
 <213> Human  
  
 30 <400> 14  
 gaaggcactg ttttgtggac tgcgacccct ggagggtggg cagggcctgg 50  
 acaggcacag gcccgcgtgg gtctccagtc ggcagaagcg gttctggttg 100

gacacccggg tggccatgcc cagccacag gtggtcgagc agggtcccc 150  
 ggccgtgctc cattctggc aggggacacc agggggcagg gaagagacaa 200  
 ggccagaaaa ctggggtcct tgggctggaa ggggctgggt ccccagtc 250  
 ctcacacccca ctcagggcag cacttgc 300  
 5 ctcctgggg tggggcagt cccagctgg cagccgcaca tcctcgctgc 350  
 acagcggcac gcaggtgaag cccgcgtc cgcagcggca gcggatgtg 400  
 cagtggggct ggaagggtctc ccctccga tacaggcggc cgttcacctc 450  
 acagctgtc tcgtcctctg ccaagaggca cagggcccc cggccaccc 500  
 gtcctgcccc gggctggcag accaggccct ggctggcg 550  
 10 agttggtcgc agggctcccc cagccgcgt gcacataccc ggcagcagcc 600  
 acagccatcc agcaccagg 650  
 agggcaggt acatggtg 700  
 aggcagagga gggagaaggc caggagg 750  
 <210> 15  
 15 <211> 227  
 <212> PRT  
 <213> Human  
 <400> 15  
 20 Gln Leu Cys Pro Thr Pro Cys Thr Cys Pro Trp Pro Pro Pro Arg  
 1 5 10 15  
 Cys Pro Leu Gly Val Pro Leu Val Leu Asp Gly Cys Gly Cys Cys  
 20 25 30  
 Arg Val Cys Ala Arg Arg Leu Gly Glu Pro Cys Asp Gln Leu His  
 35 40 45  
 25 Val Cys Asp Ala Ser Gln Gly Leu Val Cys Gln Pro Gly Ala Gly  
 50 55 60  
 Pro Gly Gly Arg Gly Ala Leu Cys Leu Leu Ala Glu Asp Asp Ser  
 65 70 75  
 30 Ser Cys Glu Val Asn Gly Arg Leu Tyr Arg Glu Gly Glu Thr Phe  
 80 85 90  
 Gln Pro His Cys Ser Ile Arg Cys Arg Cys Glu Asp Gly Gly Phe  
 95 100 105  
 Thr Cys Val Pro Leu Cys Ser Glu Asp Val Arg Leu Pro Ser Trp  
 110 115 120  
 35 Asp Cys Pro His Pro Arg Arg Val Glu Val Leu Gly Lys Cys Cys  
 125 130 135

Pro Glu Trp Val Cys Gly Gln Gly Gly Leu Gly Thr Gln Pro  
 140 145 150  
 Leu Pro Ala Gln Gly Pro Gln Phe Ser Gly Leu Val Ser Ser Leu  
 155 160 165  
 5 Pro Pro Gly Val Pro Cys Pro Glu Trp Ser Thr Ala Trp Gly Pro  
 170 175 180  
 Cys Ser Thr Thr Cys Gly Leu Gly Met Ala Thr Arg Val Ser Asn  
 185 190 195  
 Gln Asn Arg Phe Cys Arg Leu Glu Thr Gln Arg Arg Leu Cys Leu  
 10 200 205 210  
 Ser Arg Pro Cys Pro Pro Ser Arg Gly Arg Ser Pro Gln Asn Ser  
 215 220 225  
 Ala Phe  
 227  
 15 <210> 16  
 <211> 250  
 <212> PRT  
 <213> Human  
 <400> 16  
 20 Met Arg Gly Thr Pro Lys Thr His Leu Leu Ala Phe Ser Leu Leu  
 1 5 10 15  
 Cys Leu Leu Ser Lys Val Arg Thr Gln Leu Cys Pro Thr Pro Cys  
 20 25 30  
 Thr Cys Pro Trp Pro Pro Pro Arg Cys Pro Leu Gly Val Pro Leu  
 25 35 40 45  
 Val Leu Asp Gly Cys Gly Cys Cys Arg Val Cys Ala Arg Arg Leu  
 50 55 60  
 Gly Glu Pro Cys Asp Gln Leu His Val Cys Asp Ala Ser Gln Gly  
 65 70 75  
 30 Leu Val Cys Gln Pro Gly Ala Gly Pro Gly Gly Arg Gly Ala Leu  
 80 85 90  
 Cys Leu Leu Ala Glu Asp Asp Ser Ser Cys Glu Val Asn Gly Arg  
 95 100 105  
 35 Leu Tyr Arg Glu Gly Glu Thr Phe Gln Pro His Cys Ser Ile Arg  
 110 115 120  
 Cys Arg Cys Glu Asp Gly Gly Phe Thr Cys Val Pro Leu Cys Ser  
 125 130 135  
 Glu Asp Val Arg Leu Pro Ser Trp Asp Cys Pro His Pro Arg Arg  
 140 145 150  
 40 Val Glu Val Leu Gly Lys Cys Cys Pro Glu Trp Val Cys Gly Gln  
 155 160 165

Gly Gly Gly Leu Gly Thr Gln Pro Leu Pro Ala Gln Gly Pro Gln  
 170 175 180  
 Phe Ser Gly Leu Val Ser Ser Leu Pro Pro Gly Val Pro Cys Pro  
 185 190 195  
 5 Glu Trp Ser Thr Ala Trp Gly Pro Cys Ser Thr Thr Cys Gly Leu  
 200 205 210  
 Gly Met Ala Thr Arg Val Ser Asn Gln Asn Arg Phe Cys Arg Leu  
 215 220 225  
 10 Glu Thr Gln Arg Arg Leu Cys Leu Ser Arg Pro Cys Pro Pro Ser  
 230 235 240  
 Arg Gly Arg Ser Pro Gln Asn Ser Ala Phe  
 245 250  
 15 <210> 17  
 <211> 1734  
 <212> DNA  
 <213> Mouse  
 <400> 17  
 cccacgcgtc cgcgcgtcctg atctccagag gaccccgggc tgggacaggg 50  
 gccttggcga ggctgcagct gctgtggcag tagcttggga tggaggtctt 100  
 20 tcttgctggg aactgaggag ctgagaggct cctgtcagggc tcctgtccta 150  
 aactcttggc acttgcggtg gcttggcctt cacacactgt cagacacett 200  
 cttggtggcc tcctcggcct caggtttgaa gctggctcca caagggacac 250  
 ggtgacatga gggcaaccc actgatccat cttctggcca tttcatttctt 300  
 ctgcattctc tcaatggtgt attcccaagct gtgcccagca ccctgtgcct 350  
 25 gtccttggac accaccccaag tgcccacccgg gggtaaaaaat ggtgctggat 400  
 ggctgtggct gctgtcgagt gtgtgcacgg aggtgggggg agtcctgcga 450  
 ccacctgcatt gtctgcgacc ccagccaggc cctggttgtt cagcctgggg 500  
 caggcccccaag tggccgtggt gctgtgtgcc tcttcgaaga ggatgacggg 550  
 agctgtgagg tgaatggccg caggtacctg gatggggaga cttttaaacc 600  
 30 caattgcagg gttttgtgcc gctgtgatga cggtggtttc acctgcctgc 650  
 cgctgtgcag tgaggatgtg cggctgccccca gctgggactg cccacgcggc 700  
 aggagaatac aggtgccagg aaggtgctgc cccgagtggg tgggtgacca 750  
 ggcagtgtatg cagccggcaa tccagccctc ctcagcccaa ggacaccaac 800  
 tttctgcctt tgcactcct gcatctgcgg atggcccttg tccaaactgg 850  
 35 agcacagccctg gggcccccctg ctcaaccacc tgggggttgg gcatagccac 900

ccgagtatcc aaccagaacc gattctgcc 950  
tgtgtctgtc cagaccctgc ctggcatcca ggagccacgg ctcatggaac 1000  
agtgccttct agagccattg cggggatgtg gatacagggc ctgccattct 1050  
cagcaaatgt cccttaggacc aggcctgga ctgatggtag atgcccctct 1100  
5 ccatgctctt ggctgcagtt aactgtcctg ggtggattca gtgtccagag 1150  
cctctgagcg atccctgctc tgtctgaggt ggggaaagca ggtgaccagc 1200  
tccatttctc tggattctga cccaggcttc tgggttctcc tggctagttc 1250  
ctcaaaaactt ccctgtatga aaaggacaac caaaaaggacc tttaaagcta 1300  
agctgtactg ggcaaggctg gccaccatgc tggggatagt gacagtaata 1350  
10 ggtaccaggc agcagattgc ctgaaacatc caggtccctt cttggacttc 1400  
tatgtgcttg tcccaaagat tatgggtgac cttgttaagtg tgcctttcct 1450  
gatctgagaa caccctgccc ggctggaaag aattttctgg gaacatgaag 1500  
agatggaaatc acactattct taagagcggt tgccaagtcc aggaacttga 1550  
cctttgtatt tgtaaaaata cacatcttta aatgctcac aaagcaagag 1600  
15 gctccacact tctggcaggc cagggccctt ctcttcagca tgagagagac 1650  
aaggaacagt agagtaccct cctctggagg actggcccg tctggaataa 1700  
acacccaaat caagtgtgga aaaaaaaaaa aaaa 1734  
  
<210> 18  
<211> 753  
20 <212> DNA  
<213> Mouse  
  
<400> 18  
gaaggcactg ttccatgagc cgtggctcct ggatgccagg cagggtctgg 50  
acagacacag gcgacgctgg atctccagtt ggcagaatcg gttctggttg 100  
25 gatactcggg tggctatgcc caacccacag gtgggtgagc agggggccca 150  
ggctgtgctc cagtttggac aggggcccac ggcagatgca ggagtgacaa 200  
ggcagaaaag ttgggtgtcct tgggctgagg agggctggat tgccggctgc 250  
atcactgcct ggtcacacac ccactcgggg cagcaccttc ctggcacctg 300  
tattctcctg gggcgtggc agtcccagct gggcagccgc acatcctcac 350  
30 tgcacagcgg cagggcaggtg aaaccaccgt catcacagcg gcacaaaacc 400  
ctgcaattgg gtttaaaggt ctccccatcc aggtacctgc ggccattcac 450  
ctcacagctc ccgtcatcct cttcgaagag gcacacagca ccacggccac 500

tggggcctgc cccaggctga caaaccaggc cctggctggg gtcgcagaca 550  
 tgcaggtggc cgcaggactc ccccagcctc cgtgcacaca ctcgacagca 600  
 gccacagcca tccagcacca ggggtacccc cggtgggcac tggggtgtgg 650  
 tccaaggaca ggcacagggt gctgggcaca gctgggata caccatttag 700  
 5 agaatgcaga ggaaggaaat ggccagaaga tggatcagtg ggttgcccct 750  
 cat 753  
  
 <210> 19  
 <211> 228  
 <212> PRT  
 10 <213> Mouse  
  
 <400> 19  
 Gln Leu Cys Pro Ala Pro Cys Ala Cys Pro Trp Thr Pro Pro Gln  
 1 5 10 15  
  
 Cys Pro Pro Gly Val Pro Leu Val Leu Asp Gly Cys Gly Cys Cys  
 15 20 25 30  
  
 Arg Val Cys Ala Arg Arg Leu Gly Glu Ser Cys Asp His Leu His  
 35 40 45  
  
 Val Cys Asp Pro Ser Gln Gly Leu Val Cys Gln Pro Gly Ala Gly  
 50 55 60  
  
 20 Pro Ser Gly Arg Gly Ala Val Cys Leu Phe Glu Glu Asp Asp Gly  
 65 70 75  
  
 Ser Cys Glu Val Asn Gly Arg Arg Tyr Leu Asp Gly Glu Thr Phe  
 80 85 90  
  
 25 Lys Pro Asn Cys Arg Val Leu Cys Arg Cys Asp Asp Gly Gly Phe  
 95 100 105  
  
 Thr Cys Leu Pro Leu Cys Ser Glu Asp Val Arg Leu Pro Ser Trp  
 110 115 120  
  
 Asp Cys Pro Arg Pro Arg Arg Ile Gln Val Pro Gly Arg Cys Cys  
 125 130 135  
  
 30 Pro Glu Trp Val Cys Asp Gln Ala Val Met Gln Pro Ala Ile Gln  
 140 145 150  
  
 Pro Ser Ser Ala Gln Gly His Gln Leu Ser Ala Leu Val Thr Pro  
 155 160 165  
  
 Ala Ser Ala Asp Gly Pro Cys Pro Asn Trp Ser Thr Ala Trp Gly  
 170 175 180  
  
 35 Pro Cys Ser Thr Thr Cys Gly Leu Gly Ile Ala Thr Arg Val Ser  
 185 190 195  
  
 Asn Gln Asn Arg Phe Cys Gln Leu Glu Ile Gln Arg Arg Leu Cys  
 200 205 210

	Leu Ser Arg Pro Cys Leu Ala Ser Arg Ser His Gly Ser Trp Asn			
	215	220	225	
	Ser Ala Phe			
	228			
5	<210> 20			
	<211> 251			
	<212> PRT			
	<213> Mouse			
	<400> 20			
10	Met Arg Gly Asn Pro Leu Ile His Leu Leu Ala Ile Ser Phe Leu			
	1	5	10	15
	Cys Ile Leu Ser Met Val Tyr Ser Gln Leu Cys Pro Ala Pro Cys			
	20	25	30	
15	Ala Cys Pro Trp Thr Pro Pro Gln Cys Pro Pro Gly Val Pro Leu			
	35	40	45	
	Val Leu Asp Gly Cys Gly Cys Cys Arg Val Cys Ala Arg Arg Leu			
	50	55	60	
	Gly Glu Ser Cys Asp His Leu His Val Cys Asp Pro Ser Gln Gly			
	65	70	75	
20	Leu Val Cys Gln Pro Gly Ala Gly Pro Ser Gly Arg Gly Ala Val			
	80	85	90	
	Cys Leu Phe Glu Glu Asp Asp Gly Ser Cys Glu Val Asn Gly Arg			
	95	100	105	
25	Arg Tyr Leu Asp Gly Glu Thr Phe Lys Pro Asn Cys Arg Val Leu			
	110	115	120	
	Cys Arg Cys Asp Asp Gly Gly Phe Thr Cys Leu Pro Leu Cys Ser			
	125	130	135	
	Glu Asp Val Arg Leu Pro Ser Trp Asp Cys Pro Arg Pro Arg Arg			
	140	145	150	
30	Ile Gln Val Pro Gly Arg Cys Cys Pro Glu Trp Val Cys Asp Gln			
	155	160	165	
	Ala Val Met Gln Pro Ala Ile Gln Pro Ser Ser Ala Gln Gly His			
	170	175	180	
35	Gln Leu Ser Ala Leu Val Thr Pro Ala Ser Ala Asp Gly Pro Cys			
	185	190	195	
	Pro Asn Trp Ser Thr Ala Trp Gly Pro Cys Ser Thr Thr Cys Gly			
	200	205	210	
	Leu Gly Ile Ala Thr Arg Val Ser Asn Gln Asn Arg Phe Cys Gln			
	215	220	225	
40	Leu Glu Ile Gln Arg Arg Leu Cys Leu Ser Arg Pro Cys Leu Ala			
	230	235	240	

Ser Arg Ser His Gly Ser Trp Asn Ser Ala Phe  
 245 250 251

5 <210> 21  
 <211> 345  
 <212> PRT  
 <213> Human

<400> 21  
 Thr Ala Leu Ser Pro Ala Pro Thr Thr Met Asp Phe Thr Pro Ala  
 1 5 10 15

10 Pro Leu Glu Asp Thr Ser Ser Arg Pro Gln Phe Cys Lys Trp Pro  
 20 25 30

Cys Glu Cys Pro Pro Ser Pro Pro Arg Cys Pro Leu Gly Val Ser  
 35 40 45

15 Leu Ile Thr Asp Gly Cys Glu Cys Cys Lys Met Cys Ala Gln Gln  
 50 55 60

Leu Gly Asp Asn Cys Thr Glu Ala Ala Ile Cys Asp Pro His Arg  
 65 70 75

Gly Leu Tyr Cys Asp Tyr Ser Gly Asp Arg Pro Arg Tyr Ala Ile  
 80 85 90

20 Gly Val Cys Ala Gln Val Val Gly Val Gly Cys Val Leu Asp Gly  
 95 100 105

Val Arg Tyr Asn Asn Gly Gln Ser Phe Gln Pro Asn Cys Lys Tyr  
 110 115 120

25 Asn Cys Thr Cys Ile Asp Gly Ala Val Gly Cys Thr Pro Leu Cys  
 125 130 135

Leu Arg Val Arg Pro Pro Arg Leu Trp Cys Pro His Pro Arg Arg  
 140 145 150

Val Ser Ile Pro Gly His Cys Cys Glu Gln Trp Ile Cys Glu Asp  
 155 160 165

30 Asp Ala Lys Arg Pro Arg Lys Thr Ala Pro Arg Asp Thr Gly Ser  
 170 175 180

Phe Asp Ala Val Gly Glu Val Glu Ala Trp His Arg Asn Cys Ile  
 185 190 195

35 Ala Tyr Thr Ser Pro Trp Ser Pro Cys Ser Thr Ser Cys Gly Leu  
 200 205 210

Gly Val Ser Thr Arg Ile Ser Asn Val Asn Ala Gln Cys Trp Pro  
 215 220 225

Glu Gln Glu Ser Arg Leu Cys Asn Leu Arg Pro Cys Asp Val Asp  
 230 235 240

40 Ile His Thr Leu Ile Lys Ala Gly Lys Lys Cys Leu Ala Val Tyr  
 245 250 255

	Gln Pro Glu Ala Ser Met Asn Phe Thr Leu Ala Gly Cys Ile Ser			
	260	265	270	
	Thr Arg Ser Tyr Gln Pro Lys Tyr Cys Gly Val Cys Met Asp Asn			
	275	280	285	
5	Arg Cys Cys Ile Pro Tyr Lys Ser Lys Thr Ile Asp Val Ser Phe			
	290	295	300	
	Gln Cys Pro Asp Gly Leu Gly Phe Ser Arg Gln Val Leu Trp Ile			
	305	310	315	
10	Asn Ala Cys Phe Cys Asn Leu Ser Cys Arg Asn Pro Asn Asp Ile			
	320	325	330	
	Phe Ala Asp Leu Glu Ser Tyr Pro Asp Phe Ser Glu Ile Ala Asn			
	335	340	345	
	<210> 22			
	<211> 367			
15	<212> PRT			
	<213> Human			
	<400> 22			
	Met Arg Trp Phe Leu Pro Trp Thr Leu Ala Ala Val Thr Ala Ala			
	1	5	10	15
20	Ala Ala Ser Thr Val Leu Ala Thr Ala Leu Ser Pro Ala Pro Thr			
	20	25	30	
	Thr Met Asp Phe Thr Pro Ala Pro Leu Glu Asp Thr Ser Ser Arg			
	35	40	45	
25	Pro Gln Phe Cys Lys Trp Pro Cys Glu Cys Pro Pro Ser Pro Pro			
	50	55	60	
	Arg Cys Pro Leu Gly Val Ser Leu Ile Thr Asp Gly Cys Glu Cys			
	65	70	75	
	Cys Lys Met Cys Ala Gln Gln Leu Gly Asp Asn Cys Thr Glu Ala			
	80	85	90	
30	Ala Ile Cys Asp Pro His Arg Gly Leu Tyr Cys Asp Tyr Ser Gly			
	95	100	105	
	Asp Arg Pro Arg Tyr Ala Ile Gly Val Cys Ala Gln Val Val Gly			
	110	115	120	
35	Val Gly Cys Val Leu Asp Gly Val Arg Tyr Asn Asn Gly Gln Ser			
	125	130	135	
	Phe Gln Pro Asn Cys Lys Tyr Asn Cys Thr Cys Ile Asp Gly Ala			
	140	145	150	
	Val Gly Cys Thr Pro Leu Cys Leu Arg Val Arg Pro Pro Arg Leu			
	155	160	165	
40	Trp Cys Pro His Pro Arg Arg Val Ser Ile Pro Gly His Cys Cys			
	170	175	180	

	Glu	Gln	Trp	Ile	Cys	Glu	Asp	Asp	Ala	Lys	Arg	Pro	Arg	Lys	Thr
						185				190					195
	Ala	Pro	Arg	Asp	Thr	Gly	Ser	Phe	Asp	Ala	Val	Gly	Glu	Val	Glu
						200				205			210		
5	Ala	Trp	His	Arg	Asn	Cys	Ile	Ala	Tyr	Thr	Ser	Pro	Trp	Ser	Pro
						215			220			225			
	Cys	Ser	Thr	Ser	Cys	Gly	Leu	Gly	Val	Ser	Thr	Arg	Ile	Ser	Asn
						230			235			240			
10	Val	Asn	Ala	Gln	Cys	Trp	Pro	Glu	Gln	Glu	Ser	Arg	Leu	Cys	Asn
						245			250			255			
	Leu	Arg	Pro	Cys	Asp	Val	Asp	Ile	His	Thr	Leu	Ile	Lys	Ala	Gly
						260			265			270			
	Lys	Lys	Cys	Leu	Ala	Val	Tyr	Gln	Pro	Glu	Ala	Ser	Met	Asn	Phe
						275			280			285			
15	Thr	Leu	Ala	Gly	Cys	Ile	Ser	Thr	Arg	Ser	Tyr	Gln	Pro	Lys	Tyr
						290			295			300			
	Cys	Gly	Val	Cys	Met	Asp	Asn	Arg	Cys	Cys	Ile	Pro	Tyr	Lys	Ser
						305			310			315			
20	Lys	Thr	Ile	Asp	Val	Ser	Phe	Gln	Cys	Pro	Asp	Gly	Leu	Gly	Phe
						320			325			330			
	Ser	Arg	Gln	Val	Leu	Trp	Ile	Asn	Ala	Cys	Phe	Cys	Asn	Leu	Ser
						335			340			345			
	Cys	Arg	Asn	Pro	Asn	Asp	Ile	Phe	Ala	Asp	Leu	Glu	Ser	Tyr	Pro
						350			355			360			
25	Asp	Phe	Ser	Glu	Ile	Ala	Asn								
						365			367						
	<210>	23													
	<211>	1403													
	<212>	DNA													
30	<213>	Human													
	<400>	23													
	gccagtctgg	gcccgactcc	cccgagaggt	ggtcggatcc	tctgggctgc	50									
	tccgtcgatg	cctgtgccac	tgacgtccag	gcatgaggtg	gttcctgccc	100									
	tggacgctgg	cagcagtgac	agcagcagcc	gccagcaccc	tcctggccac	150									
35	ggccctctct	ccagccccca	cgaccatgga	ctttacccca	gctccactgg	200									
	aggacacctc	ctcacgcccc	caattctgca	agtggccatg	tgagtgccc	250									
	ccatccccac	cccgctgccc	gctgggggtc	agcctcatca	cagatggctg	300									
	tgagtgtgt	aagatgtgcg	ctcagcagct	tggggacaac	tgcacggagg	350									

ctgccatctg tgaccccccac cggggcctct actgtgacta cagcggggac 400  
cgcccgagag gtggtcggtg tgggctgcgt cctggatggg gtgcgcata 450  
acaacggcca gtccttccag cctaactgca agtacaactg cacgtgcac 500  
gacggcgcgg tgggctgcac accactgtgc ctccgagtgc gccccccgcg 550  
5 tctctgggtgc ccccacccgc ggcgcgtgag catacctggc cactgctgtg 600  
agcagtgggt atgtgaggac gacgccaaga ggccacgcaa gaccgcaccc 650  
cgtgacacag gagccttcga tgctgtgggt gaggtggagg catggcacag 700  
gaactgcata gcctacacaa gcccctggag cccttgcctcc accagctgcg 750  
gcctgggggt ctccactcgg atctccaatg ttaacgcccgtgctggcct 800  
10 gagcaagaga gcccgccttg caacttgcgg ccatgcgatg tggacatcca 850  
tacactcatt aaggcaggga agaagtgtct ggctgtgtac cagccagagg 900  
catccatgaa cttcacacatt gcgggctgca tcagcacacg ctccatcaa 950  
cccaagtact gtggagtttg catggacaat aggtgctgca tcccctacaa 1000  
gtctaagact atcgacgtgt cttccagtg tcctgtatggg cttggcttct 1050  
15 cccgccaggt octatggatt aatgcgtgt tctgtaacct gagctgtagg 1100  
aatcccaatg acatcttgc tgacttggaa tcctaccctg acttctcaga 1150  
aattgccaac taggcaggca caaatcttgg gtcttgggaa ctaacccaaat 1200  
gcctgtgaag cagtcagccc ttatggccaa taactttca ccaatgagcc 1250  
ttagttaccc tgatctggac cttggcctc catttctgtc tctaaccatt 1300  
20 caaatgacgc ctgatgggtc tgctcaggcc catgctatga gtttctcct 1350  
tgatatcatt cagcatctac tctaaagaaa aatgcctgtc tctagctgtt 1400  
ctg 1403  
  
<210> 24  
<211> 693  
25 <212> DNA  
<213> Human  
  
<400> 24  
tttaattaaa cccccaaggg ctgcggaagg agcatatctg gtgctcctga 50  
tggccggcc agtctggcc cagctccccc gagaggtggt cggatccctct 100  
30 gggctgtctcg gtcgatgcct gtgccactga cgtccaggca tgaggtggtt 150  
cctggccctgg acgctggcag cagtgacagc agcagccgcc agcaccgtcc 200  
tggccacggc cctctctcca gcccctacga ccatggactt taccggact 250

5           ccactggagg acacacctc ctc acgcccccaa ttctgcaagt ggccatgtga 300  
gtgcccccca tccccacccc gctgcccgtc gggggtcagc ctcacacag 350  
atggctgtga gtgctgttaag atgtgcgc ctc agcagcttgg ggacaactgc 400  
acggaggctg ccatctgtga cccccacccgg ggcctctact gtgactacag 450  
cggggaccgc ccgaggtacg caataggagt gtgtgcacgc agggaaagaag 500  
tgtctggctg tgtaccagcc agaggcatcc atgaacttca cacttgcggg 550  
ctgcatcagc acacgctcct atcaacccaa gtactgttgg gtttgcattgg 600  
acaacaggtg ctgcatcccc tacaagtctt aagactatcga cgtgtccttc 650  
cagtgccctg atgggcttgg cttctcccgc caggtccat gga 693

10           <210> 25  
<211> 683  
<212> DNA  
<213> Human

15           <400> 25  
cagaatttga actggatcc acctgtctct aaagatgggt ttccctccat 50  
gcttccacac tgcctcttttt gatcagaaac atacaaggag ctgagaacat 100  
gtcctccact ccctgggtac ctttgcgtt tagaagccaa cttgctgtcc 150  
tgtggggagg tacagccaat ttctgtgttc ctctgagttc tggggaccgc 200  
agaccttagt gtggtaaag tgagcggtgg gggctgggtgg gagctgtaga 250  
20           ttcatgcaga ttctgttccc cacacacaga tgctgtgggt gaggtggagg 300  
catggcacag gaactgcata gcctacacaa gcccctggag cccttgctcc 350  
accagctgcg gcctgggggt ctccactcgg atctccatg ttaacgcccc 400  
gtgctggcct gagcaagaga gccgcctctg caactgcgg ccatgcgtatg 450  
tggacatcca tacactcatt aaggcaggga agaagtgtct ggctgtgtac 500  
25           cagccagagg catccatgaa ctccacactt gcgggctgca tcagcacacg 550  
ctcctatcaa cccaaatgtact gtggagtttgc catggacaat aggtgctgca 600  
tcccctacaa gtctaaagact atcgacgtgt cttccagtg tcctgatggg 650  
cttggcttct cccgcccaggc cgtatggatt aat 683

30           <210> 26  
<211> 1202  
<212> DNA  
<213> Human

35           <400> 26  
gtctggggccccc agtccccccgg agaggtggtc ggatcccttg ggctgctcgg 50

tcgatgcctg tgccactgac gtccaggcat gaggtggttc ctgcctgga 100  
cgctggcagc agtgcacagca gcagccgcca gcaccgtctt ggccacggcc 150  
ctctctccag cccctacgac catggacttt accccagctc cactggagga 200  
cacccctca cgcccccata tctgcaggta gccatgttag tgccgcct 250  
5 cccccccccg ctgcccgcgt ggggtcagcc tcacacaga tggctgttag 300  
tgctgttaaga tgtgcgcgtca gcagcttggg gacaactgca cggaggctgc 350  
catctgtgac ccccacccgg gcctctactg tgactacagc ggggaccgccc 400  
cgaggtacgc aataggagtg tgtgcacgca gggaaagaagt gtctggctgt 450  
gtaccagcca gaggcatcca tgaacttcac acttgcgggc tgcacatcagca 500  
10 cacgctccata tcaacccaaag tactgtggag tttgcattgga caacaggtgc 550  
tgcatccccata acaagtctaa gactatcgac gtgtccttcc agtgcctgta 600  
tgggcttggc ttctcccgcc aggtcctatg gattaatgcc tgcttctgta 650  
acctgagctg taggaatccc aatgacatct ttgctgactt ggaatcctac 700  
cctgacttct cagaaattgc caactaggca ggcacaaatc ttgggtcttg 750  
15 gggactaacc caatgcctgt gaagcagtca gcccttatgg ccaataactt 800  
ttcaccaatg agccttagtt accctgatct ggacccttgg cctccatttc 850  
tgtctctaac cattcaaatg acgcctgatg gtgctgctca ggcccatgct 900  
atgagtttc tccttgatat cattcagcat ctactctaaa gaaaaatgcc 950  
tgtctctagc tggtctggac tacacccaaag cctgatccag cctttccaaag 1000  
20 tcactagaag tcctgctgga tcttgctaa atcccaagaa atggaatcag 1050  
gttagactttt aataactacta atttcttctt tagatgccaa accacaagac 1100  
tctttgggtc cattcagatg aatagatgga atttggaaaca atagaataat 1150  
ctattatgg gaggctgcca agaggtactg taatgggtaa ttctgacgtc 1200  
ag 1202  
25 <210> 27  
<211> 1183  
<212> DNA  
<213> Human  
  
<400> 27  
30 cagaacagct agagacaggc atttttcttt agagtagatg ctgaatgata 50  
tcaaggagaa aactcatagc atgggcctga gcagcaccat caggcgtcat 100  
ttgaatggtt agagacagaa atggaggcca agggccaga tcagggttaac 150

taaggctcat tggtgaaaag ttattggcca taagggctga ctgcttcaca 200  
ggcattgggt tagtcccaa gaccaagat ttgtgcctgc ctagttggca 250  
atttctgaga agtcaggta ggattccaag tcagcaaaga tgtcattggg 300  
attcctacag ctcaggta agaagcaggc attaatccat aggacctggc 350  
5 gggagaagcc aagcccatca ggacactgga aggacacgac gatagtctta 400  
gacttgttagg ggtgcagca cctattgtcc atgcaaactc cacagtactt 450  
gggttgatag gagcgtgtgc ttagtgcagcc cgcaagtgtg aagttcatgg 500  
atgcctctgg ctggtaacaca gccagacact tcttcctgc cttaatgagt 550  
gtatggatgt ccacatcgca tggccgcaag ttgcagagggc ggctctttg 600  
10 ctcaggccag cactggcgta taacattgga gatccgagtg gagacccca 650  
ggccgcagct ggtggagcaa gggctccagg ggcttgcgtt ggctatgcag 700  
ttcctgtgcc atgcctccac ctcacccaca gcatctgtgt gtggggaaaca 750  
gaatctgcat gaatctacag ctcccaccag cccccaacgc tcactttcac 800  
cacactaagg tctgcgggcc ccagaactca gaggaacaca gaaattggct 850  
15 gtacctcccc acuggacagc aagttggctt ctaaccagca aaggtaccca 900  
gggagtggag gacatgttct cagctcttg tatgtttctg atcaagagag 950  
gcagtgtgga agcatggag gaaacccatc ttttagagaca ggtggatccc 1000  
agttcaaatt ctgctctacc acctacaagc tgtgtgtatct tagataaccc 1050  
accctgggcc tgcctccccca tttagaacaat aacacctgccc tgcggctg 1100  
20 gcaacacaat aataaggccc tagatttta ctgagttatgc atcaatcatc 1150  
cttgctaagt gctggaaatg ggacttttt ttt 1183

<210> 28  
<211> 546  
<212> DNA  
25 <213> Human

<400> 28  
cctgatctgg acccttggcc tccaattctg tctgttaacca ttcaaattgac 50  
gcctgggtgtt gctgctcagg cccatagcaa gtttcagcct ggttaagtcc 100  
aagctgaatt agcggcccg tgcacagtag gagtgcgtgc acatgctgtg 150  
30 ggtgaggtgg aggcattggca caggaactgc atagcctaca caagccctg 200  
gagcccttgc tccaccagct gcccggctggg ggtctccact cggatctcca 250  
atgttaacgc ccagtgcgtt cctgagcaag agagccgcct ctgcaacttg 300

cggccatgcg atgtggacat ccatacactc attaaggcag ggaagaagtg 350  
 tctggctgtg taccagccag aggcattccat gaacttcaca cttgcgggct 400  
 gcatcagcac acgctcctat caacccaagt actgtggagt ttgcatggac 450  
 aataggtgct gcatacccta caagtctaag actatcgacg tgccttcca 500  
 5 gtgtcctgat gggcttggct tctccgcca ggtcctatgg attaat 546  
  
 <210> 29  
 <211> 1101  
 <212> DNA  
 <213> Human  
  
 10 <400> 29  
 ggcggcagctc ccccgagagg tggtcggatc ctctgggctg ctcggtcgt 50  
 gcctgtgcca ctgacgtcca ggcattgggt ggttcctgcc ctggacgctg 100  
 gcagcagtga cagcagcagc cgccagcacc gtcctggcca cggccctctc 150  
 tccagccct acgaccatgg actttacccc agtccactg gaggacacct 200  
 15 cctcacgccc ccaattctgc aagtggccat gtgagtgccc gccatcccc 250  
 ccccgctgcc cgctgggggt cagcctcatc acagatggct gtgagtgctg 300  
 taagatgc gtcagcagc ttggggacaa ctgcacggag gctgccatct 350  
 gtgaccccca cgggggcctc tacttgact acagcgggga cggcccgaga 400  
 ggtggtcggt gtgggctgctg tcctggatgg ggtgcgctac aacaacggcc 450  
 20 agtccttcca gcctaactgc aagtacaact gcacgtgcat cgacggcg 500  
 gtgggctgca caccactgtg cctccgagtg cgccccccgc gtctctgg 550  
 ccccccacccg cggcgcgtga gcataacctgg ccactgctgt gagcagtgg 600  
 tatgtgagga cgacgccaag aggccacgca agaccgcacc ccgtgacaca 650  
 ggagccttcg atgccagaag cgcccgctcc ctcagagatg tgacaaccaa 700  
 25 aatcatctcc agaccttcc aaatacacccc taggagacaa aattgctcg 750  
 tggagaagca gtccctgtgag gacaggagga ggcgtggagg aaagctttgt 800  
 ccccgccagc cccaggaaag caaggcagct ctcccaccac cacccccc 850  
 ggagggccac acgagggtca cggggggagc agggaggcgg aagctgtctg 900  
 ccattgtgtc tggcccgatgt accctgttct gaccgagcac aagcggagcc 950  
 30 cctgccttagc cgagatgctg tgggtgaggt ggaggcatgg cacaggaact 1000  
 gcatagccta cacaagcccc tggagccctt gtcaccacag ctgcggcctg 1050  
 ggggtctcca ctcggatctc caatgttaac gcccagtgtc ggcctgagca 1100

a 1101

<210> 30  
<211> 1335  
<212> DNA  
5 <213> Human

<220>  
<221> Unknown  
<222> 1205  
<223> Any nucleotide

10 <220>  
<221> Unknown  
<222> 1318  
<223> Any nucleotide

<400> 30  
15 gtggggtttg cagaggagac aggggagctt tgtgtacccg gagcaatgaa 50  
caagcggcga cttctctacc cctcagggtg gctccacggt cccagcgaca 100  
tgcaaaaaatc ctttttttcc actcttctgc ttgtctggct ggcacagttc 150  
tgctgcaggg tacagggcac tggaccatttata gatacaacac ctgaaggaaag 200  
gcctggagaa gtgtcagatg cacccctcagcg taaacagttt tgtcaactggc 250  
20 cttgtcaatgc ccctcagcag aagccccgtt gccctctgg agtgaggctg 300  
gtgagagatg gctgtggatg ctgtaaaatc tgtgccaagc aaccagggaa 350  
aatctgcaat gaagctgacc tctgtgaccc acacaaagggttctgttgc 400  
actactcagt agacaggcct aggtacgaga ctggagtgtg tgcatacctt 450  
gttagctgttg ggtgcgagtt caaccaggta cattatcata atggccaagt 500  
25 gtttcagccc aaccccttgt tcagctgcct ctgtgtgagt gggccattt 550  
gatgcacacc tctgttcata ccaaagctgg ctggcagtca ctgctctgga 600  
gctaaagggttgc gaaagaagtc tgatcagtca aactgttagcc tggaaccattt 650  
actacagcag ctttcaacaa gctacaaaac aatgccagct tatagagatc 700  
tccccacttat ttggaaaaaaa aaatgtcttg tgcaagcaac aaaatggact 750  
30 ccctgctcca gaacatgtgg gatggaaata tctaacagggttgcaccaatga 800  
aaacagcaac tgtgaaatga gaaaagagaa aagactgtgt tacattcagc 850  
cttgcgacag caatatatta aagacaataa agattcccaa aggaaaaaca 900  
tgccaaaccta ctttccaaact ctccaaagct gaaaaatttg tctttctgg 950  
atgctcaagt actcagagtt acaaaccac tttttgtgga atatgctgg 1000  
35 ataagagatg ctgtatccct aataagtcta aaatgattac tattcaattt 1050

gattgcccaa atgaggggtc atttaaatgg aagatgctgt ggattacatc 1100  
ttgtgtgtgt cagagaaact gcagagaacc tggagatata ttttctgagc 1150  
tcaagattct gtaaaaccaa gcaaattgggg gaaaagttag tcaatcctgt 1200  
catanaataa aaaaattagt gagtataaaa tggtggcaa tctactttgt 1250  
5 ttaaaacagt atgaatgcct attctcagat cactacattt aaggcattag 1300  
aaacttttaa aaagttanct taaaaatata cataa 1335  
  
<210> 31  
<211> 1335  
<212> DNA  
10 <213> Human  
  
<220>  
<221> Unknown  
<222> 131  
<223> Any nucleotide  
  
15 <220>  
<221> Unknown  
<222> 18  
<223> Any nucleotide  
  
<400> 31  
20 ttatgtatat tttaagnnta actttttaaa agtttctaat gccttaatg 50  
tagtgatctg agaataggca ttctactgt tttaaacaataa gtagattgc 100  
caccatttta tactcactaa tttttttatt ntatgacagg attgactaac 150  
tttccccca tttgcttggt tttacagaat cttagctca gaaaatataat 200  
ctccagggttc tctgcagttt ctctgacaca cacaagatgt aatccacagc 250  
25 atcttccatt taaatgaccc ctcatggg caatcaaatt gaatagtaat 300  
cattttagac ttatttaggga tacagcatct ctatccaag catattccac 350  
aaaaagtggg tttgttaactc tgagtacttg agcatccaga aaagacaaat 400  
tttcagctt tggagagttg gaaagttaggt tggcatgttt ttccttggg 450  
aatcttatt gtcttaata tattgctgtc gcaaggctga atgtaacaca 500  
30 gtctttctc ttttctcatt tcacagttgc tgttttcatt ggtcacccctg 550  
ttagatattc ccatccaca tggctggag cagggagtcc attttggc 600  
ttgcacaaga cattttttt tccaaataag tgggagatct ctataagctg 650  
gcattgtttt gtagcttggt gaaagctgt gtagtaatgg ttccaggctt 700  
cagtttact gatcagactt cttccaccc ttagctccag agcagtgact 750  
35 gccagccagc tttggtatga acagagggtt gcatccaatg gccccactca 800

cacagaggca gctgaacaag gggttggct gaaacacttg gccattatga 850  
 taatgtacct ggttgaactc gcacccaaca gctacaaggt atgcacacac 900  
 tccagtctcg tacctaggcc tgtctactga gtatgcacaa tacagccctt 950  
 tgtgtgggtc acagaggtaa gttcattgc agatccc tggttgcttg 1000  
 5 gcacagattt tacagcatcc acagccatct ctcaccaggc tcactccagg 1050  
 agggcaacgg ggcttctgtct gaggcattt gcaggccag tgacaaaact 1100  
 gtttacgctg aggtgcattt gacacttctc cagggcttcc ttcaggtgtt 1150  
 gtatctaattt gtccagtgcc ctgtaccctg cagcagaact gtgccaggcc 1200  
 agcaagcaga agagtggaga agaggagccc ctgcattgtcg ctgggaccgt 1250  
 10 ggagccaccc tgagggtagt agaagtcgcc gcttggcat tgctccgggt 1300  
 acacaaagct cccctgtctc ctctgcaaac cccac 1335  
  
 <210> 32  
 <211> 339  
 <212> PRT  
 15 <213> Human  
  
 <400> 32  
 Gln Phe Cys Cys Arg Val Gln Gly Thr Gly Pro Leu Asp Thr Thr  
 1 5 10 15  
  
 20 Pro Glu Gly Arg Pro Gly Glu Val Ser Asp Ala Pro Gln Arg Lys  
 20 25 30  
  
 Gln Phe Cys His Trp Pro Cys Lys Cys Pro Gln Gln Lys Pro Arg  
 35 40 45  
  
 Cys Pro Pro Gly Val Ser Leu Val Arg Asp Gly Cys Gly Cys Cys  
 50 55 60  
  
 25 Lys Ile Cys Ala Lys Gln Pro Gly Glu Ile Cys Asn Glu Ala Asp  
 65 70 75  
  
 Leu Cys Asp Pro His Lys Gly Leu Tyr Cys Asp Tyr Ser Val Asp  
 80 85 90  
  
 30 Arg Pro Arg Tyr Glu Thr Gly Val Cys Ala Tyr Leu Val Ala Val  
 95 100 105  
  
 Gly Cys Glu Phe Asn Gln Val His Tyr His Asn Gly Gln Val Phe  
 110 115 120  
  
 Gln Pro Asn Pro Leu Phe Ser Cys Leu Cys Val Ser Gly Ala Ile  
 125 130 135  
  
 35 Gly Cys Thr Pro Leu Phe Ile Pro Lys Leu Ala Gly Ser His Cys  
 140 145 150  
  
 Ser Gly Ala Lys Gly Lys Lys Ser Asp Gln Ser Asn Cys Ser

	155	160	165
	Leu Glu Pro Leu Leu Gln Gln Leu Ser Thr Ser Tyr Lys Thr Met		
	170	175	180
5	Pro Ala Tyr Arg Asp Leu Pro Leu Ile Trp Lys Lys Lys Cys Leu		
	185	190	195
	Val Gln Ala Thr Lys Trp Thr Pro Cys Ser Arg Thr Cys Gly Met		
	200	205	210
	Gly Ile Ser Asn Arg Val Thr Asn Glu Asn Ser Asn Cys Glu Met		
	215	220	225
10	Arg Lys Glu Lys Arg Leu Cys Tyr Ile Gln Pro Cys Asp Ser Asn		
	230	235	240
	Ile Leu Lys Thr Ile Lys Ile Pro Lys Gly Lys Thr Cys Gln Pro		
	245	250	255
15	Thr Phe Gln Leu Ser Lys Ala Glu Lys Phe Val Phe Ser Gly Cys		
	260	265	270
	Ser Ser Thr Gln Ser Tyr Lys Pro Thr Phe Cys Gly Ile Cys Leu		
	275	280	285
	Asp Lys Arg Cys Cys Ile Pro Asn Lys Ser Lys Met Ile Thr Ile		
	290	295	300
20	Gln Phe Asp Cys Pro Asn Glu Gly Ser Phe Lys Trp Lys Met Leu		
	305	310	315
	Trp Ile Thr Ser Cys Val Cys Gln Arg Asn Cys Arg Glu Pro Gly		
	320	325	330
25	Asp Ile Phe Ser Glu Leu Lys Ile Leu		
	335	339	
	<210> 33		
	<211> 372		
	<212> PRT		
	<213> Human		
30	<400> 33		
	Met Asn Lys Arg Arg Leu Leu Tyr Pro Ser Gly Trp Leu His Gly		
	1	5	10
			15
	Pro Ser Asp Met Gln Gly Leu Leu Phe Ser Thr Leu Leu Ala		
	20	25	30
35	Gly Leu Ala Gln Phe Cys Cys Arg Val Gln Gly Thr Gly Pro Leu		
	35	40	45
	Asp Thr Thr Pro Glu Gly Arg Pro Gly Glu Val Ser Asp Ala Pro		
	50	55	60
40	Gln Arg Lys Gln Phe Cys His Trp Pro Cys Lys Cys Pro Gln Gln		
	65	70	75

	Lys Pro Arg Cys Pro Pro Gly Val Ser Leu Val Arg Asp Gly Cys		
	80	85	90
	Gly Cys Cys Lys Ile Cys Ala Lys Gln Pro Gly Glu Ile Cys Asn		
	95	100	105
5	Glu Ala Asp Leu Cys Asp Pro His Lys Gly Leu Tyr Cys Asp Tyr		
	110	115	120
	Ser Val Asp Arg Pro Arg Tyr Glu Thr Gly Val Cys Ala Tyr Leu		
	125	130	135
10	Val Ala Val Gly Cys Glu Phe Asn Gln Val His Tyr His Asn Gly		
	140	145	150
	Gln Val Phe Gln Pro Asn Pro Leu Phe Ser Cys Leu Cys Val Ser		
	155	160	165
	Gly Ala Ile Gly Cys Thr Pro Leu Phe Ile Pro Lys Leu Ala Gly		
	170	175	180
15	Ser His Cys Ser Gly Ala Lys Gly Lys Lys Ser Asp Gln Ser		
	185	190	195
	Asn Cys Ser Leu Glu Pro Leu Leu Gln Gln Leu Ser Thr Ser Tyr		
	200	205	210
20	Lys Thr Met Pro Ala Tyr Arg Asp Leu Pro Leu Ile Trp Lys Lys		
	215	220	225
	Lys Cys Leu Val Gln Ala Thr Lys Trp Thr Pro Cys Ser Arg Thr		
	230	235	240
	Cys Gly Met Gly Ile Ser Asn Arg Val Thr Asn Glu Asn Ser Asn		
	245	250	255
25	Cys Glu Met Arg Lys Glu Lys Arg Leu Cys Tyr Ile Gln Pro Cys		
	260	265	270
	Asp Ser Asn Ile Leu Lys Thr Ile Lys Ile Pro Lys Gly Lys Thr		
	275	280	285
30	Cys Gln Pro Thr Phe Gln Leu Ser Lys Ala Glu Lys Phe Val Phe		
	290	295	300
	Ser Gly Cys Ser Ser Thr Gln Ser Tyr Lys Pro Thr Phe Cys Gly		
	305	310	315
	Ile Cys Leu Asp Lys Arg Cys Cys Ile Pro Asn Lys Ser Lys Met		
	320	325	330
35	Ile Thr Ile Gln Phe Asp Cys Pro Asn Glu Gly Ser Phe Lys Trp		
	335	340	345
	Lys Met Leu Trp Ile Thr Ser Cys Val Cys Gln Arg Asn Cys Arg		
	350	355	360
40	Glu Pro Gly Asp Ile Phe Ser Glu Leu Lys Ile Leu		
	365	370	372

<210> 34  
<211> 1212  
<212> DNA  
<213> Human

5    <400> 34  
      cacgggtccca gcgacatgca ggggctcctc ttctccactc ttctgcttgc 50  
              tggcctggca cagttctgtc gcagggtaca gggcactgga ccattagata 100  
              caaacacctga aggaaggcct ggagaagtgt cagatgcacc tcagcgtaaa 150  
              cagtttgtc actggccctg caaatgccct cagcagaagc cccgttgccc 200  
10    tcctggagtg agcctggtga gagatggctg tggatgctgt aaaatctgtg 250  
              ccaagcaacc aggggaaatc tgcaatgaag ctgacctctg tgacccacac 300  
              aaagggtgtt atttgacta ctcagtagac aggcttaggt acgagactgg 350  
              agtgtgtgca tacctttagt ctgttgggtg cgagttcaac caggtacatt 400  
              atcataatgg ccaagtgttt cagcccaacc ccttggtagt ctgcctctgt 450  
15    gtgagtgggg ccattggatg cacacctctg ttcataccaa agctggctgg 500  
              cagtcactgc tctggagcta aaggtggaaa gaagtctgtat cagtcaaact 550  
              gtagcctgga accattacta cagcagcttc caacaagcta caaaacaatg 600  
              ccagcttata gaaatctccc acttatttgg aaaaaaaaaat gtcttggca 650  
              agcaacaaaa tggactccct gtcggagaac atgtgggatg ggaatatcta 700  
20    acagggtgac caatgaaaaac agcaactgtg aaatgagaaa agagaaaaaga 750  
              ctgtgttaca ttcagccttg cgacagcaat atattaaaga caataaagat 800  
              tcccaagga aaaacatgcc aacctacttt ccaactctcc aaagctgaaa 850  
              aatttgtctt ttctggatgc tcaagtactc agagttacaa acccactttt 900  
              tgtggatat gcttggataa gagatgctgt atccctaata agtctaaaat 950  
25    gattactatt caatttgatt gcccaaatga ggggtcattt aaatggaaga 1000  
              tgctgtggat tacatcttgt gtgtgtcaga gaaactgcag agaacctgga 1050  
              gatataatttt ctgagctcaa gattctgtaa aaccaagcaa atggggaaaa 1100  
              agtttagtcaa tcctgtcata taataaaaaa atttagtgagt aaaaaaaaaa 1150  
              aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa agaaaaaaaa 1200  
30    aaaaaaaaaaa aa 1212

<210> 35  
<211> 1212  
<212> DNA

&lt;213&gt; Human

&lt;400&gt; 35

ttttttttt tttttttttt cttttttttt tttttttttt tttttttttt 50

ttttttttt tttttttttt ttactcacta attttttat tataatgacag 100

5 gattgactaa cttttcccccc atttgcttgg ttttacagaa tcttgagctc 150

agaaaatata tctccaggtt ctctgcagtt tctctgacac acacaagatg 200

taatccacag catctccat ttaaatgacc cctcatttgg gcaatcaa 250

tgaatagtaa tcattttaga cttatttaggg atacagcattc tcttatccaa 300

gcatattcca caaaaagtgg gtttgttaact ctgagttactt gagcatccag 350

10 aaaagacaaa tttttcagct ttggagagtt ggaaagttagg ttggcatgtt 400

tttcctttgg gaatctttat tgtcttaat atattgctgt cgcaaggctg 450

aatgtaacac agtctttct cttttctcat ttcacagttg ctgtttcat 500

tggtcacccct gttagatatt cccatccac atgttctggg gcagggagtc 550

cattttgttg cttgcacaaag acattttttt ttccaaataa gtgggagatt 600

15 tctataagct ggcattgttt tgttagttgt tgaaagctgc tgttagtaatg 650

gttccaggct acagtttgc tgatcagact tctttccacc tttagctcca 700

gagcagtgc tgccagccag ctttggatag aacagaggtg tgcatccaa 750

ggccccactc acacagagggc agctgaacaa ggggttgggc tgaaacactt 800

ggccattatg ataatgtacc tggttgaact cgcacccaaac agctacaagg 850

20 tatgcacaca ctccagtctc gtaccttaggc ctgtctactg agtagtcaca 900

atacagccct ttgtgtgggt cacagaggtc agcttcatttgc cagatttccc 950

ctggttgctt ggcacagatt ttacagcattc cacagccatc tctcaccagg 1000

ctcaactccag gagggaacg gggcttctgc tgagggcatt tgcaaggcc 1050

gtgacaaaac tgtttacgtt gaggtgcattc tgacacttctt ccaggccttc 1100

25 cttcaggtgt tgtatctaat ggtccagtgc cctgtaccct gcagcagaac 1150

tgtgccaggc cagcaaggcag aagagtggag aagaggagcc cctgcattgtc 1200

gctgggaccg tg 1212

&lt;210&gt; 36

&lt;211&gt; 339

30 &lt;212&gt; PRT

&lt;213&gt; Human

&lt;400&gt; 36

	Gln	Phe	Cys	Cys	Arg	Val	Gln	Gly	Thr	Gly	Pro	Leu	Asp	Thr	Thr	
1						5					10				15	
	Pro	Glu	Gly	Arg	Pro	Gly	Glu	Val	Ser	Asp	Ala	Pro	Gln	Arg	Lys	
						20					25				30	
5	Gln	Phe	Cys	His	Trp	Pro	Cys	Lys	Cys	Pro	Gln	Gln	Lys	Pro	Arg	
						35				40					45	
	Cys	Pro	Pro	Gly	Val	Ser	Leu	Val	Arg	Asp	Gly	Cys	Gly	Cys	Cys	
						50				55					60	
10	Lys	Ile	Cys	Ala	Lys	Gln	Pro	Gly	Glu	Ile	Cys	Asn	Glu	Ala	Asp	
						65				70					75	
	Leu	Cys	Asp	Pro	His	Lys	Gly	Leu	Tyr	Cys	Asp	Tyr	Ser	Val	Asp	
						80				85					90	
	Arg	Pro	Arg	Tyr	Glu	Thr	Gly	Val	Cys	Ala	Tyr	Leu	Val	Ala	Val	
						95				100					105	
15	Gly	Cys	Glu	Phe	Asn	Gln	Val	His	Tyr	His	Asn	Gly	Gln	Val	Phe	
						110				115					120	
	Gln	Pro	Asn	Pro	Leu	Phe	Ser	Cys	Leu	Cys	Val	Ser	Gly	Ala	Ile	
						125				130					135	
20	Gly	Cys	Thr	Pro	Leu	Phe	Ile	Pro	Lys	Leu	Ala	Gly	Ser	His	Cys	
						140				145					150	
	Ser	Gly	Ala	Lys	Gly	Gly	Lys	Lys	Ser	Asp	Gln	Ser	Asn	Cys	Ser	
						155				160					165	
	Leu	Glu	Pro	Leu	Leu	Gln	Gln	Leu	Ser	Thr	Ser	Tyr	Lys	Thr	Met	
						170				175					180	
25	Pro	Ala	Tyr	Arg	Asn	Leu	Pro	Leu	Ile	Trp	Lys	Lys	Lys	Cys	Leu	
						185				190					195	
	Val	Gln	Ala	Thr	Lys	Trp	Thr	Pro	Cys	Ser	Arg	Thr	Cys	Gly	Met	
						200				205					210	
30	Gly	Ile	Ser	Asn	Arg	Val	Thr	Asn	Glu	Asn	Ser	Asn	Cys	Glu	Met	
						215				220					225	
	Arg	Lys	Glu	Lys	Arg	Leu	Cys	Tyr	Ile	Gln	Pro	Cys	Asp	Ser	Asn	
						230				235					240	
	Ile	Leu	Lys	Thr	Ile	Lys	Ile	Pro	Lys	Gly	Lys	Thr	Cys	Gln	Pro	
						245				250					255	
35	Thr	Phe	Gln	Leu	Ser	Lys	Ala	Glu	Lys	Phe	Val	Phe	Ser	Gly	Cys	
						260				265					270	
	Ser	Ser	Thr	Gln	Ser	Tyr	Lys	Pro	Thr	Phe	Cys	Gly	Ile	Cys	Leu	
						275				280					285	
40	Asp	Lys	Arg	Cys	Cys	Ile	Pro	Asn	Lys	Ser	Lys	Lys	Met	Ile	Thr	Ile
						290				295					300	

	Gln Phe Asp Cys Pro Asn Glu Gly Ser Phe Lys Trp Lys Met Leu			
	305	310	315	
	Trp Ile Thr Ser Cys Val Cys Gln Arg Asn Cys Arg Glu Pro Gly			
	320	325	330	
5	Asp Ile Phe Ser Glu Leu Lys Ile Leu			
	335	339		
	<210> 37			
	<211> 354			
	<212> PRT			
10	<213> Human			
	<400> 37			
	Met Gln Gly Leu Leu Phe Ser Thr Leu Leu Leu Ala Gly Leu Ala			
	1	5	10	15
15	Gln Phe Cys Cys Arg Val Gln Gly Thr Gly Pro Leu Asp Thr Thr			
	20	25	30	
	Pro Glu Gly Arg Pro Gly Glu Val Ser Asp Ala Pro Gln Arg Lys			
	35	40	45	
	Gln Phe Cys His Trp Pro Cys Lys Cys Pro Gln Gln Lys Pro Arg			
	50	55	60	
20	Cys Pro Pro Gly Val Ser Leu Val Arg Asp Gly Cys Gly Cys Cys			
	65	70	75	
	Lys Ile Cys Ala Lys Gln Pro Gly Glu Ile Cys Asn Glu Ala Asp			
	80	85	90	
25	Leu Cys Asp Pro His Lys Gly Leu Tyr Cys Asp Tyr Ser Val Asp			
	95	100	105	
	Arg Pro Arg Tyr Glu Thr Gly Val Cys Ala Tyr Leu Val Ala Val			
	110	115	120	
	Gly Cys Glu Phe Asn Gln Val His Tyr His Asn Gly Gln Val Phe			
	125	130	135	
30	Gln Pro Asn Pro Leu Phe Ser Cys Leu Cys Val Ser Gly Ala Ile			
	140	145	150	
	Gly Cys Thr Pro Leu Phe Ile Pro Lys Leu Ala Gly Ser His Cys			
	155	160	165	
35	Ser Gly Ala Lys Gly Gly Lys Ser Asp Gln Ser Asn Cys Ser			
	170	175	180	
	Leu Glu Pro Leu Leu Gln Gln Leu Ser Thr Ser Tyr Lys Thr Met			
	185	190	195	
	Pro Ala Tyr Arg Asn Leu Pro Leu Ile Trp Lys Lys Lys Cys Leu			
	200	205	210	
40	Val Gln Ala Thr Lys Trp Thr Pro Cys Ser Arg Thr Cys Gly Met			
	215	220	225	

	Gly Ile Ser Asn Arg Val Thr Asn Glu Asn Ser Asn Cys Glu Met	
	230	240
	Arg Lys Glu Lys Arg Leu Cys Tyr Ile Gln Pro Cys Asp Ser Asn	
	245	255
5	Ile Leu Lys Thr Ile Lys Ile Pro Lys Gly Lys Thr Cys Gln Pro	
	260	265
	Thr Phe Gln Leu Ser Lys Ala Glu Lys Phe Val Phe Ser Gly Cys	
	275	285
10	Ser Ser Thr Gln Ser Tyr Lys Pro Thr Phe Cys Gly Ile Cys Leu	
	290	295
	Asp Lys Arg Cys Cys Ile Pro Asn Lys Ser Lys Met Ile Thr Ile	
	305	310
	Gln Phe Asp Cys Pro Asn Glu Gly Ser Phe Lys Trp Lys Met Leu	
	320	325
15	Trp Ile Thr Ser Cys Val Cys Gln Arg Asn Cys Arg Glu Pro Gly	
	335	340
	Asp Ile Phe Ser Glu Leu Lys Ile Leu	
	350	354
20	<210> 38	
	<211> 738	
	<212> DNA	
	<213> Human	
	<400> 38	
	ccgaagaccc acctctggc cttctccctc ctctgcctcc tctcaaaggt 50	
25	gcgtacccag ctgtgcccga caccatgtac ctgccccctgg ccacccccc 100	
	gatgcccgt gggagtaccc ctgggtgtgg atggctgtgg ctgctgccgg 150	
	gtatgtgcac ggccggctggg ggagccctgc gaccaactcc acgtctgcga 200	
	cgcacccag ggcctggct cccagccccc ggcaggaccc ggtggccggg 250	
	ggccctgtg cctttggca gaggacgaca gcagctgtga ggtgaacggc 300	
30	cgcctgtatc gggaaaggaaa gaccttccag ccccaactgca gcatccgctg 350	
	ccgctgcgag gacggcggct tcacctgcgt gccgctgtgc agcgaggatg 400	
	tgcggctgcc cagctggac tgccccacc ccaggagggt cgaggtcctg 450	
	ggcaagtgtc gcccgtggc caaggagggg gactggggac 500	
	ccagcccctt ccagccccaaag gaccccaagtt ttctggccctt gtctttccc 550	
35	tgccccctgg tgtccccctgc ccagaatgga gcacggcctg gggaccctgc 600	
	tcgaccacct gtgggctggg catggccacc cgggtgtcca accagaaccg 650	

cttctgccga ctggagaccc agcgccgcct gtgcctgtcc aggcctycc 700  
caccctccag gggtcgcagt ccacaaaaca gtgccttc 738

5 <210> 39  
<211> 841  
<212> DNA  
<213> Artificial

10 <220>  
<221> Artificial  
<222> 1-841  
<223> Sequence is synthesized

15 <400> 39  
ctgcagggga catgagaggc acacccaaga cccacccctt ggccttctcc 50  
ctcctctgcc tcctctcaaa ggtgcgtacc cagctgtgcc cgacaccatg 100  
tacctgcccc tggccaccc cccgatgccc gctgggagta cccctggtgg 150  
15 tggatggctg tggctgctgc cgggtatgtg cacggcggct gggggagccc 200  
tgcgaccaac tccacgtctg cgacgcccgc cagggcctgg tctgccagcc 250  
cggggcagga cccgggtggcc gggggccct gtgcctcttg gcagaggacg 300  
acagcagctg tgaggtgaac ggccgcctgt atcgggaagg ggagaccc 350  
cagccccact gcagcatccg ctgcccgtgc gaggacggcg gcttcacctg 400  
20 cgtgccgctg tgcagcgagg atgtgcggct gcccagctgg gactgcccc 450  
accccaggag ggtcgaggc ctggcaagt gctgccctga gtgggtgtgc 500  
ggccaaaggag ggggactggg gaccagccct tccagcccaa ggaccccaagt 550  
tttctggct tgcctcttcc ctgccccctg gtgtccccctg cccagaatgg 600  
agcacggcct ggggaccctg ctcgaccacc tgcggctgg gcatggccac 650  
25 ccgggtgtcc aaccagaacc gcttctgccg actggagacc cagcgccgccc 700  
tgtgcctgtc caggccctgc ccaccctcca ggggtcgcaag tccacaaaac 750  
agtgccttct agagccggc tggaaatggg gacacggtgtt ccaccatccc 800  
cagctggtgg ccctgtgcct gggccctggg ctgatggaag a 841

30 <210> 40  
<211> 14  
<212> DNA  
<213> Artificial sequence

35 <220>  
<221> Artificial  
<222> 1-14  
<223> Sequence is synthesized

<400> 40  
ttttgtacaa gctt 14

<210> 41  
<211> 44  
5 <212> DNA  
<213> Artificial sequence

<220>  
<221> Artificial  
<222> 1-44  
10 <223> Sequence is synthesized

<400> 41  
ctaatacgac tcactatagg gctcgagcgg ccgcggggc aggt 44

<210> 42  
<211> 43  
15 <212> DNA  
<213> Artificial sequence

<220>  
<221> Artificial  
<222> 1-43  
20 <223> Sequence is synthesized

<400> 42  
tgtagcgtga agacgacaga aagggcgtgg tgcggagggc ggt 43

<210> 43  
<211> 10  
25 <212> DNA  
<213> Artificial Sequence

<220>  
<221> Artificial  
<222> 1-10  
30 <223> Sequence is synthesized

<400> 43  
acctgcccgg 10

<210> 44  
<211> 11  
35 <212> DNA  
<213> Artificial sequence

<220>  
<221> Artificial  
<222> 1-11  
40 <223> Sequence is synthesized

<400> 44  
accgcctcc g 11

<210> 45  
<211> 22  
45 <212> DNA  
<213> Artificial sequence

```
<220>
<221> Artificial
<222> 1-22
<223> Sequence is synthesized

5   <400> 45
      ctaatacgac tcactatagg gc 22

      <210> 46
      <211> 21
      <212> DNA
10  <213> Artificial sequence

      <220>
      <221> Artificial
      <222> 1-21
      <223> Sequence is synthesized

15  <400> 46
      tgttagcgtga agacgacaga a 21

      <210> 47
      <211> 22
      <212> DNA
20  <213> Artificial sequence

      <220>
      <221> Artificial
      <222> 1-22
      <223> Sequence is synthesized

25  <400> 47
      tcgagcggcc gcccgccag gt 22

      <210> 48
      <211> 22
      <212> DNA
30  <213> Artificial sequence

      <220>
      <221> Artificial
      <222> 1-22
      <223> Sequence is synthesized

35  <400> 48
      agggcgtggc gcggaggggcgt 22

      <210> 49
      <211> 20
      <212> DNA
40  <213> Artificial sequence

      <220>
      <221> Artificial
      <222> 1-20
      <223> Sequence is synthesized

45  <400> 49
      accacagtcc atgccatcac 20
```

<210> 50  
<211> 20  
<212> DNA  
<213> Artificial sequence

5 <220>  
<221> Artificial  
<222> 1-20  
<223> Sequence is synthesized

<400> 50  
10 tccaccaccc tgttgctgta 20

<210> 51  
<211> 163  
<212> DNA  
<213> Artificial sequence

15 <220>  
<221> Artificial  
<222> 1-163  
<223> Sequence is synthesized

<400> 51  
20 tgtaatacga ctcactatacg ggcgaattgg gccccacgtc gcatgctccc 50  
ggccgcccattg gcccgggat tatcactagt gcggccgcct gcaggtcgac 100  
catatgggag agctcccaac gcgttggatg catagcttga gtattctata 150  
gtgtcaccta aat 163

<210> 52  
25 <211> 163  
<212> DNA  
<213> Artificial sequence

<220>  
<221> Artificial  
30 <222> 1-163  
<223> Sequence is synthesized

<400> 52  
atttaggtga cactatagaa tactcaagct atgcattccaa cgcgttggga 50  
gctctccat atggtcgacc tgcaggcgcc cgcactagtg attatccgc 100  
35 ggcattggcg gcccggagca tgcgacgtcg gcccatttc gccctatagt 150  
gagtcgtatt aca 163

<210> 53  
<211> 10325  
<212> DNA  
40 <213> Artificial

<220>  
<221> Artificial  
<222> 1-10325

<223> Sequence is synthesized

<400> 53  
ttcgagctcg cccgacattg attattgact agagtcgatc accggttatt 50  
aatagtaatc aattacgggg tcatagttca tagccatat atggagttcc 100  
5 gcgttacata acttacggta aatggcccgc ctggctgacc gcccaacgac 150  
ccccgccccat tgacgtcaat aatgacgtat gttcccatag taacgccaat 200  
agggactttc cattgacgtc aatgggtgga gtatttacgg taaaactgccc 250  
acttggcagt acatcaagtg tatcatatgc caagtacgccc ccctattgac 300  
gtcaatgacg gtaaaatggcc cgcctggcat tatgcccagt acatgacctt 350  
10 atgggacttt cctacttggc agtacatcta cgtatttagtc atcgcttatta 400  
ccatggtgat gcgggtttgg cagtacatca atgggcgtgg atagcggttt 450  
gactcacggg gatttccaag tctccacccc attgacgtca atgggagttt 500  
gttttggcac caaaatcaac gggactttcc aaaatgtcgt aacaactccg 550  
ccccattgac gcaaatggc ggttaggcgtg tacggtgaaa ggtctatata 600  
15 agcagagtc gtttagtgaa ccgtcagatc gcctggagac gccatccacg 650  
ctgttttgac ctggggcccg ccgaggccgc ctggccctct gagctattcc 700  
agaagtagtg aggaggctt tttggaggcc taggcttttcaaaaaagcta 750  
gcttatccgg ccgggaacgg tgcattggaa cgcggattcc ccgtgccaag 800  
agtgacgtaa gtaccgccta tagagcgact agtccaccat gaccgagttac 850  
20 aagccccacgg tgcgcctcgc caccggcgac gacgtcccgcc gggccgtacg 900  
caccctcgcc gccgcgttgc ccgactaccc cgccacgcgc cacaccgtag 950  
acccggaccg ccacatcgag cgggtcaccg agctgcaaga actcttcctc 1000  
acgcgcgtcg ggctcgacat cggcaaggtg tgggtcgccg acgacggcgc 1050  
cgcgggtggcg gtctggacca cgcggagag cgtcgaagcg ggggcgtgt 1100  
25 tcgcccagat cggcccgccgc atggccgagt tgagcggttc cggctggcc 1150  
gcgcagcaac agatggaagg cctccctggcg cccgaccggc ccaaggagcc 1200  
cgctgtggttc ctggccaccg tcggcgcttc gcccgaccac cagggcaagg 1250  
gtctggcag cgcggcgtcg ctccccggag tggaggccgc cgagcgcgc 1300  
gggggtggcccg cttccctggaa gacctcccgcc ccccgcaacc tccccttcta 1350  
30 cgagcggcgc cggccatcccg tcaccggccga cgtcgagtgc ccgaaggacc 1400

gcgcgacctg gtgcattgacc cgcaagcccc gtgccaacat ggttcgacca 1450  
ttgaactgca tcgtcgccgt gtcccaaaat atggggattt gcaagaacgg 1500  
agacctaccc tgccctccgc tcaggaacgc gttcaagtac ttccaaagaa 1550  
tgaccacaac ctcttcagtg gaaggttaaac agaatctggt gattatgggt 1600  
5 aggaaaacct ggttctccat tcctgagaag aatcgacctt taaaggacag 1650  
aattaatata gttctcagta gagaactcaa agaaccacca cgaggagctc 1700  
attttcttgc caaaagttt gatgatgcct taagacttat tgaacaaccg 1750  
gaattggcaa gtaaaagtaga catggggatgg atagtcggag gcagttctgt 1800  
ttaccaggaa gccatgaatc aaccaggcca ccttagactc tttgtgacaa 1850  
10 ggatcatgca ggaattttgaa agtgacacgt ttttccaga aattgatttg 1900  
ggaaaatata aacctctccc agaataccca ggcgtccctt ctgaggtcca 1950  
ggagggaaaaa ggcataaact ataagtttga agtctacgag aagaaagact 2000  
aacgttaact gtcctccctt taaagctatg cattttata agaccatggg 2050  
acttttgctg gcttttagatc cccttggctt cgtttagaactc cagctacaat 2100  
15 taatacataaa ccttatgtat cataacataa cgattttagt gacactata 2150  
ataacatcca ctggccctt ctctccacag gtgtccactc ccaggtccaa 2200  
ctgcaccccg gttctatcga ttgaattttt cggggatcct ctagagtcga 2250  
cctgcagaag ctgcgtatggc cgccatggcc caacttggttt attgcagctt 2300  
ataatggta caaataaagc aatagcatca caaatttcac aaataaagca 2350  
20 ttttttcac tgcatcttag ttgtgggtt tccaaactca tcaatgtatc 2400  
ttatcatgtc tggatcgatc gggaaattaat tcggcgacg accatggcct 2450  
gaaataaccc ctgaaagagg aacttggta ggtaccgact agtcgcgtt 2500  
cataacttac ggttaatggc ccgcctggct gaccgccccaa cgaccccccgc 2550  
ccattgacgt caataatgac gtatgttccc atagtaacgc caataggac 2600  
25 tttccattga cgtcaatggg tggagttttt acggtaaact gcccacttgg 2650  
cagtagatca agtgtatcat atgccaagta cgccccctat tgacgtcaat 2700  
gacggtaaat ggcccgccctg gcattatgcc cagtagatca ctttatggga 2750  
ctttcctact tggcagttaca tctacgtatt agtcatcgct attaccatgg 2800  
tgatgcgggtt ttggcagttac atcaatgggc gtggatagcg gtttgactca 2850  
30 cggggatttc caagtctcca cccattgac gtcaatggga gtttggggat 2900

actagtagca agyLcgccac gcacaagatc aatattaaca atcagtcattc 2950  
tctcttagc aataaaaagg tgaaaattta cattttaaa atgacaccat 3000  
agacgatgta tgaaaataat ctacttgaa ataaatctag gcaaagaagt 3050  
gcaagactgt tacccagaaa acttacaaat tgtaaatgag aggttagtga 3100  
5 agatttaaat gaatgaagat ctaaataaac ttataaattt tgagagaaaat 3150  
taatgaatgt ctaagttaat gcagaaacgg agagacatac tatattcatg 3200  
aactaaaaga cttaatattt tgaaggata cttcttttc acataaaattt 3250  
gtagtcaata tgttcacccc aaaaaagctg tttgttaact tgtcaacctc 3300  
atttcaaaaat gtatatagaa agcccaaaga caataacaaa aatattctt 3350  
10 tagaacaaaa tggaaagaa tgttccacta aatatcaaga ttttagagca 3400  
agcatgagat gtgtggggat agacagttag gctgataaaa tagagtagag 3450  
ctcagaaaca gaccattga tataatgtaa tgacctatga aaaaaatatg 3500  
gcattttaca atggaaaaat gatgatctt ttcttttta gaaaaacagg 3550  
gaaatataatt tataatgtaaa aaataaaagg gaacccatat gtcataccat 3600  
15 acacacaaaa aaattccagt gaattataag tctaaatgga gaaggcaaaa 3650  
ctttaaatct ttttagaaaat aatatagaag catgccatca tgacttcagt 3700  
gtagagaaaa atttctttagt actcaaagtc ctaaccacaa agaaaagatt 3750  
gttaattttaga ttgcatgaat attaagactt atttttaaaa ttaaaaaacc 3800  
attaagaaaa gtcaggccat agaatgacag aaaatatttca 3850  
20 gtaaagagaa ttgtaatatg cagattataa aaagaagtct tacaatcag 3900  
ttaaaaataa aactagacaa aaatttgaac agatgaaaga gaaactctaa 3950  
ataatcatta cacatgagaa actcaatctc agaaatcaga gaactatcat 4000  
tgcatataca cttaaattttaga gaaatattaa aaggctaagt aacatctgt 4050  
gcaatatttga tggtatataa ctttgatatg atgtgatgag aacagtactt 4100  
25 taccccatgg gtttcctccc caaaccctta ccccagtata aatcatgaca 4150  
aatatacttt aaaaaccatt accctatatac taaccagtac tcctcaaaac 4200  
tgtcaaggtc atcaaaaata agaaaagtct gaggaactgt caaaaactaag 4250  
aggaacccaa ggagacatga gaattatgt taatgtggca ttctgaatga 4300  
gatcccagaa cagaaaaaga acagtagcta aaaaactaat gaaatataaa 4350  
30 taaagtttga acttttagttt tttttttttttaa agagtagcat taacacggca 4400

aagtcatttt catattttc ttgaacatta agtacaagtc tataattaaa 4450  
aatttttaa atgtagtctg gaacatgcc agaaacagaa gtacagcagc 4500  
tatctgtgct gtcgcctaac tatccatagc tgattggctc aaaatgagat 4550  
acatcaacgc tcctccatgt tttttgtttt ctttttaat gaaaaactt 4600  
5 attttttaag aggagttca ggttcatagc aaaattgaga ggaaggata 4650  
ttcaagctga ggaagtttc ctctattcct agtttactga gagattgcat 4700  
catgaatggg tgtaaattt tgtcaaatgc ttttctgtg tctatcaata 4750  
tgaccatgtg attttcttct ttaacctgtt gatggacaa attacgtaa 4800  
ttgattttca aacgttgaac cacccttaca tatctggat aaattctact 4850  
10 tggttgtggt gtatatttt tgatacattc ttggattctt tttgctaata 4900  
ttttgtgaa aatgtttgtt tctttgttca tgagagat tggctgtt 4950  
ttttctttc ttgtaatgtc attttctagt tccggatttta aggtaatgt 5000  
ggcctagttg aatgattttag gaagtattcc ctctgtttct gtcttctgag 5050  
gtaccgcggc cgcccgtcgt tttacaacgt cgtgactggg aaaaccctgg 5100  
15 cgtaacccaa cttaatcgcc ttgcagcaca tcccccttcc gccagctggc 5150  
gtaatagcga agaggcccgc accgatcgcc cttcccaaca gttgcgcagc 5200  
ctgaatggcg aatggcgccct gatgcggtat tttctcctta cgcatctgtg 5250  
cggtatttca caccgcatac gtcaaagcaa ccatagtacg cgcctgttag 5300  
cggcgcatta agcgcggcgg gtgtgggtt tacgcgcagc gtgaccgcta 5350  
20 cacttgcacag cgcccttagcg cccgttcctt tcgctttctt cccttcctt 5400  
ctcgccacgt tcgcccggctt tccccgtcaa gctctaaatc gggggctccc 5450  
tttaggggttc cgattttagtg ctttacggca cctcgacccc aaaaaacttg 5500  
atttgggtga tggttcacgt agtggccat cgcctgata gacggttttt 5550  
cgcccttga cggtggagtc cacgttctt aatagtggac tcttgttcca 5600  
25 aactggaaca acactcaacc ctatctggg ctattcttt gatttataag 5650  
ggatttgcc gatttcggcc tattggtaa aaaatgagct gatttaacaa 5700  
aaatttaaacg cgaattttaa caaaatatta acgtttacaa ttttatggtg 5750  
cactctcagt acaatctgct ctgatgccgc atagttaaacg cagccccgac 5800  
acccgccaac acccgctgac gcgcctgac gggcttgcgtc gctccggca 5850  
30 tccgcttaca gacaagctgt gaccgtctcc gggagctgca tgtgtcagag 5900

gttttcaccg tcatcacccga aacgcgcgag acgaaaggc ctcgtatac 5950  
gcctattttt ataggtaat gtcataataa taatggtttcc ttagacgtca 6000  
ggtggcactt ttcggggaaa tgtgcgcgga acccctattt gtttattttt 6050  
ctaaatacat tcaaataatgt atccgcctat gagacaataa ccctgataaaa 6100  
5 tgcttcaata atattgaaaa aggaagagta tgagtattca acatttccgt 6150  
gtcgccctta ttccctttt tgcggcattt tgccttcctg tttttgctca 6200  
cccagaaacg ctggtgaaag taaaagatgc tgaagatcag ttgggtgcac 6250  
gagtgggtta catcgaactg gatctcaaca gcggtaagat ccttgagagt 6300  
tttcgccccg aagaacgttt tccaatgatg agcactttta aagttctgct 6350  
10 atgtggcgcg gtattatccc gtattgacgc cgggcaagag caactcggtc 6400  
gccgcataca ctattctcag aatgacttgg ttgagtactc accagtcaca 6450  
gaaaagcatac ttacggatgg catgacagta agagaattat gcagtgtgc 6500  
cataaccatg agtgataaca ctgcggccaa cttacttcgt acaacgatcg 6550  
gaggaccgaa ggagctaacc gctttttgc acaacatggg ggatcatgta 6600  
15 actcgcatttgc atcggtggaa accggagctg aatgaagcca taccaaacga 6650  
cgagcgtgac accacgatgc ctgttagaat ggcaacaacg ttgcgc当地 6700  
tattaactgg cgaactactt actctagctt cccggcaaca attaataagac 6750  
tggatggagg cgatggaaatgt tgcaaggacca cttctgcgc当地 cggcccttcc 6800  
ggctggctgg ttatttgctg ataaatctgg agccggtgag cgtgggtctc 6850  
20 gcggtatcat tgcagcactg gggccagatg gtaagccctc ccgtatcgta 6900  
gttatctaca cgacggggag tcaggcaact atggatgaac gaaatagaca 6950  
gatcgctgag ataggtgcct cactgattaa gcattggtaa ctgtcagacc 7000  
aagtttactc atatataactt tagattgatt taaaacttca ttttttaattt 7050  
aaaaggatct aggtgaagat ctttttgat aatctcatga cccaaatccc 7100  
25 ttaacgtgag ttttcgttcc actgagcgtc agaccccgta gaaaagatca 7150  
aaggatcttc ttgagatctt tttttctgc gcttaatctg ctgcttgcaa 7200  
acaaaaaaaaac caccgctacc agcgggtggtt tgtttgc当地 atcaagagct 7250  
accaactctt ttccgaagg taactggctt cagcagagcg cagataccaa 7300  
atactgtcct tctagtgttag ccgtagtttag gccaccactt caagaactct 7350  
30 gtagcaccgc ctacataacct cgctctgcta atcctgttac cagtggctgc 7400

tgccagtggc gataaagtctgt gtcttaccgg gttggactca agacgatagt 7450  
taccggataa ggcgcagcgg tcgggctgaa cgggggggttc gtgcacacag 7500  
cccagcttgg agcgaacgac ctacaccgaa ctgagatacc tacagcgtga 7550  
gctatgagaa agcgccacgc ttcccgaaagg gagaaaggcg gacaggtatc 7600  
5 cggttaagcgg cagggtcgga acaggagagc gcacgaggga gttccaggg 7650  
ggaaacgcct ggtatcttta tagtcgtcggc gggtttcgccc acctctgact 7700  
tgagcgtcga ttttgtat gtcgtcagg gggcgaggc ctatggaaaa 7750  
acgcacagaa cgcggccctt ttacggttcc tggccttttgc 7800  
gctcacatgt ttttcctgc gttatcccct gattctgtgg ataaccgtat 7850  
10 taccgcctt gagttagctg ataccgctcg cgcagccga acgaccgagc 7900  
gcagcgagtc agtgagcggag gaagcggaaag agcccgccgg caaggtcgcc 7950  
acgcacaaga tcaatattaa caatcagtca tctctcttta gcaataaaaa 8000  
ggtgaaaaat tacattttaa aaatgacacc atagacgatg tatgaaaata 8050  
atctacttgg aaataaaatct aggcaaaagaa gtgcaagact gttaccaga 8100  
15 aaacttacaa attgtaaatg agaggtagt gaagatttaa atgaatgaag 8150  
atctaaataa acttataaaat tgtgagagaa attaatgaat gtctaaatgtt 8200  
atgcagaaac ggagagacat actatattca tgaactaaaa gacttaatata 8250  
tgtgaaggta tactttcttt tcacataat ttgttagtcaa tatgttcacc 8300  
ccaaaaaaagc tgtttgttaa cttgtcaacc tcatttcaaa atgtatata 8350  
20 aaagccccaaa gacaataaca aaaatattct tgtagaacaa aatggggaaag 8400  
aatgttccac taaatataca gatttagagc aaagcatgag atgtgtgggg 8450  
atagacagtg aggctgataa aatagagtag agctcagaaa cagaccatt 8500  
gatatatgtt agtgacctat gaaaaaaaata tggcattttta caatggaaa 8550  
atgtatgtt ttttctttt tagaaaaaca gggaaatata tttatatgtt 8600  
25 aaaaataaaaaa gggAACCCat atgtcataacc atacacacaa aaaaattcca 8650  
gtgaattata agtctaaatg gagaaggcaa aactttaaat cttttagaaaa 8700  
ataatataaga agcatgccat catgacttca gtgttagagaa aaatttctta 8750  
tgactcaaag tcctaaccac aaagaaaaaga ttgttaatgtt gattgcattga 8800  
atattaagac ttatTTTaa aattaaaaaaa ccattaagaa aagtcaggcc 8850  
30 atagaatgac agaaaatatt tgcaacacccc cagtaaagag aattgtataa 8900

tgcatggattt aaaaagaagt cttacaaatc agtaaaaaat aaaactagac 8950  
aaaaatttga acagatgaaa gagaaactct aaataatcat tacacatgag 9000  
aaactcaatc tcagaaatca gagaactatc attgcatata cactaaatta 9050  
gagaaatatt aaaaggctaa gtaacatctg tggcaatatt gatggatat 9100  
5 aacccgtata tgatgtgatg agaacagtac ttacccat gggccctc 9150  
cccaaaccct tacccagta taaatcatga caaatatact taaaaacca 9200  
ttaccctata tctaaccagt actcctaaa actgtcaagg tcatcaaaaa 9250  
taagaaaagt ctgaggaact gtcaaaacta agaggaaccc aaggagacat 9300  
gagaattata tgtaatgtgg cattctgaat gagatcccag aacagaaaaa 9350  
10 gaacagttagc taaaaaacta atgaaatata aataaagttt gaacttttgt 9400  
ttttttaaa aaagagttagc attaacacgg caaagtcatt ttcatatttt 9450  
tcttgaacat taagtacaag tctataatta aaaatttttt aaatgttagc 9500  
tggaacattg ccagaaacag aagtacagca gctatctgtg ctgtcgccct 9550  
actatccata gctgatttgtt ctaaaatgag atacatcaac gtcctccat 9600  
15 gttttttgtt ttcttttaa atgaaaaact ttattttttta agaggagttt 9650  
caggttcata gcaaaattga gaggaaggta cattcaagct gaggaagttt 9700  
tcctctattt ctagtttact gagagattgc atcatgaatg ggtgttaaat 9750  
tttgtcaaat gcttttctg tgcctatcaa tatgaccatg tgattttctt 9800  
ctttaacctg ttgatggac aaattacgtt aattgatttt caaacgttga 9850  
20 accaccctta catatctgga ataaattcta cttgggttgtg gtgtatattt 9900  
tttgatacat tcttggattt tttttctaa tattttgttg aaaaatgtttg 9950  
tatctttgtt catgagagat attggctgt tgttttctt tcttgaatg 10000  
tcattttcta gttccggat taaggtaatg ctggcctagt tgaatgattt 10050  
aggaagtatt ccctctgtt ctgtcttctg aagcggaaaga gcgcccaata 10100  
25 cgcaaaccgc ctctccccgc gcttggccg attcatat gcaagctggca 10150  
cgacaggttt cccgactgga aagcgggcag tgagcgcaac gcaattaatg 10200  
tgagtttagct cactcattag gcaccccagg cttaacattt tatgcttccg 10250  
gctcgtatgt tgcgtggat tgcgtggaa taacaatttc acacaggaaa 10300  
cagctatgac atgattacga attaa 10325

<211> 10379  
<212> DNA  
<213> Artificial  
  
<220>  
5 <221> Artificial  
<222> 1-10379  
<223> Sequence is synthesized  
  
<400> 54  
aagctttact cgtaaagcga gttgaaggat catatttagt tgcgtttatg 50  
10 agataagatt gaaagcacgt gtaaaatgtt tcccgcgct tggcacaact 100  
atttacaatg cggccaagtt ataaaagatt ctaatctgat atgtttaaa 150  
acacccttgc ggcccggagtt gtttgcgtac gtgactagcg aagaagatgt 200  
gtggaccgca gaacagatag taaaacaaaa ccctagtatt ggagcaataa 250  
tcgatttaac caacacgtct aaatattatg atggtgtgca tttttgcgg 300  
15 gcgggcctgt tatacaaaaa aattcaagta cctggccaga ctttgcgc 350  
tcaaaggcata gttcaagaat ttattgacac ggtaaaagaa tttacagaaa 400  
agtgtcccg catgttggtg ggcgtcact gcacacacgg tattaatcgc 450  
accggttaca tggtgtgcag atatttaatg cacaccctgg gtattgcgc 500  
gcaggaagcc atagatagat tcgaaaaagc cagaggtcac aaaattgaaa 550  
20 gacaaaatta cgttcaagat ttattaattt aattaatatt atttgcattc 600  
tttaacaaat actttatcct atttcaaat tggcgctt cttccagcga 650  
acaaaaacta tgcttcgctt gctccgttaa gcttgcgtcc gatcagtggc 700  
gttggccaa tcgacggtag gattaggccg gatattctcc accacaatgt 750  
tggcaacgctt gatgttacgt ttatgcttt ggtttccac gtacgtctt 800  
25 tggccggtaa tagccgtaaa cgtagtgcgg tcgcgcgtca cgcacaacac 850  
cgatgtttt cgcttgcgtcc cggggtattt aaccgcgcga tccgacaat 900  
ccaccacttt ggcaactaaa tcggtgaccc ggcgtcttt tttctgcatt 950  
atttcgtctt tctttgcatt ggtttccatgg aagccgggtt acatgcgg 1000  
tagatcgttc atgacgcgcg tgacctgcaa atcttggcc tcgatctgct 1050  
30 tgccttgcattt ggcaacgcgtc cgttcaataa actcttgcattt tttaacaatgt 1100  
tcctcggtt tttgcgcac caccgcgtgc agcgcgtttt tgtgctcggt 1150  
gaatgtcgca atcagcttag tcaccaactg tttgcgttc tcctccgtt 1200  
gtttgatcgc gggatcgtac ttgcgggtgc agagcacttg aggaattact 1250

tcttctaaaa gccaattcttg taattctatg gcgtaaggca atttggactt 1300  
cataatcagc tgaatcacgc cggatttagt aatgagcaact gtatgcggct 1350  
gcaaatacag cgggtcgccc ctttcacga cgctgttaga ggtagggccc 1400  
ccatttgga tggtctgctc aaataacgtat ttgtatttat tgtctacatg 1450  
5 aacacgtata gctttatcac aaactgtata ttttaaactg ttagcgacgt 1500  
ccttggccac gaaccggacc tggcgatcgc gctctagcac gtaccggagg 1550  
ttgaacgtat cttctccaaa tttaaattct ccaattttaa cgcgagccat 1600  
tttgatacac gtgtgtcgat ttgcacaa ctattgtttt ttaacgcaaa 1650  
ctaaacttat tgtggtaagc aataattaaa tatggggaa catgcgcccgc 1700  
10 tacaacactc gtcgttatga acgcagacgg cgccggctc ggcccaagcg 1750  
gctaaaacgt gttgcgcgtt caacgcggca aacatcgcaa aagccaatag 1800  
tagattttg atttgcataat taacggcgat tttttaaattt atcttattta 1850  
ataaaatagtt atgacgccta caactccccg cccgcgttga ctcgctgcac 1900  
ctcgagcagt tcgttgacgc cttccctccgt gtggccgaac acgtcgagcg 1950  
15 ggtggtcgtt gaccagcggc gtgcgcacg cgacgcacua gatctgtac 2000  
accgaatgtat cgtcggcgaa aggcacgtcg gcctccaagt ggcaatattg 2050  
gcaaattcga aaatatac agttgggttg ttgcgcata tctatcgtgg 2100  
cgttggcat gtacgtccga acgttgattt gcatgcaagc cgaaattaaa 2150  
tcattgcgtat tagtgcgatt aaaacgttgc acatcctcgat tttaatcat 2200  
20 gccgtcgattt aaatcgccca atcgagtcaa gtgatcaaag tgtggataa 2250  
tgttttcttt gtattcccgaa gtcaagcgca ggcgttattt taacaaacta 2300  
gccatctgtt aagtttagttt catttaatgc aactttatcc aataatataat 2350  
tatgtatcgac acgtcaagaa ttaacaatgc gcccgttgc gcatctcaac 2400  
acgactatga tagagatcaa ataaagcgcg aattaaatag cttgcacgc 2450  
25 aacgtgcacg atctgtgcac gcgttccggc acgagctttg attgtataa 2500  
gtttttacga agcgatgaca tgaccccgat agtgcacacg atcacgccc 2550  
aaagaactgc cgactacaaa attacccgagt atgtcggtga cgttaaaact 2600  
atataagccat ccaatcgacc gttagtcgaa tcaggaccgc tggtgcgaga 2650  
agccgcgaag tatggcgaat gcatcgtata acgtgtggag tccgctcatt 2700  
30 agagcgtcat gtttagacaa gaaagctaca tatttaattt atcccgatga 2750

ttttattgat aaattgaccc taactccata cacggattc tacaatggcg 2800  
gggttttgtt caaaaattcc ggactgcgt tgtacatgt gttaacggct 2850  
ccgcccacta ttaatgaaat taaaaattcc aattttaaaa aacgcagcaa 2900  
gagaaacatt tgtatgaaag aatgcgtaga aggaaagaaa aatgtcgctg 2950  
5 acatgctgaa caacaagatt aatatgcctc cgtgtataaa aaaaatattg 3000  
aacgatttga aagaaaacaa tgtaccgcgc ggcggtatgt acaggaagag 3050  
gtttatacta aactgttaca ttgcaaacgt ggttcgtgt gccaagtgtg 3100  
aaaaccgatg tttaatcaag gctctgacgc atttctacaa ccacgactcc 3150  
aagtgtgtgg gtgaagtcat gcatcttta atcaaatccc aagatgtgta 3200  
10 taaaccacca aactgccaaa aaatgaaaac tgtcgacaag ctctgtccgt 3250  
ttgctggcaa ctgcaagggt ctcaatccta tttgtaatta ttgaataata 3300  
aaacaattat aaatgctaaa tttgtttttt attaacgata caaaccaaac 3350  
gcaacaagaa catttgttagt attatctata attgaaaacg cgtagttata 3400  
atcgctgagg taatatttaa aatcatttcc aaatgattca cagttat 3450  
15 gcgacaatat aattttat ttcacataaac tagacgcctt gtcgtcttct 3500  
tcttcgtatt ctttcattttt ttcattttc tcctcataaa aattaacata 3550  
gttattatcg tatccatata tgtatctatc gtatagagta aatttttgt 3600  
tgtcataaaat atatatgtct ttttaatgg ggtgtatagtt accgctgcgc 3650  
atagtttttc tgtaatttac aacagtgcta tttctggta gttcttcgga 3700  
20 gtgtgttgct ttaatttata aatttatata atcaatgaat ttgggatcgt 3750  
cggttttgta caatatgttg ccggcatagt acgcagcttc ttctagttca 3800  
attacaccat ttttagcag caccggatta acataactt cccaaatgtt 3850  
gtacgaaccg ttaaacaaaa acagttcacc tccctttct atactattgt 3900  
ctgcgagcag ttgtttgttg ttaaaaataa cagccattgt aatgagacgc 3950  
25 acaaactaat atcacaaact ggaaatgtct atcaatataat agttgctgat 4000  
atcatggaga taattaaaat gataaccatc tcgcaaataa ataagtattt 4050  
tactgttttc gtaacagttt tgtaataaaa aaacctataa atattccgga 4100  
ttattcatac cgtcccacca tcggggcgccg atccggggcc gcgaattcta 4150  
aaccaccatg gctagcagggc ctgacaaaac tcacacatgc ccaccgtgcc 4200  
30 cagcacctga actcctgggg ggaccgtcag tcttcctt ccccccaaaa 4250

ccccaggaca cccccatgat ctcccgacc cctgaggtca catgcgtgg 4300  
ggtgacgtg agccacgaag accctgaggt caagttcaac tggtaacgtgg 4350  
acggcgtgga ggtgcataat gccaagacaa agccgcggga ggagcagttac 4400  
aacagcacgt accgtgtggt cagcgtcctc accgtcctgc accaggactg 4450  
5 gctgaatggc aaggagtaca agtcaaggt ctccaacaaa gcccctccag 4500  
cccccatcga gaaaaccatc tccaaagcca aagggcagcc ccgagaacca 4550  
caggtgtaca ccctgcccccc atcccgaa gagatgacca agaaccagg 4600  
cagcctgacc tgcctggca aaggcttcta tcccagcgc atgcgggtgg 4650  
agtgggagag caatggcag ccggagaaca actacaagac cacgcctccc 4700  
10 gtgctggact ccgacggctc cttcttcctc tacagcaago tcaccgtgg 4750  
caagagcagg tggcagcagg ggaacgtctt ctcatgctcc gtgatgcattg 4800  
aggctctgca caaccactac acgcagaaga gcctctccct gtctccgggt 4850  
aaatgacata gggcatcatc atcatcatca tcattattaa ttctagacta 4900  
gtctgcagat ctgatccttt cctgggaccc ggcaagaacc aaaaactcac 4950  
15 tctttcaag gaaatccgta atgttaaacc cgacacgatg aagcttgcg 5000  
ttggatggaa aggaaaagag ttctacaggg aaacttggac ccgcttcattg 5050  
gaagacagct tccccattgt taacgaccaa gaagtgtatgg atgtttctt 5100  
tggatgtcaac atgcgtccca ctagacccaa ccgttgcattac aaattctgg 5150  
cccaacacgc tctgcgttgc gacccgact atgtacctca tgacgtgatt 5200  
20 aggtatcgatcg agccttcattg ggtggcagc aacaacgagt accgcattcg 5250  
cctggcttaag aagggcggcg gctgccaat aatgaacctt cactctgatg 5300  
acaccaactc ttgcacacag ttcatcgatc gtgtcatctg ggagaacttc 5350  
tacaagccca tcgtttacat cggtaaccgac tctgctgaag aggagggaaat 5400  
tctccctgaa gtttccctgg tggtaaaatg aaaggagttt gcaccagacg 5450  
25 cacctctgtt cactggtccg gcttattaaa acacgatata ttgttattag 5500  
tacattttt aagcgctaga ttctgtgcgt tggatattt cagacaattt 5550  
ttgtacgtat ttataataatt cattaaattt ataatcttta ggggtgtatg 5600  
tttagagcgaa aatcaaatttga ttttcagcgt ctatcttgcgtt gatattaaat 5650  
atattaaatctt caatagattt gtaaaatagg tttcgatttttcaacaa 5700  
30 gggttgtttt tccgaaccga tggctggact atctaatttgcgatc 5750

acgccacaaa acctgcacaaa tctttagca gcaatctac 5800  
ttcgtttgc ttttgcggta taataaaggc tcgacgtcgt tcacaaatatt 5850  
atgcgtttt gtatttcttt catcaactgtc gtttagtgc aattgactcg 5900  
acgtaaacac gttaaataaa gcttggacat atttacatc gggcgtgtta 5950  
5 gctttattag gccgattatc gtcgtcgtcc caaccctcgt cgtagaaagt 6000  
tgcttccgaa gacgatttg ccatagccac acgacgccta ttaattgtgt 6050  
cggtctaacac gtccgcgatc aaatttgcg tagtgcgtttt tggaattatt 6100  
tctgattgcg ggcgttttg ggcgggttc aatctaactg tgcccgattt 6150  
taattcagac aacacgttag aaagcgatgg tgcaggcggt ggtaacattt 6200  
10 cagacggcaa atctactaat ggccggcggtg gtggagctga tgataaatct 6250  
accatcggtg gaggcgcagg cggggctggc ggccggaggcg gaggcggagg 6300  
tggtggcggt gatgcagacg gcggtttagg ctcaaattgtc tctttaggca 6350  
acacagtcgg cacctcaact attgtactgg tttccggcgc cgttttgg 6400  
15 ttgaccggtc tgagacgagt gcgattttt tcgtttctaa tagcttccaa 6450  
caattgttgt ctgtcgctca aaggtgcagc gggttgaggt tccgtcggca 6500  
ttggtggagc gggcgcaat tcagacatcg atggtggtgg tggtggtgga 6550  
ggcgctggaa tgtaggcac gggagaaggt ggtggcgccg gtgcggccgg 6600  
tataatttgt tctgggttag tttgtcgac cacgattgtg ggcaccggcg 6650  
caggcgccgc tggctgcaca acggaaggc gtctgcttcg aggcagcgct 6700  
20 tggggtgtgt gcaattcaat attataattt gaatacaaat cgtaaaaatc 6750  
tgctataagc attgttaattt cgctatcggtt taccgtgccg atatttaaca 6800  
accgctcaat gtaagcaatt gtattgtaaa gagattgtct caagctccgc 6850  
acgcccataa caagcctttt cattttact acagcattgt agtggcgaga 6900  
cacttcgctg tcgtcgacgt acatgtatgc tttgttgca aaaacgtcgt 6950  
25 tggcaagctt taaaatattt aaaagaacat ctctgttcag caccactgtg 7000  
ttgtcgtaaa tggtgtttt gataattgc gcttccgcag tatcgacacg 7050  
ttcaaaaaat tgatgcgcata caattttgtt gttccttata ttgaataaat 7100  
aagattgtac agattcataat ctacgattcg tcatggccac cacaatgtc 7150  
acgctgcaaa cgctggtaca atttacgaa aactgcaaaa acgtcaaaac 7200  
30 tcggtataaaa ataatcaacg ggccgtttgg caaaatatct atttatcgc 7250

acaagccac taycaaattg tatttcaga aaacaatttc ggcgcacaat 7300  
tttaacgctg acgaaataaa agttcaccag ttaatgagcg accacccaaa 7350  
ttttataaaa atctattttt atcacggttc catcaacaac caagtatcg 7400  
tgatggacta cattgactgt cccgatttt ttgaaacact acaaattaaa 7450  
5 ggcgagcttt cgtaccaact tggtagcaat attattagac agctgtgtga 7500  
agcgctcaac gatttgcaca agcacaattt catacacaac gacataaaac 7550  
tcgaaaatgt cttatatttc gaagcacttg atcgcgtgta tggttgcgt 7600  
tacggattgt gcaaacacga aaactcactt agcgtgcacg acggcacgtt 7650  
ggagtatttt agtccggaaa aaattcgaca cacaactatg cacgtttcgt 7700  
10 ttgactggta cgccggcgtgt taacatacaa gttgctaacc ggccggttcgt 7750  
aatcatggtc atagctgttt cctgtgtgaa attgttatcc gtcacaattt 7800  
ccacacaaca tacgagccgg aagcataaaag tgtaaagcct ggggtgccta 7850  
atgagtgagc taactcacat taattgcgtt gcgcactg cccgcttc 7900  
agtcggggaaa cctgtcggtc cagctgcatt aatgaatcgg ccaacgcgcg 7950  
15 gggagaggcg gtttgcgtat tgggcgtct tccgcttcct cgctcactga 8000  
ctcgctgcgc tcggcggttc ggctgcggcg agcggtatca gctcactcaa 8050  
aggcggtaat acggttatcc acagaatcag gggataacgc aggaaagaac 8100  
atgtgagcaa aaggccagca aaaggccagg aaccgtaaaa aggccgcgtt 8150  
gctggcggtt ttccataggc tccgcgggggg tgacgagcat cacaaaaatc 8200  
20 gacgctcaag tcagaggtgg cgaaacccga caggactata aagataccag 8250  
gcgtttcccc ctggaagctc ctcgtgcgc tctcctgttc cgaccctgcc 8300  
gcttaccggta tacctgtccg cctttctccc ttccggaaagc gtggcgcttt 8350  
ctcatagctc acgctgttagg tatctcagtt cggtgttaggt cgttcgctcc 8400  
aagctgggct gtgtgcacga accccccgtt cagcccgacc gctgcgcctt 8450  
25 atccggtaac tatcgctttg agtccaaaccc ggtaagacac gacttatcgc 8500  
cactggcagc agccactggt aacaggatta gcagagcgag gtatgttaggc 8550  
ggtgctacag agttcttgaa gtggggcct aactacggct acactagaag 8600  
gacagtattt ggtatctgcg ctctgctgaa gccagttacc ttccggaaaaaa 8650  
gagttggtag ctcttgatcc ggcaaaacaaa ccaccgctgg tagcgggtgg 8700  
30 tttttgttt gcaaggcagca gattacgcgc agaaaaaaag gatctcaaga 8750

agatccttg atcctttcta cgggtctga cgctcagtgg aacgaaaact 8800  
 cacgttaagg gattttggtc atgagattat caaaaaggat cttcacctag 8850  
 atcctttaa attaaaaatg aagtttaaa tcaatctaaa gtatatatga 8900  
 gtaaacttgg tctgacagtt accaatgctt aatcagttag gcacctatct 8950  
 5 cagcgatctg tctatttcgt tcatccatag ttgcctgact ccccgctgtg 9000  
 tagataacta cgatacggga gggcttacca tctggccca gtgctgcaat 9050  
 gataccgcga gacccacgct caccggctcc agatttatca gcaataaacc 9100  
 agccagccgg aaggggccgag cgccagaatg gtccgtcaac tttatccgcc 9150  
 tccatccagt ctattaatttggaa gctagagtaa gtagttcgcc 9200  
 10 agttaatagt ttgcgcaacg ttgttgcatt tgctacaggc atcgtgggt 9250  
 cacgctcgtc gtttggatag gcttcattca gctccgggttc ccaacgatca 9300  
 aggccaggtta catgatcccc catgttgtgc aaaaaagccgg ttagctcctt 9350  
 cggtcctccg atcggtgtca gaagtaagtt ggccgcagtg ttatcactca 9400  
 tggttatggc agcactgcat aattcttta ctgtcatgcc atccgtaaga 9450  
 15 tgctttctg tgaacggtga gtactcaacc aagtcttctt gagaatagtg 9500  
 tatgcggcga ccgagttgct cttgcccggc gtcaatacgg gataataccg 9550  
 cggccacatag cagaacttta aaagtgtca tcattggaaa acgttctcg 9600  
 gggcgaaaaac tctcaaggat cttaccgtg ttgagatcca gttcgatgt 9650  
 acccactcgt gcacccaaact gatcttcagc atctttact ttcaccagcg 9700  
 20 tttctgggtg agcaaaaaca ggaaggcaaa atgcccggaaa aaagggaata 9750  
 agggcgacac ggaaatgttg aatactcata ctcttccttt ttcaatatta 9800  
 ttgaagcatt tattcagggtt attgtctcat gagcggatac atatttgaat 9850  
 gtatttagaa aaataaaacaa ataggggttc cgccgcacatt tccccgaaaa 9900  
 gtgcacactg acgtctaaaga aaccattatt atcatgacat taacctataa 9950  
 25 aaataggcgt atcacgaggc cctttcgtct cgccgcgttgc ggtgatgacg 10000  
 gtgaaaacct ctgacacatg cagctccgg agacgggtcac agcttgcgt 10050  
 taagcggatg cccggagcag acaagccgt cagggcgcgt cagcgggtgt 10100  
 tggcgggtgt cggggctggc ttaactatgc ggcacatcagag cagattgtac 10150  
 tgagagtgcg ccatatatgc ggtgtgaaat accgcacacaga tgcgtaaagga 10200  
 30 gaaaataccg catcaggcgc cattcgccat tcaggctgcg caactgttgg 10250

gaaggcgat cgycgcccc ctctcgcta ttacgccagc tggcgaaagg 10300  
gggatgtgct gcaaggcgat taagttgggt aacgccaggg ttttcccagt 10350  
cacgacgttg taaaacgacg gccagtgcc 10379

5 <210> 55  
<211> 9690  
<212> DNA  
<213> Artificial

10 <220>  
<221> Artificial  
<222> 1-9690  
<223> Sequence is synthesized

<400> 55  
aagctttact cgtaaagcga gttgaaggat catatttgt tgcgtttatg 50  
agataagatt gaaagcacgt gtaaaatgtt tcccgccgt tggcacaact 100  
15 atttacaatg cggccaagtt ataaaagatt ctaatctgat atgtttaaa 150  
acacctttgc ggccccagtt gtttgcgtac gtgactagcg aagaagatgt 200  
gtggaccgca gaacagatag taaaacaaaa ccctagtatt ggagcaataa 250  
tcgattttac caacacgtct aaatattatg atggtgtgca tttttgcgg 300  
gcgggcctgt tatacaaaaa aattcaagta cctggccaga ctttgcgcc 350  
20 taaaaggcata gttcaagaat ttattgacac ggtaaaagaa tttacagaaa 400  
agtgtcccccgg catgttggtg ggcgtgcact gcacacacgg tattaatcgc 450  
accggttaca tggtgtgcag atattaatg cacaccctgg gtattgcgcc 500  
gcaggaagcc atagatagat tcgaaaaagc cagaggtcac aaaattgaaa 550  
gacaaaatta cgttcaagat ttattaattt aattaatatt atttgcattc 600  
25 tttacaacaaat actttatcct atttcaaat tggcgctt cttccagcga 650  
accaaaaacta tgcttcgctt gctccgttta gctttagcc gatcagtggc 700  
gttggcccaa tcgacggtag gattaggccg gatattctcc accacaatgt 750  
tggcaacgtt gatgttacgt ttatgcttt ggtttccac gtacgtctt 800  
tggccggtaa tagccgtaaa cgtagtgcgcg tcgcgcgtca cgcacaacac 850  
30 cggatgtttg cgcttgcgcg cggggatttgc aaccgcgcga tccgacaaat 900  
ccaccactt ggcaactaaa tcgggtaccc ggcgcgtttt tttctgcatt 950  
atttcgtctt tctttgcatt ggtttccatgg aagccgggtt acatgcggtt 1000  
tagatcagtc atgacgcgcg tgacctgcac atcttggcc tcgatctgct 1050

tgtccttgcat ggcaacgatg cgttcaataa actcttgttt tttacaact 1100  
tcctcggtt tttgcgccac caccgcttgc agcgcgtttg tgtgctcggt 1150  
gaatgtcgca atcagcttag tcaccaactg tttgctctcc tcctcccggt 1200  
gtttgatcgc gggatcgta cttgcgggtgc agagcacttg aggaattact 1250  
5 tcttctaaaa gccattcttg taattctatg gcgttaaggca atttggactt 1300  
cataatcagc tgaatcagc cggatttagt aatgagcaact gtatgcggct 1350  
gcaaatacag cgggtcgccc ctttcacga cgctgttaga ggtagggccc 1400  
ccatTTTgga tggtctgctc aaataacgat ttgtatTTt tggctacatg 1450  
aacacgtata gctttatcac aaactgtata tttaaactg ttagcgacgt 1500  
10 ccttggccac gaaccggacc tggggatcg cgtctagcac gtaccgcagg 1550  
ttgaacgtat cttctccaaa tttaaattctt ccaattttaa cgcgaggcat 1600  
tttgatacacat gtgtgtcgat ttgcacaaa ctattgttt ttaacgaaa 1650  
ctaaacttat tggtaagc aataattaaa tatggggaa catgcggcgc 1700  
tacaacactc gtcgttatga acgcagacgg cgccggctc ggcgcaagcg 1750  
15 gctaaaacgt gttgcgcgtt caacgcggca aacatcgcaa aagccaatag 1800  
tacagTTTg atttgcataat taacggcgat ttTTTaaattt atcttattta 1850  
ataaaatagtt atgacgccta caactccccg cccgcgttga ctcgctgcac 1900  
ctcgagcagt tggggatcg cttccctccgt gtggccgaac acgtcgagcg 1950  
ggggatcgat gaccagcgcc gtcggcgcacg cgacgcacaa gtatctgtac 2000  
20 accgaatgat cgccggcgaa aggcacgtcg gcctccaatgt ggcaatattg 2050  
gcaaattcga aaatatac agttgggttg tttgcgcata tctatcgat 2100  
cgTTTggcat gtacgtccga acgttgcattt gcatgcaagc cgaaattaaa 2150  
tcattgcgtat tagtgcgatt aaaacgttgc acatcctcgat tttaaatcat 2200  
gcccgtcgatt aaatcgccaa atcgagtcaa gtgcataatgt tggaaataa 2250  
25 tggggatcgat gttttcccgat gtcaagcgca ggcgttgcattt taacaaacta 2300  
gccatcttgcgtat aagttgcattt cattaaatgc aactttatcc aataatataat 2350  
tatgtatcgat acgtcaagaa ttaacaatgc gcccgttgc gcatctcaac 2400  
acgactatga tagagatcaa ataaagcgacg aattaaatag cttgcgcacgc 2450  
aacgtgcacg atctgtgcac ggcgttccggc acgagcttgc attgtataaa 2500  
30 gttttacga agcgatgaca tgaccccgat agtgcacaacg atcacgcccc 2550

aaagaactgc cgactacaaa attaccgagt atgtcggtga cgttaaaact 2600  
atthaagccat ccaatcgacc gttagtcgaa tcaggaccgc tggtgcgaga 2650  
agccgcgaag tatggcgaat gcatcgata acgtgtggag tccgctcatt 2700  
agagcgtcat gtttagacaa gaaagctaca tatttaattt atcccgtatga 2750  
5 ttttattgtat aaattgaccc taactccata cacggtattc tacaatggcg 2800  
gggttttgtt caaaaattcc ggactgcgtat tgtacatgct gttaacggct 2850  
ccgcccacta ttaatgaaat taaaattcc aattttaaaa aacgcagcaa 2900  
gagaaacattt tgtatgaaag aatgcgtaga aggaaagaaa aatgtcgctg 2950  
acatgctgaa caacaagattt aatatgcctc cgtgtataaa aaaaatattt 3000  
10 aacgatttga aagaaaacaa tgtaccgcgc ggcggtatgtt acaggaagag 3050  
gtttatacta aactgttaca ttgcaaacgtt ggtttgcgtgtt gccaagtgtt 3100  
aaaacccatgtt ttaatcaag gctctgacgc atttctacaa ccacgactcc 3150  
aagtgtgtgg gtgaagtcat gcatcttttta atcaaattttt aagatgtgtt 3200  
taaaccacca aactgcacaa aatgaaaac ttgtcgacaaag ctctgtccgt 3250  
15 ttgctggcaa ctgcaagggtt ctcaatccta tttgttattttt ttgataata 3300  
aaacaattttt aatgtctaaa ttgtttttt attaaccata caaaccacaa 3350  
gcaacaagaa cattttgttattttt attatctata attgaaaacg cgttagttata 3400  
atcgctgagg taatatttttta aatcatttttca aatgatttca cagtttattt 3450  
gcaacaatatttttta tcacataaac tagacgcctt gtcgttttttct 3500  
20 tcttcgtattt ccttcctttt ttcattttttcccttataaa aatatttttttca 3550  
gttattatcg tatccatata ttttttttttcccttataaa aatatttttttca 3600  
tgtcataat atatatgtct ttttttttttcccttataaa aatatttttttca 3650  
atagtttttca ttgttttttttcccttataaa aatatttttttca 3700  
gtgtgttttttca ttgttttttttcccttataaa aatatttttttca 3750  
25 cgggttttttca caatatgttgc cccggatgttgc acgcagcttc ttcttttttca 3800  
attacaccat ttttttttttcccttataaa aatatttttttca 3850  
gtacgaaccgcgttgc ttttttttttcccttataaa aatatttttttca 3900  
ctgcgagcgttgc ttttttttttcccttataaa aatatttttttca 3950  
acaaaactaat atcacaaaactt gggaaatgtctt atcaatataat agttgtgtat 4000  
30 atcatggaga taatttttttcccttataaa aatatttttttca 4050

taactgtttc gtaacagttt tgtaataaaaa aaacctataa atattccgga 4100  
ttattcatac cgtcccacca tcggggcgccg atcccgccgatc gcgaattcta 4150  
aaccaccatg ggcagctgcc cgggcattcat catcatcatc atcatcatta 4200  
attcttagact agtctgcaga tctgatcctt tcctgggacc cggcaagaac 4250  
5 caaaaactca ctctcttcaa ggaaatccgt aatgttaaac ccgacacgat 4300  
gaagcttgtc gttggatgga aaggaaaaga gttctacagg gaaacttgg 4350  
cccgcttcat ggaagacagc ttccccattt ttaacgacca agaagtgtat 4400  
gatgtttcc ttgttgtcaa catgcgtccc actagaccca accgttgtta 4450  
caaattcctg gcccaacacg ctctgcgttg cgaccccgac tatgtacctc 4500  
10 atgacgtgat taggatcgtc gagccttcat gggtgggcag caacaacgag 4550  
taccgcatca gcctggctaa gaagggcgcc ggcgtcccaa taatgaacct 4600  
tcactctgag tacaccaact cgttcgaaca gttcatcgat cgtgtcatct 4650  
gggagaactt ctacaagccc atcggttaca tcggtaccga ctctgctgaa 4700  
gaggaggaaa ttctccttga agttccctg gtgttcaaag taaaggagtt 4750  
15 tgcaccagac gcacccctgt tcactggtcc ggcgttattaa aacacgatac 4800  
attgttattta gtacatttt taagcgctag attctgtgcg ttgttgcatt 4850  
acagacaatt gttgtacgta ttttaataat tcattaaatt tataatctt 4900  
agggtggat gtttagagcga aaatcaaattt attttcagcg tctttatatac 4950  
tgaatttaaa tattaaatcc tcaatagatt tgtaaaatag gtttcgatta 5000  
20 gtttcaaaca agggttgttt ttccgaaccg atggctggac tatctaattgg 5050  
attttcgctc aacgccacaa aacttgccaa atcttgcgtc agcaatctag 5100  
ctttgtcgat attcgttgt gttttgtttt gtaataaaagg ttgcacgtcg 5150  
ttcaaaaatattat tatgcgtttt tgcattttttt tcattactgt cgttagtgta 5200  
caatttgactc gacgttaaaca cgttaaataa agcttggaca tatttaacat 5250  
25 cgggcgtgtt agctttattta ggccgattat cgtcgctgatc ccaaccctcg 5300  
tcgttagaag ttgcgttccga agacgattttt gccatagcca cacgacgcct 5350  
attaatttgatc tcggctaaaca cgtccgcgtat cttttttt gttgagctt 5400  
tttggaaattttt ttctgttttgc gggcggtttt gggcggtttt caatctaact 5450  
gtgcccgtt ttaattcaga caacacgtta gaaagcgatc gtgcaggcgg 5500  
30 tggtaacatt tcagacggca aatctactaa tggcgccggtt ggtggagctg 5550

atgataaatac taccatcggt ggaggcgcag gcggggctgg cggcggaggc 5600  
ggaggcggag gtggtggcgg ttagtgcagac ggccgttttag gctcaaatgt 5650  
ctctttaggc aacacagtcg gcacctaacc tattgtactg gtttcggcgc 5700  
ccgttttgg tttgaccggc ctgagacgag tgcgattttt ttctgtttcta 5750  
5 atagcttcca acaattgttg tctgtcgctc aaaggtgcag cgggttgagg 5800  
ttccgtcggc attggtggag cgggcggcaa ttcaagacatc gatggtggtg 5850  
gtggtggtgg aggcgctgga atgttaggca cgggagaagg tggtggcggc 5900  
ggtgccgccc gtataatttg ttctgtttt gtttgcgc gcacgattgt 5950  
gggcacccgc gcaggcgcgc ctggctgcac aacggaaggt cgtctgcttc 6000  
10 gaggcagcgc ttgggggtggt ggcaattcaa tattataattt ggaataaaaa 6050  
tcgtaaaaat ctgctataag cattgttaatt tcgctatcg ttaccgtgcc 6100  
gatatttaac aaccgctcaa tgtaagcaat tgtattgtaa agagattgtc 6150  
tcaagctccg cacgcccata acaagcctt tcatttttac tacagcattt 6200  
tagtggcgcag acacttcgct gtcgtcgacg tacatgtatg ctttgcgc 6250  
15 aaaaacgtcg ttggcaagct ttaaaaatattt taaaagaaca tctctgttca 6300  
gcaccactgt gttgtcgtaa atgttggttt tgataatttg cgcttccgca 6350  
gtatcgacac gttcaaaaaa ttgatgcgc tcaattttgt tgttccattt 6400  
attgaataaa taagattgtt cagattcata tctacgattt gtcatggcca 6450  
ccacaaaatgc tacgctgcaa acgctggta aattttacga aaactgcaaa 6500  
20 aacgtcaaaa ctcggtaaa aataatcaac gggcgctttg gcaaaaatatac 6550  
tattttatacg cacaagccca ctagcaaattt gtatttgcag aaaacaattt 6600  
cggcgcacaa ttttaacgct gacgaaataa aagttcacca gttaatgagc 6650  
gaccacccaa atttataaaa aatctatttt aatcacggtt ccatcaacaa 6700  
ccaagtgtac gtgatggact acattgactg tcccgattt tttgaaacac 6750  
25 tacaattaa aggcgagctt tcgtaccaac ttgttagcaa tattattaga 6800  
cagctgtgtg aagcgctcaa cgatttgcac aagcacaattt tcatacacaa 6850  
cgacataaaa ctcgaaaaatg tcttatattt cgaagcactt gatcgctgt 6900  
atgtttgcga ttacggattt tgcaaaacacg aaaactcact tagcgtgcac 6950  
gacggcacgt tggagtattt tagtccggaa aaaattcgac acacaactat 7000  
30 gcacgtttcg tttgactggc acgcggcgtg ttaacataca agttgctaac 7050

cgccggttcg taaccatggt catacgcttt tcctgtgtga aattgttatac 7100  
cgctcacaat tccacacaaac atacgagccg gaagcataaa gtgtaaagcc 7150  
tggggtgcct aatgagtgag ctaactcaca ttaattgcgt tgcgctcact 7200  
gcccgccttc cagtcgggaa acctgtcgta ccagctgcat taatgaatcg 7250  
5 gccaacgcgc ggggagagggc ggtttgcgtt ttgggcgtc ttccgcctcc 7300  
tcgctcactg actcgctgctg ctcggcggtt cggtgcggc gagcggtatc 7350  
agctcactca aaggcggtaa tacggttatc cacagaatca ggggataacg 7400  
cagggaaagaa catgtgagca aaaggccagc aaaaggccag gaaccgtaaa 7450  
aaggccgcgt tgctggcggtt ttccatagg ctccgcctcc ctgacgagca 7500  
10 tcacaaaaat cgacgctcaa gtcagagggtg gcgaaaccccg acaggactat 7550  
aaagatacca ggcgtttccc cctggaagct ccctcggtcg ctctcctgtt 7600  
ccgaccctgc cgcttaccgg atacctgtcc gcctttctcc ctccgggaag 7650  
cgtggcgctt tctcatagct cacgctgttagt gtatctcagt tcggtgttagg 7700  
tcgttcgcgc caagctggc tgggtgcacg aaccccccgt tcagccgcac 7750  
15 cgctgcgcct tatccggtaa ctatcgctt gagtcaacc cggtaagaca 7800  
cgacttatcg ccactggcag cagccactgg taacaggatt agcagagcga 7850  
ggtatgttagg cggtgctaca gagttcttga agtggtgcc taactacggc 7900  
tacactagaa ggacagtatt tggtatctgc gctctgctga agccagttac 7950  
cttcggaaaa agagttggta gctcttgatc cggcaaacaa accaccgctg 8000  
20 gtagcggtgg tttttttgtt tgcaagcagc agattacgcg cagaaaaaaaa 8050  
ggatctcaag aagatccttt gatctttct acggggctcg acgctcagt 8100  
gaacgaaaac tcacgttaag ggattttgggt catgagatta tcaaaaagga 8150  
tcttcaccta gatcctttta aattaaaaat gaagttttaa atcaatctaa 8200  
agtatataatg agtaaacttg gtctgacagt taccatgtt taatcagtga 8250  
25 ggcacctatc tcagcgatct gtctatttcg ttcatccata gttgcctgac 8300  
tccccgtcggt gtagataact acgatacggg agggcttacc atctggccccc 8350  
agtgcgtcaa tgataaccgcg agacccacgc tcaccggctc cagatttatac 8400  
agcaataaac cagccagccg gaagggccga gcgcagaagt ggtcctgcaa 8450  
ctttatccgc ctccatccag tctattaatt gttgccggga agctagagta 8500  
30 agtagttcgc cagttaatag tttgcgcaac gttgttgcca ttgctacagg 8550

catcggtgtc tcaugctcgt cgtttggtat ggcttcattc agctccgggt 8600  
 cccaacgatc aaggcgagtt acatgateccc ccatgttggc caaaaaaagcg 8650  
 gtttagctcct tcggtcctcc gatcggttgc agaagtaagt tggccgcagt 8700  
 gttatcactc atggttatgg cagcactgca taattcttactgtcatgc 8750  
 5 catccgtaag atgctttct gtgactgggt agtactcaac caagtcattc 8800  
 tgagaatagt gtatgcggcg accgagttgc tcttgcggcg cgtcaatacg 8850  
 ggataatacc gcgccacata gcagaacttt aaaagtgctc atcattggaa 8900  
 aacgttcttc ggggcgaaaa ctctcaagga tcttaccgct gttgagatcc 8950  
 agttcgatgt aacccactcg tgcacccaaac tgatcttcag catctttac 9000  
 10 tttcaccagc gtttctgggt gagcaaaaac aggaaggcaa aatgccgcaa 9050  
 aaaaggaaat aaggcgaca cggaaatgtt gaataactcat actcttcctt 9100  
 tttcaatatt attgaagcat ttatcagggt tattgtctca tgagcggata 9150  
 catatggaa tgtatggaa aaaataaaaca aataggggtt ccgcgcacat 9200  
 ttccccgaaa agtgccacct gacgtctaag aaaccattat tatcatgaca 9250  
 15 ttaacctata aaaataggcg tatcacgagg cccttcgtc tcgcgcgttt 9300  
 cggtgatgac ggtgaaaacc tctgacacat gcagctcccg gagacggtca 9350  
 cagcttgcgtct gtaagcggat gccgggagca gacaagcccg tcagggcg 9400  
 tcagcgggtg ttggcgggtg tcggggctgg cttactatg cggcatcaga 9450  
 gcagattgta ctgagagtgc accatatacg cggtgtgaaa taccgcacag 9500  
 20 atgcgttaagg agaaaatacc gcatcaggcg ccattcgcca ttcaggctgc 9550  
 gcaactgttg ggaagggcga tcgggtcggg cctcttcgct attacgccag 9600  
 ctggcggaaag ggggatgtgc tgcaaggcga ttaagttggg taacgccagg 9650  
 gttttccag tcacgacgtt gtaaaacgac ggccagtgcc 9690  
  
 <210> 56  
 25 <211> 249  
 <212> PRT  
 <213> Human  
  
 <400> 56  
 Arg Gly Thr Pro Lys Thr His Leu Leu Ala Phe Ser Leu Leu Cys  
 30 1 5 10 15  
 Leu Leu Ser Lys Val Arg Thr Gln Leu Cys Pro Thr Pro Cys Thr  
 20 25 30  
 Cys Pro Trp Pro Pro Arg Cys Pro Leu Gly Val Pro Leu Val

	35	40	45
	Leu Asp Gly Cys Gly Cys Cys Arg Val Cys Ala Arg Arg Leu Gly		
	50	55	60
5	Glu Pro Cys Asp Gln Leu His Val Cys Asp Ala Ser Gln Gly Leu		
	65	70	75
	Val Cys Gln Pro Gly Ala Gly Pro Gly Gly Arg Gly Ala Leu Cys		
	80	85	90
	Leu Leu Ala Glu Asp Asp Ser Ser Cys Glu Val Asn Gly Arg Leu		
	95	100	105
10	Tyr Arg Glu Gly Glu Thr Phe Gln Pro His Cys Ser Ile Arg Cys		
	110	115	120
	Arg Cys Glu Asp Gly Gly Phe Thr Cys Val Pro Leu Cys Ser Glu		
	125	130	135
15	Asp Val Arg Leu Pro Ser Trp Asp Cys Pro His Pro Arg Arg Val		
	140	145	150
	Glu Val Leu Gly Lys Cys Cys Pro Glu Trp Val Cys Gly Gln Gly		
	155	160	165
	Gly Gly Leu Gly Thr Gln Pro Leu Pro Ala Gln Gly Pro Gln Phe		
	170	175	180
20	Ser Gly Leu Val Ser Ser Leu Pro Pro Gly Val Pro Cys Pro Glu		
	185	190	195
	Trp Ser Thr Ala Trp Gly Pro Cys Ser Thr Thr Cys Gly Leu Gly		
	200	205	210
25	Met Ala Thr Arg Val Ser Asn Gln Asn Arg Phe Cys Arg Leu Glu		
	215	220	225
	Thr Gln Arg Arg Leu Cys Leu Ser Arg Pro Cys Pro Pro Ser Arg		
	230	235	240
	Gly Arg Ser Pro Gln Asn Ser Ala Phe		
	245	249	
30	<210> 57		
	<211> 248		
	<212> PRT		
	<213> Human		
	<400> 57		
35	Gly Thr Pro Lys Thr His Leu Leu Ala Phe Ser Leu Leu Cys Leu		
	1	5	10
	Leu Ser Lys Val Arg Thr Gln Leu Cys Pro Thr Pro Cys Thr Cys		
	20	25	30
40	Pro Trp Pro Pro Pro Arg Cys Pro Leu Gly Val Pro Leu Val Leu		
	35	40	45

	Asp	Gly	Cys	Gly	Cys	Cys	Arg	Val	Cys	Ala	Arg	Arg	Leu	Gly	Glu		
														50	55	60	
	Pro	Cys	Asp	Gln	Leu	His	Val	Cys	Asp	Ala	Ser	Gln	Gly	Leu	Val		
														65	70	75	
5	Cys	Gln	Pro	Gly	Ala	Gly	Pro	Gly	Gly	Arg	Gly	Ala	Leu	Cys	Leu		
														80	85	90	
	Leu	Ala	Glu	Asp	Asp	Ser	Ser	Cys	Glu	Val	Asn	Gly	Arg	Leu	Tyr		
														95	100	105	
10	Arg	Glu	Gly	Glu	Thr	Phe	Gln	Pro	His	Cys	Ser	Ile	Arg	Cys	Arg		
														110	115	120	
	Cys	Glu	Asp	Gly	Gly	Phe	Thr	Cys	Val	Pro	Leu	Cys	Ser	Glu	Asp		
														125	130	135	
	Val	Arg	Leu	Pro	Ser	Trp	Asp	Cys	Pro	His	Pro	Arg	Arg	Val	Glu		
														140	145	150	
15	Val	Leu	Gly	Lys	Cys	Cys	Pro	Glu	Trp	Val	Cys	Gly	Gln	Gly	Gly		
														155	160	165	
	Gly	Leu	Gly	Thr	Gln	Pro	Leu	Pro	Ala	Gln	Gly	Pro	Gln	Phe	Ser		
														170	175	180	
20	Gly	Leu	Val	Ser	Ser	Leu	Pro	Pro	Gly	Val	Pro	Cys	Pro	Glu	Trp		
														185	190	195	
	Ser	Thr	Ala	Trp	Gly	Pro	Cys	Ser	Thr	Thr	Cys	Gly	Leu	Gly	Met		
														200	205	210	
	Ala	Thr	Arg	Val	Ser	Asn	Gln	Asn	Arg	Phe	Cys	Arg	Leu	Glu	Thr		
														215	220	225	
25	Gln	Arg	Arg	Leu	Cys	Leu	Ser	Arg	Pro	Cys	Pro	Pro	Ser	Arg	Gly		
														230	235	240	
	Arg	Ser	Pro	Gln	Asn	Ser	Ala	Phe									
														245	248		
30	<210>	58															
	<211>	247															
	<212>	PRT															
	<213>	Human															
	<400>	58															
35	Thr	Pro	Lys	Thr	His	Leu	Leu	Ala	Phe	Ser	Leu	Leu	Cys	Leu	Leu		
														1	5	10	15
	Ser	Lys	Val	Arg	Thr	Gln	Leu	Cys	Pro	Thr	Pro	Cys	Thr	Cys	Pro		
														20	25	30	
	Trp	Pro	Pro	Pro	Arg	Cys	Pro	Leu	Gly	Val	Pro	Leu	Val	Leu	Asp		
														35	40	45	
40	Gly	Cys	Gly	Cys	Cys	Arg	Val	Cys	Ala	Arg	Arg	Leu	Gly	Glu	Pro		
														50	55	60	

5	Cys Asp Gln Leu His Val Cys Asp Ala Ser Gln Gly Leu Val Cys	65	70	75
	Gln Pro Gly Ala Gly Pro Gly Gly Arg Gly Ala Leu Cys Leu Leu	80	85	90
10	Ala Glu Asp Asp Ser Ser Cys Glu Val Asn Gly Arg Leu Tyr Arg	95	100	105
	Glu Gly Glu Thr Phe Gln Pro His Cys Ser Ile Arg Cys Arg Cys	110	115	120
15	Glu Asp Gly Gly Phe Thr Cys Val Pro Leu Cys Ser Glu Asp Val	125	130	135
	Arg Leu Pro Ser Trp Asp Cys Pro His Pro Arg Arg Val Glu Val	140	145	150
20	Leu Gly Lys Cys Cys Pro Glu Trp Val Cys Gly Gln Gly Gly	155	160	165
	Leu Gly Thr Gln Pro Leu Pro Ala Gln Gly Pro Gln Phe Ser Gly	170	175	180
25	Leu Val Ser Ser Leu Pro Pro Gly Val Pro Cys Pro Glu Trp Ser	185	190	195
	Thr Ala Trp Gl, Pro Cys Ser Thr Thr Cys Gly Leu Gly Met Ala	200	205	210
30	Thr Arg Val Ser Asn Gln Asn Arg Phe Cys Arg Leu Glu Thr Gln	215	220	225
	Arg Arg Leu Cys Leu Ser Arg Pro Cys Pro Pro Ser Arg Gly Arg	230	235	240
35	Ser Pro Gln Asn Ser Ala Phe	245	247	
	<210> 59			
	<211> 246			
	<212> PRT			
	<213> Human			
40	<400> 59			
	Pro Lys Thr His Leu Leu Ala Phe Ser Leu Leu Cys Leu Leu Ser	1	5	15
	Lys Val Arg Thr Gln Leu Cys Pro Thr Pro Cys Thr Cys Pro Trp	20	25	30
	Pro Pro Pro Arg Cys Pro Leu Gly Val Pro Leu Val Leu Asp Gly	35	40	45
	Cys Gly Cys Cys Arg Val Cys Ala Arg Arg Leu Gly Glu Pro Cys	50	55	60
	Asp Gln Leu His Val Cys Asp Ala Ser Gln Gly Leu Val Cys Gln	65	70	75

Pro Gly Ala Gly Pro Gly Gly Arg Gly Ala Leu Cys Leu Leu Ala  
 80 85 90  
 Glu Asp Asp Ser Ser Cys Glu Val Asn Gly Arg Leu Tyr Arg Glu  
 95 100 105  
 5 Gly Glu Thr Phe Gln Pro His Cys Ser Ile Arg Cys Arg Cys Glu  
 110 115 120  
 Asp Gly Gly Phe Thr Cys Val Pro Leu Cys Ser Glu Asp Val Arg  
 125 130 135  
 10 Leu Pro Ser Trp Asp Cys Pro His Pro Arg Arg Val Glu Val Leu  
 140 145 150  
 Gly Lys Cys Cys Pro Glu Trp Val Cys Gly Gln Gly Gly Gly Leu  
 155 160 165  
 Gly Thr Gln Pro Leu Pro Ala Gln Gly Pro Gln Phe Ser Gly Leu  
 170 175 180  
 15 Val Ser Ser Leu Pro Pro Gly Val Pro Cys Pro Glu Trp Ser Thr  
 185 190 195  
 Ala Trp Gly Pro Cys Ser Thr Thr Cys Gly Leu Gly Met Ala Thr  
 200 205 210  
 Arg Val Ser Asn Gln Asn Arg Phe Cys Arg Leu Glu Thr Gln Arg  
 215 220 225  
 20 Arg Leu Cys Leu Ser Arg Pro Cys Pro Pro Ser Arg Gly Arg Ser  
 230 235 240  
 Pro Gln Asn Ser Ala Phe  
 245 246  
 25 <210> 60  
 <211> 245  
 <212> PRT  
 <213> Human  
 <400> 60  
 30 Lys Thr His Leu Leu Ala Phe Ser Leu Leu Cys Leu Leu Ser Lys  
 1 5 10 15  
 Val Arg Thr Gln Leu Cys Pro Thr Pro Cys Thr Cys Pro Trp Pro  
 20 25 30  
 35 Pro Pro Arg Cys Pro Leu Gly Val Pro Leu Val Leu Asp Gly Cys  
 35 40 45  
 Gly Cys Cys Arg Val Cys Ala Arg Arg Leu Gly Glu Pro Cys Asp  
 50 55 60  
 Gln Leu His Val Cys Asp Ala Ser Gln Gly Leu Val Cys Gln Pro  
 65 70 75  
 40 Gly Ala Gly Pro Gly Gly Arg Gly Ala Leu Cys Leu Leu Ala Glu  
 80 85 90

	Asp Asp Ser Ser Cys Glu Val Asn Gly Arg Leu Tyr Arg Glu Gly	
	95	100 105
	Glu Thr Phe Gln Pro His Cys Ser Ile Arg Cys Arg Cys Glu Asp	
	110	115 120
5	Gly Gly Phe Thr Cys Val Pro Leu Cys Ser Glu Asp Val Arg Leu	
	125	130 135
	Pro Ser Trp Asp Cys Pro His Pro Arg Arg Val Glu Val Leu Gly	
	140	145 150
10	Lys Cys Cys Pro Glu Trp Val Cys Gly Gln Gly Gly Gly Leu Gly	
	155	160 165
	Thr Gln Pro Leu Pro Ala Gln Gly Pro Gln Phe Ser Gly Leu Val	
	170	175 180
	Ser Ser Leu Pro Pro Gly Val Pro Cys Pro Glu Trp Ser Thr Ala	
	185	190 195
15	Trp Gly Pro Cys Ser Thr Thr Cys Gly Leu Gly Met Ala Thr Arg	
	200	205 210
	Val Ser Asn Gln Asn Arg Phe Cys Arg Leu Glu Thr Gln Arg Arg	
	215	220 225
20	Ieu Cys Leu Ser Arg Pro Cys Pro Pro Ser Arg Gly Arg Ser Pro	
	230	235 240
	Gln Asn Ser Ala Phe	
	245	
	<210> 61	
	<211> 244	
25	<212> PRT	
	<213> Human	
	<400> 61	
	Thr His Leu Leu Ala Phe Ser Leu Leu Cys Leu Leu Ser Lys Val	
	1 5 10 15	
30	Arg Thr Gln Leu Cys Pro Thr Pro Cys Thr Cys Pro Trp Pro Pro	
	20 25 30	
	Pro Arg Cys Pro Leu Gly Val Pro Leu Val Leu Asp Gly Cys Gly	
	35 40 45	
35	Cys Cys Arg Val Cys Ala Arg Arg Leu Gly Glu Pro Cys Asp Gln	
	50 55 60	
	Leu His Val Cys Asp Ala Ser Gln Gly Leu Val Cys Gln Pro Gly	
	65 70 75	
	Ala Gly Pro Gly Gly Arg Gly Ala Leu Cys Leu Leu Ala Glu Asp	
	80 85 90	
40	Asp Ser Ser Cys Glu Val Asn Gly Arg Leu Tyr Arg Glu Gly Glu	
	95 100 105	

	Thr Phe Gln Pro His Cys Ser Ile Arg Cys Arg Cys Glu Asp Gly		
	110	115	120
	Gly Phe Thr Cys Val Pro Leu Cys Ser Glu Asp Val Arg Leu Pro		
	125	130	135
5	Ser Trp Asp Cys Pro His Pro Arg Arg Val Glu Val Leu Gly Lys		
	140	145	150
	Cys Cys Pro Glu Trp Val Cys Gly Gln Gly Gly Leu Gly Thr		
	155	160	165
10	Gln Pro Leu Pro Ala Gln Gly Pro Gln Phe Ser Gly Leu Val Ser		
	170	175	180
	Ser Leu Pro Pro Gly Val Pro Cys Pro Glu Trp Ser Thr Ala Trp		
	185	190	195
	Gly Pro Cys Ser Thr Thr Cys Gly Leu Gly Met Ala Thr Arg Val		
	200	205	210
15	Ser Asn Gln Asn Arg Phe Cys Arg Leu Glu Thr Gln Arg Arg Leu		
	215	220	225
	Cys Leu Ser Arg Pro Cys Pro Pro Ser Arg Gly Arg Ser Pro Gln		
	230	235	240
20	Asn Ser Ala Phe		
	244		
	<210> 62		
	<211> 243		
	<212> PRT		
	<213> Human		
25	<400> 62		
	His Leu Leu Ala Phe Ser Leu Leu Cys Leu Leu Ser Lys Val Arg		
	1	5	10
	15		
	Thr Gln Leu Cys Pro Thr Pro Cys Thr Cys Pro Trp Pro Pro Pro		
	20	25	30
30	Arg Cys Pro Leu Gly Val Pro Leu Val Leu Asp Gly Cys Gly Cys		
	35	40	45
	Cys Arg Val Cys Ala Arg Arg Leu Gly Glu Pro Cys Asp Gln Leu		
	50	55	60
35	His Val Cys Asp Ala Ser Gln Gly Leu Val Cys Gln Pro Gly Ala		
	65	70	75
	Gly Pro Gly Gly Arg Gly Ala Leu Cys Leu Leu Ala Glu Asp Asp		
	80	85	90
	Ser Ser Cys Glu Val Asn Gly Arg Leu Tyr Arg Glu Gly Glu Thr		
	95	100	105
40	Phe Gln Pro His Cys Ser Ile Arg Cys Arg Cys Glu Asp Gly Gly		
	110	115	120

	Phe	Thr	Cys	Val	Pro	Leu	Cys	Ser	Glu	Asp	Val	Arg	Leu	Pro	Ser	
														125	130	135
	Trp	Asp	Cys	Pro	His	Pro	Arg	Arg	Val	Glu	Val	Leu	Gly	Lys	Cys	
														140	145	150
5	Cys	Pro	Glu	Trp	Val	Cys	Gly	Gln	Gly	Gly	Gly	Leu	Gly	Thr	Gln	
														155	160	165
	Pro	Leu	Pro	Ala	Gln	Gly	Pro	Gln	Phe	Ser	Gly	Leu	Val	Ser	Ser	
														170	175	180
10	Leu	Pro	Pro	Gly	Val	Pro	Cys	Pro	Glu	Trp	Ser	Thr	Ala	Trp	Gly	
														185	190	195
	Pro	Cys	Ser	Thr	Thr	Cys	Gly	Leu	Gly	Met	Ala	Thr	Arg	Val	Ser	
														200	205	210
	Asn	Gln	Asn	Arg	Phe	Cys	Arg	Leu	Glu	Thr	Gln	Arg	Arg	Leu	Cys	
														215	220	225
15	Leu	Ser	Arg	Pro	Cys	Pro	Pro	Ser	Arg	Gly	Arg	Ser	Pro	Gln	Asn	
														230	235	240
	Ser	Ala	Phe													
														243		
20	<210>	63														
	<211>	242														
	<212>	PRT														
	<213>	Human														
25	<400>	63														
	Leu	Leu	Ala	Phe	Ser	Leu	Leu	Cys	Leu	Leu	Ser	Lys	Val	Arg	Thr	
	1					5						10			15	
	Gln	Leu	Cys	Pro	Thr	Pro	Cys	Thr	Cys	Pro	Trp	Pro	Pro	Pro	Arg	
														20	25	30
	Cys	Pro	Leu	Gly	Val	Pro	Leu	Val	Leu	Asp	Gly	Cys	Gly	Cys	Cys	
														35	40	45
30	Arg	Val	Cys	Ala	Arg	Arg	Leu	Gly	Glu	Pro	Cys	Asp	Gln	Leu	His	
														50	55	60
	Val	Cys	Asp	Ala	Ser	Gln	Gly	Leu	Val	Cys	Gln	Pro	Gly	Ala	Gly	
														65	70	75
35	Pro	Gly	Gly	Arg	Gly	Ala	Leu	Cys	Leu	Leu	Ala	Glu	Asp	Asp	Ser	
														80	85	90
	Ser	Cys	Glu	Val	Asn	Gly	Arg	Leu	Tyr	Arg	Glu	Gly	Glu	Thr	Phe	
														95	100	105
	Gln	Pro	His	Cys	Ser	Ile	Arg	Cys	Arg	Cys	Glu	Asp	Gly	Gly	Phe	
														110	115	120
40	Thr	Cys	Val	Pro	Leu	Cys	Ser	Glu	Asp	Val	Arg	Leu	Pro	Ser	Trp	
														125	130	135

	Asp Cys Pro His Pro Arg Arg Val Glu Val Leu Gly Lys Cys Cys			
	140	145	150	
	Pro Glu Trp Val Cys Gly Gln Gly Gly Leu Gly Thr Gln Pro			
	155	160	165	
5	Leu Pro Ala Gln Gly Pro Gln Phe Ser Gly Leu Val Ser Ser Leu			
	170	175	180	
	Pro Pro Gly Val Pro Cys Pro Glu Trp Ser Thr Ala Trp Gly Pro			
	185	190	195	
10	Cys Ser Thr Thr Cys Gly Leu Gly Met Ala Thr Arg Val Ser Asn			
	200	205	210	
	Gln Asn Arg Phe Cys Arg Leu Glu Thr Gln Arg Arg Leu Cys Leu			
	215	220	225	
	Ser Arg Pro Cys Pro Pro Ser Arg Gly Arg Ser Pro Gln Asn Ser			
	230	235	240	
15	Ala Phe			
	242			
	<210> 64			
	<211> 241			
	<212> PRT			
20	<213> Human			
	<400> 64			
	Leu Ala Phe Ser Leu Leu Cys Leu Leu Ser Lys Val Arg Thr Gln			
	1	5	10	15
25	Leu Cys Pro Thr Pro Cys Thr Cys Pro Trp Pro Pro Pro Arg Cys			
	20	25	30	
	Pro Leu Gly Val Pro Leu Val Leu Asp Gly Cys Gly Cys Cys Arg			
	35	40	45	
	Val Cys Ala Arg Arg Leu Gly Glu Pro Cys Asp Gln Leu His Val			
	50	55	60	
30	Cys Asp Ala Ser Gln Gly Leu Val Cys Gln Pro Gly Ala Gly Pro			
	65	70	75	
	Gly Gly Arg Gly Ala Leu Cys Leu Leu Ala Glu Asp Asp Ser Ser			
	80	85	90	
35	Cys Glu Val Asn Gly Arg Leu Tyr Arg Glu Gly Glu Thr Phe Gln			
	95	100	105	
	Pro His Cys Ser Ile Arg Cys Arg Cys Glu Asp Gly Gly Phe Thr			
	110	115	120	
	Cys Val Pro Leu Cys Ser Glu Asp Val Arg Leu Pro Ser Trp Asp			
	125	130	135	
40	Cys Pro His Pro Arg Arg Val Glu Val Leu Gly Lys Cys Cys Pro			
	140	145	150	

	Glu Trp Val Cys Gly Gln Gly Gly Gly Leu Gly Thr Gln Pro Leu			
	155	160	165	
	Pro Ala Gln Gly Pro Gln Phe Ser Gly Leu Val Ser Ser Leu Pro			
	170	175	180	
5	Pro Gly Val Pro Cys Pro Glu Trp Ser Thr Ala Trp Gly Pro Cys			
	185	190	195	
	Ser Thr Thr Cys Gly Leu Gly Met Ala Thr Arg Val Ser Asn Gln			
	200	205	210	
10	Asn Arg Phe Cys Arg Leu Glu Thr Gln Arg Arg Leu Cys Leu Ser			
	215	220	225	
	Arg Pro Cys Pro Pro Ser Arg Gly Arg Ser Pro Gln Asn Ser Ala			
	230	235	240	
	Phe			
	241			
15	<210> 65			
	<211> 240			
	<212> PRT			
	<213> Human			
	<400> 65			
20	Ala Phe Ser Leu Leu Cys Leu Leu Ser Lys Val Arg Thr Gln Leu			
	1	5	10	15
	Cys Pro Thr Pro Cys Thr Cys Pro Trp Pro Pro Pro Arg Cys Pro			
	20	25	30	
	Leu Gly Val Pro Leu Val Leu Asp Gly Cys Gly Cys Cys Arg Val			
25	35	40	45	
	Cys Ala Arg Arg Leu Gly Glu Pro Cys Asp Gln Leu His Val Cys			
	50	55	60	
	Asp Ala Ser Gln Gly Leu Val Cys Gln Pro Gly Ala Gly Pro Gly			
	65	70	75	
30	Gly Arg Gly Ala Leu Cys Leu Leu Ala Glu Asp Asp Ser Ser Cys			
	80	85	90	
	Glu Val Asn Gly Arg Leu Tyr Arg Glu Gly Glu Thr Phe Gln Pro			
	95	100	105	
	His Cys Ser Ile Arg Cys Arg Cys Glu Asp Gly Gly Phe Thr Cys			
35	110	115	120	
	Val Pro Leu Cys Ser Glu Asp Val Arg Leu Pro Ser Trp Asp Cys			
	125	130	135	
	Pro His Pro Arg Arg Val Glu Val Leu Gly Lys Cys Cys Pro Glu			
	140	145	150	
40	Trp Val Cys Gly Gln Gly Gly Leu Gly Thr Gln Pro Leu Pro			
	155	160	165	

	Ala Gln Gly Pro Gln Phe Ser Gly Leu Val Ser Ser Leu Pro Pro			
	170	175	180	
	Gly Val Pro Cys Pro Glu Trp Ser Thr Ala Trp Gly Pro Cys Ser			
	185	190	195	
5	Thr Thr Cys Gly Leu Gly Met Ala Thr Arg Val Ser Asn Gln Asn			
	200	205	210	
	Arg Phe Cys Arg Leu Glu Thr Gln Arg Arg Leu Cys Leu Ser Arg			
	215	220	225	
10	Pro Cys Pro Pro Ser Arg Gly Arg Ser Pro Gln Asn Ser Ala Phe			
	230	235	240	
	<210> 66			
	<211> 239			
	<212> PRT			
	<213> Human			
15	<400> 66			
	Phe Ser Leu Leu Cys Leu Leu Ser Lys Val Arg Thr Gln Leu Cys			
	1	5	10	15
	Pro Thr Pro Cys Thr Cys Pro Trp Pro Pro Pro Arg Cys Pro Leu			
	20	25	30	
20	Gly Val Pro Leu Val Leu Asp Gly Cys Gly Cys Cys Arg Val Cys			
	35	40	45	
	Ala Arg Arg Leu Gly Glu Pro Cys Asp Gln Leu His Val Cys Asp			
	50	55	60	
25	Ala Ser Gln Gly Leu Val Cys Gln Pro Gly Ala Gly Pro Gly Gly			
	65	70	75	
	Arg Gly Ala Leu Cys Leu Leu Ala Glu Asp Asp Ser Ser Cys Glu			
	80	85	90	
	Val Asn Gly Arg Leu Tyr Arg Glu Gly Glu Thr Phe Gln Pro His			
	95	100	105	
30	Cys Ser Ile Arg Cys Arg Cys Glu Asp Gly Gly Phe Thr Cys Val			
	110	115	120	
	Pro Leu Cys Ser Glu Asp Val Arg Leu Pro Ser Trp Asp Cys Pro			
	125	130	135	
35	His Pro Arg Arg Val Glu Val Leu Gly Lys Cys Cys Pro Glu Trp			
	140	145	150	
	Val Cys Gly Gln Gly Gly Leu Gly Thr Gln Pro Leu Pro Ala			
	155	160	165	
	Gln Gly Pro Gln Phe Ser Gly Leu Val Ser Ser Leu Pro Pro Gly			
	170	175	180	
40	Val Pro Cys Pro Glu Trp Ser Thr Ala Trp Gly Pro Cys Ser Thr			
	185	190	195	

	Thr Cys Gly Leu Gly Met Ala Thr Arg Val Ser Asn Gln Asn Arg			
	200	205	210	
	Phe Cys Arg Leu Glu Thr Gln Arg Arg Leu Cys Leu Ser Arg Pro			
	215	220	225	
5	Cys Pro Pro Ser Arg Gly Arg Ser Pro Gln Asn Ser Ala Phe			
	230	235	239	
	<210> 67			
	<211> 238			
	<212> PRT			
10	<213> Human			
	<400> 67			
	Ser Leu Leu Cys Leu Leu Ser Lys Val Arg Thr Gln Leu Cys Pro			
	1	5	10	15
15	Thr Pro Cys Thr Cys Pro Trp Pro Pro Pro Arg Cys Pro Leu Gly			
	20	25	30	
	Val Pro Leu Val Leu Asp Gly Cys Gly Cys Cys Arg Val Cys Ala			
	35	40	45	
	Arg Arg Leu Gly Glu Pro Cys Asp Gln Leu His Val Cys Asp Ala			
	50	55	60	
20	Ser Gln Gly Leu Val Cys Gln Pro Gly Ala Gly Pro Gly Gly Arg			
	65	70	75	
	Gly Ala Leu Cys Leu Leu Ala Glu Asp Asp Ser Ser Cys Glu Val			
	80	85	90	
25	Asn Gly Arg Leu Tyr Arg Glu Gly Glu Thr Phe Gln Pro His Cys			
	95	100	105	
	Ser Ile Arg Cys Arg Cys Glu Asp Gly Gly Phe Thr Cys Val Pro			
	110	115	120	
	Leu Cys Ser Glu Asp Val Arg Leu Pro Ser Trp Asp Cys Pro His			
	125	130	135	
30	Pro Arg Arg Val Glu Val Leu Gly Lys Cys Cys Pro Glu Trp Val			
	140	145	150	
	Cys Gly Gln Gly Gly Leu Gly Thr Gln Pro Leu Pro Ala Gln			
	155	160	165	
35	Gly Pro Gln Phe Ser Gly Leu Val Ser Ser Leu Pro Pro Gly Val			
	170	175	180	
	Pro Cys Pro Glu Trp Ser Thr Ala Trp Gly Pro Cys Ser Thr Thr			
	185	190	195	
	Cys Gly Leu Gly Met Ala Thr Arg Val Ser Asn Gln Asn Arg Phe			
	200	205	210	
40	Cys Arg Leu Glu Thr Gln Arg Arg Leu Cys Leu Ser Arg Pro Cys			
	215	220	225	

Pro Pro Ser Arg Gly Arg Ser Pro Gln Asn Ser Ala Phe  
 230 235 238

5 <210> 68  
 <211> 237  
 <212> PRT  
 <213> Human

10 <400> 68  
 Leu Leu Cys Leu Leu Ser Lys Val Arg Thr Gln Leu Cys Pro Thr  
 1 5 10 15

15 Pro Cys Thr Cys Pro Trp Pro Pro Pro Arg Cys Pro Leu Gly Val  
 20 25 30

Pro Leu Val Leu Asp Gly Cys Gly Cys Cys Arg Val Cys Ala Arg  
 35 40 45

20 Arg Leu Gly Glu Pro Cys Asp Gln Leu His Val Cys Asp Ala Ser  
 50 55 60

25 Gln Gly Leu Val Cys Gln Pro Gly Ala Gly Pro Gly Arg Gly  
 65 70 75

Ala Leu Cys Leu Leu Ala Glu Asp Asp Ser Ser Cys Glu Val Asn  
 80 85 90

30 Gly Arg Leu Tyr Arg Glu Gly Glu Thr Phe Gln Pro His Cys Ser  
 95 100 105

Ile Arg Cys Arg Cys Glu Asp Gly Gly Phe Thr Cys Val Pro Leu  
 110 115 120

35 Cys Ser Glu Asp Val Arg Leu Pro Ser Trp Asp Cys Pro His Pro  
 125 130 135

Arg Arg Val Glu Val Leu Gly Lys Cys Cys Pro Glu Trp Val Cys  
 140 145 150

Gly Gln Gly Gly Leu Gly Thr Gln Pro Leu Pro Ala Gln Gly  
 155 160 165

40 Pro Gln Phe Ser Gly Leu Val Ser Ser Leu Pro Pro Gly Val Pro  
 170 175 180

Cys Pro Glu Trp Ser Thr Ala Trp Gly Pro Cys Ser Thr Thr Cys  
 185 190 195

Gly Leu Gly Met Ala Thr Arg Val Ser Asn Gln Asn Arg Phe Cys  
 200 205 210

Arg Leu Glu Thr Gln Arg Arg Leu Cys Leu Ser Arg Pro Cys Pro  
 215 220 225

Pro Ser Arg Gly Arg Ser Pro Gln Asn Ser Ala Phe  
 230 235 237

45 <210> 69  
 <211> 236

<212> PRT  
 <213> Human

<400> 69  
 Leu Cys Leu Leu Ser Lys Val Arg Thr Gln Leu Cys Pro Thr Pro  
 5 1 5 10 15  
 Cys Thr Cys Pro Trp Pro Pro Arg Cys Pro Leu Gly Val Pro  
 20 25 30  
 Leu Val Leu Asp Gly Cys Gly Cys Cys Arg Val Cys Ala Arg Arg  
 35 40 45  
 10 Leu Gly Glu Pro Cys Asp Gln Leu His Val Cys Asp Ala Ser Gln  
 50 55 60  
 Gly Leu Val Cys Gln Pro Gly Ala Gly Pro Gly Gly Arg Gly Ala  
 65 70 75  
 15 Leu Cys Leu Leu Ala Glu Asp Asp Ser Ser Cys Glu Val Asn Gly  
 80 85 90  
 Arg Leu Tyr Arg Glu Gly Glu Thr Phe Gln Pro His Cys Ser Ile  
 95 100 105  
 Arg Cys Arg Cys Glu Asp Gly Gly Phe Thr Cys Val Pro Leu Cys  
 110 115 120  
 20 Ser Glu Asp Val Arg Leu Pro Ser Trp Asp Cys Pro His Pro Arg  
 125 130 135  
 Arg Val Glu Val Leu Gly Lys Cys Cys Pro Glu Trp Val Cys Gly  
 140 145 150  
 25 Gln Gly Gly Leu Gly Thr Gln Pro Leu Pro Ala Gln Gly Pro  
 155 160 165  
 Gln Phe Ser Gly Leu Val Ser Ser Leu Pro Pro Gly Val Pro Cys  
 170 175 180  
 Pro Glu Trp Ser Thr Ala Trp Gly Pro Cys Ser Thr Thr Cys Gly  
 185 190 195  
 30 Leu Gly Met Ala Thr Arg Val Ser Asn Gln Asn Arg Phe Cys Arg  
 200 205 210  
 Leu Glu Thr Gln Arg Arg Leu Cys Leu Ser Arg Pro Cys Pro Pro  
 215 220 225  
 35 Ser Arg Gly Arg Ser Pro Gln Asn Ser Ala Phe  
 230 235 236  
 <210> 70  
 <211> 235  
 <212> PRT  
 <213> Human  
 40 <400> 70  
 Cys Leu Leu Ser Lys Val Arg Thr Gln Leu Cys Pro Thr Pro Cys

1	5	10	15
Thr Cys Pro Trp Pro Pro Pro Arg Cys Pro Leu Gly Val Pro Leu			
20 25 30			
Val Leu Asp Gly Cys Gly Cys Cys Arg Val Cys Ala Arg Arg Leu			
5	35	40	45
Gly Glu Pro Cys Asp Gln Leu His Val Cys Asp Ala Ser Gln Gly			
50 55 60			
Leu Val Cys Gln Pro Gly Ala Gly Pro Gly Gly Arg Gly Ala Leu			
65 70 75			
10	Cys Leu Leu Ala Glu Asp Asp Ser Ser Cys Glu Val Asn Gly Arg	80 85	90
Leu Tyr Arg Glu Gly Glu Thr Phe Gln Pro His Cys Ser Ile Arg			
95 100 105			
Cys Arg Cys Glu Asp Gly Gly Phe Thr Cys Val Pro Leu Cys Ser			
15	110	115	120
Glu Asp Val Arg Leu Pro Ser Trp Asp Cys Pro His Pro Arg Arg			
125 130 135			
Val Glu Val Leu Gly Lys Cys Cys Pro Glu Trp Val Cys Gly Gln			
140 145 150			
20	Gly Gly Gly Leu Gly Thr Gln Pro Leu Pro Ala Gln Gly Pro Gln	155 160	165
Phe Ser Gly Leu Val Ser Ser Leu Pro Pro Gly Val Pro Cys Pro			
170 175 180			
Glu Trp Ser Thr Ala Trp Gly Pro Cys Ser Thr Thr Cys Gly Leu			
25	185	190	195
Gly Met Ala Thr Arg Val Ser Asn Gln Asn Arg Phe Cys Arg Leu			
200 205 210			
Glu Thr Gln Arg Arg Leu Cys Leu Ser Arg Pro Cys Pro Pro Ser			
215 220 225			
30	Arg Gly Arg Ser Pro Gln Asn Ser Ala Phe	230	235
<210> 71			
<211> 234			
<212> PRT			
35	<213> Human		
<400> 71			
Leu Leu Ser Lys Val Arg Thr Gln Leu Cys Pro Thr Pro Cys Thr			
1 5 10 15			
Cys Pro Trp Pro Pro Pro Arg Cys Pro Leu Gly Val Pro Leu Val			
40	20	25	30

	Leu Asp Gly Cys Gly Cys Cys Arg Val Cys Ala Arg Arg Leu Gly			
	35	40	45	
	Glu Pro Cys Asp Gln Leu His Val Cys Asp Ala Ser Gln Gly Leu			
	50	55	60	
5	Val Cys Gln Pro Gly Ala Gly Pro Gly Gly Arg Gly Ala Leu Cys			
	65	70	75	
	Leu Leu Ala Glu Asp Asp Ser Ser Cys Glu Val Asn Gly Arg Leu			
	80	85	90	
10	Tyr Arg Glu Gly Glu Thr Phe Gln Pro His Cys Ser Ile Arg Cys			
	95	100	105	
	Arg Cys Glu Asp Gly Gly Phe Thr Cys Val Pro Leu Cys Ser Glu			
	110	115	120	
	Asp Val Arg Leu Pro Ser Trp Asp Cys Pro His Pro Arg Arg Val			
	125	130	135	
15	Glu Val Leu Gly Lys Cys Cys Pro Glu Trp Val Cys Gly Gln Gly			
	140	145	150	
	Gly Gly Leu Gly Thr Gln Pro Leu Pro Ala Gln Gly Pro Gln Phe			
	155	160	165	
20	Ser Gly Leu Val Ser Ser Leu Pro Pro Gly Val Pro Cys Pro Glu			
	170	175	180	
	Trp Ser Thr Ala Trp Gly Pro Cys Ser Thr Thr Cys Gly Leu Gly			
	185	190	195	
	Met Ala Thr Arg Val Ser Asn Gln Asn Arg Phe Cys Arg Leu Glu			
	200	205	210	
25	Thr Gln Arg Arg Leu Cys Leu Ser Arg Pro Cys Pro Pro Ser Arg			
	215	220	225	
	Gly Arg Ser Pro Gln Asn Ser Ala Phe			
	230	234		
	<210> 72			
30	<211> 233			
	<212> PRT			
	<213> Human			
	<400> 72			
	Leu Ser Lys Val Arg Thr Gln Leu Cys Pro Thr Pro Cys Thr Cys			
35	1	5	10	15
	Pro Trp Pro Pro Pro Arg Cys Pro Leu Gly Val Pro Leu Val Leu			
	20	25	30	
	Asp Gly Cys Gly Cys Cys Arg Val Cys Ala Arg Arg Leu Gly Glu			
	35	40	45	
40	Pro Cys Asp Gln Leu His Val Cys Asp Ala Ser Gln Gly Leu Val			
	50	55	60	

	Cys	Gln	Pro	Gly	Ala	Gly	Pro	Gly	Gly	Arg	Gly	Ala	Leu	Cys	Leu
					65					70					75
	Leu	Ala	Glu	Asp	Asp	Ser	Ser	Cys	Glu	Val	Asn	Gly	Arg	Leu	Tyr
					80					85					90
5	Arg	Glu	Gly	Glu	Thr	Phe	Gln	Pro	His	Cys	Ser	Ile	Arg	Cys	Arg
					95					100					105
	Cys	Glu	Asp	Gly	Gly	Phe	Thr	Cys	Val	Pro	Leu	Cys	Ser	Glu	Asp
					110					115					120
10	Val	Arg	Leu	Pro	Ser	Trp	Asp	Cys	Pro	His	Pro	Arg	Arg	Val	Glu
					125					130					135
	Val	Leu	Gly	Lys	Cys	Cys	Pro	Glu	Trp	Val	Cys	Gly	Gln	Gly	Gly
					140					145					150
	Gly	Leu	Gly	Thr	Gln	Pro	Leu	Pro	Ala	Gln	Gly	Pro	Gln	Phe	Ser
					155					160					165
15	Gly	Leu	Val	Ser	Ser	Leu	Pro	Pro	Gly	Val	Pro	Cys	Pro	Glu	Trp
					170					175					180
	Ser	Thr	Ala	Trp	Gly	Pro	Cys	Ser	Thr	Thr	Cys	Gly	Leu	Gly	Met
					185					190					195
20	Ala	Thr	Arg	Val	Ser	Asn	Gln	Asn	Arg	Phe	Cys	Arg	Leu	Glu	Thr
					200					205					210
	Gln	Arg	Arg	Leu	Cys	Leu	Ser	Arg	Pro	Cys	Pro	Pro	Ser	Arg	Gly
					215					220					225
	Arg	Ser	Pro	Gln	Asn	Ser	Ala	Phe							
					230					233					
25	<210>	73													
	<211>	232													
	<212>	PRT													
	<213>	Human													
	<400>	73													
30	Ser	Lys	Val	Arg	Thr	Gln	Leu	Cys	Pro	Thr	Pro	Cys	Thr	Cys	Pro
					1		5			10					15
	Trp	Pro	Pro	Pro	Arg	Cys	Pro	Leu	Gly	Val	Pro	Leu	Val	Leu	Asp
					20					25					30
35	Gly	Cys	Gly	Cys	Cys	Arg	Val	Cys	Ala	Arg	Arg	Leu	Gly	Glu	Pro
					35					40					45
	Cys	Asp	Gln	Leu	His	Val	Cys	Asp	Ala	Ser	Gln	Gly	Leu	Val	Cys
					50					55					60
	Gln	Pro	Gly	Ala	Gly	Pro	Gly	Gly	Arg	Gly	Ala	Leu	Cys	Leu	Leu
					65					70					75
40	Ala	Glu	Asp	Asp	Ser	Ser	Cys	Glu	Val	Asn	Gly	Arg	Leu	Tyr	Arg
					80					85					90

5	Glu	Gly	Glu	Thr	Phe	Gln	Pro	His	Cys	Ser	Ile	Arg	Cys	Arg	Cys	105
					95											
	Glu	Asp	Gly	Gly	Phe	Thr	Cys	Val	Pro	Leu	Cys	Ser	Glu	Asp	Val	120
					110											
10	Arg	Leu	Pro	Ser	Trp	Asp	Cys	Pro	His	Pro	Arg	Arg	Val	Glu	Val	135
					125					130						
	Leu	Gly	Lys	Cys	Cys	Pro	Glu	Trp	Val	Cys	Gly	Gln	Gly	Gly	Gly	150
					140					145						
15	Leu	Gly	Thr	Gln	Pro	Leu	Pro	Ala	Gln	Gly	Pro	Gln	Phe	Ser	Gly	165
					155					160						
	Leu	Val	Ser	Ser	Leu	Pro	Pro	Gly	Val	Pro	Cys	Pro	Glu	Trp	Ser	180
					170					175						
20	Thr	Ala	Trp	Gly	Pro	Cys	Ser	Thr	Thr	Cys	Gly	Leu	Gly	Met	Ala	195
					185					190						
25	Thr	Arg	Val	Ser	Asn	Gln	Asn	Arg	Phe	Cys	Arg	Leu	Glu	Thr	Gln	210
					200					205						
	Arg	Arg	Leu	Cys	Leu	Ser	Arg	Pro	Cys	Pro	Pro	Ser	Arg	Gly	Arg	225
					215					220						
30	Ser	Pro	Gln	Asn	Ser	Ala	Phe									
					230					232						
	<210>	74														
	<211>	231														
	<212>	PRT														
	<213>	Human														
35	<400>	74														
	Lys	Val	Arg	Thr	Gln	Leu	Cys	Pro	Thr	Pro	Cys	Thr	Cys	Pro	Trp	15
					1					10						
	Pro	Pro	Pro	Arg	Cys	Pro	Leu	Gly	Val	Pro	Leu	Val	Leu	Asp	Gly	30
					20					25						
40	Cys	Gly	Cys	Cys	Arg	Val	Cys	Ala	Arg	Arg	Leu	Gly	Glu	Pro	Cys	45
					35					40						
	Asp	Gln	Leu	His	Val	Cys	Asp	Ala	Ser	Gln	Gly	Leu	Val	Cys	Gln	60
					50					55						
	Pro	Gly	Ala	Gly	Pro	Gly	Gly	Arg	Gly	Ala	Leu	Cys	Leu	Leu	Ala	75
					65					70						
	Glu	Asp	Asp	Ser	Ser	Cys	Glu	Val	Asn	Gly	Arg	Leu	Tyr	Arg	Glu	90
					80					85						
	Gly	Glu	Thr	Phe	Gln	Pro	His	Cys	Ser	Ile	Arg	Cys	Arg	Cys	Glu	105
					95					100						
45	Asp	Gly	Gly	Phe	Thr	Cys	Val	Pro	Leu	Cys	Ser	Glu	Asp	Val	Arg	120
					110					115						

	Leu Pro Ser Trp Asp Cys Pro His Pro Arg Arg Val Glu Val Leu		
	125	130	135
	Gly Lys Cys Cys Pro Glu Trp Val Cys Gly Gln Gly Gly Leu		
	140	145	150
5	Gly Thr Gln Pro Leu Pro Ala Gln Gly Pro Gln Phe Ser Gly Leu		
	155	160	165
	Val Ser Ser Leu Pro Pro Gly Val Pro Cys Pro Glu Trp Ser Thr		
	170	175	180
10	Ala Trp Gly Pro Cys Ser Thr Thr Cys Gly Leu Gly Met Ala Thr		
	185	190	195
	Arg Val Ser Asn Gln Asn Arg Phe Cys Arg Leu Glu Thr Gln Arg		
	200	205	210
	Arg Leu Cys Leu Ser Arg Pro Cys Pro Pro Ser Arg Gly Arg Ser		
	215	220	225
15	Pro Gln Asn Ser Ala Phe		
	230 231		
	<210> 75		
	<211> 230		
	<212> PRT		
20	<213> Human		
	<400> 75		
	Val Arg Thr Gln Leu Cys Pro Thr Pro Cys Thr Cys Pro Trp Pro		
	1 5 10 15		
	Pro Pro Arg Cys Pro Leu Gly Val Pro Leu Val Leu Asp Gly Cys		
25	20 25 30		
	Gly Cys Cys Arg Val Cys Ala Arg Arg Leu Gly Glu Pro Cys Asp		
	35 40 45		
	Gln Leu His Val Cys Asp Ala Ser Gln Gly Leu Val Cys Gln Pro		
	50 55 60		
30	Gly Ala Gly Pro Gly Gly Arg Gly Ala Leu Cys Leu Leu Ala Glu		
	65 70 75		
	Asp Asp Ser Ser Cys Glu Val Asn Gly Arg Leu Tyr Arg Glu Gly		
	80 85 90		
	Glu Thr Phe Gln Pro His Cys Ser Ile Arg Cys Arg Cys Glu Asp		
35	95 100 105		
	Gly Gly Phe Thr Cys Val Pro Leu Cys Ser Glu Asp Val Arg Leu		
	110 115 120		
	Pro Ser Trp Asp Cys Pro His Pro Arg Arg Val Glu Val Leu Gly		
	125 130 135		
40	Lys Cys Cys Pro Glu Trp Val Cys Gly Gln Gly Gly Leu Gly		
	140 145 150		

Thr Gln Pro Leu Pro Ala Gln Gly Pro Gln Phe Ser Gly Leu Val  
 155 160 165  
 Ser Ser Leu Pro Pro Gly Val Pro Cys Pro Glu Trp Ser Thr Ala  
 170 175 180  
 5 Trp Gly Pro Cys Ser Thr Thr Cys Gly Leu Gly Met Ala Thr Arg  
 185 190 195  
 Val Ser Asn Gln Asn Arg Phe Cys Arg Leu Glu Thr Gln Arg Arg  
 200 205 210  
 10 Leu Cys Leu Ser Arg Pro Cys Pro Pro Ser Arg Gly Arg Ser Pro  
 215 220 225  
 Gln Asn Ser Ala Phe  
 230  
 <210> 76  
 <211> 229  
 15 <212> PRT  
 <213> Human  
 <400> 76  
 Arg Thr Gln Leu Cys Pro Thr Pro Cys Thr Cys Pro Trp Pro Pro  
 1 5 10 15  
 20 Pro Arg Cys Pro Leu Gly Val Pro Leu Val Leu Asp Gly Cys Gly  
 20 25 30  
 Cys Cys Arg Val Cys Ala Arg Arg Leu Gly Glu Pro Cys Asp Gln  
 35 40 45  
 Leu His Val Cys Asp Ala Ser Gln Gly Leu Val Cys Gln Pro Gly  
 25 50 55 60  
 Ala Gly Pro Gly Gly Arg Gly Ala Leu Cys Leu Leu Ala Glu Asp  
 65 70 75  
 Asp Ser Ser Cys Glu Val Asn Gly Arg Leu Tyr Arg Glu Gly Glu  
 80 85 90  
 30 Thr Phe Gln Pro His Cys Ser Ile Arg Cys Arg Cys Glu Asp Gly  
 95 100 105  
 Gly Phe Thr Cys Val Pro Leu Cys Ser Glu Asp Val Arg Leu Pro  
 110 115 120  
 35 Ser Trp Asp Cys Pro His Pro Arg Arg Val Glu Val Leu Gly Lys  
 125 130 135  
 Cys Cys Pro Glu Trp Val Cys Gly Gln Gly Gly Leu Gly Thr  
 140 145 150  
 Gln Pro Leu Pro Ala Gln Gly Pro Gln Phe Ser Gly Leu Val Ser  
 155 160 165  
 40 Ser Leu Pro Pro Gly Val Pro Cys Pro Glu Trp Ser Thr Ala Trp  
 170 175 180

	Gly Pro Cys Ser Thr Thr Cys Gly Leu Gly Met Ala Thr Arg Val			
	185	190	195	
	Ser Asn Gln Asn Arg Phe Cys Arg Leu Glu Thr Gln Arg Arg Leu			
	200	205	210	
5	Cys Leu Ser Arg Pro Cys Pro Pro Ser Arg Gly Arg Ser Pro Gln			
	215	220	225	
	Asn Ser Ala Phe			
	229			
	<210> 77			
10	<211> 228			
	<212> PRT			
	<213> Human			
	<400> 77			
15	Thr Gln Leu Cys Pro Thr Pro Cys Thr Cys Pro Trp Pro Pro Pro			
	1	5	10	15
	Arg Cys Pro Leu Gly Val Pro Leu Val Leu Asp Gly Cys Gly Cys			
	20	25	30	
	Cys Arg Val Cys Ala Arg Arg Leu Gly Glu Pro Cys Asp Gln Leu			
	35	40	45	
20	His Val Cys Asp Ala Ser Gln Gly Leu Val Cys Gln Pro Gly Ala			
	50	55	60	
	Gly Pro Gly Gly Arg Gly Ala Leu Cys Leu Leu Ala Glu Asp Asp			
	65	70	75	
25	Ser Ser Cys Glu Val Asn Gly Arg Leu Tyr Arg Glu Gly Glu Thr			
	80	85	90	
	Phe Gln Pro His Cys Ser Ile Arg Cys Arg Cys Glu Asp Gly Gly			
	95	100	105	
	Phe Thr Cys Val Pro Leu Cys Ser Glu Asp Val Arg Leu Pro Ser			
	110	115	120	
30	Trp Asp Cys Pro His Pro Arg Arg Val Glu Val Leu Gly Lys Cys			
	125	130	135	
	Cys Pro Glu Trp Val Cys Gly Gln Gly Gly Leu Gly Thr Gln			
	140	145	150	
35	Pro Leu Pro Ala Gln Gly Pro Gln Phe Ser Gly Leu Val Ser Ser			
	155	160	165	
	Leu Pro Pro Gly Val Pro Cys Pro Glu Trp Ser Thr Ala Trp Gly			
	170	175	180	
	Pro Cys Ser Thr Thr Cys Gly Leu Gly Met Ala Thr Arg Val Ser			
	185	190	195	
40	Asn Gln Asn Arg Phe Cys Arg Leu Glu Thr Gln Arg Arg Leu Cys			
	200	205	210	

	Leu Ser Arg Pro Cys Pro Pro Ser Arg Gly Arg Ser Pro Gln Asn			
	215	220	225	
	Ser Ala Phe			
	228			
5	<210> 78			
	<211> 250			
	<212> PRT			
	<213> Human			
	<400> 78			
10	Arg Gly Asn Pro Leu Ile His Leu Leu Ala Ile Ser Phe Leu Cys			
	1	5	10	15
	Ile Leu Ser Met Val Tyr Ser Gln Leu Cys Pro Ala Pro Cys Ala			
	20	25	30	
15	Cys Pro Trp Thr Pro Pro Gln Cys Pro Pro Gly Val Pro Leu Val			
	35	40	45	
	Leu Asp Gly Cys Gly Cys Cys Arg Val Cys Ala Arg Arg Leu Gly			
	50	55	60	
	Glu Ser Cys Asp His Leu His Val Cys Asp Pro Ser Gln Gly Leu			
	65	70	75	
20	Val Cys Gln Pro Gly Ala Gly Pro Ser Gly Arg Gly Ala Val Cys			
	80	85	90	
	Leu Phe Glu Glu Asp Asp Gly Ser Cys Glu Val Asn Gly Arg Arg			
	95	100	105	
25	Tyr Leu Asp Gly Glu Thr Phe Lys Pro Asn Cys Arg Val Leu Cys			
	110	115	120	
	Arg Cys Asp Asp Gly Gly Phe Thr Cys Leu Pro Leu Cys Ser Glu			
	125	130	135	
	Asp Val Arg Leu Pro Ser Trp Asp Cys Pro Arg Pro Arg Arg Ile			
	140	145	150	
30	Gln Val Pro Gly Arg Cys Cys Pro Glu Trp Val Cys Asp Gln Ala			
	155	160	165	
	Val Met Gln Pro Ala Ile Gln Pro Ser Ser Ala Gln Gly His Gln			
	170	175	180	
35	Leu Ser Ala Leu Val Thr Pro Ala Ser Ala Asp Gly Pro Cys Pro			
	185	190	195	
	Asn Trp Ser Thr Ala Trp Gly Pro Cys Ser Thr Thr Cys Gly Leu			
	200	205	210	
	Gly Ile Ala Thr Arg Val Ser Asn Gln Asn Arg Phe Cys Gln Leu			
	215	220	225	
40	Glu Ile Gln Arg Arg Leu Cys Leu Ser Arg Pro Cys Leu Ala Ser			
	230	235	240	

Arg Ser His **Gly** Ser Trp Asn Ser Ala Phe  
 245 250

5      <210> 79  
 <211> 249  
 <212> PRT  
 <213> Human

10     <400> 79  
 Gly Asn Pro Leu Ile His Leu Leu Ala Ile Ser Phe Leu Cys Ile  
 1                        5                        10                        15

15     Leu Ser Met Val Tyr Ser Gln Leu Cys Pro Ala Pro Cys Ala Cys  
 20                        25                        30

20     Pro Trp Thr Pro Pro Gln Cys Pro Pro Gly Val Pro Leu Val Leu  
 35                        40                        45

25     Asp Gly Cys Gly Cys Cys Arg Val Cys Ala Arg Arg Leu Gly Glu  
 30                        55                        60

30     Ser Cys Asp His Leu His Val Cys Asp Pro Ser Gln Gly Leu Val  
 35                        65                        75

35     Cys Gln Pro Gly Ala Gly Pro Ser Gly Arg Gly Ala Val Cys Leu  
 40                        80                        90

40     Phe Glu Glu Asp Asp Gly Ser Cys Glu Val Asn Gly Arg Arg Tyr  
 45                        95                        105

45     Leu Asp Gly Glu Thr Phe Lys Pro Asn Cys Arg Val Leu Cys Arg  
 50                        110                        120

50     Cys Asp Asp Gly Gly Phe Thr Cys Leu Pro Leu Cys Ser Glu Asp  
 55                        125                        135

55     Val Arg Leu Pro Ser Trp Asp Cys Pro Arg Pro Arg Arg Ile Gln  
 60                        140                        150

60     Val Pro Gly Arg Cys Cys Pro Glu Trp Val Cys Asp Gln Ala Val  
 65                        155                        165

65     30     Met Gln Pro Ala Ile Gln Pro Ser Ser Ala Gln Gly His Gln Leu  
 70                        170                        180

70     Ser Ala Leu Val Thr Pro Ala Ser Ala Asp Gly Pro Cys Pro Asn  
 75                        185                        195

75     35     Trp Ser Thr Ala Trp Gly Pro Cys Ser Thr Thr Cys Gly Leu Gly  
 80                        200                        210

80     Ile Ala Thr Arg Val Ser Asn Gln Asn Arg Phe Cys Gln Leu Glu  
 85                        215                        225

85     Ile Gln Arg Arg Leu Cys Leu Ser Arg Pro Cys Leu Ala Ser Arg  
 90                        230                        240

90     40     Ser His Gly Ser Trp Asn Ser Ala Phe  
 95                        245                        249

<210> 80  
 <211> 248  
 <212> PRT  
 <213> Human

5      <400> 80  
 Asn Pro Leu Ile His Leu Leu Ala Ile Ser Phe Leu Cys Ile Leu  
 1                    5                    10                    15

Ser Met Val Tyr Ser Gln Leu Cys Pro Ala Pro Cys Ala Cys Pro  
 20                    25                    30

10     Trp Thr Pro Pro Gln Cys Pro Pro Gly Val Pro Leu Val Leu Asp  
 35                    40                    45

Gly Cys Gly Cys Cys Arg Val Cys Ala Arg Arg Leu Gly Glu Ser  
 50                    55                    60

15     Cys Asp His Leu His Val Cys Asp Pro Ser Gln Gly Leu Val Cys  
 65                    70                    75

Gln Pro Gly Ala Gly Pro Ser Gly Arg Gly Ala Val Cys Leu Phe  
 80                    85                    90

Glu Glu Asp Asp Gly Ser Cys Glu Val Asn Gly Arg Arg Tyr Leu  
 95                    100                    105

20     Asp Glu Thr Phe Lys Pro Asn Cys Arg Val Leu Cys Arg Cys  
 110                    115                    120

Asp Asp Gly Gly Phe Thr Cys Leu Pro Leu Cys Ser Glu Asp Val  
 125                    130                    135

25     Arg Leu Pro Ser Trp Asp Cys Pro Arg Pro Arg Arg Ile Gln Val  
 140                    145                    150

Pro Gly Arg Cys Cys Pro Glu Trp Val Cys Asp Gln Ala Val Met  
 155                    160                    165

Gln Pro Ala Ile Gln Pro Ser Ser Ala Gln Gly His Gln Leu Ser  
 170                    175                    180

30     Ala Leu Val Thr Pro Ala Ser Ala Asp Gly Pro Cys Pro Asn Trp  
 185                    190                    195

Ser Thr Ala Trp Gly Pro Cys Ser Thr Thr Cys Gly Leu Gly Ile  
 200                    205                    210

35     Ala Thr Arg Val Ser Asn Gln Asn Arg Phe Cys Gln Leu Glu Ile  
 215                    220                    225

Gln Arg Arg Leu Cys Leu Ser Arg Pro Cys Leu Ala Ser Arg Ser  
 230                    235                    240

His Gly Ser Trp Asn Ser Ala Phe  
 245                    248

40     <210> 81  
 <211> 247

<212> PRT  
 <213> Human

<400> 81  
 Pro Leu Ile His Leu Leu Ala Ile Ser Phe Leu Cys Ile Leu Ser  
 5 1 5 10 15  
 Met Val Tyr Ser Gln Leu Cys Pro Ala Pro Cys Ala Cys Pro Trp  
 20 25 30  
 Thr Pro Pro Gln Cys Pro Pro Gly Val Pro Leu Val Leu Asp Gly  
 35 40 45  
 10 Cys Gly Cys Cys Arg Val Cys Ala Arg Arg Leu Gly Glu Ser Cys  
 50 55 60  
 Asp His Leu His Val Cys Asp Pro Ser Gln Gly Leu Val Cys Gln  
 65 70 75  
 Pro Gly Ala Gly Pro Ser Gly Arg Gly Ala Val Cys Leu Phe Glu  
 15 80 85 90  
 Glu Asp Asp Gly Ser Cys Glu Val Asn Gly Arg Arg Tyr Leu Asp  
 95 100 105  
 Gly Glu Thr Phe Lys Pro Asn Cys Arg Val Leu Cys Arg Cys Asp  
 110 115 120  
 20 Asp Gly Gly Phe Thr Cys Leu Pro Leu Cys Ser Glu Asp Val Arg  
 125 130 135  
 Leu Pro Ser Trp Asp Cys Pro Arg Pro Arg Arg Ile Gln Val Pro  
 140 145 150  
 Gly Arg Cys Cys Pro Glu Trp Val Cys Asp Gln Ala Val Met Gln  
 25 155 160 165  
 Pro Ala Ile Gln Pro Ser Ser Ala Gln Gly His Gln Leu Ser Ala  
 170 175 180  
 Leu Val Thr Pro Ala Ser Ala Asp Gly Pro Cys Pro Asn Trp Ser  
 185 190 195  
 30 Thr Ala Trp Gly Pro Cys Ser Thr Thr Cys Gly Leu Gly Ile Ala  
 200 205 210  
 Thr Arg Val Ser Asn Gln Asn Arg Phe Cys Gln Leu Glu Ile Gln  
 215 220 225  
 Arg Arg Leu Cys Leu Ser Arg Pro Cys Leu Ala Ser Arg Ser His  
 35 230 235 240  
 Gly Ser Trp Asn Ser Ala Phe  
 245 247

<210> 82  
 <211> 246  
 40 <212> PRT  
 <213> Human

<400> 82  
 Leu Ile His Leu Leu Ala Ile Ser Phe Leu Cys Ile Leu Ser Met  
 1 5 10 15  
 Val Tyr Ser Gln Leu Cys Pro Ala Pro Cys Ala Cys Pro Trp Thr  
 5 20 25 30  
 Pro Pro Gln Cys Pro Pro Gly Val Pro Leu Val Leu Asp Gly Cys  
 35 40 45  
 Gly Cys Cys Arg Val Cys Ala Arg Arg Leu Gly Glu Ser Cys Asp  
 50 55 60  
 10 His Leu His Val Cys Asp Pro Ser Gln Gly Leu Val Cys Gln Pro  
 65 70 75  
 Gly Ala Gly Pro Ser Gly Arg Gly Ala Val Cys Leu Phe Glu Glu  
 80 85 90  
 15 Asp Asp Gly Ser Cys Glu Val Asn Gly Arg Arg Tyr Leu Asp Gly  
 95 100 105  
 Glu Thr Phe Lys Pro Asn Cys Arg Val Leu Cys Arg Cys Asp Asp  
 110 115 120  
 Gly Gly Phe Thr Cys Leu Pro Leu Cys Ser Glu Asp Val Arg Leu  
 125 130 135  
 20 Pro Ser Trp Asp Cys Pro Arg Pro Arg Arg Ile Gln Val Prc Gly  
 140 145 150  
 Arg Cys Cys Pro Glu Trp Val Cys Asp Gln Ala Val Met Gln Pro  
 155 160 165  
 Ala Ile Gln Pro Ser Ser Ala Gln Gly His Gln Leu Ser Ala Leu  
 170 175 180  
 25 Val Thr Pro Ala Ser Ala Asp Gly Pro Cys Pro Asn Trp Ser Thr  
 185 190 195  
 Ala Trp Gly Pro Cys Ser Thr Thr Cys Gly Leu Gly Ile Ala Thr  
 200 205 210  
 30 Arg Val Ser Asn Gln Asn Arg Phe Cys Gln Leu Glu Ile Gln Arg  
 215 220 225  
 Arg Leu Cys Leu Ser Arg Pro Cys Leu Ala Ser Arg Ser His Gly  
 230 235 240  
 35 Ser Trp Asn Ser Ala Phe  
 245 246  
 <210> 83  
 <211> 245  
 <212> PRT  
 <213> Human  
 40 <400> 83  
 Ile His Leu Leu Ala Ile Ser Phe Leu Cys Ile Leu Ser Met Val

1	5	10	15
	Tyr Ser Gln Leu Cys Pro Ala Pro Cys Ala Cys Pro Trp Thr Pro		
	20	25	30
5	Pro Gln Cys Pro Pro Gly Val Pro Leu Val Leu Asp Gly Cys Gly		
	35	40	45
	Cys Cys Arg Val Cys Ala Arg Arg Leu Gly Glu Ser Cys Asp His		
	50	55	60
	Leu His Val Cys Asp Pro Ser Gln Gly Leu Val Cys Gln Pro Gly		
	65	70	75
10	Ala Gly Pro Ser Gly Arg Gly Ala Val Cys Leu Phe Glu Glu Asp		
	80	85	90
	Asp Gly Ser Cys Glu Val Asn Gly Arg Arg Tyr Leu Asp Gly Glu		
	95	100	105
15	Thr Phe Lys Pro Asn Cys Arg Val Leu Cys Arg Cys Asp Asp Gly		
	110	115	120
	Gly Phe Thr Cys Leu Pro Leu Cys Ser Glu Asp Val Arg Leu Pro		
	125	130	135
	Ser Trp Asp Cys Pro Arg Pro Arg Arg Ile Gln Val Pro Gly Arg		
	140	145	150
20	Cys Cys Pro Glu Trp Val Cys Asp Gln Ala Val Met Gln Pro Ala		
	155	160	165
	Ile Gln Pro Ser Ser Ala Gln Gly His Gln Leu Ser Ala Leu Val		
	170	175	180
25	Thr Pro Ala Ser Ala Asp Gly Pro Cys Pro Asn Trp Ser Thr Ala		
	185	190	195
	Trp Gly Pro Cys Ser Thr Thr Cys Gly Leu Gly Ile Ala Thr Arg		
	200	205	210
	Val Ser Asn Gln Asn Arg Phe Cys Gln Leu Glu Ile Gln Arg Arg		
	215	220	225
30	Leu Cys Leu Ser Arg Pro Cys Leu Ala Ser Arg Ser His Gly Ser		
	230	235	240
	Trp Asn Ser Ala Phe		
	245		
	<210> 84		
35	<211> 244		
	<212> PRT		
	<213> Human		
	<400> 84		
40	His Leu Leu Ala Ile Ser Phe Leu Cys Ile Leu Ser Met Val Tyr		
	1	5	10
	15		

	Ser Gln Leu Cys Pro Ala Pro Cys Ala Cys Pro Trp Thr Pro Pro			
	20	25	30	
	Gln Cys Pro Pro Gly Val Pro Leu Val Leu Asp Gly Cys Gly Cys			
	35	40	45	
5	Cys Arg Val Cys Ala Arg Arg Leu Gly Glu Ser Cys Asp His Leu			
	50	55	60	
	His Val Cys Asp Pro Ser Gln Gly Leu Val Cys Gln Pro Gly Ala			
	65	70	75	
10	Gly Pro Ser Gly Arg Gly Ala Val Cys Leu Phe Glu Glu Asp Asp			
	80	85	90	
	Gly Ser Cys Glu Val Asn Gly Arg Arg Tyr Leu Asp Gly Glu Thr			
	95	100	105	
	Phe Lys Pro Asn Cys Arg Val Leu Cys Arg Cys Asp Asp Gly Gly			
	110	115	120	
15	Phe Thr Cys Leu Pro Leu Cys Ser Glu Asp Val Arg Leu Pro Ser			
	125	130	135	
	Trp Asp Cys Pro Arg Pro Arg Arg Ile Gln Val Pro Gly Arg Cys			
	140	145	150	
20	Cys Pro Glu Trp Val Cys Asp Gln Ala Val Met Gln Pro Ala Ile			
	155	160	165	
	Gln Pro Ser Ser Ala Gln Gly His Gln Leu Ser Ala Leu Val Thr			
	170	175	180	
	Pro Ala Ser Ala Asp Gly Pro Cys Pro Asn Trp Ser Thr Ala Trp			
	185	190	195	
25	Gly Pro Cys Ser Thr Thr Cys Gly Leu Gly Ile Ala Thr Arg Val			
	200	205	210	
	Ser Asn Gln Asn Arg Phe Cys Gln Leu Glu Ile Gln Arg Arg Leu			
	215	220	225	
30	Cys Leu Ser Arg Pro Cys Leu Ala Ser Arg Ser His Gly Ser Trp			
	230	235	240	
	Asn Ser Ala Phe			
	244			
	<210> 85			
	<211> 243			
35	<212> PRT			
	<213> Human			
	<400> 85			
	Leu Leu Ala Ile Ser Phe Leu Cys Ile Leu Ser Met Val Tyr Ser			
	1	5	10	15
40	Gln Leu Cys Pro Ala Pro Cys Ala Cys Pro Trp Thr Pro Pro Gln			
	20	25	30	

	Cys Pro Pro Gly Val Pro Leu Val Leu Asp Gly Cys Gly Cys Cys			
	35	40	45	
	Arg Val Cys Ala Arg Arg Leu Gly Glu Ser Cys Asp His Leu His			
	50	55	60	
5	Val Cys Asp Pro Ser Gln Gly Leu Val Cys Gln Pro Gly Ala Gly			
	65	70	75	
	Pro Ser Gly Arg Gly Ala Val Cys Leu Phe Glu Glu Asp Asp Gly			
	80	85	90	
10	Ser Cys Glu Val Asn Gly Arg Arg Tyr Leu Asp Gly Glu Thr Phe			
	95	100	105	
	Lys Pro Asn Cys Arg Val Leu Cys Arg Cys Asp Asp Gly Gly Phe			
	110	115	120	
	Thr Cys Leu Pro Leu Cys Ser Glu Asp Val Arg Leu Pro Ser Trp			
	125	130	135	
15	Asp Cys Pro Arg Pro Arg Arg Ile Gln Val Pro Gly Arg Cys Cys			
	140	145	150	
	Pro Glu Trp Val Cys Asp Gln Ala Val Met Gln Pro Ala Ile Gln			
	155	160	165	
20	Pro Ser Ser Ala Gln Gly His Gln Leu Ser Ala Leu Val Thr Pro			
	170	175	180	
	Ala Ser Ala Asp Gly Pro Cys Pro Asn Trp Ser Thr Ala Trp Gly			
	185	190	195	
	Pro Cys Ser Thr Thr Cys Gly Leu Gly Ile Ala Thr Arg Val Ser			
	200	205	210	
25	Asn Gln Asn Arg Phe Cys Gln Leu Glu Ile Gln Arg Arg Leu Cys			
	215	220	225	
	Leu Ser Arg Pro Cys Leu Ala Ser Arg Ser His Gly Ser Trp Asn			
	230	235	240	
30	Ser Ala Phe			
	243			
	<210> 86			
	<211> 242			
	<212> PRT			
	<213> Human			
35	<400> 86			
	Leu Ala Ile Ser Phe Leu Cys Ile Leu Ser Met Val Tyr Ser Gln			
	1	5	10	15
	Leu Cys Pro Ala Pro Cys Ala Cys Pro Trp Thr Pro Pro Gln Cys			
	20	25	30	
40	Pro Pro Gly Val Pro Leu Val Leu Asp Gly Cys Gly Cys Cys Arg			
	35	40	45	

	Val Cys Ala Arg Arg Leu Gly Glu Ser Cys Asp His Leu His Val			
	50	55	60	
	Cys Asp Pro Ser Gln Gly Leu Val Cys Gln Pro Gly Ala Gly Pro			
	65	70	75	
5	Ser Gly Arg Gly Ala Val Cys Leu Phe Glu Glu Asp Asp Gly Ser			
	80	85	90	
	Cys Glu Val Asn Gly Arg Arg Tyr Leu Asp Gly Glu Thr Phe Lys			
	95	100	105	
10	Pro Asn Cys Arg Val Leu Cys Arg Cys Asp Asp Gly Gly Phe Thr			
	110	115	120	
	Cys Leu Pro Leu Cys Ser Glu Asp Val Arg Leu Pro Ser Trp Asp			
	125	130	135	
	Cys Pro Arg Pro Arg Arg Ile Gln Val Pro Gly Arg Cys Cys Pro			
	140	145	150	
15	Glu Trp Val Cys Asp Gln Ala Val Met Gln Pro Ala Ile Gln Pro			
	155	160	165	
	Ser Ser Ala Gln Gly His Gln Leu Ser Ala Leu Val Thr Pro Ala			
	170	175	180	
20	Ser Ala Asp Gly Pro Cys Pro Asn Trp Ser Thr Ala Trp Gly Pro			
	185	190	195	
	Cys Ser Thr Thr Cys Gly Leu Gly Ile Ala Thr Arg Val Ser Asn			
	200	205	210	
	Gln Asn Arg Phe Cys Gln Leu Glu Ile Gln Arg Arg Leu Cys Leu			
	215	220	225	
25	Ser Arg Pro Cys Leu Ala Ser Arg Ser His Gly Ser Trp Asn Ser			
	230	235	240	
	Ala Phe			
	242			
	<210> 87			
30	<211> 241			
	<212> PRT			
	<213> Human			
	<400> 87			
35	Ala Ile Ser Phe Leu Cys Ile Leu Ser Met Val Tyr Ser Gln Leu			
	1	5	10	15
	Cys Pro Ala Pro Cys Ala Cys Pro Trp Thr Pro Pro Gln Cys Pro			
	20	25	30	
	Pro Gly Val Pro Leu Val Leu Asp Gly Cys Gly Cys Cys Arg Val			
	35	40	45	
40	Cys Ala Arg Arg Leu Gly Glu Ser Cys Asp His Leu His Val Cys			
	50	55	60	

	Asp Pro Ser G...	Gly Leu Val Cys Gln Pro Gly Ala Gly Pro Ser	
	65	70	75
	Gly Arg Gly Ala Val Cys Leu Phe Glu Glu Asp Asp Gly Ser Cys		
	80	85	90
5	Glu Val Asn Gly Arg Arg Tyr Leu Asp Gly Glu Thr Phe Lys Pro		
	95	100	105
	Asn Cys Arg Val Leu Cys Arg Cys Asp Asp Gly Gly Phe Thr Cys		
	110	115	120
10	Leu Pro Leu Cys Ser Glu Asp Val Arg Leu Pro Ser Trp Asp Cys		
	125	130	135
	Pro Arg Pro Arg Arg Ile Gln Val Pro Gly Arg Cys Cys Pro Glu		
	140	145	150
	Trp Val Cys Asp Gln Ala Val Met Gln Pro Ala Ile Gln Pro Ser		
	155	160	165
15	Ser Ala Gln Gly His Gln Leu Ser Ala Leu Val Thr Pro Ala Ser		
	170	175	180
	Ala Asp Gly Pro Cys Pro Asn Trp Ser Thr Ala Trp Gly Pro Cys		
	185	190	195
20	Ser Thr Thr Cys Gly Leu Gly Ile Ala Thr Arg Val Ser Asn Gln		
	200	205	210
	Asn Arg Phe Cys Gln Leu Glu Ile Gln Arg Arg Leu Cys Leu Ser		
	215	220	225
	Arg Pro Cys Leu Ala Ser Arg Ser His Gly Ser Trp Asn Ser Ala		
	230	235	240
25	Phe		
	241		
	<210> 88		
	<211> 240		
	<212> PRT		
30	<213> Human		
	<400> 88		
	Ile Ser Phe Leu Cys Ile Leu Ser Met Val Tyr Ser Gln Leu Cys		
	1	5	10
	15		
35	Pro Ala Pro Cys Ala Cys Pro Trp Thr Pro Pro Gln Cys Pro Pro		
	20	25	30
	Gly Val Pro Leu Val Leu Asp Gly Cys Gly Cys Cys Arg Val Cys		
	35	40	45
	Ala Arg Arg Leu Gly Glu Ser Cys Asp His Leu His Val Cys Asp		
	50	55	60
40	Pro Ser Gln Gly Leu Val Cys Gln Pro Gly Ala Gly Pro Ser Gly		
	65	70	75

	Arg	Gly	Ala	Val	Cys	Leu	Phe	Glu	Glu	Asp	Asp	Gly	Ser	Cys	Glu
						80				85					90
	Val	Asn	Gly	Arg	Arg	Tyr	Leu	Asp	Gly	Glu	Thr	Phe	Lys	Pro	Asn
						95				100					105
5	Cys	Arg	Val	Leu	Cys	Arg	Cys	Asp	Asp	Gly	Gly	Phe	Thr	Cys	Leu
						110				115					120
	Pro	Leu	Cys	Ser	Glu	Asp	Val	Arg	Leu	Pro	Ser	Trp	Asp	Cys	Pro
						125				130					135
10	Arg	Pro	Arg	Arg	Ile	Gln	Val	Pro	Gly	Arg	Cys	Cys	Pro	Glu	Trp
						140				145					150
	Val	Cys	Asp	Gln	Ala	Val	Met	Gln	Pro	Ala	Ile	Gln	Pro	Ser	Ser
						155				160					165
	Ala	Gln	Gly	His	Gln	Leu	Ser	Ala	Leu	Val	Thr	Pro	Ala	Ser	Ala
						170				175					180
15	Asp	Gly	Pro	Cys	Pro	Asn	Trp	Ser	Thr	Ala	Trp	Gly	Pro	Cys	Ser
						185				190					195
	Thr	Thr	Cys	Gly	Leu	Gly	Ile	Ala	Thr	Arg	Val	Ser	Asn	Gln	Asn
						200				205					210
20	Arg	Phe	Cys	Gln	Leu	Gl-	Ile	Gln	Arg	Arg	Leu	Cys	Leu	Ser	Arg
						215				220					225
	Pro	Cys	Leu	Ala	Ser	Arg	Ser	His	Gly	Ser	Trp	Asn	Ser	Ala	Phe
						230				235					240
	<210>	89													
	<211>	239													
25	<212>	PRT													
	<213>	Human													
	<400>	89													
	Ser	Phe	Leu	Cys	Ile	Leu	Ser	Met	Val	Tyr	Ser	Gln	Leu	Cys	Pro
						1			5			10			15
30	Ala	Pro	Cys	Ala	Cys	Pro	Trp	Thr	Pro	Pro	Gln	Cys	Pro	Pro	Gly
						20			25			30			
	Val	Pro	Leu	Val	Leu	Asp	Gly	Cys	Gly	Cys	Cys	Arg	Val	Cys	Ala
						35				40					45
35	Arg	Arg	Leu	Gly	Glu	Ser	Cys	Asp	His	Leu	His	Val	Cys	Asp	Pro
						50				55					60
	Ser	Gln	Gly	Leu	Val	Cys	Gln	Pro	Gly	Ala	Gly	Pro	Ser	Gly	Arg
						65				70					75
	Gly	Ala	Val	Cys	Leu	Phe	Glu	Glu	Asp	Asp	Gly	Ser	Cys	Glu	Val
						80				85					90
40	Asn	Gly	Arg	Arg	Tyr	Leu	Asp	Gly	Glu	Thr	Phe	Lys	Pro	Asn	Cys
						95				100					105

	Arg Val Leu Cys Arg Cys Asp Asp Gly Gly Phe Thr Cys Leu Pro		
	110	115	120
	Leu Cys Ser Glu Asp Val Arg Leu Pro Ser Trp Asp Cys Pro Arg		
	125	130	135
5	Pro Arg Arg Ile Gln Val Pro Gly Arg Cys Cys Pro Glu Trp Val		
	140	145	150
	Cys Asp Gln Ala Val Met Gln Pro Ala Ile Gln Pro Ser Ser Ala		
	155	160	165
10	Gln Gly His Gln Leu Ser Ala Leu Val Thr Pro Ala Ser Ala Asp		
	170	175	180
	Gly Pro Cys Pro Asn Trp Ser Thr Ala Trp Gly Pro Cys Ser Thr		
	185	190	195
	Thr Cys Gly Leu Gly Ile Ala Thr Arg Val Ser Asn Gln Asn Arg		
	200	205	210
15	Phe Cys Gln Leu Glu Ile Gln Arg Arg Leu Cys Leu Ser Arg Pro		
	215	220	225
	Cys Leu Ala Ser Arg Ser His Gly Ser Trp Asn Ser Ala Phe		
	230	235	239
20	<210> 90		
	<211> 238		
	<212> PRT		
	<213> Human		
	<400> 90		
25	Phe Leu Cys Ile Leu Ser Met Val Tyr Ser Gln Leu Cys Pro Ala		
	1	5	10
	15		
	Pro Cys Ala Cys Pro Trp Thr Pro Pro Gln Cys Pro Pro Gly Val		
	20	25	30
	Pro Leu Val Leu Asp Gly Cys Gly Cys Cys Arg Val Cys Ala Arg		
	35	40	45
30	Arg Leu Gly Glu Ser Cys Asp His Leu His Val Cys Asp Pro Ser		
	50	55	60
	Gln Gly Leu Val Cys Gln Pro Gly Ala Gly Pro Ser Gly Arg Gly		
	65	70	75
35	Ala Val Cys Leu Phe Glu Glu Asp Asp Gly Ser Cys Glu Val Asn		
	80	85	90
	Gly Arg Arg Tyr Leu Asp Gly Glu Thr Phe Lys Pro Asn Cys Arg		
	95	100	105
	Val Leu Cys Arg Cys Asp Asp Gly Gly Phe Thr Cys Leu Pro Leu		
	110	115	120
40	Cys Ser Glu Asp Val Arg Leu Pro Ser Trp Asp Cys Pro Arg Pro		
	125	130	135

	Arg Arg Ile Gln Val Pro Gly Arg Cys Cys Pro Glu Trp val Cys			
	140	145	150	
	Asp Gln Ala Val Met Gln Pro Ala Ile Gln Pro Ser Ser Ala Gln			
	155	160	165	
5	Gly His Gln Leu Ser Ala Leu Val Thr Pro Ala Ser Ala Asp Gly			
	170	175	180	
	Pro Cys Pro Asn Trp Ser Thr Ala Trp Gly Pro Cys Ser Thr Thr			
	185	190	195	
10	Cys Gly Leu Gly Ile Ala Thr Arg Val Ser Asn Gln Asn Arg Phe			
	200	205	210	
	Cys Gln Leu Glu Ile Gln Arg Arg Leu Cys Leu Ser Arg Pro Cys			
	215	220	225	
	Leu Ala Ser Arg Ser His Gly Ser Trp Asn Ser Ala Phe			
	230	235	238	
15	<210> 91			
	<211> 237			
	<212> PRT			
	<213> Human			
20	<400> 91			
	Leu Cys Ile Leu Ser Met Val Tyr Ser Gln Leu Cys Pro Ala Pro			
	1	5	10	15
	Cys Ala Cys Pro Trp Thr Pro Pro Gln Cys Prc Pro Gly Val Pro			
	20	25	30	
25	Leu Val Leu Asp Gly Cys Gly Cys Cys Arg Val Cys Ala Arg Arg			
	35	40	45	
	Leu Gly Glu Ser Cys Asp His Leu His Val Cys Asp Pro Ser Gln			
	50	55	60	
	Gly Leu Val Cys Gln Pro Gly Ala Gly Pro Ser Gly Arg Gly Ala			
	65	70	75	
30	Val Cys Leu Phe Glu Glu Asp Asp Gly Ser Cys Glu Val Asn Gly			
	80	85	90	
	Arg Arg Tyr Leu Asp Gly Glu Thr Phe Lys Pro Asn Cys Arg Val			
	95	100	105	
35	Leu Cys Arg Cys Asp Asp Gly Gly Phe Thr Cys Leu Pro Leu Cys			
	110	115	120	
	Ser Glu Asp Val Arg Leu Pro Ser Trp Asp Cys Pro Arg Pro Arg			
	125	130	135	
	Arg Ile Gln Val Pro Gly Arg Cys Cys Pro Glu Trp Val Cys Asp			
	140	145	150	
40	Gln Ala Val Met Gln Pro Ala Ile Gln Pro Ser Ser Ala Gln Gly			
	155	160	165	

	His Gln Leu Ser Ala Leu Val Thr Pro Ala Ser Ala Asp Gly Pro			
	170	175	180	
	Cys Pro Asn Trp Ser Thr Ala Trp Gly Pro Cys Ser Thr Thr Cys			
	185	190	195	
5	Gly Leu Gly Ile Ala Thr Arg Val Ser Asn Gln Asn Arg Phe Cys			
	200	205	210	
	Gln Leu Glu Ile Gln Arg Arg Leu Cys Leu Ser Arg Pro Cys Leu			
	215	220	225	
10	Ala Ser Arg Ser His Gly Ser Trp Asn Ser Ala Phe			
	230	235	237	
	<210> 92			
	<211> 236			
	<212> PRT			
	<213> Human			
15	<400> 92			
	Cys Ile Leu Ser Met Val Tyr Ser Gln Leu Cys Pro Ala Pro Cys			
	1	5	10	15
	Ala Cys Pro Trp Thr Pro Pro Gln Cys Pro Pro Gly Val Pro Leu			
	20	25	30	
20	Val L.u Asp Gly Cys Gly Cys Cys Arg Val Cys Ala Arg Arg Leu			
	35	40	45	
	Gly Glu Ser Cys Asp His Leu His Val Cys Asp Pro Ser Gln Gly			
	50	55	60	
25	Leu Val Cys Gln Pro Gly Ala Gly Pro Ser Gly Arg Gly Ala Val			
	65	70	75	
	Cys Leu Phe Glu Glu Asp Asp Gly Ser Cys Glu Val Asn Gly Arg			
	80	85	90	
	Arg Tyr Leu Asp Gly Glu Thr Phe Lys Pro Asn Cys Arg Val Leu			
	95	100	105	
30	Cys Arg Cys Asp Asp Gly Gly Phe Thr Cys Leu Pro Leu Cys Ser			
	110	115	120	
	Glu Asp Val Arg Leu Pro Ser Trp Asp Cys Pro Arg Pro Arg Arg			
	125	130	135	
35	Ile Gln Val Pro Gly Arg Cys Cys Pro Glu Trp Val Cys Asp Gln			
	140	145	150	
	Ala Val Met Gln Pro Ala Ile Gln Pro Ser Ser Ala Gln Gly His			
	155	160	165	
	Gln Leu Ser Ala Leu Val Thr Pro Ala Ser Ala Asp Gly Pro Cys			
	170	175	180	
40	Pro Asn Trp Ser Thr Ala Trp Gly Pro Cys Ser Thr Thr Cys Gly			
	185	190	195	

	Leu	Gly	Ile	Ala	Thr	Arg	Val	Ser	Asn	Gln	Asn	Arg	Phe	Cys	Gln		
																200	
																205	
																210	
	Leu	Glu	Ile	Gln	Arg	Arg	Leu	Cys	Leu	Ser	Arg	Pro	Cys	Leu	Ala		
																215	
																220	
																225	
5	Ser	Arg	Ser	His	Gly	Ser	Trp	Asn	Ser	Ala	Phe						
																230	
																235 236	
	<210>	93															
	<211>	235															
	<212>	PRT															
10	<213>	Human															
	<400>	93															
	Ile	Leu	Ser	Met	Val	Tyr	Ser	Gln	Leu	Cys	Pro	Ala	Pro	Cys	Ala		
																1	
																5	
																10	
																15	
15	Cys	Pro	Trp	Thr	Pro	Pro	Gln	Cys	Pro	Pro	Gly	Val	Pro	Leu	Val		
																20	
																25	
																30	
	Leu	Asp	Gly	Cys	Gly	Cys	Cys	Arg	Val	Cys	Ala	Arg	Arg	Leu	Gly		
																35	
																40	
																45	
	Glu	Ser	Cys	Asp	His	Leu	His	Val	Cys	Asp	Pro	Ser	Gln	Gly	Leu		
																50	
																55	
																60	
20	V	.1	Cys	Gln	Pro	Gly	Ala	Gly	Pro	Ser	Gly	Arg	Gly	Ala	Val	Cys	
																65	
																70	
																75	
	Leu	Phe	Glu	Glu	Asp	Asp	Gly	Ser	Cys	Glu	Val	Asn	Gly	Arg	Arg		
																80	
																85	
																90	
25	Tyr	Leu	Asp	Gly	Glu	Thr	Phe	Lys	Pro	Asn	Cys	Arg	Val	Leu	Cys		
																95	
																100	
																105	
	Arg	Cys	Asp	Asp	Gly	Gly	Phe	Thr	Cys	Leu	Pro	Leu	Cys	Ser	Glu		
																110	
																115	
																120	
	Asp	Val	Arg	Leu	Pro	Ser	Trp	Asp	Cys	Pro	Arg	Pro	Arg	Arg	Ile		
																125	
																130	
																135	
30	Gln	Val	Pro	Gly	Arg	Cys	Cys	Pro	Glu	Trp	Val	Cys	Asp	Gln	Ala		
																140	
																145	
																150	
	Val	Met	Gln	Pro	Ala	Ile	Gln	Pro	Ser	Ser	Ala	Gln	Gly	His	Gln		
																155	
																160	
																165	
35	Leu	Ser	Ala	Leu	Val	Thr	Pro	Ala	Ser	Ala	Asp	Gly	Pro	Cys	Pro		
																170	
																175	
																180	
	Asn	Trp	Ser	Thr	Ala	Trp	Gly	Pro	Cys	Ser	Thr	Thr	Cys	Gly	Leu		
																185	
																190	
																195	
	Gly	Ile	Ala	Thr	Arg	Val	Ser	Asn	Gln	Asn	Arg	Phe	Cys	Gln	Leu		
																200	
																205	
																210	
40	Glu	Ile	Gln	Arg	Arg	Leu	Cys	Leu	Ser	Arg	Pro	Cys	Leu	Ala	Ser		
																215	
																220	
																225	

Arg Ser His G<sub>1</sub>, Ser Trp Asn Ser Ala Phe  
 230 235

5 <210> 94  
 <211> 234  
 <212> PRT  
 <213> Human

10 <400> 94  
 Leu Ser Met Val Tyr Ser Gln Leu Cys Pro Ala Pro Cys Ala Cys  
 1 5 10 15

15 Pro Trp Thr Pro Pro Gln Cys Pro Pro Gly Val Pro Leu Val Leu  
 20 25 30

Asp Gly Cys Gly Cys Cys Arg Val Cys Ala Arg Arg Leu Gly Glu  
 35 40 45

20 Ser Cys Asp His Leu His Val Cys Asp Pro Ser Gln Gly Leu Val  
 50 55 60

25 Cys Gln Pro Gly Ala Gly Pro Ser Gly Arg Gly Ala Val Cys Leu  
 65 70 75

30 Phe Glu Glu Asp Asp Gly Ser Cys Glu Val Asn Gly Arg Arg Tyr  
 80 85 90

35 Leu Asp Gly Glu Thr Phe Lys Pro Asn Cys Arg Val Leu Cys Arg  
 95 100 105

40 Cys Asp Asp Gly Gly Phe Thr Cys Leu Pro Leu Cys Ser Glu Asp  
 110 115 120

45 Val Arg Leu Pro Ser Trp Asp Cys Pro Arg Pro Arg Arg Ile Gln  
 125 130 135

50 Val Pro Gly Arg Cys Cys Pro Glu Trp Val Cys Asp Gln Ala Val  
 140 145 150

55 Met Gln Pro Ala Ile Gln Pro Ser Ser Ala Gln Gly His Gln Leu  
 155 160 165

60 Ser Ala Leu Val Thr Pro Ala Ser Ala Asp Gly Pro Cys Pro Asn  
 170 175 180

65 Trp Ser Thr Ala Trp Gly Pro Cys Ser Thr Thr Cys Gly Leu Gly  
 185 190 195

70 Ile Ala Thr Arg Val Ser Asn Gln Asn Arg Phe Cys Gln Leu Glu  
 200 205 210

75 Ile Gln Arg Arg Leu Cys Leu Ser Arg Pro Cys Leu Ala Ser Arg  
 215 220 225

80 Ser His Gly Ser Trp Asn Ser Ala Phe  
 230 234

85 40 <210> 95  
 <211> 233

<212> PRT  
 <213> Human

<400> 95  
 Ser Met Val Tyr Ser Gln Leu Cys Pro Ala Pro Cys Ala Cys Pro  
 5 1 5 10 15  
 Trp Thr Pro Pro Gln Cys Pro Pro Gly Val Pro Leu Val Leu Asp  
 20 25 30  
 Gly Cys Gly Cys Cys Arg Val Cys Ala Arg Arg Leu Gly Glu Ser  
 35 40 45  
 10 Cys Asp His Leu His Val Cys Asp Pro Ser Gln Gly Leu Val Cys  
 50 55 60  
 Gln Pro Gly Ala Gly Pro Ser Gly Arg Gly Ala Val Cys Leu Phe  
 65 70 75  
 Glu Glu Asp Asp Gly Ser Cys Glu Val Asn Gly Arg Arg Tyr Leu  
 15 80 85 90  
 Asp Gly Glu Thr Phe Lys Pro Asn Cys Arg Val Leu Cys Arg Cys  
 95 100 105  
 Asp Asp Gly Gly Phe Thr Cys Leu Pro Leu Cys Ser Glu Asp Val  
 110 115 120  
 20 Arg Leu Pro Ser Trp Asp Cys Pro Arg Pro Arg Arg Ile Gln Val  
 125 130 135  
 Pro Gly Arg Cys Cys Pro Glu Trp Val Cys Asp Gln Ala Val Met  
 140 145 150  
 Gln Pro Ala Ile Gln Pro Ser Ser Ala Gln Gly His Gln Leu Ser  
 25 155 160 165  
 Ala Leu Val Thr Pro Ala Ser Ala Asp Gly Pro Cys Pro Asn Trp  
 170 175 180  
 Ser Thr Ala Trp Gly Pro Cys Ser Thr Thr Cys Gly Leu Gly Ile  
 185 190 195  
 30 Ala Thr Arg Val Ser Asn Gln Asn Arg Phe Cys Gln Leu Glu Ile  
 200 205 210  
 Gln Arg Arg Leu Cys Leu Ser Arg Pro Cys Leu Ala Ser Arg Ser  
 215 220 225  
 His Gly Ser Trp Asn Ser Ala Phe  
 35 230 233  
 <210> 96  
 <211> 232  
 <212> PRT  
 <213> Human  
 40 <400> 96  
 Met Val Tyr Ser Gln Leu Cys Pro Ala Pro Cys Ala Cys Pro Trp

1	5	10	15
Thr Pro Pro Gln Cys Pro Pro Gly Val Pro Leu Val Leu Asp Gly			
20 25 30			
Cys Gly Cys Cys Arg Val Cys Ala Arg Arg Leu Gly Glu Ser Cys			
5	35	40	45
Asp His Leu His Val Cys Asp Pro Ser Gln Gly Leu Val Cys Gln			
50 55 60			
Pro Gly Ala Gly Pro Ser Gly Arg Gly Ala Val Cys Leu Phe Glu			
65 70 75			
10	Glu Asp Asp Gly Ser Cys Glu Val Asn Gly Arg Arg Tyr Leu Asp	80	85 90
Gly Glu Thr Phe Lys Pro Asn Cys Arg Val Leu Cys Arg Cys Asp			
95 100 105			
15	Asp Gly Gly Phe Thr Cys Leu Pro Leu Cys Ser Glu Asp Val Arg	110	115 120
Leu Pro Ser Trp Asp Cys Pro Arg Pro Arg Arg Ile Gln Val Pro			
125 130 135			
Gly Arg Cys Cys Pro Glu Trp Val Cys Asp Gln Ala Val Met Gln			
140 145 150			
20	Pro Ala Ile Gln Pro Ser Ser Ala Gln Gly His Gln Leu Ser Ala	155	160 165
Leu Val Thr Pro Ala Ser Ala Asp Gly Pro Cys Pro Asn Trp Ser			
170 175 180			
25	Thr Ala Trp Gly Pro Cys Ser Thr Thr Cys Gly Leu Gly Ile Ala	185	190 195
Thr Arg Val Ser Asn Gln Asn Arg Phe Cys Gln Leu Glu Ile Gln			
200 205 210			
Arg Arg Leu Cys Leu Ser Arg Pro Cys Leu Ala Ser Arg Ser His			
215 220 225			
30	Gly Ser Trp Asn Ser Ala Phe	230	232
<210> 97			
<211> 231			
<212> PRT			
35	<213> Human		
<400> 97			
Val Tyr Ser Gln Leu Cys Pro Ala Pro Cys Ala Cys Pro Trp Thr			
1 5 10 15			
Pro Pro Gln Cys Pro Pro Gly Val Pro Leu Val Leu Asp Gly Cys			
40	20	25	30

	Gly Cys Cys A- <sub>3</sub> Val Cys Ala Arg Arg Leu Gly Glu Ser Cys Asp		
	35	40	45
	His Leu His Val Cys Asp Pro Ser Gln Gly Leu Val Cys Gln Pro		
	50	55	60
5	Gly Ala Gly Pro Ser Gly Arg Gly Ala Val Cys Leu Phe Glu Glu		
	65	70	75
	Asp Asp Gly Ser Cys Glu Val Asn Gly Arg Arg Tyr Leu Asp Gly		
	80	85	90
10	Glu Thr Phe Lys Pro Asn Cys Arg Val Leu Cys Arg Cys Asp Asp		
	95	100	105
	Gly Gly Phe Thr Cys Leu Pro Leu Cys Ser Glu Asp Val Arg Leu		
	110	115	120
	Pro Ser Trp Asp Cys Pro Arg Pro Arg Arg Ile Gln Val Pro Gly		
	125	130	135
15	Arg Cys Cys Pro Glu Trp Val Cys Asp Gln Ala Val Met Gln Pro		
	140	145	150
	Ala Ile Gln Pro Ser Ser Ala Gln Gly His Gln Leu Ser Ala Leu		
	155	160	165
20	Val Thr Pro Ala Ser Ala Asp Gly Pro Cys Pro Asn Trp Ser Thr		
	170	175	180
	Ala Trp Gly Pro Cys Ser Thr Thr Cys Gly Leu Gly Ile Ala Thr		
	185	190	195
	Arg Val Ser Asn Gln Asn Arg Phe Cys Gln Leu Glu Ile Gln Arg		
	200	205	210
25	Arg Leu Cys Leu Ser Arg Pro Cys Leu Ala Ser Arg Ser His Gly		
	215	220	225
	Ser Trp Asn Ser Ala Phe		
	230 231		
	<210> 98		
30	<211> 230		
	<212> PRT		
	<213> Human		
	<400> 98		
35	Tyr Ser Gln Leu Cys Pro Ala Pro Cys Ala Cys Pro Trp Thr Pro		
	1 5 10 15		
	Pro Gln Cys Pro Pro Gly Val Pro Leu Val Leu Asp Gly Cys Gly		
	20 25 30		
	Cys Cys Arg Val Cys Ala Arg Arg Leu Gly Glu Ser Cys Asp His		
	35 40 45		
40	Leu His Val Cys Asp Pro Ser Gln Gly Leu Val Cys Gln Pro Gly		
	50 55 60		

Ala Gly Pro Ser Gly Arg Gly Ala Val Cys Leu Phe Glu Glu Asp  
 65 70 75  
 Asp Gly Ser Cys Glu Val Asn Gly Arg Arg Tyr Leu Asp Gly Glu  
 80 85 90  
 5 Thr Phe Lys Pro Asn Cys Arg Val Leu Cys Arg Cys Asp Asp Gly  
 95 100 105  
 Gly Phe Thr Cys Leu Pro Leu Cys Ser Glu Asp Val Arg Leu Pro  
 110 115 120  
 10 Ser Trp Asp Cys Pro Arg Pro Arg Arg Ile Gln Val Pro Gly Arg  
 125 130 135  
 Cys Cys Pro Glu Trp Val Cys Asp Gln Ala Val Met Gln Pro Ala  
 140 145 150  
 Ile Gln Pro Ser Ser Ala Gln Gly His Gln Leu Ser Ala Leu Val  
 155 160 165  
 15 Thr Pro Ala Ser Ala Asp Gly Pro Cys Pro Asn Trp Ser Thr Ala  
 170 175 180  
 Trp Gly Pro Cys Ser Thr Thr Cys Gly Leu Gly Ile Ala Thr Arg  
 185 190 195  
 20 Val Ser Asn Gln Asn Arg Phe Cys Gln Leu Glu Ile Gln Arg Arg  
 200 205 210  
 Leu Cys Leu Ser Arg Pro Cys Leu Ala Ser Arg Ser His Gly Ser  
 215 220 225  
 Trp Asn Ser Ala Phe  
 230  
 25 <210> 99  
 <211> 229  
 <212> PRT  
 <213> Human  
 30 <400> 99  
 Ser Gln Leu Cys Pro Ala Pro Cys Ala Cys Pro Trp Thr Pro Pro  
 1 5 10 15  
 Gln Cys Pro Pro Gly Val Pro Leu Val Leu Asp Gly Cys Gly Cys  
 20 25 30  
 35 Cys Arg Val Cys Ala Arg Arg Leu Gly Glu Ser Cys Asp His Leu  
 35 40 45  
 His Val Cys Asp Pro Ser Gln Gly Leu Val Cys Gln Pro Gly Ala  
 50 55 60  
 Gly Pro Ser Gly Arg Gly Ala Val Cys Leu Phe Glu Glu Asp Asp  
 65 70 75  
 40 Gly Ser Cys Glu Val Asn Gly Arg Arg Tyr Leu Asp Gly Glu Thr  
 80 85 90

	Phe Lys Pro Asn Cys Arg Val Leu Cys Arg Cys Asp Asp Gly Gly		
	95	100	105
	Phe Thr Cys Leu Pro Leu Cys Ser Glu Asp Val Arg Leu Pro Ser		
	110	115	120
5	Trp Asp Cys Pro Arg Pro Arg Arg Ile Gln Val Pro Gly Arg Cys		
	125	130	135
	Cys Pro Glu Trp Val Cys Asp Gln Ala Val Met Gln Pro Ala Ile		
	140	145	150
10	Gln Pro Ser Ser Ala Gln Gly His Gln Leu Ser Ala Leu Val Thr		
	155	160	165
	Pro Ala Ser Ala Asp Gly Pro Cys Pro Asn Trp Ser Thr Ala Trp		
	170	175	180
	Gly Pro Cys Ser Thr Thr Cys Gly Leu Gly Ile Ala Thr Arg Val		
	185	190	195
15	Ser Asn Gln Asn Arg Phe Cys Gln Leu Glu Ile Gln Arg Arg Leu		
	200	205	210
	Cys Leu Ser Arg Pro Cys Leu Ala Ser Arg Ser His Gly Ser Trp		
	215	220	225
20	Asn Ser Ala Phe		
	229		
	<210> 100		
	<211> 22		
	<212> DNA		
	<213> Artificial		
25	<220>		
	<221> Artificial		
	<222> 1-22		
	<223> Sequence is synthesized		
	<400> 100		
30	ccagccagag gaggccacga ac 22		
	<210> 101		
	<211> 24		
	<212> DNA		
	<213> Artificial		
35	<220>		
	<221> Artificial		
	<222> 1-24		
	<223> Sequence is synthesized		
	<400> 101		
40	gtacttgggt cggtaggtgc gtgt 24		
	<210> 102		
	<211> 23		
	<212> DNA		

<213> Artificial  
  
<220>  
<221> Artificial  
<222> 1-23  
5 <223> Sequence is synthesized  
  
<400> 102  
gtggcccatg ctctggcaga ggg 23  
  
<210> 103  
<211> 24  
10 <212> DNA  
<213> Artificial  
  
<220>  
<221> Artificial  
<222> 1-24  
15 <223> Sequence is synthesized  
  
<400> 103  
gactggagca aggtcgtcct cgcc 24  
  
<210> 104  
<211> 24  
20 <212> DNA  
<213> Artificial  
  
<220>  
<221> Artificial  
<222> 1-24  
25 <223> Sequence is synthesized  
  
<400> 104  
gcaccaccca caaggaagcc atcc 24  
  
<210> 105  
<211> 24  
30 <212> DNA  
<213> Artificial  
  
<220>  
<221> Artificial  
<222> 1-24  
35 <223> Sequence is synthesized  
  
<400> 105  
gacgaaaggg aagccggcat cacc 24  
  
<210> 106  
<211> 24  
40 <212> DNA  
<213> Artificial  
  
<220>  
<221> Artificial  
<222> 1-24  
45 <223> Sequence is synthesized

<400> 106  
gagaaggctcg tgttcgagca aacc 24

5 <210> 107  
<211> 24  
<212> DNA  
<213> Artificial

<220>  
<221> Artificial  
<222> 1-24  
10 <223> Sequence is synthesized

<400> 107  
cttctcgatgt acttcctgtg cctg 24

<210> 108  
<211> 24  
15 <212> DNA  
<213> Artificial

<220>  
<221> Artificial  
<222> 1-24  
20 <223> Sequence is synthesized

<400> 108  
cacgtcagct ggccatgcaca gctc 24

<210> 109  
<211> 23  
25 <212> PRT  
<213> Artificial

<220>  
<221> Artificial  
<222> 1-23  
30 <223> Sequence is synthesized

<400> 109  
Gln Pro Glu Glu Ala Thr Asn Phe Thr Leu Ala Gly Cys Val Ser  
1 5 10 15

35 Thr Arg Thr Tyr Arg Pro Lys Tyr  
20 23

<210> 110  
<211> 24  
<212> DNA  
<213> Artificial

40 <220>  
<221> Artificial  
<222> 1-24  
<223> Sequence is synthesized

<400> 110  
45 ggccctggcc tgccagaagt gtgg 24

<210> 111  
<211> 24  
<212> DNA  
<213> Artificial

5 <220>  
<221> Artificial  
<222> 1-24  
<223> Sequence is synthesized

<400> 111  
10 gtgtgccttt cctgatctga gaac 24

<210> 112  
<211> 50  
<212> DNA  
<213> Artificial

15 <220>  
<221> Artificial  
<222> 1-50  
<223> Sequence is synthesized

<400> 112  
20 gtgattccat ctcttcatgt tcccagaaaa ttcttcccag ccgggcaggg 50

<210> 113  
<211> 70  
<212> DNA  
<213> Artificial

25 <220>  
<221> Artificial  
<222> 1-70  
<223> Sequence is synthesized

<400> 113  
30 ccagccagag gaggccacga acttcactct cgcaggctgt gtcagcacac 50  
gcacctaccg acccaagtac 70

<210> 114  
<211> 50  
<212> DNA  
35 <213> Artificial

<220>  
<221> Artificial  
<222> 1-50  
<223> Sequence is synthesized

40 <400> 114  
gcccctggag cccttgctcc accagctgcg gcctgggggt ctccactcg 50

<210> 115  
<211> 23  
<212> DNA  
45 <213> Artificial

<220>  
<221> Artificial  
<222> 1-23  
<223> Sequence is synthesized

5 <400> 115  
aaagggtgcgt acccagctgt gcc 23

<210> 116  
<211> 24  
<212> DNA  
10 <213> Artificial

<220>  
<221> Artificial  
<222> 1-24  
<223> Sequence is synthesized

15 <400> 116  
ggtcttggcg aagacggctg acct 24

<210> 117  
<211> 51  
<212> DNA  
20 <213> Artificial

<220>  
<221> Artificial  
<222> 1-51  
<223> Sequence is synthesized

25 <400> 117  
cctggtgctg gatggctgtg gctgctgccc ggtatgtgca cggcggctgg 50

g 51

<210> 118  
<211> 28  
30 <212> DNA  
<213> Artificial

<220>  
<221> Artificial  
<222> 1-28  
35 <223> Sequence is synthesized

<400> 118  
gtcttgca agcaacaaaa tggactcc 28

<210> 119  
<211> 27  
40 <212> DNA  
<213> Artificial

<220>  
<221> Artificial  
<222> 1-27  
45 <223> Sequence is synthesized

<400> 119  
gctgtcgcaa ggctgaatgt aacacag 27

5 <210> 120  
<211> 50  
<212> DNA  
<213> Artificial

<220>  
<221> Artificial  
<222> 1-50  
10 <223> Sequence is synthesized

<400> 120  
gctccagaac atgtggatg ggaatatcta acagggtgac caatgaaaac 50

15 <210> 121  
<211> 23  
<212> DNA  
<213> Artificial

<220>  
<221> Artificial  
<222> 1-23  
20 <223> Sequence is synthesized

<400> 121  
cctggagtga gcctggtag aga 23

25 <210> 122  
<211> 27  
<212> DNA  
<213> Artificial

<220>  
<221> Artificial  
<222> 1-27  
30 <223> Sequence is synthesized

<400> 122  
acaatacagc cctttgtgtg ggtcaca 27

35 <210> 123  
<211> 44  
<212> DNA  
<213> Artificial

<220>  
<221> Artificial  
<222> 1-44  
40 <223> Sequence is synthesized

<400> 123  
tggttgcttg gcacagattt tacagcatcc acagccatct ctca 44

45 <210> 124  
<211> 27  
<212> DNA  
<213> Artificial

<220>  
<221> Artificial  
<222> 1-27  
<223> Sequence is synthesized

5 <400> 124  
tgacttccag gcatgaggtg gtcctg 27

<210> 125  
<211> 34  
<212> DNA

10 <213> Artificial

<220>  
<221> Artificial  
<222> 1-34  
<223> Sequence is synthesized

15 <400> 125  
attggcaatc tcttcgaagt caggtaaga ttcc 34

<210> 126  
<211> 40  
<212> DNA

20 <213> Artificial

<220>  
<221> Artificial  
<222> 1-40  
<223> Sequence is synthesized

25 <400> 126  
ggtacgtcta gactaattgg caatctttc gaagtcaggg 40

<210> 127  
<211> 42  
<212> DNA

30 <213> Artificial

<220>  
<221> Artificial  
<222> 1-42  
<223> Sequence is synthesized

35 <400> 127  
tttcccttg gatcctaaac caacatgagg tggctcctgc cc 42

<210> 128  
<211> 20  
<212> DNA

40 <213> Artificial

<220>  
<221> Artificial  
<222> 1-20  
<223> Sequence is synthesized

45 <400> 128  
cagattggtg ctggatatgc 20

<210> 129  
<211> 20  
<212> DNA  
<213> Artificial

5 <220>  
<221> Artificial  
<222> 1-20  
<223> Sequence is synthesized.

<400> 129  
10 actgccttga ttactcctac 20

<210> 130  
<211> 18  
<212> DNA  
<213> Artificial

15 <220>  
<221> Artificial  
<222> 1-18  
<223> Sequence is synthesized

<400> 130  
20 agttgcagat gtggctct 18

<210> 131  
<211> 18  
<212> DNA  
<213> Artificial

25 <220>  
<221> Artificial  
<222> 1-18  
<223> Sequence is synthesized

<400> 131  
30 agtccaagag tctcagca 18

<210> 132  
<211> 18  
<212> DNA  
<213> Artificial

35 <220>  
<221> Artificial  
<222> 1-18  
<223> Sequence is synthesized

<400> 132  
40 acaactggaa gcactgga 18

<210> 133  
<211> 18  
<212> DNA  
<213> Artificial

45 <220>  
<221> Artificial

<222> 1-18  
<223> Sequence is synthesized

<400> 133  
tcttattcca gaggaacc 18

5 <210> 134  
<211> 22  
<212> DNA  
<213> Artificial

<220>  
10 <221> Artificial  
<222> 1-22  
<223> Sequence is synthesized

<400> 134  
tccctgtacg cttctggtcg ta 22

15 <210> 135  
<211> 22  
<212> DNA  
<213> Artificial

<220>  
20 <221> Artificial  
<222> 1-22  
<223> Sequence is synthesized

<400> 135  
tctcaaagtc caaagccaca ta 22

25 <210> 136  
<211> 18  
<212> DNA  
<213> Artificial

<220>  
30 <221> Artificial  
<222> 1-18  
<223> Sequence is synthesized

<400> 136  
cacagttcca gcaaatac 18

35 <210> 137  
<211> 18  
<212> DNA  
<213> Artificial

<220>  
40 <221> Artificial  
<222> 1-18  
<223> Sequence is synthesized

<400> 137  
ggaatcaggc ggtacagt 18

45 <210> 138

<211> 31  
<212> DNA  
<213> Artificial

5 <220>  
<221> Artificial  
<222> 1-31  
<223> Sequence is synthesized

<400> 138  
agccttcca agtcactaga agtcctgctg g 31

10 <210> 139  
<211> 21  
<212> DNA  
<213> Artificial

<220>  
15 <221> Artificial  
<222> 1-21  
<223> Sequence is synthesized

<400> 139  
ctggactaca cccaaaggctg a 21

20 <210> 140  
<211> 23  
<212> DNA  
<213> Artificial

<220>  
25 <221> Artificial  
<222> 1-23  
<223> Sequence is synthesized

<400> 140  
catttcttgg gattttaggca aga 23

30 <210> 141  
<211> 19  
<212> DNA  
<213> Artificial

<220>  
35 <221> Artificial  
<222> 1-19  
<223> Sequence is synthesized

<400> 141  
tcttagcccac tccctgcct 19

40 <210> 142  
<211> 21  
<212> DNA  
<213> Artificial

<220>  
45 <221> Artificial  
<222> 1-21

<223> Sequence is synthesized

<400> 142  
gaagtcggag agaaaagctcg c 21

5 <210> 143  
<211> 30  
<212> DNA  
<213> Artificial

<220>  
<221> Artificial  
10 <222> 1-30  
<223> Sequence is synthesized

<400> 143  
cacacacagc ctatataaaa catgcacacg 30

15 <210> 144  
<211> 38  
<212> DNA  
<213> Artificial

<220>  
<221> Artificial  
20 <222> 1-38  
<223> Sequence is synthesized

<400> 144  
cttgagactg aaagatttag ccataatgta aactgcct 38

25 <210> 145  
<211> 22  
<212> DNA  
<213> Artificial

<220>  
<221> Artificial  
30 <222> 1-22  
<223> Sequence is synthesized

<400> 145  
caaatgcaac ctcacaacct tg 22

35 <210> 146  
<211> 24  
<212> DNA  
<213> Artificial

<220>  
<221> Artificial  
40 <222> 1-24  
<223> Sequence is synthesized

<400> 146  
ttcttttatg cccaaagtcc aatt 24

45 <210> 147  
<211> 48

<212> DNA  
<213> Artificial

<220>  
<221> Artificial  
5 <222> 1-48  
<223> Sequence is synthesized

<400> 147  
ggattctaat acgactcact atagggcgtc cctggccagt gctgtgag 48

10 <210> 148  
<211> 48  
<212> DNA  
<213> Artificial

<220>  
<221> Artificial  
15 <222> 1-48  
<223> Sequence is synthesized

<400> 148  
ctatgaaatt aaccctcact aaagggaggg ccaggcttg cttccatt 48

20 <210> 149  
<211> 47  
<212> DNA  
<213> Artificial

<220>  
<221> Artificial  
25 <222> 1-47  
<223> Sequence is synthesized

<400> 149  
ggattctaat acgactcact atagggctgg aggcattggca caggaac 47

30 <210> 150  
<211> 48  
<212> DNA  
<213> Artificial

<220>  
<221> Artificial  
35 <222> 1-48  
<223> Sequence is synthesized

<400> 150  
ctatgaaatt aaccctcact aaagggatcc ggatcaggct tgggtgta 48

40 <210> 151  
<211> 48  
<212> DNA  
<213> Artificial

<220>  
<221> Artificial  
45 <222> 1-48  
<223> Sequence is synthesized

<400> 151  
ggattctaat acgactcact atagggcagc ttgggatgga ggtcttcc 48

5 <210> 152  
<211> 44  
<212> DNA  
<213> Artificial

<220>  
<221> Artificial  
<222> 1-44  
10 <223> Sequence is synthesized

<400> 152  
ctatgaaatt aaccctcact aaagggaggg cactggggtg gtgt 44

15 <210> 153  
<211> 45  
<212> DNA  
<213> Artificial

<220>  
<221> Artificial  
<222> 1-45  
20 <223> Sequence is synthesized

<400> 153  
ggattctaat acgactcact atagggcgcg aggacggcgg cttca 45

25 <210> 154  
<211> 48  
<212> DNA  
<213> Artificial

<220>  
<221> Artificial  
<222> 1-48  
30 <223> Sequence is synthesized

<400> 154  
ctatgaaatt aaccctcact aaagggaaaga gtcgcggccg cccttttt 48

35 <210> 155  
<211> 48  
<212> DNA  
<213> Artificial

<220>  
<221> Artificial  
<222> 1-48  
40 <223> Sequence is synthesized

<400> 155  
ggattctaat acgactcact atagggcgccg gtcctcttc tccactct 48

45 <210> 156  
<211> 48  
<212> DNA  
<213> Artificial

<220>  
<221> Artificial  
<222> 1-48  
<223> Sequence is synthesized

5 <400> 156  
ctatgaaatt aaccctcact aaaggagct gtcgcaaggc tgaatgta 48

# INTERNATIONAL SEARCH REPORT

Intern	1st Application No
PCT/US 98/22991	

A. CLASSIFICATION OF SUBJECT MATTER	IPC 6 C12N15/12 C07K14/47 C12N15/62 C07K16/18
-------------------------------------	---

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>DATABASE EMBL - EMEST1            Entry Aa592984, Acc.no. AA592984,            24 September 1997            STRAUSBERG, R.: "nn03e01.s1 NCI_CGAP_Pr4.1            Homo sapiens cDNA clone IMAGE:1076664            similar to TR:G984956 G984956 CONNECTIVE            TISSUE GROWTH FACTOR"            XP002094092            see the whole document</p> <p style="text-align: center;">-/-</p>	47, 49-54, 57-60, 62-68, 71,72, 79,81, 83,85,86

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

\* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority, claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

19 February 1999

05/03/1999

Name and mailing address of the ISA

Authorized officer

European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax: (+31-70) 340-3016

Smalt, R

**INTERNATIONAL SEARCH REPORT**

Interr	nal Application No
PCT/US 98/22991	

**C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT**

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>DATABASE EMBL - EMHUM1            Entry Hs14217, Acc.no. Z99289,            17 September 1997            TUBBY B.: "Homo sapiens DNA sequence from            PAC 142L7 on chromosome 6q21. Contains            a...Connective tissue growth factor (NOV,            GIG) LIKE gene,..."            XP002094093            nt. 12398-12855</p> <p>---</p>	47, 49-54, 57-60, 62-68, 71,72, 79,81, 83,85,86
Y	<p>OEMAR, B.S. ET AL.: "Connective tissue            growth factor - friend or foe?"            ARTERIOSCLEROSIS, THROMBOSIS, AND VASCULAR            BIOLOGY,            vol. 17, no. 8, August 1997, pages 1483-9,            XP002094090            cited in the application            see the whole document</p> <p>---</p>	47, 49-54, 57-60, 62-68, 71,72, 79,81, 83,85,86
A	<p>DATABASE EMBL - EMEST10            Entry HS01627, Acc.no T55016,            28 February 1995            HILLIER, L. ET AL.: "yb42e03.r1 Homo            sapiens cDNA clone 73852 5'"            XP002094094            see abstract</p> <p>---</p>	1,13
A	<p>DATABASE EMBL - EMEST18            Entry Hszz82583, Acc.no. AA377456,            18 April 1997            ADAMS, M.D. ET AL.: "EST90040 Synovial            membrane Homo sapiens cDNA 5' end."            XP002094095            see the whole document            -&amp; ADAMS, M.D. ET AL.: "Initial            assessment of human gene diversity and            expression patterns based upon 83 million            nucleotides of cDNA sequence"            NATURE,            vol. 377, 1995, pages 3-17, XP002042918            see the whole document</p> <p>---</p>	26, 28-30,35
P,X	<p>HASHIMOTO, Y. ET AL.: "Expression of the            Elml gene, a novel gene of the CCN            (Connective tissue growth factor,            Cyr61/Cef10, and neuroblastoma            overexpressed gene) family, suppresses in            vivo tumor growth and metastasis of K-1735            murine melanoma cells."            JOURNAL OF EXPERIMENTAL MEDICINE,            vol. 187, no. 3, 2 February 1998, pages            289-96, XP002094091            cited in the application            see whole document, particularly fig. 1</p> <p>---</p> <p align="center">-/-</p>	1,9,10, 12-19, 24,25

## INTERNATIONAL SEARCH REPORT

Interr	nal Application No
PCT/US 98/22991	

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	<p>WO 98 21236 A (HUMAN GENOME SCIENCES INC ;CHOPRA ARVIND (US); EBNER REINHARD (US)) 22 May 1998</p> <p>see whole document, particularly seq. 1 and 2, example 1, claim 18</p> <p>-----</p>	26, 28-30, 35-46, 77,78, 83,85, 86,88, 92,111
P, X	<p>ZHANG, R. ET AL.: "Identification of rCop-1, a new member of the CCN protein family, as a negative regulator for cell transformation" MOLECULAR AND CELLULAR BIOLOGY, vol. 18, no. 10, October 1998, pages 6131-41, XP002094139 cited in the application</p> <p>see whole document, particularly fig.2 and p.6132, left-hand column, second full paragraph</p> <p>-----</p>	26, 30-32, 34,35, 37-40, 42-46,92

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 98/ 22991

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: 2, 11, 27, 48, 61  
because they relate to subject matter not required to be searched by this Authority, namely:  
See Further Information sheet PCT/ISA/210
  
2.  Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
See Further Information sheet PCT/ISA/210
  
3.  Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1.  As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
  
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
  
3.  As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
  
4.  No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
- No protest accompanied the payment of additional search fees.

## INTERNATIONAL SEARCH REPORT

International Application No. PCT/US 98/22991

### FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Although claims 89-91 and 101, and claims 102-104 and 107 in as far as they relate to use *in vivo*, are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

---

Claims Nos.: 2,11,27,48,61

Claims 2,11,27,48, and 61, referring to biological activities of the claimed WISP proteins, could not be searched due to lack of support of such activities in the description (Article 6, PCT).

Claims 74,76,78,80,82,105,108,111,114, and 115 referring to antagonists of the claimed WISP polypeptides and/or inhibitors of expression of the claimed WISP genes, could not be searched to completion due to insufficient disclosure of the compounds in the description (Article 6, PCT).

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International Application No  
PCT/US 98/22991

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9821236 A	22-05-1998 AU	7610396 A	03-06-1998